Crypt-top and crypt-bottom colonic epithelial cell population microRNA expression demonstrates cell type-specificity and correlation with endoscopic activity in ulcerative colitis

Journal:	*Journal of Crohn's and Colitis*
Manuscript ID	Draft
Manuscript Type:	Original Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Inciuraite, Ruta; Lithuanian University of Health Sciences, Institute for Digestive Research Ramonaite, Rima; Lithuanian University of Health Sciences, Institute for Digestive Research Kupcinskas, Juozas; Lithuanian University of Health Sciences, Institute for Digestive Research; Lithuanian University of Health Sciences, Department of Gastroenterology Dalgediene, Indre; Vilnius University, Life Sciences Center, Institute of Biotechnology Kulokiene, Ugne; Lithuanian University of Health Sciences, Institute for Digestive Research Kiudelis, Vytautas; Lithuanian University of Health Sciences, Institute for Digestive Research; Lithuanian University of Health Sciences, Department of Gastroenterology Varkalaite, Greta; Lithuanian University of Health Sciences, Institute for Digestive Research Zvirbliene, Aurelija; Vilnius University, Institute of Biotechnology Jonaitis, Laimas Virginijus; Lithuanian University of Health Sciences, Institute of Biotechnology; Lithuanian University of Health Sciences, Department of Gastroenterology Kiudelis, Gediminas; Lithuanian University of Health Sciences, Institute for Digestive Research; Lithuanian University of Health Sciences, Department of Gastroenterology Franke, Andre; Christian-Albrechts-Universitat zu Kiel, Institute of Clinical Molecular Biology Schreiber, Stefan; Universitatsklinikum Schleswig-Holstein, Dept. of Internal Medicine I Juzenas, Simonas; Lithuanian University of Health Sciences, Institute for Digestive Research; Vilnius University, Institute of Biotechnology Skieceviciene, Jurgita; Lithuanian University of Health Sciences, Institute for Digestive Research

Subject:	Basic science, experimental models and pathophysiology, Biomarkers
Classifications:	Genetics and molecular epidemiology, Biomarkers

SCHOLARONE™
Manuscripts

Title: ***Crypt-top and crypt-bottom colonic epithelial cell population microRNA expression demonstrates cell type-specificity and correlation with endoscopic activity in ulcerative colitis***

Short title: Colonic epithelial cell miRNome in aUC and qUC

Authors: Ruta Inciuraite[1*], Rima Ramonaite[1*], Juozas Kupcinskas[1,2*], Indre Dalgediene[3], Ugne Kulokiene[1], Vytautas Kiudelis[1,2], Greta Varkalaite[1], Aurelija Zvirbliene[3], Laimas Virginijus Jonaitis[1,2], Gediminas Kiudelis[1,2], Andre Franke[4], Stefan Schreiber[4], Simonas Juzenas[1,3*], Jurgita Skieceviciene[1*]

[1] Institute for Digestive Research, Academy of Medicine, Lithuanian University of Health Sciences, Kaunas, Lithuania

[2] Department of Gastroenterology, Academy of Medicine, Lithuanian University of Health Sciences, Kaunas, Lithuania

[3] Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania

[4] Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany

* These authors contributed equally to this work

Contact details (Email) and ORCiD IDs: Ruta Inciuraite: Email: ruta.inciuraite@lsmuni.lt, ORCiD ID: 000-0002-5806-6155; Rima Ramonaite: Email: rima.ramonaite@lsmuni.lt, ORCiD ID: 0000-0001-5093-9305, Juozas Kupcinskas: Email: juozas.kupcinskas@lsmuni.lt, ORCiD ID: 0000-0002-8760-7416; Indre Dalgediene: indre.dalgediene@bti.vu.lt, ORCiD ID: 0000-0003-4113-4761; Ugne Kulokiene: ugne.kulokiene@lsmuni.lt, ORCiD ID: 0000-0002-1130-2472; Vytautas Kiudelis: vytautas.kiudelis@lsmuni.lt, ORCiD ID: 0000-0003-3680-1320; Greta Varkalaite: greta.varkalaite@lsmuni.lt, ORCiD: 0000-0003-3488-2171; Aurelija Zvirbliene: aurelija.zvirbliene@bti.vu.lt, ORCiD ID: 0000-0003-3122-8895; Laimas Virginijus Jonaitis: laimas.jonaitis@lsmuni.lt, ORCiD OD: 0000-0001-9086-3675; Gediminas Kiudelis: gediminas.kiudelis@lsmuni.lt, ORCiD ID: 0000-0001-5945-8284; Andre Franke:

For Review Only

a.franke@ikmb.uni-kiel.de, ORCiD ID: 0000-0003-1530-5811; Stefan Schreiber: s.schreiber@mucosa.de; Simonas Juzenas: simonas.juzenas@gmc.vu.lt, ORCiD ID: 0000-0001-9293-0691; Jurgita Skieceviciene: jurgita.skieceviciene@lsmuni.lt, ORCiD ID: 0000-0002-4893-6612.

Address for correspondence: Jurgita Skieceviciene, PhD, Institute for Digestive Research, Academy of Medicine, Lithuanian University of Health Sciences, Eiveniu st. 4, LT-50161, Kaunas, Lithuania. Email: jurgita.skieceviciene@lsmuni.lt.

Conference presentation: Part of this work was presented at the 16th Congress of ECCO Virtual - Inflammatory Bowel Diseases 2021, July 2-3 & 8-10, 2021.

For Review Only

Abstract

Background and Aims. Colonic epithelial barrier loss and dysfunction are one of the early events in ulcerative colitis (UC) and microRNAs (miRNAs) participate in its regulation. However, cell type-specific profile of miRNAs during inflammation in UC is still unknown. Thus, we aimed to perform miRNA profiling on colon tissue and epithelial cell levels in active and quiescent UC.

Methods. Small RNA-sequencing in colon tissue, crypt-bottom ($CD44^+$), and crypt-top ($CD66a^+$) colonic epithelial cell populations from two independent cohorts of UC patients (active and quiescent, n=74), and healthy individuals (n=50) was performed. Data analysis encompassed differential expression, weighted gene co-expression network (WGCNA), correlation, gene-set enrichment analyses (GSEA).

Results. In colon tissue of active and quiescent UC, differentially expressed miRNAs were shown to be potentially involved in intestinal barrier integrity regulation. Consecutive analysis of crypt-bottom and crypt-top colonic epithelial cells revealed distinct miRNA expression patterns in response to UC-caused inflammation. GSEA indicated that differentially expressed epithelial miRNAs are commonly involved in inflammation- and intestinal barrier integrity-related processes (such as signalling of interleukin-4 and interleukin-13), while miRNA differences between cell populations might reflect their function, i.e., crypt-bottom cell miRNA target genes involved in regulation of cell differentiation. Finally, pro-inflammatory miRNA co-expression module correlating with endoscopic UC activity was defined not only in both epithelial cell populations, but also in the colon tissue.

Conclusions. miRNA expression patterns are colon epithelial cell population- and UC state-specific and correlate with endoscopic UC activity. Irrespective of the UC stage deregulated epithelial miRNAs are potentially involved in regulation of intestinal barrier integrity.

Keywords

Colon crypt-bottom epithelial cells; colon crypt-top epithelial cells; microRNA; Ulcerative coliti

For Review Only

Introduction

Colonic epithelial cells and their secreted products primarily form and maintain frontline intestinal barrier function which deteriorates early in ulcerative colitis (UC)[1]. Colonic crypt epithelial cells such as colonocytes, Goblet and epithelial stem cells have been shown to play an important role in UC pathogenesis via reduced epithelial mucus secretion and/or increased barrier permeability[2]. Since one of the aims in UC management is to induce and then to maintain remission, disentangling molecular mechanisms regulating epithelial barrier may help to modulate its permeability and retain long-lasting remission in UC.

Recent studies provide evidence for microRNAs (miRNAs) to be involved in regulation of intestinal epithelial integrity and barrier permeability via interference with protein-coding genes responsible for tight and adherent junctions[3], also in UC[4]. However, most of the studies have been either based on immortalized cell cultures or bulk tissue experiments, thus the exact cellular context of miRNA deregulation during colonic inflammation remains elusive. Therefore, the search for cell type specific deregulation of miRNAs in UC might uncover novel aspects of underlying regulatory pathways and molecular targets for therapeutic development. Here, we report the comprehensive miRNA expression profiling on colon tissue and colonic crypt-bottom ($CD44^+$) and crypt-top ($CD66a^+$) cell population levels in active and quiescent UC. By employing small RNA-seq we determine UC activity-specific, as well as epithelial cell population-specific, miRNA expression signatures during colonic inflammation. Additionally, we describe miRNA co-expression network and evaluate its relations to clinical characteristic of UC. Finally, we explore putative biological pathways in which the deregulated miRNAs are involved and provide potential miRNA candidates for further development of UC management.

For Review Only

Materials and Methods

Ethics and consent

The approval to perform the study was received from Kaunas Regional Biomedical Research Ethics Committee (No. BE-2-31, 22-03-2018). All subjects have signed a written informed consent form to participate in the study.

Study samples

Study subject recruitment was conducted at the Department of Gastroenterology, Lithuanian University of Health Sciences (Kaunas, Lithuania) during the period of 2011-2014 (Study group I and III) and 2017-2019 (Study group II). For miRNA sequencing, colon biopsies were collected in two independent groups: the first study group contained 23 patients with active UC, 20 patients with quiescent UC and 33 healthy control individuals (HC), while the second study group was composed of 16 patients with active UC, 15 patients with quiescent UC and 17 HC individuals. Additionally, colon biopsies for qPCR-based gene expression analysis were collected in the third independent group which contained 75 patients with active UC, 50 patients with quiescent UC and 75 HC individuals. Demographic and clinical characteristics of subjects of Study groups I and II are presented in **Table 1**, Study group III – in **Supplementary Table S1**. Tissue samples of patients with active UC and quiescent UC were collected from sigmoid colon. Endoscopic activity was determined using the Mayo endoscopic subscore[5]. Quiescent UC was defined as mucosal healing (endoscopic Mayo subscore ≤ 1) with no clinical symptoms. The variables collected for the individuals of both study groups were such as age, sex, body mass index (BMI), smoking status, disease activity, localization, rectal bleeding, stool frequency, endoscopic Mayo subscore, global assessment score, full Mayo score.

For Review Only

Table 1. Demographic and clinical characteristics of subjects

	Study group I, n=76			Study group II, n=48		
	Active UC, n=23	Quiescent UC, n=20	HC, n=33	Active UC, n=16	Quiescent UC, n=15	HC, n=17
Age						
Mean ± SD	43.9± 16.1 *	47.2 ± 13.5 *	58.5 ± 12.7 *	41.6 ± 16.3 **	57.3 ± 12.1 **	50.5 ± 16.1
Sex, n (%)						
Female	10 (43.5)	9 (45.0)	21 (73.6)	4 (25.0) ***	10 (66.7) ***	10 (58.8) ***
Full Mayo score, n (%)						
Remission	0 (0.0)	20 (100.0)	-	0 (0.0)	15 (100.0)	-
Mild	1 (4.4)	0 (0.0)	-	4 (25.0)	0 (0.0)	-
Moderate	21 (91.3)	0 (0.0)	-	11 (68.8)	0 (0.0)	-
Severe	1 (4.4)	0 (0.0)	-	1 (6.3)	0 (0.0)	-
Endoscopic Mayo subscore, n (%)						
Normal to mild	0 (0.00)	20 (100.0)	33 (100.0)	0 (0.0)	15 (100.0)	17 (100.0)
Moderate to severe	23 (100.0)	0 (0.0)	-	16 (100.0)	0 (0.0)	-
Smoking status, n (%)						
Never	8 (34.8)	11 (55.0)	23 (69.7)	9 (56.3)	10 (66.7)	12 (70.6)
Smoking	8 (34.8)	6 (30.0)	5 (15.2)	3 (18.8)	1 (6.7)	3 (17.7)
Ex-smoker	3 (13.1)	2 (10.0)	1 (5.0)	4 (25.0)	4 (26.7)	2 (11.8)
Unknown	4 (17.4)	1 (5.0)	1 (3.0)	-	-	-
BMI, kg/m^2						
Median, (range)	26.8 (18.1–56.2)	26.2 (19.7–31.5)	27.7 (19.6–39.5)	25.5 (18.0–37.2)	28.4 (19.8–32.7)	25.9 (18.9–31.9)
Unknown, n (%)	1 (4.4)	1 (5.0)	2 (6.1)	-	1 (6.7)	-

* Age differed between both active and quiescent UC groups, and HC, estimated *P* value < 0.05 (*t*-test)

**Age differed between both active and quiescent UC groups, and HC, estimated *P* value < 0.05 (*t*-test)

For Review Only

***Sex distribution differed between three groups, estimated *P* value < 0.05 (Pearson's chi-squared test)

SD - Standard deviation

All subjects with active and quiescent UC had a routine colonoscopy performed as a part of their planned examination programme. The diagnosis of UC was based on standard clinical, endoscopic, radiological, and histological criteria[6]. The control individuals included in both study groups consisted of healthy subjects who either underwent colonoscopy due to positive faecal occult blood test or were consulted on functional complaints, but had a normal colonoscopy, uninflamed mucosa during histopathological examination and no previous history of intestinal inflammation. All patients enrolled in the study were of European descent.

Colon tissue disaggregation

Colon biopsies were mechanically and enzymatically separated into single-cell suspensions. Briefly, four to six biopsies (5–10 mg wet weight each) were washed with PBS solution containing 50 IU/mL penicillin, 50 µg/mL streptomycin, and 0.5 mg/mL gentamicin. Biopsies were minced into small pieces (approx. 1-2 mm^3) and incubated in 1X trypsin-EDTA solution for 40-45 min at room temperature on an agitator to dissociate single epithelial cells from the lamina propria. After incubation, tissue fragments were gently transferred into PBS and shaken. The isolated cell suspension was filtered and suspended in DMEM:Ham's F-12 medium (1:1) with 15 mM HEPES (Gibco, USA) buffer for flow cytometry procedures.

Flow cytometry and fluorescence activated cell sorting

In order to minimize the loss of cell viability, fresh cell suspensions prepared shortly before flow cytometry were used in all cell sorting experiments. Antibody staining was performed in PBS supplemented with 1% heat-inactivated fetal bovine serum. To minimize nonspecific binding of antibodies, cells were first incubated with Human TruStain FcX™ (Fc Receptor Blocking Solution) (BioLegend Inc., USA) for 10 min at a concentration of 3-10 × 10^5 cells/100

For Review Only

169 µl. Cells were subsequently stained without washing with antibodies at dilutions recommended
170 by manufacturers. Antibodies used in this study were selected based on previous study[7] and
171 included: mouse anti-human CD326/EpCAM-FITC (clone VU-1D9, RRID: AB_2534535m Life
172 Technologies, USA), mouse anti-human CD44-APC (clone G44-26, RRID: AB_395868, BD
173 Biosciences, USA), mouse anti-human CD66a-PE (clone 283340, R&D Systems, USA). Cells
174 positive for expression of non-epithelial lineage markers were excluded by staining with mouse
175 anti-human CD45-APC-Cy7 (clone 2D1, RRID: AB_2566375, Biolegend Inc., USA) (see
176 gating strategy in **Supplementary Figure S1a**). After 20 min, stained cells were washed of
177 excess unbound antibodies and resuspended in PBS supplemented with 1% heat-inactivated
178 fetal bovine serum. Flow-cytometry analysis was performed using a CyFlow® Space cell sorter
179 (Sysmex Partec, Germany) (see representative plots of flow cytometry data in
180 **Supplementary Figure S1b-d**). In cell sorting experiments, each population of interest was
181 sorted individually, using a protocol already built-in within the CyFlow® Space flow cytometer
182 software package (FloMax® 2.8), with appropriate adjustments. Data was analysed and
183 visualised using FlowJo™ v10.7 (BD FlowJo, USA). Two cell populations ($CD45^-$
184 $/EpCAM^+/CD44^+/CD66a^+$ and $CD45^-/EpCAM^+/CD44^-/CD66a^+$) were further described based
185 on the literature and single-cell RNA-seq dataset of the human colon, available in GEO
186 database with accession number GSE116222 (see the single-cell RNA-seq data-derived
187 expression plot of three main cell surface markers in **Supplementary Figure S2**). $CD45^-$
188 $/EpCAM^+/CD44^+/CD66a^-$ population was entitled as crypt-bottom cells (consisting of
189 undifferentiated colonic epithelial cells as well as secretory Goblet and enteroendocrine cells),
190 while $CD45^-/EpCAM^+/CD44^-/CD66a^+$ population was entitled as crypt-top cells (consisting of
191 absorptive colonocytes and $BEST4^+/OTOP2^+$ cells). Sorted cell samples were frozen and
192 stored at -70 °C prior to total RNA extraction.
193

194 ***Total RNA extraction***

195 Total RNA extraction from colon biopsies and sorted cells was performed using standard
196 protocols of commercial miRNeasy Mini Kit (Qiagen, Germany) and Single Cell RNA

For Review Only

Purification Kit (Norgen, Canada), respectively. Total RNA concentration was evaluated by NanoDrop2000 spectrophotometer (Thermo Scientific, USA) and Qubit 4 fluorometer (Invitrogen, USA). Total RNA quality was assessed using Agilent 2100 Bioanalyzer (Agilent Biotechnologies, USA).

Quantitative Reverse Transcription PCR and data analysis

To estimate the expression of *IL-4* and *IL-13* genes in colon tissue of UC patients, total RNA from colon tissue samples was reverse transcribed using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems™, USA). Further, expression levels were measured using TaqMan™ Gene Expression Assays (Assay IDs: *IL-4* Hs00174122_m1; *IL-13* Hs00174379_m1) on the 7500 Fast Real-Time PCR System (Applied Biosystems™, USA). The cycle threshold (C_T) values of *IL-4* and *IL-13* were normalized to the value of *GAPDH* (Assay ID: Hs99999905_m1) reference gene. All the procedures were performed in accordance with the manufacturer's protocol. Statistical analysis was performed using R studio software (version 4.0.3). Data distribution was determined using the Shapiro-Wilk test, gene expression differences were analysed the two-sided Mann-Whitney U test. The difference between the values was considered significant when $P < 0.05$.

Preparation of small RNA libraries and next-generation sequencing

Small RNA libraries from tissue samples were prepared using TruSeq Small RNA Sample Preparation Kit (Illumina, USA) with 1 µg of total RNA input per sample. Small RNA libraries from sorted cells were prepared using NEXTFLEX Small RNA-seq Kit v3 (Bioo Scientific, USA) with up to 50 ng of total RNA input per sample. Procedures were conducted according to the manufacturers' protocols. The yield of sequencing libraries was assessed using the Agilent 2200 TapeStation system (Agilent Biotechnologies, USA). Subsequently, the TruSeq libraries were pooled with around 24 samples per lane, while the NEXTFLEX libraries were pooled with around 16 samples per lane and then sequenced on HiSeq 4000 (Illumina, USA) next-generation sequencing platform.

For Review Only

Bioinformatics and statistical analysis of small RNA-seq data

The demultiplexed raw reads (.fastq) were processed with nf-core/smrnaseq v1.0.0 best-practise analysis pipeline using default parameters (Nextflow version v20.01.0)[8]. The pipeline was executed within a Docker container. Briefly, depending on the small RNA-seq library preparation kits, “illumina” or “nextflex” protocol was selected for processing of the libraries generated from tissue and sorted cell samples, respectively. First, Trim Galore (v0.6.3) was used to remove 3’ adapter (5’ - TGGAATTCTCGGGTGCCAAGG - 3’ for both “illumina” and “nextflex” protocols) sequences from the reads and additional 4 nucleotides from both 5’ and 3’ ends of reads (only for “nextflex” protocol). Second, to reduce computational time, the reads with identical sequences were collapsed using seqcluster[9] while saving the information about the read counts. Third, Bowtie1 v1.2.2[10] was used to perform the alignment of collapsed reads against mature and hairpin miRNA sequences in miRbase database v22.1[11]. Finally, miRNA annotation was performed using the mirTOP v0.4.23[12]. Further, sample and miRNA QC was performed: samples with initial read count < 1.5 IQR and number of detected miRNAs < 1.5 IQR on $\log_2$ scale as well as non-expressed (mean raw < 1) and non-variable miRNAs were excluded from further analysis. Subsequently, to perform differential expression analyses of the size factor normalized counts of mature miRNAs between samples, negative binomial generalized linear models implemented in the R package DESeq2[13] were used including age (scaled and centred) and sex as covariates in the model. The *P*-values resulting from Wald tests were corrected for false discovery rate (FDR) according to Benjamini and Hochberg. The miRNAs with FDR < 0.05 and absolute value of $\log_2$FC > 1 were considered to be significantly differentially expressed. A multidimensional scaling (MDS) analysis using Euclidean distance was performed on variance stabilizing transformation (VST) normalized miRNA count data. Additionally, Spearman’s rank correlation analysis was performed between sex- and age-adjusted normalized miRNA read counts and endoscopic Mayo subscore. FDR < 0.05 was considered statistically significant. Removal of sex and age effects from normalized data was performed using removeBatchEffect function from the limma R package[14]. Statistical analyses

For Review Only

and data processing were performed using R version 4.0.3[15]. Visualization of graphs was performed using the ggplot2 package[16].

Gene set enrichment analysis

In order to obtain putative biological functions of differentially expressed miRNAs, gene set enrichment analysis (GSEA) was performed using Reactome pathways[17] and GO categories[18]. More specifically, luciferase assay-validated miRNA-target interactions (MTIs) were obtained from miRecords[19], miRTarBase[20] and TarBase[21] using the multiMiR package[22]. The retrieved MTIs were then submitted to a hypergeometric test implemented in the enrichPathway (from the ReactomePA package[23]) and enrichGO (from the clusterProfiler package[24]) functions using genes that are expressed in colon crypt-bottom ($CD44^+$) and crypt-top ($CD66a^+$) cells as a background reference (defined as universe). The universe genes were obtained from single-cell RNA-seq data of the human colon, available in GEO database with accession number GSE116222[25]. The pathways with FDR < 0.05 were considered to be significantly deregulated.

miRNA co-expression analysis

Samples of study group II were used for weighted gene co-expression network analysis (WGCNA) aiming to identify modules of co-expressed miRNAs using CEMiTool package[26] (version 1.22.0) for R. Normalized (variance stabilizing transformation) miRNA count table was used to generate the co-expression modules. Filtering based on variance was applied on gene expression table prior to identification of miRNA co-expression modules. Minimal number of miRNAs per submodule as well as minimum size of gene sets for GSEA analysis was set to five, while *P*-value threshold for filtering was set to 0.1. Further, the eigengene value of the co-expression module identified in colonic epithelial cells was also calculated in colon tissue data using the expression table of co-expressed miRNAs and WGCNA package[27] (version 1.72-1) for R. Next, Spearman's rank correlation coefficients were calculated between module eigengene values and endoscopic Mayo subscore in both colonic epithelial cell populations

For Review Only

as well as in colon tissue. FDR < 0.05 was considered statistically significant. Finally, to assess the performance of the identified module eigengene value for distinguishing between the active and quiescent UC in both colon tissue and distinct colonic epithelial cell populations, analysis of Area Under the Receiver Operating Characteristic curve (AUC-ROC) was applied using pROC package[28] (version 1.18.4) for R.

For Review Only

Results

Differentially expressed miRNAs in active and quiescent UC tissues are involved in regulation of inflammation-related pathways

To identify differentially expressed miRNAs and their putative regulatory processes during chronic colon inflammation, small RNA-seq was performed on inflamed (active) and non-inflamed (quiescent) colonic mucosal biopsies of UC patients and healthy controls (HC) (**Figure 1a**).



Figure 1: Small RNA-seq defines differentially expressed miRNAs involved in inflammation-associated pathways in active and quiescent UC tissues. (a) Design of the initial study phase. **(b)**

MDS plot showing the similarity structure of the miRNA transcriptomes in active (aUC) (n=23), quiescent UC (qUC) (n=20) and HC (n=30) tissue samples based on normalized expression values. The dots represent samples coloured by group. The centroid of ellipses corresponds to the group mean; the shapes are defined by covariance within a given group. **(c)** Differentially expressed miRNAs in active (aUC) (n=23) and quiescent UC (qUC) (n=20). The red colour represents significantly (FDR < 0.05) differentially expressed miRNAs with an absolute value of $\log_2$FC > 1, while the blue colour represents non-differentially expressed miRNAs. **(d)** Top 10 overrepresented pathways in active (aUC) (n=23) and quiescent UC (qUC) (n=20) tissues identified by miRNA set enrichment analysis. Dot size represents the number of miRNA-target gene count in the significantly enriched (FDR < 0.05) Reactome pathways.

After count data normalization and quality control, 573 unique miRNAs were found to be expressed in colon tissue samples. The overall similarity structure (based on MDS analysis; see **Methods**) of colon miRNA transcriptomes revealed two clearly resolved clusters corresponding to active UC and HC tissues, while the third cluster corresponding to quiescent UC overlapped with both active UC and HC clusters, suggesting a shift of miRNA expression from healthy to inflammatory state (**Figure 1b**). To evaluate expression of specific miRNAs in active UC and quiescent UC, differential gene expression analysis was performed. As expected, the most profound miRNA deregulation was observed comparing active UC to HC or to quiescent UC (93 and 59 differentially expressed miRNAs [FDR < 0.05 and $|\log_2 FC| > 1$], respectively). Interestingly, although substantially lower than in active UC, a differential expression of miRNAs (n=32) was also observed in quiescent UC compared to HC (**Figure 1c**; **Supplementary Table S2**). Among the differentially expressed miRNAs, a considerable number (n=13) of molecules, including miR-106-5p, miR-125b-1-3p, miR-205-5p and miR-3182 were deregulated in both active and quiescent UC compared to HC. Contrarily, majority of miRNAs (n=80) including, miR-190a-5p, miR-3168, miR-378i, and miR-223-3p were deregulated only in active UC, while miRNAs (n=19) such as miR-331-3p, miR-409-5p, miR-4497 and miR-629-5p - only in the quiescent UC. In addition, the gradual decrease in miR-1-3p expression was found in all pairwise comparisons (active UC vs quiescent UC, active UC

For Review Only

vs HC and quiescent UC vs HC; **Supplementary Table S2**). Thus, besides shared miRNA deregulation patterns, the data also suggests unique and perhaps non-overlapping functions of some miRNAs in active and quiescent UC.

To further determine the biological function of differentially expressed miRNAs in UC pathogenesis, GSEA was performed for each pairwise comparison (active UC vs HC; quiescent UC vs HC; active vs quiescent UC) using validated target genes of significantly deregulated miRNAs and Reactome pathways (**Supplementary Table S3**). Intriguingly, both active UC and quiescent UC compared to HC had over-represented interleukin signalling-related pathways among the top significant ones, such as "*Signaling by Interleukins*" [R-HSA-449147] and "*Interleukin-4 and Interleukin-13 signaling*" [R-HSA-6785807] (**Figure 1d**). To further evaluate this finding, the expression patterns of two main cytokines IL-4 and IL-13 in colon tissue was analysed. The gradual increase in *IL-13* expression was observed between UC patients and HC individuals (2.19-fold [P = 0.031] increase in quiescent UC vs. HC, 2.91-fold [P = 0.0007] increase in active UC vs. quiescent UC, 6.38-fold [$P = 2 \times 10^{-10}$] increase in active UC vs. HC), whereas the expression of *IL-4* did not differ between the groups (**Supplementary Figure S3**). *In silico* (enrichment in the interleukin signalling-related target genes), as well as *in vivo* (interleukin expression in colon tissue) analysis confirmed that these pathways remain dysregulated in the colonic mucosa during the disease course of UC.

Taken together, differential miRNA expression and GSEA analyses in UC tissues suggest that dysregulated miRNAs are likely involved in regulation of inflammation-related pathways and that some of the pathways, i.e., interleukin-4 and interleukin-13 signalling, remarkably, remain dysregulated in the colonic mucosa of quiescent UC.

Sequencing of FACS-sorted colonic epithelial cells shows cell type-specific miRNA expression during colonic inflammation in UC

The role of interleukin-4 and interleukin-13 in mediating permeability of epithelial barrier as well as its relation to the pathogenesis of UC has been previously described[29]. Given that this pathway is deregulated in active UC tissues and remains deregulated in quiescent UC (based

For Review Only

on miRNA and mRNA expression levels in our study) and the fact that it affects epithelial barrier function, we further decided to focus on miRNA expression in crypt-bottom (CD44⁺) and crypt-top (CD66a⁺) colonic epithelial cells.

FACS was applied to select and enrich for crypt-bottom and crypt-top colonic epithelial cells from active and quiescent UC patients and healthy controls using CD44⁺ and CD66a⁺ surface markers (**Supplementary Figure S1**). Analysis of FACS enriched cell populations over single-cell analysis was chosen due to limitations of single-cell transcriptome sequencing technology, which is not yet compatible with small RNA-seq. Interestingly, analysis of flow cytometry showed significant (FDR < 0.05) increase in crypt-bottom (CD44⁺) cells in active UC compared to HC (**Figure 2a**), suggesting a potential inflammation-stimulated cell proliferation[30,31].



Figure 2: Sequencing data reveals differentially expressed miRNAs in colonic epithelial cells of patients with active and quiescent UC. (a) FACS of colonic epithelial cells and distribution of crypt-top CD44⁻CD66⁺ and crypt-bottom CD44⁺CD66⁻ epithelial cell types in inflammatory (aUC) (n=16) and non-inflammatory (qUC and HC) (n=15 and 17) colon tissues. Each dot represents a sample from the patients of the second study group. Mean ±SD of each group is represented by vertical lines. To compare the groups a nonparametric Mann–Whitney U test was performed, p* < 0.05. **(b)** MDS plot

showing the similarity structure of the miRNA transcriptomes in crypt-top (CD66a$^+$) and crypt-bottom (CD44$^+$) colonic epithelial cell populations in active (aUC) (n=16), quiescent UC (qUC) (n=15), and in HC (n=17) based on normalized expression values. The dots represent samples shaped by cell population. Dot colours represent condition. The centroid of ellipses corresponds to the condition group mean; the shapes are defined by covariance within the group. **(c, d)** Volcano plots of differentially expressed miRNAs in crypt-top (CD66a$^+$) and crypt-bottom (CD44$^+$) colonic epithelial cell populations in active (aUC) (n=16), quiescent UC (qUC) (n=15), and HC (n=17). Colours indicate significantly (FDR < 0.05) differentially expressed miRNAs with an absolute value of $\log_2$FC > 1 between compared groups. **(e-g)** Venn diagrams representing the numbers of commonly and uniquely differentially expressed miRNAs in **(e)** crypt-bottom (CD44$^+$) and **(f)** crypt-top (CD66a$^+$) epithelial cell populations in different UC activity, and **(g)** between crypt-bottom and crypt-top cells in the same condition.

Using sequencing, a total number of 436 unique miRNAs were found to be expressed in crypt-bottom (CD44$^+$) and crypt-top (CD66a$^+$) epithelial cells. Although miRNA transcriptomes of these colonic epithelial cell populations were strongly overlapping (**Figure 2b**), significant changes in expression profiles were observed within and between cell populations in different stages of the disease (**Figure 2c and 2d**; **Supplementary Table S4**). Initially, pairwise comparisons were performed in the same epithelial cell population to identify UC inflammation-associated miRNAs. As in the tissue data, the number of differentially expressed miRNAs (FDR < 0.05 and $|\log_2\text{FC}| > 1$) in both colonic epithelial cell populations were gradually increased depending on the disease activity, i.e., the highest number of differentially expressed miRNAs were observed in active UC compared to HC and to quiescent UC (**Figure 2c**). Among deregulated molecules, none of miRNAs were commonly differentially expressed across all three comparisons (active UC vs HC; quiescent UC vs HC; active UC vs quiescent UC) in both crypt-bottom (CD44$^+$) and crypt-top (CD66a$^+$) colonic epithelial cells. However, six miRNAs (miR-15b-5p, miR-222-3p, miR-223-3p, miR-194-3p, miR-3195 and miR-574-3p) were identified as commonly differentially expressed in crypt-bottom (CD44$^+$) cells and eight miRNAs (let-7c-5p, miR-106b-3p, miR-125b-5p, miR-1-3p, miR-1290, miR-194-3p, miR-335-5p, miR-552-3p) - in crypt-top (CD66a$^+$) cells in the active and quiescent UC when compared

For Review Only

to HC (**Figure 2e and 2f**). Further, the response of distinct epithelial cell populations to inflammation was determined by performing pairwise comparisons with the separate populations of colonic epithelial cells. Twenty-four miRNAs (such as miR-501-3p, miR-1-3p, miR-296-5p, and miR-122-5p) were identified to be differentially expressed in active UC, nine miRNAs (such as miR-1290, miR-3168, and miR-660-5p) in quiescent UC, and twenty-two miRNAs (such as miR-598-3p, miR-340-3p, and miR-223-3p) - HC when compared crypt-bottom (CD44$^+$) and crypt-top (CD66a$^+$) colonic epithelial cells (**Figure 2d, Supplementary Table S4**). Notably, the vast majority of identified differentially expressed miRNAs between distinct epithelial cell types in different stages of inflammation were found to be uniquely dysregulated. Only two commonly differentially expressed miRNAs were observed between two comparison groups (miR-106b-3p and miR-1290 in active UC CD44$^+$ vs CD66a$^+$ and quiescent UC CD44$^+$ vs CD66a$^+$; miR-296-5p and miR-432-5p active UC CD44$^+$ vs CD66a$^+$ and HC CD44$^+$ vs CD66a$^+$) (**Figure 2g**). This suggests that even at different disease activity stages there are cell population-specific responses, in terms of miRNA expression.

Aberrantly expressed miRNAs in crypt-top (CD66a$^+$) and crypt-bottom (CD44$^+$) colonic epithelial cells are involved in regulation of inflammation and intestinal epithelial barrier function-related processes

To further evaluate the potential functional role of differentially expressed miRNAs in crypt-bottom (CD44$^+$) and crypt-top (CD66a$^+$) colonic epithelial cells in UC pathogenesis, GSEA was performed on validated target genes of differentially expressed miRNAs (**Supplementary Table S5**). Similarly, to the colonic tissue data (**Figure 1b**), majority of the overrepresented pathways in both colonic epithelial cell populations in both stages of disease activity overlapped and included signalling pathways such as "*Signaling by Interleukins*" (R-HSA-449147), "*Interleukin-4 and Interleukin-13 signaling*" [R-HSA-6785807], "*Signaling by Receptor Tyrosine Kinases*" [R-HSA-9006934] (**Figure 3a**). This supports that observations in the colon biopsy samples were mainly driven by colonic epithelial cells. Notably, not all comparison groups in crypt-bottom (CD44$^+$) cells showed uniform results. The most

For Review Only

overrepresented Reactome pathways in crypt-bottom (CD44$^+$) cells of quiescent UC patient group differed from those in active UC groups and exclusively included *"Signaling by Nuclear Receptors"* (R-HSA-9006931), *"Extra-nuclear estrogen signaling"* [R-HSA-9009391] pathways which were shown to regulate the permeability of intestinal epithelium and thus be associated with pathogenesis of inflammatory bowel disease[32] (**Figure 3a**). Finally, to assess which biological processes (from Gene Ontology terms) are overrepresented in crypt-bottom (CD44$^+$) compared to crypt-top (CD66a$^+$) cells, GSEA of deregulated miRNAs in active UC, quiescent UC, and HC groups was performed. The results revealed that overrepresented processes between the cell populations were mainly related to cell differentiation and motility in both active UC and HC (**Figure 3b**), suggesting that in inflamed and healthy colon mucosa these pathways are differentially regulated between the cell types. In addition, significant enrichment between crypt-bottom (CD44$^+$) and crypt-top (CD66a$^+$) cells in "*epithelium migration"* [GO:0090132] and *"epithelial cell migration"* [GO:0010631] were uniquely identified only in active UC among the most overrepresented biological processes (**Figure 3b**). Target genes of differentially expressed miRNAs between cell populations in the UC remission group were mainly related to cell migration and were least different between those populations (**Figure 3b**).

For Review Only



Figure 3: Aberrantly expressed miRNAs of crypt-top (CD66a$^+$) and crypt-bottom (CD44$^+$) colonic epithelial cells are involved in UC-related processes. Top 10 overrepresented pathways within **(a)** and between **(b)** crypt-top (CD66a$^+$) and crypt-bottom (CD44$^+$) colonic epithelial cell populations during active (aUC) (n=16), quiescent UC (qUC) (n=15) and in controls (HC) (n=17) identified by miRNA-target gene set enrichment analysis. Dot size represents the number of miRNA gene-target count in the significantly enriched (FDR < 0.05) Reactome pathways **(a)** and GO categories **(b)**.

To summarize, despite the significant overlap of aberrantly expressed miRNAs of both colonic epithelial cell populations in regulatory signalling pathways, GSEA results reveal unique

involvement of miRNAs in UC-, inflammation- and intestinal barrier integrity-related processes in different stages of disease activity and/or cell population.

miRNAs in crypt-top (CD66a⁺) and crypt-bottom (CD44⁺) colonic epithelial cells exhibit co-expression pattern which is related to UC activity

First, to unveil the relation between individual miRNA expression levels and endoscopic Mayo subscore in crypt-top (CD66a⁺) and crypt-bottom (CD44⁺) colonic epithelial cells, Spearman correlation analysis was applied. In crypt-bottom (CD44⁺) and crypt-top (CD66a⁺) colonic epithelial cells, a number (n=34 and n=23, respectively) moderate positive (0.4 < rho < 0.7; FDR < 0.05) and a few (n=6 and n=7, respectively) moderate negative (-0.7 < rho < -0.4; FDR < 0.05) correlations were observed among the normalized miRNA expression levels and endoscopic Mayo subscore (**Supplementary Figure S5; Supplementary Table S6; Supplementary Table S7)**. Noteworthy, analysis resulted not only in a substantial overlapping in disease activity-associated miRNAs between both colonic epithelial cell populations (29 common moderately correlating miRNAs), but also revealed few cell population-unique correlations.

Subsequently, we decided to perform more complex analysis and evaluate if certain colonic epithelial cell miRNAs of both populations are co-expressed together. First, WGCNA performed on all miRNAs of colonic epithelial cell populations uncovered the miRNA co-expression network (**Figure 4a**) and identified two co-expression modules (M1 and M2). Module M1 was comprised of 13 miRNAs (miR-10b-5p, miR-182-5p, miR-146a-5p, miR-196b-5p, miR-222-3p, miR-27a-3p, miR-221-3p, miR-194-3p, miR-183-5p, miR-223-3p, miR-574-5p, miR-135b-5p, miR-31-5p); while module M2 consisted of 11 miRNAs such as let-7b-5p, miR-143-3p, miR-125a-5p, miR-15b-5p, let-7e-5p, miR-5100, miR-181b-5p, miR-1-3p, miR-125b-5p, miR-100-5p, miR-195-5p. Module enrichment analysis based on the evaluation of normalized enrichment score (NES) (**Figure 4b**) further revealed that module M1 was significantly enriched in both crypt-top (CD66a⁺) and crypt-bottom (CD44⁺) epithelial cells of patients with active UC (NES = 1.71 [$P_{adj.} = 9.7 \times 10^{-3}$] and 1.67 [$P_{adj.} = 2.9 \times 10^{-2}$], respectively),

For Review Only

while in both cell populations of control group individuals it was decreased (NES = -1.79 [$P_{adj.}$ = 7.7 × 10^{-3}] and -1.74 [$P_{adj.}$ = 5.0 × 10^{-2}], respectively). Interestingly, the enrichment values for the module M2 were opposite to what was observed for M1, meaning the normalized expression of module M2 in both crypt-top (CD66a^{+}) and crypt-bottom (CD44^{+}) epithelial cell populations of patients with active UC was significantly decreased (NES = -1.84 [$P_{adj.}$ = 9.7 × 10^{-3}] and -1.80 [$P_{adj.}$ = 2.9 × 10^{-2}], respectively), while it was significantly enriched exclusively in crypt-bottom (CD44^{+}) cells of patients with quiescent UC (NES = 2.08 [$P_{adj.}$ = 3.3 × 10^{-4}]). Further, we focused on potentially pro-inflammatory module M1 and explored whether the expression of this module in each of the studied epithelial cell populations is associated with clinical characteristics of UC. Therefore, Spearman correlation analysis was applied to check for the association between endoscopic Mayo subscore and module M1 eigengene value (summarized module expression value). Analysis resulted in the significant moderate positive correlation in both crypt-top (CD66a^{+}) and crypt-bottom (CD44^{+}) cells (rho = 0.68 [P = 1.08 × 10^{-7}] and 0.60 [P = 1.07 × 10^{-5}], respectively) (**Figure 4c**). Next, AUC-ROC analysis was employed to assess the performance of the module M1 eigengene value at distinguishing between the active and quiescent UC in each of the studied colonic epithelial cell populations. In the crypt-bottom (CD44^{+}) cells, analysis resulted in the AUC value of 80.0% (confidence interval (CI): 63.6% - 96.4%), while in the crypt-top (CD66a^{+}) cells M1 eigengene expression value demonstrated even better performance and showed the AUC value of 87.9% (CI: 74.0% - 100.0%) when separating quiescent *vs.* active UC (**Figure 4d**). To evaluate the concordance of the epithelial cell population-derived data with the situation in the colon tissue, we calculated module M1 eigengene values in the tissue and performed analogous analysis as in the crypt-top and crypt-bottom cell populations. Briefly, analysis provided almost identical results to those observed in colonic epithelial cell populations with higher similarity to crypt-top cells. More precisely, in colon tissue, module M1 eigenvalue showed strong positive correlation with endoscopic Mayo subscore (rho = 0.703 [P = 1.22 × 10^{-11}]) and produced AUC value of 85.0% (CI: 72.2% - 97.1%).

For Review Only

Generally, the results uncovered potential UC endoscopic activity-related miRNA co-expression patterns that are not only characteristic for both crypt-top and crypt-bottom colonic epithelial cell populations, but also reflect the overall situation in the more heterogenous colon tissue.



Figure 4: WGCNA in colonic epithelial cell populations reveals miRNA co-expression module which reflects endoscopic activity of UC. (a) Network displaying identified co-expression modules (M1 and M2) in crypt-top (CD66a) and crypt-bottom (CD44) colonic epithelial cells of patients with active (aUC) (n=16), quiescent UC (qUC) (n=15) and control individuals (n=17). The color and size of the node represents distinct modules and strength of connectivity, respectively. **(b)** The dot plot showing normalized enrichment score (NES) of the modules M1 and M2 in crypt-top (CD66a) and crypt-bottom (CD44) colonic epithelial cells of patients with active, quiescent UC and control individuals. The color and size of the dot represents the value and absolute value of NES, respectively. The box marks significant value ($p_{adj,} < 0.05$). Plots **(c)** and **(e)** show the correlation between module M1 eigengene

value and Mayo endoscopic activity in crypt-bottom (CD44) and crypt-top (CD66a) colonic epithelial cells as well as colon tissue, respectively. rho – Spearman correlation coefficient. Each dot represents different sample. Plots **(d)** and **(f)** show the AUC-ROC curves reflecting the performance of M1 module eigengene value at distinguishing between active (aUC) and quiescent UC (qUC) in crypt-bottom (CD44) and crypt-top (CD66a) colonic epithelial cells as well as in colon tissue, respectively.

For Review Only

Discussion

Although UC is a well-studied complex disease and huge efforts have been made to explore its molecular mechanisms, the disease pathogenesis still remains largely unclear[33]. Especially, there is a substantial knowledge gap about expression patterns of regulatory non-coding miRNA in UC in a cell type-specific context. Thus, here we provide an overview of the miRNA expression in the unsorted whole colonic mucosa samples of UC patients and present detailed colonic epithelial cell population-specific miRNA expression profiles from active and quiescent UC patients and describe differences in miRNA expression patterns between two distinct - crypt-bottom ($CD44^+$) and crypt-top ($CD66a^+$) - cell populations. Furthermore, we describe putative biological pathways in which deregulated miRNAs of UC colonic epithelial cell populations might be involved, identify potential inflammatory miRNA co-expression module, determine its associations with endoscopic disease activity and evaluate the performance in distinguishing between active and quiescent stages of UC.

Most importantly, we determined distinct responses in miRNA expression of different colonic epithelial cell populations during UC. Our findings showed that in colon crypt-bottom ($CD44^+$) cells (compared to crypt-top [$CD66a^+$] cells) inflammation promoted/suppressed the expression of several miRNAs possibly involved in cell proliferation, differentiation and/or permeability of intestinal barrier. For example, let-7c-5p showed considerable down-regulation and miR-501-3p up-regulation in crypt-bottom ($CD44^+$) cells during active UC. It has previously been shown that overexpression of let-7c-5p as well as inhibition of miR-501-3p can reduce the proliferation of colorectal cancer cells[34,35]. Thus, deregulation of these miRNAs might be related to the relative increase of the crypt-bottom ($CD44^+$) cells in active UC when compared to controls, as it has been shown in our flow cytometry experiment. On the other hand, we observed increased expression of miR-1-3p and decreased expression of miR-125b-5p in crypt-bottom compared to crypt-top cells only during active UC. Both miRNAs were shown to be involved in barrier function dysregulation, where decrease of miR-125b-5p[36] and increase of miR-1-3p[37] contribute to disruption of epithelial barrier in colon tissue. This would suggest

For Review Only

that epithelial barrier is already impaired in crypt-bottom epithelial cells during active UC; however, it remains unclear if this is a UC specific event or rather a normal cell response to inflammation in the gut.

Furthermore, our analysis showed that not only certain individual miRNAs are associated with the endoscopic Mayo subscore, but they also form an inflammation-related co-expression network, which directly correlates with clinical disease activity. Of two identified miRNA co-expression modules in both crypt-bottom (CD44$^+$) and/or crypt-top (CD66a$^+$) cells, module M1 was significantly enriched in both epithelial cell populations of active UC patients and was comprised of such miRNAs as miR-31-5p, miR-135b-5p, miR-27a-3p, miR-222-3p, miR-223-3p, etc. In the literature, these small non-coding RNAs are also reported to be upregulated in inflamed, non-inflamed and/or pre-cancerous colon tissues as well as in faeces (specifically, miR-223-3p) of UC patients[38–43] and are involved in the regulation of inflammatory response (e.g. miR-222-3p targets *SOCS1* and activates STAT3 signalling)[44–46]. Additionally, we observed that all miRNAs belonging to module M1 were involved in Reactome pathways related to interleukin signalling by targeting various validated genes (such as *FOXO3*, *IGF1R, ICAM1, STAT6, STAT1, STAT5A, CCND1*, etc.). Interestingly, when comparing crypt-top and crypt-bottom cell populations-derived module M1 performance and association results to colon tissue, both the correlation coefficient and AUC values in tissue were more like those observed in crypt-top (CD66a$^+$) cells. This may be at least partially explained by the cellular composition of the colon mucosa, the most abundant cell type in mucosal layer being absorptive colonocytes[47]. Of note, even though the second identified miRNA co-expression module M2 did not show meaningful associations with clinical characteristics of UC, its exclusive enrichment in crypt-bottom (CD44$^+$) colonic epithelial cells of patients with quiescent disease provides novel insights in regulatory mechanisms during UC. For example, among module M2 miRNAs we identified let-7e-5p, the individual expression of which also negatively correlated with the endoscopic Mayo subscore exclusively in crypt-bottom (CD44$^+$) colonic epithelial cells. Additionally, in the intestinal epithelium let-7 family member let-7b appears to be among the highest-expressed miRNAs in let-7 group/family (**Supplementary Figure S4**). It has

For Review Only

previously been shown that expression of let-7 miRNAs (especially let-7e) is increased and affects maintenance of cell differentiation[48]. Altogether, these observations suggest the relevance of let-7 miRNAs during intestinal inflammation via maintenance of stemness of crypt-bottom (CD44$^+$) cells and thereby explain their expression correlation with disease activity, exclusively in undifferentiated colonic epithelial cells.

Finally, we described potential involvement of differentially expressed miRNAs in regulatory biological pathways. Our initial small RNA-seq of colonic mucosa biopsies from active and quiescent UC compared to healthy controls, at first, revealed multiple deregulated miRNAs, which were significantly enriched in inflammation- and intestinal epithelial barrier function-related biological pathways. Interestingly, miRNAs enriched in interleukin biological pathways, such as interleukin-4 and interleukin-13 signalling, were deregulated not only in active, but also in quiescent UC, suggesting lasting derangement of this pathway in mucosa of UC. The interleukin-4 and interleukin-13 pathway is known to differentially regulate epithelial chloride secretion and cause epithelial barrier dysfunction[49]. It has been shown that large amounts of interleukin-13 are produced in colon mucosa of UC patients and thereby impair epithelial barrier function by affecting epithelial apoptosis, tight junctions, and restitution velocity[29,50]. We also confirmed the increased expression of interleukin-13 gene during the course of UC when analysing active and quiescent UC patient colon tissue samples. Contrarily, some studies report decreased mucosal amounts of interleukin-13 in active UC[51]. Nevertheless, the attempts are still being made to adapt the inhibition of interleukin-13-based treatment to induce UC remission (e.g., clinical trials of anti-interleukin-13 monoclonal antibodies (tralokinumab and anrukinzumab)[52] and preclinical studies of anti-interleukin-Rα2[53]). Our findings on differentially expressed miRNA involvement in interleukin-4 and interleukin-13 regulation even in quiescent UC as well as controversial data in the literature led us to further focus on miRNA expression analysis in less differentiated crypt-bottom (CD44$^+$) and fully differentiated absorptive crypt-top (CD66a$^+$) colonic epithelial cells, which are responsible for intestinal barrier integrity and permeability[2]. Similarly to the results in colonic biopsies, both crypt-bottom (CD44$^+$) and crypt-top (CD66a$^+$) epithelial cell populations showed deregulation in miRNAs

For Review Only

during UC, the targets of which were significantly enriched in the interleukin-4 and interleukin-13 signalling pathway. Since interleukin-4 and interleukin-13 cytokines are predominantly produced by immune cells[54], the expected regulatory action of deregulated miRNAs in the colonic epithelial cells would be downstream targets of the pathway, such as *STAT3*, *FOXO3*, *SOCS1*, etc. During active UC in both crypt-bottom (CD44$^+$) and crypt-top (CD66a$^+$) cells, we found miR-221-3p, miR-182-6p, miR-222-3p and miR-31-5p to be up-regulated, which are known to target *FOXO3* gene[22]. The up-regulation of the aforementioned miRNAs, theoretically, would lead to decreased expression of the *FOXO3* gene, which was already observed in colonic mucosa of UC patients[55]. This in turn, may lead to more severe colonic inflammation during UC[56]. Additionally, both crypt-bottom (CD44$^+$) and crypt-top (CD66a$^+$) cells of patients with active UC had increased expression of hsa-miR-221-3p and hsa-miR-21-5p, that target *SOCS1* gene[22]. SOCS1 is an important regulator of interleukin-4 signalling, and its forced expression was shown to inhibit interleukin-13 signalling in epithelial cells[57]. In addition to involvement in interleukin signalling pathways, we also detected unique intestinal epithelial barrier function-related processes regulated by disease stage and/or cell population-specific miRNAs. For example, differentially expressed miRNAs, such as miR-222-3p, miR-223-3p, miR-15b-5p, in crypt-bottom (CD44$^+$) colonic epithelial cells of quiescent UC could potentially regulate nuclear receptors and extra-nuclear estrogen signalling pathways. These findings fall in accordance with other studies demonstrating the importance of impairment of signal transduction via nuclear receptors in inflammatory bowel disease, as nuclear receptors regulate essential aspects of intestinal barrier functions such as mucus secretion, expression of tight junction proteins and others[32]. Moreover, we observed a few aberrantly expressed miRNAs between crypt-bottom (CD44$^+$) and crypt-top (CD66a$^+$) cells in active UC, that possibly exert their biological function through regulation of epithelial cell migration, which is known to happen along the crypt-villus axis[58] and is increased during IBD[59]. Noteworthy, the GSEA results should be treated with caution, since the selection of miRNA targets significantly affects the results[60]. However, currently, there are no methods to solve this issue, since miRNA

For Review Only

target prediction as well as its dosage to affect target expression are still rather unsolved problems in the field.

In summary, our study determined crypt-bottom ($CD44^+$) and crypt-top ($CD66a^+$) colonic epithelial cell-specific miRNA deregulation in UC in cell type- and disease stage-dependent manner. We also revealed cell population-specific miRNA expression patterns and networks as well as their associations with clinical disease activity. Furthermore, we unveiled the potential functional role of differentially expressed miRNAs and observed their possible involvement in biological pathways associated with maintenance of intestinal barrier function in active as well as quiescent UC, in both epithelial cell populations. Together, these observations not only highlight regulatory importance of miRNAs in distinct colonic epithelial cell populations during pathogenesis of UC, but also provide potential miRNA candidates for the development of new treatment strategies to maintain the remission of mucosal inflammation.

For Review Only

Funding

This work was supported by the Research Council of Lithuania and European Crohn's and Colitis Organisation (grant numbers S-MIP-20-56 and ECCO Grant 2016, respectively).

Conflict of Interest

The authors declare no conflict of interest.

Data Availability

The small RNA-seq data underlying this article are available in Gene Expression Omnibus (GEO) Database and can be accessed with accession numbers GSE185101 (reviewer token: **gxytcgywnvejvit**) and GSE185102 (reviewer token: **ijydywoajxyvxmr**).

Author contributions

JS, SJ, and JK participated in the concept and design of the study. JK, LVJ, VK, UK, GV and GK participated in patient recruitment and material collection and sample processing. RR, ID, and AZ were responsible for fluorescence-activated cell sorting. AF and SS provided infrastructure for small RNA library preparation and sequencing. RI and SJ were responsible for bioinformatics, statistical analysis, data interpretation and writing the first draft of the manuscript. All authors were members of the writing group and participated in the drafting revision of the manuscript.

For Review Only

References

1. Antoni L., Nuding S., Wehkamp J., Stange EF. Intestinal barrier in inflammatory bowel disease. *World J Gastroenterol* 2014;**20**(5):1165–79.
2. Nyström EEL., Martinez-Abad B., Arike L., Birchenough GMH., Nonnecke EB., Castillo PA., et al. An intercrypt subpopulation of goblet cells is essential for colonic mucus barrier function. *Science* 2021;**372**(6539).
3. Cichon C., Sabharwal H., Rüter C., Schmidt MA. MicroRNAs regulate tight junction proteins and modulate epithelial/endothelial barrier functions. *Tissue Barriers* 2014;**2**(4).
4. Ye D., Guo S., Alsadi R., Ma TY. MicroRNA regulation of intestinal epithelial tight junction permeability. *Gastroenterology* 2011;**141**(4):1323–33.
5. Schroeder KW., Tremaine WJ., Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. *N Engl J Med* 1987;**317**(26):1625–9.
6. Magro F., Gionchetti P., Eliakim R., Ardizzone S., Armuzzi A., Barreiro-de Acosta M., et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. *J Crohns Colitis* 2017;**11**(6):649–70.
7. Dalerba P., Kalisky T., Sahoo D., Rajendran PS., Rothenberg ME., Leyrat AA., et al. Single-cell dissection of transcriptional heterogeneity in human colon tumors. *Nat Biotechnol* 2011;**29**(12):1120–7.
8. Ewels PA., Peltzer A., Fillinger S., Patel H., Alneberg J., Wilm A., et al. The nf-core framework for community-curated bioinformatics pipelines. *Nat Biotechnol* 2020:276–8.

For Review Only

9. Pantano L., Estivill X., Martí E. A non-biased framework for the annotation and classification of the non-miRNA small RNA transcriptome. *Bioinformatics* 2011;**27**(22):3202–3.

10. Langmead B., Trapnell C., Pop M., Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol* 2009;**10**(3):1–10.

11. Kozomara A., Birgaoanu M., Griffiths-Jones S. miRBase: from microRNA sequences to function. *Nucleic Acids Res* 2019;**47**(D1):D155–62.

12. Desvignes T., Loher P., Eilbeck K., Ma J., Urgese G., Fromm B., et al. Unification of miRNA and isomiR research: the mirGFF3 format and the mirtop API. *Bioinformatics* 2020;**36**(3):698–703.

13. Love MI., Huber W., Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 2014;**15**(12):1–21.

14. Ritchie ME., Phipson B., Wu D., Hu Y., Law CW., Shi W., et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* 2015;**43**(7):e47.

15. R Foundation for Statistical Computing. R Core Team. R: A language and environment for statistical computing 2021:https://www.r-project.org/.

16. Wickham H. ggplot2: Elegant Graphics for Data Analysis 2016.

17. Jassal B., Matthews L., Viteri G., Gong C., Lorente P., Fabregat A., et al. The reactome pathway knowledgebase. *Nucleic Acids Res* 2020;**48**(D1):D498–503.

18. Thomas PD., Ebert D., Muruganujan A., Mushayahama T., Albou LP., Mi H. PANTHER: Making genome-scale phylogenetics accessible to all. *Protein Sci* 2022;**31**(1):8–22.

19. Xiao F., Zuo Z., Cai G., Kang S., Gao X., Li T. miRecords: an integrated resource

For Review Only

for microRNA-target interactions. *Nucleic Acids Res* 2009;**37**(Database issue):D105–10.

20. Hsu S-D., Lin F-M., Wu W-Y., Liang C., Huang W-C., Chan W-L., et al. miRTarBase: a database curates experimentally validated microRNA-target interactions. *Nucleic Acids Res* 2011;**39**(Database issue):D163–9.

21. Karagkouni D., Paraskevopoulou MD., Chatzopoulos S., Vlachos IS., Tastsoglou S., Kanellos I., et al. DIANA-TarBase v8: a decade-long collection of experimentally supported miRNA-gene interactions. *Nucleic Acids Res* 2018;**46**(D1):D239–45.

22. Ru Y., Kechris KJ., Tabakoff B., Hoffman P., Radcliffe RA., Bowler R., et al. The multiMiR R package and database: integration of microRNA-target interactions along with their disease and drug associations. *Nucleic Acids Res* 2014;**42**(17):e133.

23. Yu G., He Q-Y. ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization. *Mol Biosyst* 2016;**12**(2):477–9.

24. Wu T., Hu E., Xu S., Chen M., Guo P., Dai Z., et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. *Innov* 2021;**2**(3).

25. Parikh K., Antanaviciute A., Fawkner-Corbett D., Jagielowicz M., Aulicino A., Lagerholm C., et al. Colonic epithelial cell diversity in health and inflammatory bowel disease. *Nature* 2019;**567**(7746):49–55.

26. Russo PST., Ferreira GR., Cardozo LE., Bürger MC., Arias-Carrasco R., Maruyama SR., et al. CEMiTool: a Bioconductor package for performing comprehensive modular co-expression analyses. *BMC Bioinformatics* 2018;**19**(1):56.

27. Langfelder P., Horvath S. WGCNA: an R package for weighted correlation

For Review Only

network analysis. *BMC Bioinformatics* 2008;**9**(1):559.

28. Robin X., Turck N., Hainard A., Tiberti N., Lisacek F., Sanchez J-C., et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. *BMC Bioinformatics* 2011;**12**(1):77.

29. Heller F., Florian P., Bojarski C., Richter J., Christ M., Hillenbrand B., et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. *Gastroenterology* 2005;**129**(2):550–64.

30. Yao D., Dong M., Dai C., Wu S. Inflammation and Inflammatory Cytokine Contribute to the Initiation and Development of Ulcerative Colitis and Its Associated Cancer. *Inflamm Bowel Dis* 2019;**25**(10):1595–602.

31. MacDonald TT. Epithelial proliferation in response to gastrointestinal inflammation. *Ann N Y Acad Sci* 1992;**664**:202–9.

32. Jacenik D., Zielińska M., Mokrowiecka A., Michlewska S., Małecka-Panas E., Kordek R., et al. G protein-coupled estrogen receptor mediates anti-inflammatory action in Crohn's disease. *Sci Rep* 2019;**9**(1):6749.

33. Ungaro R., Mehandru S., Allen PB., Peyrin-Biroulet L., Colombel J-F. Ulcerative colitis. *Lancet (London, England)* 2017;**389**(10080):1756–70.

34. Wu F., Xing T., Gao X., Liu F. miR-501-3p promotes colorectal cancer progression via activation of Wnt/β-catenin signaling. *Int J Oncol* 2019;**55**(3):671–83.

35. Akao Y., Nakagawa Y., Naoe T. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. *Biol Pharm Bull* 2006;**29**(5):903–6.

36. Martínez C., Rodiño-Janeiro BK., Lobo B., Stanifer ML., Klaus B., Granzow M., et al. miR-16 and miR-125b are involved in barrier function dysregulation

For Review Only

through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea. *Gut* 2017;**66**(9):1537–8.

37. Sun T-Y., Li Y-Q., Zhao F-Q., Sun H-M., Gao Y., Wu B., et al. MiR-1-3p and MiR-124-3p Synergistically Damage the Intestinal Barrier in the Ageing Colon. *J Crohns Colitis* 2022;**16**(4):656–67.

38. Tian Y., Xu J., Li Y., Zhao R., Du S., Lv C., et al. MicroRNA-31 Reduces Inflammatory Signaling and Promotes Regeneration in Colon Epithelium, and Delivery of Mimics in Microspheres Reduces Colitis in Mice. *Gastroenterology* 2019;**156**(8):2281-2296.e6.

39. Masi L., Capobianco I., Magrì C., Marafini I., Petito V., Scaldaferri F. MicroRNAs as Innovative Biomarkers for Inflammatory Bowel Disease and Prediction of Colorectal Cancer. *Int J Mol Sci* 2022.

40. Su C., Huang D-P., Liu J-W., Liu W-Y., Cao Y-O. miR-27a-3p regulates proliferation and apoptosis of colon cancer cells by potentially targeting BTG1. *Oncol Lett* 2019;**18**(3):2825–34.

41. Zhou J., Liu J., Gao Y., Shen L., Li S., Chen S. miRNA-Based Potential Biomarkers and New Molecular Insights in Ulcerative Colitis. *Front Pharmacol* 2021;**12**:707776.

42. Béres NJ., Szabó D., Kocsis D., Szűcs D., Kiss Z., Müller KE., et al. Role of Altered Expression of miR-146a, miR-155, and miR-122 in Pediatric Patients with Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2016;**22**(2):327–35.

43. Neudecker V., Haneklaus M., Jensen O., Khailova L., Masterson JC., Tye H., et al. Myeloid-derived miR-223 regulates intestinal inflammation via repression of the NLRP3 inflammasome. *J Exp Med* 2017;**214**(6):1737–52.

44. Gwiggner M., Martinez-Nunez RT., Whiteoak SR., Bondanese VP., Claridge A.,

For Review Only

Collins JE., et al. MicroRNA-31 and MicroRNA-155 Are Overexpressed in Ulcerative Colitis and Regulate IL-13 Signaling by Targeting Interleukin 13 Receptor α-1. *Genes (Basel)* 2018.

45. Xia F., Bo W., Ding J., Yu Y., Wang J. MiR-222-3p Aggravates the Inflammatory Response by Targeting SOCS1 to Activate STAT3 Signaling in Ulcerative Colitis. *Turkish J Gastroenterol Off J Turkish Soc Gastroenterol* 2022;**33**(11):934–44.

46. Wang H., Chao K., Ng SC., Bai AH., Yu Q., Yu J., et al. Pro-inflammatory miR-223 mediates the cross-talk between the IL23 pathway and the intestinal barrier in inflammatory bowel disease. *Genome Biol* 2016;**17**:58.

47. Allaire JM., Crowley SM., Law HT., Chang S-Y., Ko H-J., Vallance BA. The Intestinal Epithelium: Central Coordinator of Mucosal Immunity. *Trends Immunol* 2018;**39**(9):677–96.

48. Chirshev E., Oberg KC., Ioffe YJ., Unternaehrer JJ. Let-7 as biomarker, prognostic indicator, and therapy for precision medicine in cancer. *Clin Transl Med* 2019;**8**(1):24.

49. Saatian B., Rezaee F., Desando S., Emo J., Chapman T., Knowlden S., et al. Interleukin-4 and interleukin-13 cause barrier dysfunction in human airway epithelial cells. *Tissue Barriers* 2013;**1**(2):e24333.

50. Rosen MJ., Frey MR., Washington MK., Chaturvedi R., Kuhnhein LA., Matta P., et al. STAT6 activation in ulcerative colitis: a new target for prevention of IL-13-induced colon epithelial cell dysfunction. *Inflamm Bowel Dis* 2011;**17**(11):2224–34.

51. Kadivar K., Ruchelli ED., Markowitz JE., Defelice ML., Strogatz ML., Kanzaria MM., et al. Intestinal interleukin-13 in pediatric inflammatory bowel disease

For Review Only

patients. *Inflamm Bowel Dis* 2004;**10**(5):593–8.

52. Giuffrida P., Caprioli F., Facciotti F., Di Sabatino A. The role of interleukin-13 in chronic inflammatory intestinal disorders. *Autoimmun Rev* 2019;**18**(5):549–55.

53. Karmele EP., Pasricha TS., Ramalingam TR., Thompson RW., Gieseck RL 3rd., Knilans KJ., et al. Anti-IL-13Rα2 therapy promotes recovery in a murine model of inflammatory bowel disease. *Mucosal Immunol* 2019;**12**(5):1174–86.

54. Junttila IS. Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes. *Front Immunol* 2018;**9**:888.

55. Min M., Yang J., Yang Y-S., Liu Y., Liu L-M., Xu Y. Expression of Transcription Factor FOXO3a is Decreased in Patients with Ulcerative Colitis. *Chin Med J (Engl)* 2015;**128**(20):2759–63.

56. Snoeks L., Weber CR., Wasland K., Turner JR., Vainder C., Qi W., et al. Tumor suppressor FOXO3 participates in the regulation of intestinal inflammation. *Lab Invest* 2009;**89**(9):1053–62.

57. Doran E., Choy DF., Shikotra A., Butler CA., O'Rourke DM., Johnston JA., et al. Reduced epithelial suppressor of cytokine signalling 1 in severe eosinophilic asthma. *Eur Respir J* 2016;**48**(3):715–25.

58. Krndija D., El Marjou F., Guirao B., Richon S., Leroy O., Bellaiche Y., et al. Active cell migration is critical for steady-state epithelial turnover in the gut. *Science* 2019;**365**(6454):705–10.

59. Martini E., Krug SM., Siegmund B., Neurath MF., Becker C. Mend Your Fences: The Epithelial Barrier and its Relationship With Mucosal Immunity in Inflammatory Bowel Disease. *Cell Mol Gastroenterol Hepatol* 2017;**4**(1):33–46.

60. Godard P., van Eyll J. Pathway analysis from lists of microRNAs: common pitfalls and alternative strategy. *Nucleic Acids Res* 2015;**43**(7):3490–7.

For Review Only



Supplementary Figure S1: Fluorescence-activated cell sorting (FACS) of crypt-bottom (CD44⁺) and crypt-top (CD66a⁺) colonic epithelial cells from patients with active and quiescent UC and healthy controls (HC). (a) Gating strategy for FACS isolation of crypt-top CD44+/CD66a- and crypt-bottom CD44-/CD66a+ epithelial cell populations: selection of epithelial cells by CD45 exclusion, EpCAM inclusion and further isolation of populations by CD44 and CD66a expression. **(b-d)** Representative plots of flow cytometry data showing distribution of CD44+/CD66a- and CD44-/CD66a+ colonic epithelial cell populations during **(b)** active UC (aUC), **(c)** quiescent UC (qUC), and **(d)** in healthy controls (HC).



Supplementary Figure S2: The expression levels of *IL-4* and *IL-13* genes measured by RT-qPCR in colon tissue samples of an independent cohort of HC, active UC, and quiescent UC individuals. Dots represent outliers in each group. Gene expression is represented in logarithmic scale, ΔCt values are inversed in order to show true direction of the expression. Significance levels: * p <= 0.05, *** p <= 0.001, **** p <= 0.0001, ns – not significant.

For Review Only



Supplementary Figure S3. Most abundant (top 20) miRNA expression in colonic epithelial cell CD44+ and CD66a+ populations from UC patients (active and remission) and healthy controls. In each cell population and condition, the median normalized expression levels are represented by color, and rank by dot size. Most abundant miRNAs are ranked in descending order, to be precise, the highest expression value is ranked as 1.

Supplementary Table S1. Demographic and clinical characteristics of Study group III subjects recruited for *IL-4* and *IL-13* gene expression analysis in colon tissues

	Study group III, n=200		
	Active UC, n=75	Quiescent UC, n=50	HC, n=75
Age			
Mean ± SD	46.1 ± 13.7	47.3 ± 16.1	46.3 ± 11.9
Sex, n (%)			
Female	37 (49.3)	24 (48.0)	38 (50.7)
Full Mayo score, n (%)			
Remission	0 (0.0)	50 (100.0)	-
Mild	3 (4.0)	0 (0.0)	-
Moderate	70 (93.3)	0 (0.0)	-
Severe	2 (2.7)	0 (0.0)	-
Endoscopic Mayo subscore, n (%)			
Normal to mild	0 (0.0)	50 (100.0)	75 (100.0)
Moderate to severe	75 (100.0)	0 (0.0)	-
Smoking status, n (%)			
Never	43 (57.3)	24 (48.0)	43 (57.3)
Smoking	8 (10.7)	8 (16.0)	17 (22.7)
Ex-smoker	22 (29.3)	16 (32.0)	12 (16.0)
Unknown	2 (2.7)	2 (4.0)	3 (4.0)
BMI, kg/m^2			
Median, (range)	24.9 (16.2–41.5)	25.8 (19.5–34.6)	24.9 (16.9–49.3)
Unknown, n (%)		2 (4.0)	5 (6.7)

SD - Standard deviation

For Review Only

Supplementary Table S2. The list of differentially expressed colon tissue miRNAs in active (aUC) and quiescent (qUC) UC

mir	baseMean	log2FoldChange	lfcSE	stat	pvalue	padj	comparison
hsa-let-7i-3p	86,84697092	1,032192316	0,162608863	6,347700233	2,18557E-10	2,85686E-09	aUC_vs_HC
hsa-miR-1-3p	45,63524901	-2,177255122	0,308443343	-7,058849456	1,67887E-12	3,84041E-11	aUC_vs_HC
hsa-miR-101-3p	5009,576619	-1,021882072	0,113592099	-8,996066427	2,3395E-19	3,21096E-17	aUC_vs_HC
hsa-miR-106a-5p	7,864580879	-2,173205539	0,455936996	-4,766460185	1,87491E-06	1,06116E-05	aUC_vs_HC
hsa-miR-10b-5p	122360,1491	-1,569178268	0,20857132	-7,523461367	5,33448E-14	1,83039E-12	aUC_vs_HC
hsa-miR-1180-3p	21,60809363	1,225578767	0,245182637	4,998636046	5,77373E-07	3,60202E-06	aUC_vs_HC
hsa-miR-1185-1-3p	3,125659317	1,507760439	0,282196711	5,342941224	9,14504E-08	6,87757E-07	aUC_vs_HC
hsa-miR-124-3p	1,968730778	-1,502208785	0,435183154	-3,451900126	0,000556654	0,001898155	aUC_vs_HC
hsa-miR-1247-3p	4,964618308	-1,052171052	0,339634825	-3,097948077	0,001948656	0,005486215	aUC_vs_HC
hsa-miR-125b-1-3p	26,59922677	1,951882024	0,258606278	7,547697745	4,4302E-14	1,62145E-12	aUC_vs_HC
hsa-miR-1261	6,828010694	1,107609554	0,264311253	4,190550117	2,78279E-05	0,00012125	aUC_vs_HC
hsa-miR-1271-5p	5,030666509	-1,556292302	0,558285461	-2,787628213	0,005309544	0,012955287	aUC_vs_HC
hsa-miR-130b-3p	320,174747	1,179371908	0,133733179	8,818842995	1,15648E-18	1,26982E-16	aUC_vs_HC
hsa-miR-132-5p	21,32720117	1,353139976	0,195751344	6,912544992	4,76035E-12	9,67938E-11	aUC_vs_HC
hsa-miR-135a-5p	1,478716928	-1,357836125	0,597622986	-2,272061412	0,023082801	0,047285291	aUC_vs_HC
hsa-miR-137-3p	1,561737961	-1,411311512	0,437967787	-3,222409393	0,001271174	0,003792795	aUC_vs_HC
hsa-miR-138-1-3p	2,017574347	1,891697916	0,421088218	4,492402866	7,0424E-06	3,45204E-05	aUC_vs_HC
hsa-miR-138-5p	58,32514755	1,185434796	0,210999646	5,618183817	1,92975E-08	1,59918E-07	aUC_vs_HC
hsa-miR-146a-5p	2578,691154	1,438063623	0,239982974	5,992356877	2,06821E-09	2,18356E-08	aUC_vs_HC
hsa-miR-146b-3p	131,694782	1,091530489	0,170292315	6,409746039	1,45762E-10	2,05188E-09	aUC_vs_HC
hsa-miR-150-3p	10,85123407	1,665312473	0,324159634	5,137322158	2,78681E-07	1,82138E-06	aUC_vs_HC
hsa-miR-150-5p	2111,72082	1,000240405	0,234036173	4,273870975	1,92108E-05	8,78895E-05	aUC_vs_HC
hsa-miR-155-5p	990,5539321	1,427450703	0,186793564	7,641862342	2,14102E-14	8,39586E-13	aUC_vs_HC
hsa-miR-181b-3p	1,83619171	1,133378149	0,349597803	3,241948719	0,001187154	0,003561461	aUC_vs_HC
hsa-miR-185-3p	3,736284581	1,12778486	0,274959224	4,101644038	4,10225E-05	0,000171919	aUC_vs_HC
hsa-miR-190a-3p	9,619305454	-1,037177475	0,252801228	-4,102739066	4,08288E-05	0,000171919	aUC_vs_HC
hsa-miR-190a-5p	464,0866948	-2,371130192	0,226927531	-10,4488432	1,48323E-25	8,14295E-23	aUC_vs_HC
hsa-miR-191-3p	6,696832516	1,227723929	0,265322231	4,627293862	3,70475E-06	1,93705E-05	aUC_vs_HC
hsa-miR-192-5p	406326,2139	-1,3899334	0,174124233	-7,9824237	1,43488E-15	8,75274E-14	aUC_vs_HC
hsa-miR-194-3p	150,6914997	-1,272355981	0,162716803	-7,81945048	5,30544E-15	2,42724E-13	aUC_vs_HC
hsa-miR-200c-3p	4008,129423	-1,024502993	0,152360528	-6,72420215	1,76557E-11	2,78785E-10	aUC_vs_HC
hsa-miR-204-5p	62,05433726	-1,204955314	0,264681881	-4,552466197	5,30207E-06	2,64621E-05	aUC_vs_HC
hsa-miR-205-5p	17,95505274	-9,943858929	2,289954432	-4,342382883	1,40946E-05	6,55755E-05	aUC_vs_HC
hsa-miR-20a-5p	811,7990547	-1,396745706	0,173751808	-8,038740564	9,07665E-16	6,22885E-14	aUC_vs_HC
hsa-miR-212-3p	30,48085194	1,577523626	0,193123203	8,168483122	3,12291E-16	2,44925E-14	aUC_vs_HC
hsa-miR-218-5p	77,94441265	-1,064708207	0,163008098	-6,531627672	6,50587E-11	9,39927E-10	aUC_vs_HC
hsa-miR-222-5p	1,053424073	1,653489648	0,545302847	3,032240993	0,002427453	0,006597385	aUC_vs_HC
hsa-miR-223-3p	651,8784999	2,392458551	0,255755992	9,354457462	8,40299E-21	2,30662E-18	aUC_vs_HC
hsa-miR-223-5p	9,333993505	1,642102616	0,329461765	4,984197841	6,22194E-07	3,83803E-06	aUC_vs_HC
hsa-miR-25-5p	11,60936066	1,323947131	0,223766747	5,916639311	3,28586E-09	3,22132E-08	aUC_vs_HC
hsa-miR-27a-5p	27,7926062	1,153381048	0,226109365	5,100987523	3,37886E-07	2,15697E-06	aUC_vs_HC
hsa-miR-31-5p	165,9807895	2,190879573	0,63845352	3,431541223	0,000600162	0,001996902	aUC_vs_HC
hsa-miR-3117-3p	1,989608279	1,285027211	0,4054146	3,1696619	0,001526164	0,004480557	aUC_vs_HC
hsa-miR-3131	1,15081761	-1,182126445	0,479479484	-2,465436966	0,013684625	0,030051437	aUC_vs_HC
hsa-miR-3150b-3p	1,703386787	-1,005305904	0,38058088	-2,641503964	0,008253884	0,019364882	aUC_vs_HC
hsa-miR-3168	4,064948507	4,463050883	0,815284531	5,474224906	4,39431E-08	3,35066E-07	aUC_vs_HC
hsa-miR-3176	5,988027981	1,265612221	0,339932062	3,723132829	0,000196766	0,000744997	aUC_vs_HC
hsa-miR-3182	6,296971943	2,499271721	0,547890208	4,561628744	5,07583E-06	2,55654E-05	aUC_vs_HC
hsa-miR-342-5p	8,253483302	2,014707864	0,315663253	6,382459297	1,74266E-10	2,33347E-09	aUC_vs_HC
hsa-miR-34a-3p	1,245512505	1,159761855	0,434338232	2,670181369	0,007581029	0,017939589	aUC_vs_HC
hsa-miR-3605-3p	5,610256945	1,54692813	0,299422539	5,166371689	2,38682E-07	1,59984E-06	aUC_vs_HC
hsa-miR-3609	1,222421126	1,868048216	0,47017792	3,973066654	7,09532E-05	0,000286421	aUC_vs_HC
hsa-miR-3614-5p	10,11772198	1,049562412	0,224786747	4,669147208	3,02453E-06	1,6121E-05	aUC_vs_HC
hsa-miR-3615	37,87345141	1,422727385	0,228825106	6,217531857	5,05036E-10	5,77635E-09	aUC_vs_HC
hsa-miR-362-5p	44,73684131	-1,661882245	0,247184865	-6,723236256	1,77732E-11	2,78785E-10	aUC_vs_HC
hsa-miR-378a-3p	20556,27074	-1,176076514	0,148448231	-7,922469018	2,3284E-15	1,24589E-13	aUC_vs_HC
hsa-miR-378a-5p	134,3466478	-1,495187584	0,214151454	-6,981916556	2,9118E-12	6,39431E-11	aUC_vs_HC
hsa-miR-378i	8,278677288	-3,080178358	0,579172494	-5,318240055	1,04776E-07	7,77323E-07	aUC_vs_HC
hsa-miR-423-5p	842,8864905	1,513286332	0,22711965	6,662947633	2,68389E-11	4,09294E-10	aUC_vs_HC
hsa-miR-424-3p	21,42277155	1,420632599	0,222459834	6,386018427	1,7026E-10	2,33347E-09	aUC_vs_HC
hsa-miR-431-3p	2,39402778	1,158190324	0,378233373	3,062105057	0,002197863	0,006033134	aUC_vs_HC

For Review Only

hsa-miR-431-5p	10,71876204	1,829237631	0,268459786	6,813823615	9,50382E-12	1,6831E-10	aUC_vs_HC
hsa-miR-4326	4,597156676	1,106142242	0,282106077	3,921015291	8,81767E-05	0,00035079	aUC_vs_HC
hsa-miR-4448	5,359009229	2,612686845	0,507761522	5,14549987	2,66809E-07	1,7648E-06	aUC_vs_HC
hsa-miR-4454	32,35078856	1,05156346	0,247938123	4,241233444	2,22295E-05	0,000100859	aUC_vs_HC
hsa-miR-4455	1,825290976	1,383568973	0,438537318	3,154962912	0,001605185	0,00466268	aUC_vs_HC
hsa-miR-449c-5p	1,553470785	1,413938598	0,58906155	2,400324039	0,016380564	0,035545177	aUC_vs_HC
hsa-miR-4516	25,0311553	1,848471166	0,50832383	3,6364047	0,00027647	0,001018671	aUC_vs_HC
hsa-miR-451a	3390,36826	-1,056383964	0,291925832	-3,618672448	0,000296118	0,001077432	aUC_vs_HC
hsa-miR-4636	1,622644125	-1,583538451	0,442206344	-3,580994423	0,000342289	0,001212365	aUC_vs_HC
hsa-miR-486-5p	6784,687476	-1,100433516	0,271604255	-4,051606325	5,08672E-05	0,000209971	aUC_vs_HC
hsa-miR-493-3p	18,42199711	1,031030186	0,197013565	5,233295402	1,66514E-07	1,20285E-06	aUC_vs_HC
hsa-miR-511-5p	9,780917612	1,527305649	0,275784363	5,538042964	3,0587E-08	2,43366E-07	aUC_vs_HC
hsa-miR-548au-5p	1,45074882	1,431312293	0,395556653	3,618476096	0,000296343	0,001077432	aUC_vs_HC
hsa-miR-548az-5p	1,378670418	-1,649262186	0,534920327	-3,083192213	0,002047928	0,005707171	aUC_vs_HC
hsa-miR-549a-5p	2,928751124	2,771494101	0,60229855	4,601528765	4,19401E-06	2,15188E-05	aUC_vs_HC
hsa-miR-550a-5p	2,193287616	1,709816147	0,410506507	4,165137744	3,11165E-05	0,000134511	aUC_vs_HC
hsa-miR-551b-3p	4,182970423	-1,002532044	0,386211821	-2,595808804	0,009436856	0,021952686	aUC_vs_HC
hsa-miR-552-3p	17,46052299	-1,625010798	0,245018121	-6,632206593	3,30705E-11	4,90695E-10	aUC_vs_HC
hsa-miR-552-5p	11,81078551	-1,606097138	0,268580888	-5,979938305	2,23222E-09	2,31224E-08	aUC_vs_HC
hsa-miR-5571-3p	14,88030368	1,846041382	0,315286278	5,855127583	4,76644E-09	4,43521E-08	aUC_vs_HC
hsa-miR-5571-5p	6,465962202	2,645368813	0,36622185	7,223405191	5,07017E-13	1,46501E-11	aUC_vs_HC
hsa-miR-584-5p	29,79418754	1,438767611	0,212231354	6,779241532	1,20808E-11	2,07262E-10	aUC_vs_HC
hsa-miR-618	1,854002716	1,272536742	0,407762644	3,120778131	0,001803739	0,005130842	aUC_vs_HC
hsa-miR-625-3p	21,77849347	1,11155585	0,236537817	4,6992733	2,61089E-06	1,44786E-05	aUC_vs_HC
hsa-miR-625-5p	34,05882263	1,249226796	0,136573291	9,146933408	5,85726E-20	1,07188E-17	aUC_vs_HC
hsa-miR-628-5p	14,9630011	1,02350918	0,167631953	6,10569263	1,02356E-09	1,12387E-08	aUC_vs_HC
hsa-miR-651-5p	15,83452534	-1,032889311	0,176142301	-5,863948095	4,51989E-09	4,27831E-08	aUC_vs_HC
hsa-miR-668-3p	1,181534903	1,377406478	0,529978525	2,598985454	0,009349974	0,02184313	aUC_vs_HC
hsa-miR-708-5p	33,37604443	1,179952575	0,286299066	4,121398624	3,76579E-05	0,000160265	aUC_vs_HC
hsa-miR-766-3p	6,389347077	1,413112638	0,253895989	5,56571471	2,6108E-08	2,10784E-07	aUC_vs_HC
hsa-miR-7974	13,65651025	1,50645337	0,342528561	4,398037245	1,09234E-05	5,26049E-05	aUC_vs_HC
hsa-miR-9-5p	131,5546171	-1,285655064	0,162457183	-7,913808676	2,49632E-15	1,24589E-13	aUC_vs_HC
hsa-let-7i-5p	7433,139774	1,020338489	0,190482182	5,356608579	8,47985E-08	1,43901E-06	aUC_vs_qUC
hsa-miR-1-3p	45,63524901	-1,118583549	0,32843045	-3,405846039	0,000659594	0,002777236	aUC_vs_qUC
hsa-miR-1180-3p	21,60809363	1,42086927	0,269663409	5,269047341	1,37134E-07	1,9691E-06	aUC_vs_qUC
hsa-miR-1249-3p	2,635178737	-1,267964412	0,343241513	-3,694088169	0,000220677	0,001123448	aUC_vs_qUC
hsa-miR-1261	6,828010694	1,125706136	0,303460486	3,709564134	0,000207616	0,001066653	aUC_vs_qUC
hsa-miR-130b-3p	320,174747	1,064506299	0,144266943	7,378726391	1,59811E-13	2,00831E-11	aUC_vs_qUC
hsa-miR-132-5p	21,32720117	1,175089726	0,214143544	5,487392725	4,0791E-08	7,36869E-07	aUC_vs_qUC
hsa-miR-137-3p	1,561737961	-1,492382145	0,468351732	-3,186455912	0,001440274	0,005449687	aUC_vs_qUC
hsa-miR-138-1-3p	2,017574347	1,377890506	0,463012627	2,975924251	0,00292107	0,0097369	aUC_vs_qUC
hsa-miR-145-5p	1857,847135	-1,297235809	0,255432445	-5,078586665	3,80253E-07	4,34575E-06	aUC_vs_qUC
hsa-miR-146a-5p	2578,691154	1,452360548	0,258678444	5,614540291	1,97086E-08	4,0877E-07	aUC_vs_qUC
hsa-miR-150-3p	10,85123407	1,56892364	0,355995555	4,407143909	1,04743E-05	8,26139E-05	aUC_vs_qUC
hsa-miR-155-5p	990,5539321	1,192023232	0,201296912	5,921716442	3,18599E-09	8,10978E-08	aUC_vs_qUC
hsa-miR-16-2-3p	179,5440595	1,062484547	0,176939342	6,004795401	1,91573E-09	5,64637E-08	aUC_vs_qUC
hsa-miR-183-3p	3,053337942	1,242735461	0,394527906	3,149930443	0,001633093	0,00601666	aUC_vs_qUC
hsa-miR-190a-5p	464,0866948	-1,575056325	0,243686017	-6,46346617	1,02331E-10	4,09326E-09	aUC_vs_qUC
hsa-miR-191-3p	6,696832516	1,488382123	0,315385635	4,719245136	2,36721E-06	2,32568E-05	aUC_vs_qUC
hsa-miR-204-5p	62,05433726	-1,210955602	0,281455256	-4,302479975	1,68897E-05	0,000127814	aUC_vs_qUC
hsa-miR-205-5p	17,95505274	7,94850066	2,499092458	3,180554859	0,001469933	0,005524581	aUC_vs_qUC
hsa-miR-212-3p	30,48085194	1,286936457	0,209019706	6,157010187	7,41311E-10	2,44197E-08	aUC_vs_qUC
hsa-miR-223-3p	651,8784999	1,407810163	0,275343743	5,112918656	3,17219E-07	3,91563E-06	aUC_vs_qUC
hsa-miR-23a-5p	5,650538118	1,153718646	0,314739359	3,665631934	0,000246729	0,001222726	aUC_vs_qUC
hsa-miR-25-5p	11,60936066	1,301270978	0,252876278	5,145879989	2,6627E-07	3,42434E-06	aUC_vs_qUC
hsa-miR-3168	4,064948507	3,329171651	0,89060354	3,738107366	0,000185411	0,000970374	aUC_vs_qUC
hsa-miR-331-3p	72,3342511	-1,702956249	0,253483773	-6,718206172	1,83975E-11	9,36601E-10	aUC_vs_qUC
hsa-miR-342-5p	8,253483302	1,826371265	0,349511534	5,225496405	1,73688E-07	2,37233E-06	aUC_vs_qUC
hsa-miR-3605-3p	5,610256945	1,582894539	0,348727124	4,539063444	5,65046E-06	4,86809E-05	aUC_vs_qUC
hsa-miR-3609	1,222421126	2,752158095	0,646294343	4,25836637	2,05926E-05	0,000151735	aUC_vs_qUC
hsa-miR-3614-5p	10,11772198	1,271515613	0,259245737	4,904673186	9,3583E-07	9,88802E-06	aUC_vs_qUC
hsa-miR-362-5p	44,73684131	-1,235684662	0,262172958	-4,71324224	2,43806E-06	2,35399E-05	aUC_vs_qUC
hsa-miR-378a-5p	134,3466478	-1,270871535	0,229182838	-5,545229952	2,93568E-08	5,87136E-07	aUC_vs_qUC

For Review Only

hsa-miR-378i	8,278677288	-2,086653578	0,622182333	-3,353765395	0,000797199	0,003282585	aUC_vs_qUC
hsa-miR-381-3p	544,4493226	-1,024188654	0,159532866	-6,419922618	1,36344E-10	5,09016E-09	aUC_vs_qUC
hsa-miR-423-5p	842,8864905	1,879580063	0,244999954	7,671756795	1,69656E-14	3,16692E-12	aUC_vs_qUC
hsa-miR-431-5p	10,71876204	1,035720321	0,282105069	3,671399189	0,000241226	0,001206131	aUC_vs_qUC
hsa-miR-4326	4,597156676	1,18460341	0,325354265	3,640964745	0,000271618	0,001334265	aUC_vs_qUC
hsa-miR-4448	5,359009229	1,364867864	0,537145828	2,540963351	0,011054751	0,03207596	aUC_vs_qUC
hsa-miR-4492	19,8462304	-2,159800637	0,459393303	-4,701419505	2,58359E-06	2,41135E-05	aUC_vs_qUC
hsa-miR-4497	6,888801966	-6,285829022	0,803188276	-7,826096579	5,03251E-15	1,4091E-12	aUC_vs_qUC
hsa-miR-4508	7,739863441	-3,958074545	0,567154719	-6,978826789	2,97655E-12	1,85208E-10	aUC_vs_qUC
hsa-miR-4516	25,0311553	-1,715580754	0,531055205	-3,230513018	0,001235683	0,004707363	aUC_vs_qUC
hsa-miR-4636	1,622644125	-1,658358209	0,465230523	-3,564594597	0,000364419	0,001677164	aUC_vs_qUC
hsa-miR-504-5p	1,981209572	-1,673709625	0,414017013	-4,042610749	5,28593E-05	0,000340244	aUC_vs_qUC
hsa-miR-511-5p	9,780917612	1,58678953	0,308478282	5,143926245	2,69055E-07	3,42434E-06	aUC_vs_qUC
hsa-miR-548au-5p	1,45074882	1,170855248	0,464063165	2,523051463	0,011634137	0,033583077	aUC_vs_qUC
hsa-miR-548f-3p	1,978397462	-1,268703006	0,379704811	-3,341287677	0,000833908	0,003408674	aUC_vs_qUC
hsa-miR-549a-5p	2,928751124	2,755832669	0,695924434	3,959959636	7,49624E-05	0,000441884	aUC_vs_qUC
hsa-miR-5571-3p	14,88030368	1,183245521	0,336347185	3,51792902	0,000434929	0,001964194	aUC_vs_qUC
hsa-miR-5571-5p	6,465962202	1,758760029	0,389645136	4,513748193	6,36918E-06	5,40416E-05	aUC_vs_qUC
hsa-miR-5701	65,08592096	-1,1363678	0,280365815	-4,053161053	5,05302E-05	0,000332905	aUC_vs_qUC
hsa-miR-584-5p	29,79418754	1,335067879	0,23166853	5,762836592	8,27119E-09	1,92994E-07	aUC_vs_qUC
hsa-miR-6126	1,448649919	-4,553327338	0,897327063	-5,074322982	3,88878E-07	4,35543E-06	aUC_vs_qUC
hsa-miR-625-5p	34,05882263	1,113132941	0,151171501	7,363378255	1,79313E-13	2,00831E-11	aUC_vs_qUC
hsa-miR-664a-3p	33,73200555	-1,314729348	0,217786666	-6,036776143	1,57224E-09	4,8914E-08	aUC_vs_qUC
hsa-miR-744-5p	150,5376248	1,143721244	0,173680843	6,585189402	4,54306E-11	1,95701E-09	aUC_vs_qUC
hsa-miR-7704	33,46400331	-2,176009889	0,365493131	-5,95362731	2,62264E-09	7,26746E-08	aUC_vs_qUC
hsa-miR-7974	13,65651025	1,096117188	0,369498492	2,966499758	0,003012106	0,009980943	aUC_vs_qUC
hsa-miR-873-5p	2,38577459	-1,000145635	0,37974992	-2,633695447	0,008446121	0,024980831	aUC_vs_qUC
hsa-miR-942-5p	7,341665876	1,835028413	0,343278281	5,345600095	9,0118E-08	1,4843E-06	aUC_vs_qUC
hsa-miR-1-3p	45,63524901	-1,058671574	0,327880779	-3,228830844	0,001242974	0,011048657	qUC_vs_HC
hsa-miR-106a-5p	7,864580879	-2,327070819	0,502042393	-4,635207805	3,56579E-06	0,000117461	qUC_vs_HC
hsa-miR-1185-1-3p	3,125659317	1,198969427	0,309074489	3,879224812	0,00010479	0,001892978	qUC_vs_HC
hsa-miR-1249-3p	2,635178737	1,159333073	0,323413991	3,58467199	0,000337502	0,004108721	qUC_vs_HC
hsa-miR-125b-1-3p	26,59922677	1,117442697	0,284176821	3,932209151	8,41688E-05	0,001571151	qUC_vs_HC
hsa-miR-1271-5p	5,030666509	-1,83818757	0,612650828	-3,000383718	0,002696397	0,019868187	qUC_vs_HC
hsa-miR-205-5p	17,95505274	-17,89235959	2,528753253	-7,075565623	1,4884E-12	8,33506E-10	qUC_vs_HC
hsa-miR-3150b-3p	1,703386787	-1,270996447	0,457448061	-2,778449741	0,005461896	0,032196441	qUC_vs_HC
hsa-miR-3182	6,296971943	1,601455594	0,60406854	2,651115706	0,008022635	0,043922256	qUC_vs_HC
hsa-miR-3195	6,477130497	1,170273018	0,407422682	2,872380628	0,00407392	0,026341669	qUC_vs_HC
hsa-miR-331-3p	72,3342511	1,174028046	0,256487658	4,577327634	4,70954E-06	0,000146519	qUC_vs_HC
hsa-miR-409-5p	2,593071508	-1,934984291	0,647826962	-2,986884466	0,002818362	0,020497179	qUC_vs_HC
hsa-miR-424-5p	118,0502618	1,108730662	0,27587833	4,018911753	5,84676E-05	0,001212661	qUC_vs_HC
hsa-miR-4286	26,85650667	1,000016514	0,17513754	5,709892415	1,13048E-08	6,33067E-07	qUC_vs_HC
hsa-miR-431-3p	2,39402778	1,28212261	0,39635033	3,234821605	0,001217188	0,010993952	qUC_vs_HC
hsa-miR-4454	32,35078856	1,032187639	0,269389475	3,831581167	0,000127322	0,002160622	qUC_vs_HC
hsa-miR-4492	19,8462304	2,459136743	0,468984804	5,243531816	1,57532E-07	7,35148E-06	qUC_vs_HC
hsa-miR-4497	6,888801966	4,842669712	0,765598795	6,325336118	2,52682E-10	2,83004E-08	qUC_vs_HC
hsa-miR-4508	7,739863441	3,660547664	0,560463122	6,531290854	6,52052E-11	1,21716E-08	qUC_vs_HC
hsa-miR-4516	25,0311553	3,56405192	0,549516664	6,485794065	8,82657E-11	1,23572E-08	qUC_vs_HC
hsa-miR-485-3p	5,547149404	1,16588218	0,233354671	4,996181024	5,84768E-07	2,18313E-05	qUC_vs_HC
hsa-miR-501-3p	61,37291486	-1,031649877	0,280432546	-3,678780842	0,000234352	0,003525806	qUC_vs_HC
hsa-miR-504-5p	1,981209572	1,028898675	0,36975191	2,782673054	0,00539131	0,032196441	qUC_vs_HC
hsa-miR-5100	6,950990718	1,415941659	0,272979896	5,186981452	2,1373E-07	9,20683E-06	qUC_vs_HC
hsa-miR-6126	1,448649919	4,024984824	0,903125629	4,456727495	8,32203E-06	0,000233017	qUC_vs_HC
hsa-miR-629-5p	23,74957856	-1,044094731	0,208875649	-4,998642654	5,77353E-07	2,18313E-05	qUC_vs_HC
hsa-miR-665	5,880670429	1,025254911	0,324606292	3,158456681	0,001586069	0,013664593	qUC_vs_HC
hsa-miR-708-3p	17,66362198	1,05339501	0,302606236	3,481075024	0,000499406	0,005593343	qUC_vs_HC
hsa-miR-708-5p	33,37604443	1,126245844	0,311895979	3,610966222	0,000305058	0,003882561	qUC_vs_HC
hsa-miR-766-3p	6,389347077	1,118059539	0,275575308	4,057183308	4,96681E-05	0,001069774	qUC_vs_HC
hsa-miR-7704	33,46400331	2,249926451	0,371696766	6,053123558	1,42064E-09	1,32593E-07	qUC_vs_HC
hsa-miR-873-5p	2,38577459	1,07876081	0,369268202	2,92134769	0,003485206	0,024705261	qUC_vs_HC

For Review Only

Supplemenatry Table S3. The list of Reactome pathways significantly enriched with differentially expressed colon tissue miRNAs in active (aUC) and quiescent (qUC)

comparison	ID	Description	GeneRatio	BgRatio	pvalue	p.adjust	qvalue
aUC_vs_qUC	R-HSA-449147	Signaling by Interleukins	72/422	461/10704	9,77431E-25	1,10254E-21	7,09924E-22
aUC_vs_qUC	R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling	34/422	108/10704	4,56679E-22	2,46706E-19	1,58853E-19
aUC_vs_qUC	R-HSA-5663202	Diseases of signal transduction by growth factor receptors and second messengers	62/422	387/10704	6,56134E-22	2,46706E-19	1,58853E-19
aUC_vs_qUC	R-HSA-2219528	PI3K/AKT Signaling in Cancer	25/422	101/10704	7,88546E-14	2,2237E-11	1,43183E-11
aUC_vs_qUC	R-HSA-1257604	PIP3 activates AKT signaling	39/422	264/10704	6,59585E-13	1,48802E-10	9,58134E-11
aUC_vs_qUC	R-HSA-9006925	Intracellular signaling by second messengers	42/422	306/10704	1,02743E-12	1,93157E-10	1,24373E-10
aUC_vs_qUC	R-HSA-9659787	Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects	11/422	17/10704	3,14586E-12	4,43566E-10	2,85611E-10
aUC_vs_qUC	R-HSA-9661069	Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	11/422	17/10704	3,14586E-12	4,43566E-10	2,85611E-10
aUC_vs_qUC	R-HSA-8848021	Signaling by PTK6	17/422	54/10704	1,20202E-11	1,35588E-09	8,73047E-10
aUC_vs_qUC	R-HSA-9006927	Signaling by Non-Receptor Tyrosine Kinases	17/422	54/10704	1,20202E-11	1,35588E-09	8,73047E-10
aUC_vs_qUC	R-HSA-199418	Negative regulation of the PI3K/AKT network	23/422	110/10704	3,41806E-11	3,50507E-09	2,2569E-09
aUC_vs_qUC	R-HSA-8878166	Transcriptional regulation by RUNX2	23/422	121/10704	2,60669E-10	2,45029E-08	1,57773E-08
aUC_vs_qUC	R-HSA-1433557	Signaling by SCF-KIT	14/422	43/10704	4,87164E-10	4,22709E-08	2,72181E-08
aUC_vs_qUC	R-HSA-8939211	ESR-mediated signaling	31/422	223/10704	7,98434E-10	6,4331E-08	4,14225E-08
aUC_vs_qUC	R-HSA-9669938	Signaling by KIT in disease	10/422	20/10704	1,05864E-09	7,46342E-08	4,80567E-08
aUC_vs_qUC	R-HSA-9670439	Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	10/422	20/10704	1,05864E-09	7,46342E-08	4,80567E-08
aUC_vs_qUC	R-HSA-166520	Signaling by NTRKs	23/422	134/10704	2,13508E-09	1,39847E-07	9,0047E-08
aUC_vs_qUC	R-HSA-9673767	Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants	8/422	12/10704	2,35558E-09	1,39847E-07	9,0047E-08
aUC_vs_qUC	R-HSA-9673770	Signaling by PDGFRA extracellular domain mutants	8/422	12/10704	2,35558E-09	1,39847E-07	9,0047E-08
aUC_vs_qUC	R-HSA-6811558	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	20/422	103/10704	2,64693E-09	1,49287E-07	9,61254E-08
aUC_vs_qUC	R-HSA-1236394	Signaling by ERBB4	15/422	58/10704	4,23752E-09	2,27615E-07	1,46561E-07
aUC_vs_qUC	R-HSA-194138	Signaling by VEGF	20/422	108/10704	6,27625E-09	3,0054E-07	1,93517E-07
aUC_vs_qUC	R-HSA-9675126	Diseases of mitotic cell cycle	12/422	36/10704	6,39447E-09	3,0054E-07	1,93517E-07
aUC_vs_qUC	R-HSA-9687139	Aberrant regulation of mitotic cell cycle due to RB1 defects	12/422	36/10704	6,39447E-09	3,0054E-07	1,93517E-07
aUC_vs_qUC	R-HSA-9006931	Signaling by Nuclear Receptors	35/422	299/10704	6,81092E-09	3,07309E-07	1,97875E-07
aUC_vs_qUC	R-HSA-4420097	VEGFA-VEGFR2 Pathway	19/422	99/10704	8,1477E-09	3,53485E-07	2,27608E-07
aUC_vs_qUC	R-HSA-452723	Transcriptional regulation of pluripotent stem cells	10/422	24/10704	9,74798E-09	4,07249E-07	2,62226E-07
aUC_vs_qUC	R-HSA-8986944	Transcriptional Regulation by MECP2	15/422	62/10704	1,1465E-08	4,61877E-07	2,97401E-07
aUC_vs_qUC	R-HSA-2559583	Cellular Senescence	27/422	197/10704	1,39146E-08	5,41232E-07	3,48497E-07
aUC_vs_qUC	R-HSA-187037	Signaling by NTRK1 (TRKA)	20/422	115/10704	1,92802E-08	7,24936E-07	4,66784E-07
aUC_vs_qUC	R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer	16/422	75/10704	2,5859E-08	9,40934E-07	6,05865E-07
aUC_vs_qUC	R-HSA-2559585	Oncogene Induced Senescence	11/422	33/10704	2,77518E-08	9,78252E-07	6,29894E-07
aUC_vs_qUC	R-HSA-9009391	Extra-nuclear estrogen signaling	16/422	77/10704	3,84523E-08	1,31437E-06	8,46319E-07
aUC_vs_qUC	R-HSA-9617828	FOXO-mediated transcription of cell cycle genes	8/422	17/10704	9,71455E-08	3,22294E-06	2,07524E-06
aUC_vs_qUC	R-HSA-166016	Toll Like Receptor 4 (TLR4) Cascade	20/422	129/10704	1,40832E-07	4,3702E-06	2,81396E-06
aUC_vs_qUC	R-HSA-5655302	Signaling by FGFR1 in disease	11/422	38/10704	1,44336E-07	4,3702E-06	2,81396E-06
aUC_vs_qUC	R-HSA-166058	MyD88:MAL(TIRAP) cascade initiated on plasma membrane	17/422	95/10704	1,47223E-07	4,3702E-06	2,81396E-06
aUC_vs_qUC	R-HSA-168188	Toll Like Receptor TLR6:TLR2 Cascade	17/422	95/10704	1,47223E-07	4,3702E-06	2,81396E-06
aUC_vs_qUC	R-HSA-9614085	FOXO-mediated transcription	14/422	65/10704	1,71194E-07	4,90452E-06	3,158E-06
aUC_vs_qUC	R-HSA-69231	Cyclin D associated events in G1	12/422	47/10704	1,79886E-07	4,90452E-06	3,158E-06
aUC_vs_qUC	R-HSA-69236	G1 Phase	12/422	47/10704	1,79886E-07	4,90452E-06	3,158E-06
aUC_vs_qUC	R-HSA-5683057	MAPK family signaling cascades	34/422	325/10704	1,82615E-07	4,90452E-06	3,158E-06
aUC_vs_qUC	R-HSA-168179	Toll Like Receptor TLR1:TLR2 Cascade	17/422	98/10704	2,3536E-07	5,9058E-06	3,80273E-06
aUC_vs_qUC	R-HSA-181438	Toll Like Receptor 2 (TLR2) Cascade	17/422	98/10704	2,3536E-07	5,9058E-06	3,80273E-06
aUC_vs_qUC	R-HSA-8941326	RUNX2 regulates bone development	10/422	32/10704	2,4136E-07	5,9058E-06	3,80273E-06
aUC_vs_qUC	R-HSA-9006115	Signaling by NTRK2 (TRKB)	9/422	25/10704	2,46075E-07	5,9058E-06	3,80273E-06
aUC_vs_qUC	R-HSA-9664565	Signaling by ERBB2 KD Mutants	9/422	25/10704	2,46075E-07	5,9058E-06	3,80273E-06
aUC_vs_qUC	R-HSA-166166	MyD88-independent TLR4 cascade	17/422	99/10704	2,74023E-07	6,30812E-06	4,06178E-06
aUC_vs_qUC	R-HSA-937061	TRIF(TICAM1)-mediated TLR4 signaling	17/422	99/10704	2,74023E-07	6,30812E-06	4,06178E-06
aUC_vs_qUC	R-HSA-1227990	Signaling by ERBB2 in Cancer	9/422	26/10704	3,63332E-07	8,19677E-06	5,27787E-06
aUC_vs_qUC	R-HSA-1227986	Signaling by ERBB2	12/422	50/10704	3,7534E-07	8,30164E-06	5,3454E-06
aUC_vs_qUC	R-HSA-9671555	Signaling by PDGFR in disease	8/422	20/10704	4,53381E-07	9,83487E-06	6,33264E-06
aUC_vs_qUC	R-HSA-75153	Apoptotic execution phase	12/422	52/10704	5,93963E-07	1,26413E-05	8,13971E-06
aUC_vs_qUC	R-HSA-8853334	Signaling by FGFR3 fusions in cancer	6/422	10/10704	6,65412E-07	1,38997E-05	8,94999E-06
aUC_vs_qUC	R-HSA-168164	Toll Like Receptor 3 (TLR3) Cascade	16/422	94/10704	6,96998E-07	1,42268E-05	9,1606E-06
aUC_vs_qUC	R-HSA-168898	Toll-like Receptor Cascades	21/422	155/10704	7,06295E-07	1,42268E-05	9,1606E-06
aUC_vs_qUC	R-HSA-186763	Downstream signal transduction	9/422	29/10704	1,04793E-06	2,0738E-05	1,33531E-05
aUC_vs_qUC	R-HSA-1250196	SHC1 events in ERBB2 signaling	8/422	22/10704	1,07342E-06	2,08761E-05	1,34421E-05
aUC_vs_qUC	R-HSA-9665348	Signaling by ERBB2 ECD mutants	7/422	16/10704	1,18357E-06	2,26283E-05	1,45703E-05
aUC_vs_qUC	R-HSA-2990846	SUMOylation	23/422	188/10704	1,30781E-06	2,45869E-05	1,58314E-05
aUC_vs_qUC	R-HSA-168643	Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways	12/422	56/10704	1,39262E-06	2,5201E-05	1,62269E-05
aUC_vs_qUC	R-HSA-5655291	Signaling by FGFR4 in disease	6/422	11/10704	1,41524E-06	2,5201E-05	1,62269E-05
aUC_vs_qUC	R-HSA-9028731	Activated NTRK2 signals through FRS2 and FRS3	6/422	11/10704	1,41524E-06	2,5201E-05	1,62269E-05
aUC_vs_qUC	R-HSA-111465	Apoptotic cleavage of cellular proteins	10/422	38/10704	1,42985E-06	2,5201E-05	1,62269E-05
aUC_vs_qUC	R-HSA-6783783	Interleukin-10 signaling	11/422	47/10704	1,5157E-06	2,63032E-05	1,69365E-05
aUC_vs_qUC	R-HSA-9034015	Signaling by NTRK3 (TRKC)	7/422	17/10704	1,94407E-06	3,3226E-05	2,13941E-05
aUC_vs_qUC	R-HSA-982772	Growth hormone receptor signaling	8/422	24/10704	2,30281E-06	3,87696E-05	2,49637E-05
aUC_vs_qUC	R-HSA-975138	TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation	15/422	91/10704	2,36659E-06	3,92576E-05	2,52778E-05
aUC_vs_qUC	R-HSA-3108232	SUMO E3 ligases SUMOylate target proteins	22/422	182/10704	2,72418E-06	4,39489E-05	2,82985E-05
aUC_vs_qUC	R-HSA-975155	MyD88 dependent cascade initiated on endosome	15/422	92/10704	2,72732E-06	4,39489E-05	2,82985E-05
aUC_vs_qUC	R-HSA-168181	Toll Like Receptor 7/8 (TLR7/8) Cascade	15/422	93/10704	3,13648E-06	4,98303E-05	3,20856E-05
aUC_vs_qUC	R-HSA-5674400	Constitutive Signaling by AKT1 E17K in Cancer	8/422	25/10704	3,27068E-06	5,05387E-05	3,25417E-05
aUC_vs_qUC	R-HSA-9006335	Signaling by Erythropoietin	8/422	25/10704	3,27068E-06	5,05387E-05	3,25417E-05
aUC_vs_qUC	R-HSA-2428928	IRS-related events triggered by IGF1R	11/422	52/10704	4,39947E-06	6,70622E-05	4,31812E-05
aUC_vs_qUC	R-HSA-168138	Toll Like Receptor 9 (TLR9) Cascade	15/422	96/10704	4,71333E-06	6,99558E-05	4,50443E-05
aUC_vs_qUC	R-HSA-8878159	Transcriptional regulation by RUNX3	15/422	96/10704	4,71333E-06	6,99558E-05	4,50443E-05
aUC_vs_qUC	R-HSA-1226099	Signaling by FGFR in disease	12/422	63/10704	5,18117E-06	7,31289E-05	4,70875E-05
aUC_vs_qUC	R-HSA-168142	Toll Like Receptor 10 (TLR10) Cascade	14/422	85/10704	5,18644E-06	7,31289E-05	4,70875E-05
aUC_vs_qUC	R-HSA-168176	Toll Like Receptor 5 (TLR5) Cascade	14/422	85/10704	5,18644E-06	7,31289E-05	4,70875E-05
aUC_vs_qUC	R-HSA-975871	MyD88 cascade initiated on plasma membrane	14/422	85/10704	5,18644E-06	7,31289E-05	4,70875E-05
aUC_vs_qUC	R-HSA-2428924	IGF1R signaling cascade	11/422	53/10704	5,3577E-06	7,46109E-05	4,80417E-05
aUC_vs_qUC	R-HSA-451927	Interleukin-2 family signaling	10/422	44/10704	6,06938E-06	8,3491E-05	5,37596E-05
aUC_vs_qUC	R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	11/422	54/10704	6,49319E-06	8,82448E-05	5,68206E-05
aUC_vs_qUC	R-HSA-8849471	PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases	6/422	14/10704	8,3129E-06	0,00011163	7,18784E-05
aUC_vs_qUC	R-HSA-9616222	Transcriptional regulation of granulopoiesis	14/422	90/10704	1,03064E-05	0,000135284	8,7109E-05
aUC_vs_qUC	R-HSA-73887	Death Receptor Signalling	18/422	141/10704	1,03142E-05	0,000135284	8,7109E-05
aUC_vs_qUC	R-HSA-9615017	FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	8/422	29/10704	1,12948E-05	0,000145814	9,38893E-05
aUC_vs_qUC	R-HSA-6806834	Signaling by MET	13/422	79/10704	1,13756E-05	0,000145814	9,38893E-05
aUC_vs_qUC	R-HSA-5637810	Constitutive Signaling by EGFRvIII	6/422	15/10704	1,33955E-05	0,00016789	0,000108104
aUC_vs_qUC	R-HSA-5637812	Signaling by EGFRvIII in Cancer	6/422	15/10704	1,33955E-05	0,00016789	0,000108104
aUC_vs_qUC	R-HSA-9665686	Signaling by ERBB2 TMD/JMD mutants	7/422	22/10704	1,43593E-05	0,000177993	0,000114609
aUC_vs_qUC	R-HSA-525793	Myogenesis	8/422	30/10704	1,48764E-05	0,000182397	0,000117445
aUC_vs_qUC	R-HSA-157118	Signaling by NOTCH	24/422	236/10704	1,95897E-05	0,000237604	0,000152993
aUC_vs_qUC	R-HSA-1963640	GRB2 events in ERBB2 signaling	6/422	16/10704	2,07226E-05	0,000246053	0,000158433
aUC_vs_qUC	R-HSA-1963642	PI3K events in ERBB2 signaling	6/422	16/10704	2,07226E-05	0,000246053	0,000158433
aUC_vs_qUC	R-HSA-381340	Transcriptional regulation of white adipocyte differentiation	13/422	84/10704	2,25489E-05	0,000264949	0,0001706
aUC_vs_qUC	R-HSA-170834	Signaling by TGF-beta Receptor Complex	12/422	73/10704	2,498E-05	0,000290489	0,000187045
aUC_vs_qUC	R-HSA-8940973	RUNX2 regulates osteoblast differentiation	7/422	24/10704	2,7211E-05	0,000313204	0,000201671
aUC_vs_qUC	R-HSA-2586552	Signaling by Leptin	5/422	11/10704	3,52944E-05	0,00039888	0,000256837
aUC_vs_qUC	R-HSA-450294	MAP kinase activation	11/422	64/10704	3,53617E-05	0,00039888	0,000256837
aUC_vs_qUC	R-HSA-400685	Sema4D in semaphorin signaling	7/422	25/10704	3,65211E-05	0,000407879	0,000262632
aUC_vs_qUC	R-HSA-9006936	Signaling by TGFB family members	14/422	102/10704	4,40495E-05	0,000483156	0,000311103
aUC_vs_qUC	R-HSA-1839117	Signaling by cytosolic FGFR1 fusion mutants	6/422	18/10704	4,49112E-05	0,000483156	0,000311103
aUC_vs_qUC	R-HSA-210993	Tie2 Signaling	6/422	18/10704	4,49112E-05	0,000483156	0,000311103
aUC_vs_qUC	R-HSA-5688426	Deubiquitination	27/422	297/10704	4,49746E-05	0,000483156	0,000311103
aUC_vs_qUC	R-HSA-3700989	Transcriptional Regulation by TP53	31/422	365/10704	4,62076E-05	0,000491718	0,000316616
aUC_vs_qUC	R-HSA-5357801	Programmed Cell Death	20/422	190/10704	5,92462E-05	0,000624613	0,000402186
aUC_vs_qUC	R-HSA-5684996	MAPK1/MAPK3 signaling	26/422	286/10704	6,21867E-05	0,000644983	0,000415303
aUC_vs_qUC	R-HSA-912526	Interleukin receptor SHC signaling	7/422	27/10704	6,30066E-05	0,000644983	0,000415303
aUC_vs_qUC	R-HSA-1236382	Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants	6/422	19/10704	6,34691E-05	0,000644983	0,000415303
aUC_vs_qUC	R-HSA-5637815	Signaling by Ligand-Responsive EGFR Variants in Cancer	6/422	19/10704	6,34691E-05	0,000644983	0,000415303
aUC_vs_qUC	R-HSA-109581	Apoptosis	19/422	178/10704	7,47871E-05	0,000753213	0,000484992
aUC_vs_qUC	R-HSA-168638	NOD1/2 Signaling Pathway	8/422	37/10704	7,69907E-05	0,000768544	0,000494863
aUC_vs_qUC	R-HSA-453279	Mitotic G1 phase and G1/S transition	17/422	149/10704	7,76953E-05	0,000768774	0,000495011
aUC_vs_qUC	R-HSA-9018519	Estrogen-dependent gene expression	17/422	150/10704	8,45162E-05	0,000828894	0,000533787
aUC_vs_qUC	R-HSA-112399	IRS-mediated signalling	9/422	48/10704	9,01656E-05	0,000869289	0,000559733
aUC_vs_qUC	R-HSA-512988	Interleukin-3, Interleukin-5 and GM-CSF signaling	9/422	48/10704	9,01656E-05	0,000869289	0,000559733
aUC_vs_qUC	R-HSA-2892247	POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation	5/422	13/10704	9,20732E-05	0,000880158	0,000566731
aUC_vs_qUC	R-HSA-8864260	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	8/422	38/10704	9,42054E-05	0,000892972	0,000574982
aUC_vs_qUC	R-HSA-202733	Cell surface interactions at the vascular wall	16/422	137/10704	9,50191E-05	0,000893179	0,000575115
aUC_vs_qUC	R-HSA-9607240	FLT3 Signaling	26/422	294/10704	9,83365E-05	0,000916724	0,000590276
aUC_vs_qUC	R-HSA-448424	Interleukin-17 signaling	11/422	72/10704	0,000108248	0,001000846	0,000644442
aUC_vs_qUC	R-HSA-8853884	Transcriptional Regulation by VENTX	8/422	39/10704	0,000114488	0,001043896	0,000672162
aUC_vs_qUC	R-HSA-5673001	RAF/MAP kinase cascade	25/422	280/10704	0,000114488	0,001043896	0,000672162
aUC_vs_qUC	R-HSA-177929	Signaling by EGFR	9/422	50/10704	0,000125614	0,001133539	0,000729882
aUC_vs_qUC	R-HSA-4090294	SUMOylation of intracellular receptors	7/422	30/10704	0,000130374	0,001157965	0,00074561
aUC_vs_qUC	R-HSA-5654696	Downstream signaling of activated FGFR2	7/422	30/10704	0,000130374	0,001157965	0,00074561
aUC_vs_qUC	R-HSA-198323	AKT phosphorylates targets in the cytosol	5/422	14/10704	0,000138607	0,001200995	0,000773317
aUC_vs_qUC	R-HSA-6804116	TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest	5/422	14/10704	0,000138607	0,001200995	0,000773317
aUC_vs_qUC	R-HSA-9027284	Erythropoietin activates RAS	5/422	14/10704	0,000138607	0,001200995	0,000773317
aUC_vs_qUC	R-HSA-1980143	Signaling by NOTCH1	11/422	74/10704	0,000139477	0,001200995	0,000773317
aUC_vs_qUC	R-HSA-5655332	Signaling by FGFR3 in disease	6/422	22/10704	0,000157816	0,001338466	0,000861834
aUC_vs_qUC	R-HSA-8853338	Signaling by FGFR3 point mutants in cancer	6/422	22/10704	0,000157816	0,001338466	0,000861834
aUC_vs_qUC	R-HSA-1839124	FGFR1 mutant receptor activation	7/422	31/10704	0,000162751	0,001359872	0,000875618
aUC_vs_qUC	R-HSA-4641262	Disassembly of the destruction complex and recruitment of AXIN to the membrane	7/422	31/10704	0,000162751	0,001359872	0,000875618
aUC_vs_qUC	R-HSA-383280	Nuclear Receptor transcription pathway	9/422	52/10704	0,000172025	0,001426792	0,000918707
aUC_vs_qUC	R-HSA-3769402	Deactivation of the beta-catenin transactivating complex	8/422	42/10704	0,000198015	0,001544954	0,000994791
aUC_vs_qUC	R-HSA-4839743	phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex	5/422	15/10704	0,000201212	0,001544954	0,000994791
aUC_vs_qUC	R-HSA-5339716	Missplaced GSK3beta mutants stabilize beta-catenin	5/422	15/10704	0,000201212	0,001544954	0,000994791
aUC_vs_qUC	R-HSA-5358508	Mismatch Repair	5/422	15/10704	0,000201212	0,001544954	0,000994791
aUC_vs_qUC	R-HSA-5358747	S33 mutants of beta-catenin aren't phosphorylated	5/422	15/10704	0,000201212	0,001544954	0,000994791
aUC_vs_qUC	R-HSA-5358749	S37 mutants of beta-catenin aren't phosphorylated	5/422	15/10704	0,000201212	0,001544954	0,000994791
aUC_vs_qUC	R-HSA-5358751	S45 mutants of beta-catenin aren't phosphorylated	5/422	15/10704	0,000201212	0,001544954	0,000994791
aUC_vs_qUC	R-HSA-5358752	T41 mutants of beta-catenin aren't phosphorylated	5/422	15/10704	0,000201212	0,001544954	0,000994791
aUC_vs_qUC	R-HSA-6785631	ERBB2 Regulates Cell Motility	5/422	15/10704	0,000201212	0,001544954	0,000994791
aUC_vs_qUC	R-HSA-8866910	TFAP2 (AP-2) family regulates transcription of growth factors and their receptors	5/422	15/10704	0,000201212	0,001544954	0,000994791
aUC_vs_qUC	R-HSA-1251985	Nuclear signaling by ERBB4	7/422	32/10704	0,000201337	0,001544954	0,000994791
aUC_vs_qUC	R-HSA-74751	Insulin receptor signalling cascade	9/422	54/10704	0,000231908	0,001767517	0,001138099
aUC_vs_qUC	R-HSA-389356	CD28 co-stimulation	7/422	33/10704	0,000246981	0,001857299	0,001195909
aUC_vs_qUC	R-HSA-445989	TAK1 activates NFkB by phosphorylation and activation of IKKs complex	7/422	33/10704	0,000246981	0,001857299	0,001195909
aUC_vs_qUC	R-HSA-2454202	Fc epsilon receptor (FCERI) signaling	15/422	134/10704	0,00025079	0,001873448	0,001206308
aUC_vs_qUC	R-HSA-5260271	Diseases of Immune System	6/422	24/10704	0,00026623	0,001937469	0,001247531
aUC_vs_qUC	R-HSA-5602358	Diseases associated with the TLR signaling cascade	6/422	24/10704	0,00026623	0,001937469	0,001247531
aUC_vs_qUC	R-HSA-6783589	Interleukin-6 family signaling	6/422	24/10704	0,00026623	0,001937469	0,001247531
aUC_vs_qUC	R-HSA-9634638	Estrogen-dependent nuclear events downstream of ESR-membrane signaling	6/422	24/10704	0,00026623	0,001937469	0,001247531
aUC_vs_qUC	R-HSA-2173793	Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	8/422	44/10704	0,000277509	0,002006605	0,001292047

For Review Only

aUC_vs_qUC	R-HSA-187687	Signalling to ERKs	7/422	34/10704	0,000300599	0,002146049	0,001381834
aUC_vs_qUC	R-HSA-4791275	Signaling by WNT in cancer	7/422	34/10704	0,000300599	0,002146049	0,001381834
aUC_vs_qUC	R-HSA-2151201	Transcriptional activation of mitochondrial biogenesis	9/422	56/10704	0,000308146	0,002186092	0,001407618
aUC_vs_qUC	R-HSA-1643713	Signaling by EGFR in Cancer	6/422	25/10704	0,00033877	0,002373494	0,001528286
aUC_vs_qUC	R-HSA-5654708	Downstream signaling of activated FGFR3	6/422	25/10704	0,00033877	0,002373494	0,001528286
aUC_vs_qUC	R-HSA-196299	Beta-catenin phosphorylation cascade	5/422	17/10704	0,000388373	0,002671249	0,001720009
aUC_vs_qUC	R-HSA-8934593	Regulation of RUNX1 Expression and Activity	5/422	17/10704	0,000388373	0,002671249	0,001720009
aUC_vs_qUC	R-HSA-9022699	MECP2 regulates neuronal receptors and channels	5/422	17/10704	0,000388373	0,002671249	0,001720009
aUC_vs_qUC	R-HSA-186797	Signaling by PDGF	9/422	58/10704	0,00040401	0,002680723	0,001726109
aUC_vs_qUC	R-HSA-2644602	Signaling by NOTCH1 PEST Domain Mutants in Cancer	9/422	58/10704	0,00040401	0,002680723	0,001726109
aUC_vs_qUC	R-HSA-2644603	Signaling by NOTCH1 in Cancer	9/422	58/10704	0,00040401	0,002680723	0,001726109
aUC_vs_qUC	R-HSA-2644606	Constitutive Signaling by NOTCH1 PEST Domain Mutants	9/422	58/10704	0,00040401	0,002680723	0,001726109
aUC_vs_qUC	R-HSA-2894858	Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer	9/422	58/10704	0,00040401	0,002680723	0,001726109
aUC_vs_qUC	R-HSA-2894862	Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants	9/422	58/10704	0,00040401	0,002680723	0,001726109
aUC_vs_qUC	R-HSA-9617629	Regulation of FOXO transcriptional activity by acetylation	4/422	10/10704	0,000413875	0,00271425	0,001747697
aUC_vs_qUC	R-HSA-9675135	Diseases of DNA repair	4/422	10/10704	0,000413875	0,00271425	0,001747697
aUC_vs_qUC	R-HSA-1912420	Pre-NOTCH Processing in Golgi	5/422	18/10704	0,000520474	0,003374106	0,002172577
aUC_vs_qUC	R-HSA-881907	Gastrin-CREB signalling pathway via PKC and MAPK	5/422	18/10704	0,000520474	0,003374106	0,002172577
aUC_vs_qUC	R-HSA-5654716	Downstream signaling of activated FGFR4	6/422	27/10704	0,0005296	0,003413649	0,002198039
aUC_vs_qUC	R-HSA-1059683	Interleukin-6 signaling	4/422	11/10704	0,000630207	0,003971359	0,002557146
aUC_vs_qUC	R-HSA-351906	Apoptotic cleavage of cell adhesion proteins	4/422	11/10704	0,000630207	0,003971359	0,002557146
aUC_vs_qUC	R-HSA-8851805	MET activates RAS signaling	4/422	11/10704	0,000630207	0,003971359	0,002557146
aUC_vs_qUC	R-HSA-9634285	Constitutive Signaling by Overexpressed ERBB2	4/422	11/10704	0,000630207	0,003971359	0,002557146
aUC_vs_qUC	R-HSA-350054	Notch-HLH transcription pathway	6/422	28/10704	0,000651895	0,004085206	0,002630452
aUC_vs_qUC	R-HSA-5654736	Signaling by FGFR1	8/422	50/10704	0,000683704	0,004260875	0,002743564
aUC_vs_qUC	R-HSA-5654741	Signaling by FGFR3	7/422	40/10704	0,000849576	0,005265504	0,003390442
aUC_vs_qUC	R-HSA-1181150	Signaling by NODAL	5/422	20/10704	0,000882362	0,005380022	0,00346418
aUC_vs_qUC	R-HSA-167044	Signalling to RAS	5/422	20/10704	0,000882362	0,005380022	0,00346418
aUC_vs_qUC	R-HSA-5625900	RHO GTPases activate CIT	5/422	20/10704	0,000882362	0,005380022	0,00346418
aUC_vs_qUC	R-HSA-389359	CD28 dependent Vav1 pathway	4/422	12/10704	0,000916035	0,00546713	0,003520268
aUC_vs_qUC	R-HSA-9027276	Erythropoietin activates Phosphoinositide-3-kinase (PI3K)	4/422	12/10704	0,000916035	0,00546713	0,003520268
aUC_vs_qUC	R-HSA-9664420	Killing mechanisms	4/422	12/10704	0,000916035	0,00546713	0,003520268
aUC_vs_qUC	R-HSA-9673324	WNT5:FZD7-mediated leishmania damping	4/422	12/10704	0,000916035	0,00546713	0,003520268
aUC_vs_qUC	R-HSA-168928	DDX58/IFIH1-mediated induction of interferon-alpha/beta	10/422	78/10704	0,000931065	0,005498647	0,003540562
aUC_vs_qUC	R-HSA-74752	Signaling by Insulin receptor	10/422	78/10704	0,000931065	0,005498647	0,003540562
aUC_vs_qUC	R-HSA-373755	Semaphorin interactions	9/422	65/10704	0,000950994	0,00558709	0,003597511
aUC_vs_qUC	R-HSA-2424491	DAP12 signaling	6/422	30/10704	0,000961124	0,005617345	0,003616991
aUC_vs_qUC	R-HSA-5654743	Signaling by FGFR4	7/422	41/10704	0,000990327	0,005758188	0,00370768
aUC_vs_qUC	R-HSA-416572	Sema4D induced cell migration and growth-cone collapse	5/422	21/10704	0,001121009	0,00645152	0,004154114
aUC_vs_qUC	R-HSA-445144	Signal transduction by L1	5/422	21/10704	0,001121009	0,00645152	0,004154114
aUC_vs_qUC	R-HSA-5654687	Downstream signaling of activated FGFR1	6/422	31/10704	0,001152733	0,006600422	0,004249992
aUC_vs_qUC	R-HSA-171007	p38MAPK events	4/422	13/10704	0,00128224	0,007195856	0,00463339
aUC_vs_qUC	R-HSA-179812	GRB2 events in EGFR signaling	4/422	13/10704	0,00128224	0,007195856	0,00463339
aUC_vs_qUC	R-HSA-209560	NF-kB is activated and signals survival	4/422	13/10704	0,00128224	0,007195856	0,00463339
aUC_vs_qUC	R-HSA-8847993	ERBB2 Activates PTK6 Signaling	4/422	13/10704	0,00128224	0,007195856	0,00463339
aUC_vs_qUC	R-HSA-5655253	Signaling by FGFR2 in disease	7/422	43/10704	0,001326466	0,007407194	0,00476947
aUC_vs_qUC	R-HSA-2173789	TGF-beta receptor signaling activates SMADs	6/422	32/10704	0,001372286	0,007587935	0,004885849
aUC_vs_qUC	R-HSA-2173796	SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	6/422	32/10704	0,001372286	0,007587935	0,004885849
aUC_vs_qUC	R-HSA-195721	Signaling by WNT	25/422	332/10704	0,001458574	0,008025715	0,005167734
aUC_vs_qUC	R-HSA-193704	p75 NTR receptor-mediated signalling	11/422	97/10704	0,001475171	0,008077634	0,005201164
aUC_vs_qUC	R-HSA-2559582	Senescence-Associated Secretory Phenotype (SASP)	12/422	112/10704	0,001502881	0,008189613	0,005273267
aUC_vs_qUC	R-HSA-69202	Cyclin E associated events during G1/S transition	10/422	83/10704	0,00151132	0,008196004	0,005277382
aUC_vs_qUC	R-HSA-75893	TNF signaling	7/422	44/10704	0,001524917	0,008230173	0,005299384
aUC_vs_qUC	R-HSA-9022692	Regulation of MECP2 expression and activity	6/422	33/10704	0,001622354	0,008714358	0,005611149
aUC_vs_qUC	R-HSA-2173795	Downregulation of SMAD2/3:SMAD4 transcriptional activity	5/422	23/10704	0,00173703	0,008830555	0,005685967
aUC_vs_qUC	R-HSA-1250347	SHC1 events in ERBB4 signaling	4/422	14/10704	0,001739694	0,008830555	0,005685967
aUC_vs_qUC	R-HSA-180336	SHC1 events in EGFR signaling	4/422	14/10704	0,001739694	0,008830555	0,005685967
aUC_vs_qUC	R-HSA-4839735	AXIN mutants destabilize the destruction complex, activating WNT signaling	4/422	14/10704	0,001739694	0,008830555	0,005685967
aUC_vs_qUC	R-HSA-4839744	truncated APC mutants destabilize the destruction complex	4/422	14/10704	0,001739694	0,008830555	0,005685967
aUC_vs_qUC	R-HSA-4839748	AMER1 mutants destabilize the destruction complex	4/422	14/10704	0,001739694	0,008830555	0,005685967
aUC_vs_qUC	R-HSA-5358565	Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)	4/422	14/10704	0,001739694	0,008830555	0,005685967
aUC_vs_qUC	R-HSA-5358606	Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)	4/422	14/10704	0,001739694	0,008830555	0,005685967
aUC_vs_qUC	R-HSA-5467337	APC truncation mutants have impaired AXIN binding	4/422	14/10704	0,001739694	0,008830555	0,005685967
aUC_vs_qUC	R-HSA-5467340	AXIN missense mutants destabilize the destruction complex	4/422	14/10704	0,001739694	0,008830555	0,005685967
aUC_vs_qUC	R-HSA-5467348	Truncations of AMER1 destabilize the destruction complex	4/422	14/10704	0,001739694	0,008830555	0,005685967
aUC_vs_qUC	R-HSA-877312	Regulation of IFNG signaling	4/422	14/10704	0,001739694	0,008830555	0,005685967
aUC_vs_qUC	R-HSA-1566948	Elastic fibre formation	7/422	45/10704	0,001844757	0,008830555	0,005685967
aUC_vs_qUC	R-HSA-69656	Cyclin A:Cdk2-associated events at S phase entry	10/422	85/10704	0,001813255	0,009131035	0,005879446
aUC_vs_qUC	R-HSA-2029480	Fcgamma receptor (FCGR) dependent phagocytosis	10/422	86/10704	0,001981533	0,009934083	0,006396526
aUC_vs_qUC	R-HSA-5627123	RHO GTPases activate PAKs	5/422	24/10704	0,002124083	0,010554913	0,006796277
aUC_vs_qUC	R-HSA-933542	TRAF6 mediated NF-kB activation	5/422	24/10704	0,002124083	0,010554913	0,006796277
aUC_vs_qUC	R-HSA-190236	Signaling by FGFR	10/422	87/10704	0,002162186	0,010697131	0,00688785
aUC_vs_qUC	R-HSA-5654738	Signaling by FGFR2	9/422	73/10704	0,002189343	0,010737299	0,006913715
aUC_vs_qUC	R-HSA-8939902	Regulation of RUNX2 expression and activity	9/422	73/10704	0,002189343	0,010737299	0,006913715
aUC_vs_qUC	R-HSA-114604	GPVI-mediated activation cascade	6/422	35/10704	0,002224707	0,010863505	0,006994978
aUC_vs_qUC	R-HSA-2691230	Signaling by NOTCH1 HD Domain Mutants in Cancer	4/422	15/10704	0,002299141	0,011083041	0,007136337
aUC_vs_qUC	R-HSA-2691232	Constitutive Signaling by NOTCH1 HD Domain Mutants	4/422	15/10704	0,002299141	0,011083041	0,007136337
aUC_vs_qUC	R-HSA-71336	Pentose phosphate pathway	4/422	15/10704	0,002299141	0,011083041	0,007136337
aUC_vs_qUC	R-HSA-9658195	Leishmania infection	20/422	252/10704	0,002312373	0,01109939	0,007146864
aUC_vs_qUC	R-HSA-195258	RHO GTPase Effectors	24/422	327/10704	0,002528486	0,012037423	0,007750861
aUC_vs_qUC	R-HSA-2122947	NOTCH1 Intracellular Domain Regulates Transcription	7/422	48/10704	0,002559503	0,012037423	0,007750861
aUC_vs_qUC	R-HSA-6791312	TP53 Regulates Transcription of Cell Cycle Genes	7/422	48/10704	0,002559503	0,012037423	0,007750861
aUC_vs_qUC	R-HSA-5654700	FRS-mediated FGFR2 signaling	5/422	25/10704	0,002570411	0,012037423	0,007750861
aUC_vs_qUC	R-HSA-8854691	Interleukin-20 family signaling	5/422	25/10704	0,002570411	0,012037423	0,007750861
aUC_vs_qUC	R-HSA-1266695	Interleukin-7 signaling	6/422	36/10704	0,002582497	0,012037423	0,007750861
aUC_vs_qUC	R-HSA-5673000	RAF activation	6/422	36/10704	0,002582497	0,012037423	0,007750861
aUC_vs_qUC	R-HSA-5689880	Ub-specific processing proteases	18/422	220/10704	0,0027111	0,012584859	0,008103352
aUC_vs_qUC	R-HSA-1433559	Regulation of KIT signaling	4/422	16/10704	0,002971104	0,0136236	0,008772195
aUC_vs_qUC	R-HSA-193639	p75NTR signals via NF-kB	4/422	16/10704	0,002971104	0,0136236	0,008772195
aUC_vs_qUC	R-HSA-2173791	TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)	4/422	16/10704	0,002971104	0,0136236	0,008772195
aUC_vs_qUC	R-HSA-2173788	Downregulation of TGF-beta receptor signaling	5/422	26/10704	0,003081006	0,014070342	0,009059851
aUC_vs_qUC	R-HSA-373752	Netrin-1 signaling	7/422	50/10704	0,003245697	0,014762687	0,009505649
aUC_vs_qUC	R-HSA-2682334	EPH-Ephrin signaling	10/422	92/10704	0,003274411	0,014774144	0,009513027
aUC_vs_qUC	R-HSA-6804756	Regulation of TP53 Activity through Phosphorylation	10/422	92/10704	0,003274411	0,014774144	0,009513027
aUC_vs_qUC	R-HSA-2129379	Molecules associated with elastic fibres	6/422	38/10704	0,003425473	0,015333068	0,009872916
aUC_vs_qUC	R-HSA-5689896	Ovarian tumor domain proteases	6/422	38/10704	0,003425473	0,015333068	0,009872916
aUC_vs_qUC	R-HSA-180292	GAB1 signalosome	4/422	17/10704	0,003765791	0,01678977	0,010810882
aUC_vs_qUC	R-HSA-2559586	DNA Damage/Telomere Stress Induced Senescence	9/422	80/10704	0,004107433	0,018240886	0,011745251
aUC_vs_qUC	R-HSA-1592230	Mitochondrial biogenesis	10/422	95/10704	0,004134362	0,018288473	0,011775892
aUC_vs_qUC	R-HSA-8853659	RET signaling	6/422	40/10704	0,004457664	0,019641581	0,012647154
aUC_vs_qUC	R-HSA-6802952	Signaling by BRAF and RAF fusions	8/422	67/10704	0,004641358	0,020371406	0,013117087
aUC_vs_qUC	R-HSA-69242	S Phase	14/422	162/10704	0,004801298	0,020991721	0,013516506
aUC_vs_qUC	R-HSA-1500931	Cell-Cell communication	12/422	129/10704	0,004890108	0,021297457	0,013713368
aUC_vs_qUC	R-HSA-5218920	VEGFR2 mediated vascular permeability	5/422	29/10704	0,005048334	0,021750872	0,014005321
aUC_vs_qUC	R-HSA-9645723	Diseases of programmed cell death	5/422	29/10704	0,005048334	0,021750872	0,014005321
aUC_vs_qUC	R-HSA-8875878	MET promotes cell motility	6/422	41/10704	0,005052064	0,021750872	0,014005321
aUC_vs_qUC	R-HSA-9679506	SARS-CoV Infections	13/422	147/10704	0,005332736	0,022871962	0,014727187
aUC_vs_qUC	R-HSA-69206	G1/S Transition	12/422	131/10704	0,005528314	0,023570575	0,015177022
aUC_vs_qUC	R-HSA-3371453	Regulation of HSF1-mediated heat shock response	8/422	69/10704	0,005558309	0,023570575	0,015177022
aUC_vs_qUC	R-HSA-388841	Costimulation by the CD28 family	8/422	69/10704	0,005558309	0,023570575	0,015177022
aUC_vs_qUC	R-HSA-6802957	Oncogenic MAPK signaling	9/422	84/10704	0,005681856	0,024002031	0,015454835
aUC_vs_qUC	R-HSA-3928662	EPHB-mediated forward signaling	6/422	42/10704	0,00570261	0,024002031	0,015454835
aUC_vs_qUC	R-HSA-8874081	MET activates PTK2 signaling	5/422	30/10704	0,005865776	0,024597009	0,01583794
aUC_vs_qUC	R-HSA-1250342	PI3K events in ERBB4 signaling	3/422	10/10704	0,005935239	0,024613787	0,015848743
aUC_vs_qUC	R-HSA-74749	Signal attenuation	3/422	10/10704	0,005935239	0,024613787	0,015848743
aUC_vs_qUC	R-HSA-9020958	Interleukin-21 signaling	3/422	10/10704	0,005935239	0,024613787	0,015848743
aUC_vs_qUC	R-HSA-400253	Circadian Clock	8/422	70/10704	0,006065581	0,024970711	0,016078566
aUC_vs_qUC	R-HSA-909733	Interferon alpha/beta signaling	8/422	70/10704	0,006065581	0,024970711	0,016078566
aUC_vs_qUC	R-HSA-9656223	Signaling by RAF1 mutants	6/422	43/10704	0,006412255	0,026301905	0,016935717
aUC_vs_qUC	R-HSA-2122948	Activated NOTCH1 Transmits Signal to the Nucleus	5/422	31/10704	0,00677213	0,027548092	0,017738133
aUC_vs_qUC	R-HSA-450282	MAPK targets/ Nuclear events mediated by MAP kinases	5/422	31/10704	0,00677213	0,027548092	0,017738133
aUC_vs_qUC	R-HSA-447115	Interleukin-12 family signaling	7/422	57/10704	0,006789335	0,027548092	0,017738133
aUC_vs_qUC	R-HSA-5627117	RHO GTPases Activate ROCKs	4/422	20/10704	0,006982134	0,027928538	0,017983101
aUC_vs_qUC	R-HSA-5654706	FRS-mediated FGFR3 signaling	4/422	20/10704	0,006982134	0,027928538	0,017983101
aUC_vs_qUC	R-HSA-622312	Inflammasomes	4/422	20/10704	0,006982134	0,027928538	0,017983101
aUC_vs_qUC	R-HSA-8876384	Listeria monocytogenes entry into host cells	4/422	20/10704	0,006982134	0,027928538	0,017983101
aUC_vs_qUC	R-HSA-109704	PI3K Cascade	6/422	44/10704	0,00718394	0,028634221	0,018437488
aUC_vs_qUC	R-HSA-373760	L1CAM interactions	11/422	119/10704	0,007239603	0,028754478	0,018514922
aUC_vs_qUC	R-HSA-2871796	FCERI mediated MAPK activation	5/422	32/10704	0,007772102	0,03050846	0,019644305
aUC_vs_qUC	R-HSA-5626467	RHO GTPases activate IQGAPs	5/422	32/10704	0,007772102	0,03050846	0,019644305
aUC_vs_qUC	R-HSA-193692	Regulated proteolysis of p75NTR	3/422	11/10704	0,007924627	0,03050846	0,019644305
aUC_vs_qUC	R-HSA-2025928	Calcineurin activates NFAT	3/422	11/10704	0,007924627	0,03050846	0,019644305
aUC_vs_qUC	R-HSA-376172	DSCAM interactions	3/422	11/10704	0,007924627	0,03050846	0,019644305
aUC_vs_qUC	R-HSA-5603041	IRAK4 deficiency (TLR2/4)	3/422	11/10704	0,007924627	0,03050846	0,019644305
aUC_vs_qUC	R-HSA-5625970	RHO GTPases activate KTN1	3/422	11/10704	0,007924627	0,03050846	0,019644305
aUC_vs_qUC	R-HSA-68689	CDC6 association with the ORC:origin complex	3/422	11/10704	0,007924627	0,03050846	0,019644305
aUC_vs_qUC	R-HSA-9020956	Interleukin-27 signaling	3/422	11/10704	0,007924627	0,03050846	0,019644305
aUC_vs_qUC	R-HSA-2172127	DAP12 interactions	6/422	45/10704	0,008020584	0,030772852	0,019814547
aUC_vs_qUC	R-HSA-9664407	Parasite infection	7/422	59/10704	0,008192564	0,031115193	0,020034979
aUC_vs_qUC	R-HSA-9664417	Leishmania phagocytosis	7/422	59/10704	0,008192564	0,031115193	0,020034979
aUC_vs_qUC	R-HSA-9664422	FCGR3A-mediated phagocytosis	7/422	59/10704	0,008192564	0,031115193	0,020034979
aUC_vs_qUC	R-HSA-3371556	Cellular response to heat stress	9/422	89/10704	0,008262581	0,031275812	0,020138401
aUC_vs_qUC	R-HSA-5218921	VEGFR2 mediated cell proliferation	4/422	21/10704	0,008361223	0,031543342	0,020310663
aUC_vs_qUC	R-HSA-446652	Interleukin-1 family signaling	12/422	140/10704	0,009262775	0,034828036	0,022425667
aUC_vs_qUC	R-HSA-446728	Cell junction organization	9/422	91/10704	0,009513211	0,035650838	0,022955467
aUC_vs_qUC	R-HSA-198725	Nuclear Events (kinase and transcription factor activation)	7/422	61/10704	0,009798498	0,036049444	0,023212128
aUC_vs_qUC	R-HSA-6802946	Signaling by moderate kinase activity BRAF mutants	6/422	47/10704	0,009900258	0,036049444	0,023212128
aUC_vs_qUC	R-HSA-6802949	Signaling by RAS mutants	6/422	47/10704	0,009900258	0,036049444	0,023212128
aUC_vs_qUC	R-HSA-6802955	Paradoxical activation of RAF signaling by kinase inactive BRAF	6/422	47/10704	0,009900258	0,036049444	0,023212128
aUC_vs_qUC	R-HSA-9649948	Signaling downstream of RAS mutants	6/422	47/10704	0,009900258	0,036049444	0,023212128
aUC_vs_qUC	R-HSA-389357	CD28 dependent PI3K/Akt signaling	4/422	22/10704	0,009907205	0,036049444	0,023212128
aUC_vs_qUC	R-HSA-5654712	FRS-mediated FGFR4 signaling	4/422	22/10704	0,009907205	0,036049444	0,023212128
aUC_vs_qUC	R-HSA-8862803	Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models	4/422	22/10704	0,009907205	0,036049444	0,023212128
aUC_vs_qUC	R-HSA-8863678	Neurodegenerative Diseases	4/422	22/10704	0,009907205	0,036049444	0,023212128
aUC_vs_qUC	R-HSA-264870	Caspase-mediated cleavage of cytoskeletal proteins	3/422	12/10704	0,010260824	0,037096825	0,023886533
aUC_vs_qUC	R-HSA-8984722	Interleukin-35 Signalling	3/422	12/10704	0,010260824	0,037096825	0,023886533
aUC_vs_qUC	R-HSA-381426	Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	11/422	125/10704	0,010332515	0,037236669	0,023976579
aUC_vs_qUC	R-HSA-5633007	Regulation of TP53 Activity	13/422	160/10704	0,01062468	0,038167642	0,024576029

For Review Only

aUC_vs_qUC	R-HSA-1912422	Pre-NOTCH Expression and Processing	10/422	109/10704	0,010741839	0,038466013	0,02476815
aUC_vs_qUC	R-HSA-201681	TCF dependent signaling in response to WNT	17/422	233/10704	0,010787535	0,038507403	0,0247948
aUC_vs_qUC	R-HSA-400508	Incretin synthesis, secretion, and inactivation	4/422	23/10704	0,011627242	0,040986029	0,02639078
aUC_vs_qUC	R-HSA-5654693	FRS-mediated FGFR1 signaling	4/422	23/10704	0,011627242	0,040986029	0,02639078
aUC_vs_qUC	R-HSA-5654695	PI-3K cascade:FGFR2	4/422	23/10704	0,011627242	0,040986029	0,02639078
aUC_vs_qUC	R-HSA-5654699	SHC-mediated cascade:FGFR2	4/422	23/10704	0,011627242	0,040986029	0,02639078
aUC_vs_qUC	R-HSA-9012852	Signaling by NOTCH3	6/422	49/10704	0,012073857	0,042427758	0,027319105
aUC_vs_qUC	R-HSA-983705	Signaling by the B Cell Receptor (BCR)	10/422	112/10704	0,012857115	0,044550494	0,028685928
aUC_vs_qUC	R-HSA-194315	Signaling by Rho GTPases	28/422	455/10704	0,012940983	0,044550494	0,028685928
aUC_vs_qUC	R-HSA-111461	Cytochrome c-mediated apoptotic response	3/422	13/10704	0,012954399	0,044550494	0,028685928
aUC_vs_qUC	R-HSA-140342	Apoptosis induced DNA fragmentation	3/422	13/10704	0,012954399	0,044550494	0,028685928
aUC_vs_qUC	R-HSA-1502540	Signaling by Activin	3/422	13/10704	0,012954399	0,044550494	0,028685928
aUC_vs_qUC	R-HSA-5607763	CLEC7A (Dectin-1) induces NFAT activation	3/422	13/10704	0,012954399	0,044550494	0,028685928
aUC_vs_qUC	R-HSA-75205	Dissolution of Fibrin Clot	3/422	13/10704	0,012954399	0,044550494	0,028685928
aUC_vs_qUC	R-HSA-449836	Other interleukin signaling	4/422	24/10704	0,013527874	0,046240734	0,029774269
aUC_vs_qUC	R-HSA-450302	activated TAK1 mediates p38 MAPK activation	4/422	24/10704	0,013527874	0,046240734	0,029774269
aUC_vs_qUC	R-HSA-6806003	Regulation of TP53 Expression and Degradation	5/422	37/10704	0,014331281	0,048838928	0,031447238
aUC_vs_qUC	R-HSA-9678108	SARS-CoV-1 Infection	6/422	51/10704	0,014563068	0,04947934	0,031859597
aUC_vs_HC	R-HSA-449147	Signaling by Interleukins	107/709	461/10704	3,12022E-32	3,87843E-29	2,39764E-29
aUC_vs_HC	R-HSA-5663202	Diseases of signal transduction by growth factor receptors and second messengers	94/709	387/10704	6,25139E-30	3,88524E-27	2,40185E-27
aUC_vs_HC	R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling	46/709	108/10704	2,25773E-26	9,35453E-24	5,78296E-24
aUC_vs_HC	R-HSA-194138	Signaling by VEGF	40/709	108/10704	2,1697E-20	6,74233E-18	4,1681E-18
aUC_vs_HC	R-HSA-4420097	VEGFA-VEGFR2 Pathway	36/709	99/10704	3,62701E-18	9,01676E-16	5,57415E-16
aUC_vs_HC	R-HSA-2219528	PI3K/AKT Signaling in Cancer	36/709	101/10704	7,7557E-18	1,4696E-15	9,08506E-16
aUC_vs_HC	R-HSA-1257604	PIP3 activates AKT signaling	60/709	264/10704	8,27612E-18	1,4696E-15	9,08506E-16
aUC_vs_HC	R-HSA-9006925	Intracellular signaling by second messengers	64/709	306/10704	5,37394E-17	8,34975E-15	5,16181E-15
aUC_vs_HC	R-HSA-166520	Signaling by NTRKs	39/709	134/10704	8,97066E-16	1,23895E-13	7,65916E-14
aUC_vs_HC	R-HSA-199418	Negative regulation of the PI3K/AKT network	35/709	110/10704	1,30857E-15	1,62655E-13	1,00553E-13
aUC_vs_HC	R-HSA-8878166	Transcriptional regulation by RUNX2	36/709	121/10704	5,47338E-15	6,18492E-13	3,82351E-13
aUC_vs_HC	R-HSA-9009391	Extra-nuclear estrogen signaling	28/709	77/10704	2,05254E-14	2,12608E-12	1,31434E-12
aUC_vs_HC	R-HSA-8939211	ESR-mediated signaling	49/709	223/10704	3,9049E-14	3,73368E-12	2,30816E-12
aUC_vs_HC	R-HSA-9006931	Signaling by Nuclear Receptors	58/709	299/10704	5,63133E-14	4,99982E-12	3,09088E-12
aUC_vs_HC	R-HSA-8848021	Signaling by PTK6	23/709	54/10704	8,31543E-14	6,46005E-12	3,9936E-12
aUC_vs_HC	R-HSA-9006927	Signaling by Non-Receptor Tyrosine Kinases	23/709	54/10704	8,31543E-14	6,46005E-12	3,9936E-12
aUC_vs_HC	R-HSA-2559583	Cellular Senescence	45/709	197/10704	1,01447E-13	7,41756E-12	4,58553E-12
aUC_vs_HC	R-HSA-9659787	Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects	13/709	17/10704	7,90134E-13	5,16914E-11	3,19556E-11
aUC_vs_HC	R-HSA-9661069	Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	13/709	17/10704	7,90134E-13	5,16914E-11	3,19556E-11
aUC_vs_HC	R-HSA-166058	MyD88:MAL(TIRAP) cascade initiated on plasma membrane	29/709	95/10704	1,21809E-12	7,20993E-11	4,45717E-11
aUC_vs_HC	R-HSA-168188	Toll Like Receptor TLR6:TLR2 Cascade	29/709	95/10704	1,21809E-12	7,20993E-11	4,45717E-11
aUC_vs_HC	R-HSA-6811558	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	30/709	103/10704	1,93542E-12	1,09351E-10	6,76008E-11
aUC_vs_HC	R-HSA-5683057	MAPK family signaling cascades	58/709	325/10704	2,2806E-12	1,23251E-10	7,61939E-11
aUC_vs_HC	R-HSA-168179	Toll Like Receptor TLR1:TLR2 Cascade	29/709	98/10704	2,922E-12	1,45282E-10	8,98129E-11
aUC_vs_HC	R-HSA-181438	Toll Like Receptor 2 (TLR2) Cascade	29/709	98/10704	2,922E-12	1,45282E-10	8,98129E-11
aUC_vs_HC	R-HSA-186763	Downstream signal transduction	16/709	29/10704	3,50658E-12	1,60677E-10	9,93306E-11
aUC_vs_HC	R-HSA-69231	Cyclin D associated events in G1	20/709	47/10704	3,62435E-12	1,60677E-10	9,93306E-11
aUC_vs_HC	R-HSA-69236	G1 Phase	20/709	47/10704	3,62435E-12	1,60677E-10	9,93306E-11
aUC_vs_HC	R-HSA-166166	MyD88-independent TLR4 cascade	29/709	99/10704	3,87798E-12	1,60677E-10	9,93306E-11
aUC_vs_HC	R-HSA-937061	TRIF(TICAM1)-mediated TLR4 signaling	29/709	99/10704	3,87798E-12	1,60677E-10	9,93306E-11
aUC_vs_HC	R-HSA-1433557	Signaling by SCF-KIT	19/709	43/10704	5,57549E-12	2,23559E-10	1,38204E-10
aUC_vs_HC	R-HSA-168164	Toll Like Receptor 3 (TLR3) Cascade	28/709	94/10704	5,82955E-12	2,26442E-10	1,39986E-10
aUC_vs_HC	R-HSA-187037	Signaling by NTRK1 (TRKA)	31/709	115/10704	7,86699E-12	2,91633E-10	1,80287E-10
aUC_vs_HC	R-HSA-166016	Toll Like Receptor 4 (TLR4) Cascade	33/709	129/10704	7,97709E-12	2,91633E-10	1,80287E-10
aUC_vs_HC	R-HSA-975138	TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation	27/709	91/10704	1,54859E-11	5,49969E-10	3,3999E-10
aUC_vs_HC	R-HSA-168142	Toll Like Receptor 10 (TLR10) Cascade	26/709	85/10704	1,71371E-11	5,60564E-10	3,4654E-10
aUC_vs_HC	R-HSA-168176	Toll Like Receptor 5 (TLR5) Cascade	26/709	85/10704	1,71371E-11	5,60564E-10	3,4654E-10
aUC_vs_HC	R-HSA-975871	MyD88 cascade initiated on plasma membrane	26/709	85/10704	1,71371E-11	5,60564E-10	3,4654E-10
aUC_vs_HC	R-HSA-975155	MyD88 dependent cascade initiated on endosome	27/709	92/10704	2,0569E-11	6,47272E-10	4,00143E-10
aUC_vs_HC	R-HSA-9669938	Signaling by KIT in disease	13/709	20/10704	2,13501E-11	6,47272E-10	4,00143E-10
aUC_vs_HC	R-HSA-9670439	Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	13/709	20/10704	2,13501E-11	6,47272E-10	4,00143E-10
aUC_vs_HC	R-HSA-168181	Toll Like Receptor 7/8 (TLR7/8) Cascade	27/709	93/10704	2,71993E-11	8,0497E-10	4,97631E-10
aUC_vs_HC	R-HSA-9634638	Estrogen-dependent nuclear events downstream of ESR-membrane signaling	14/709	24/10704	2,91024E-11	8,41263E-10	5,20068E-10
aUC_vs_HC	R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer	24/709	75/10704	3,55822E-11	1,0052E-09	6,21412E-10
aUC_vs_HC	R-HSA-168138	Toll Like Receptor 9 (TLR9) Cascade	27/709	96/10704	6,13008E-11	1,69327E-09	1,04677E-09
aUC_vs_HC	R-HSA-168898	Toll-like Receptor Cascades	35/709	155/10704	8,37313E-11	2,26257E-09	1,39872E-09
aUC_vs_HC	R-HSA-9006936	Signaling by TGFB family members	27/709	102/10704	2,80011E-10	7,40539E-09	4,578E-09
aUC_vs_HC	R-HSA-1236394	Signaling by ERBB4	20/709	58/10704	3,42086E-10	8,85859E-09	5,47637E-09
aUC_vs_HC	R-HSA-9607240	FLT3 Signaling	50/709	294/10704	4,67934E-10	1,18704E-08	7,33828E-09
aUC_vs_HC	R-HSA-9614085	FOXO-mediated transcription	21/709	65/10704	4,94671E-10	1,22975E-08	7,60231E-09
aUC_vs_HC	R-HSA-5684996	MAPK1/MAPK3 signaling	49/709	286/10704	5,41186E-10	1,31901E-08	8,1541E-09
aUC_vs_HC	R-HSA-9034015	Signaling by NTRK3 (TRKC)	11/709	17/10704	8,55909E-10	2,01912E-08	1,24822E-08
aUC_vs_HC	R-HSA-170834	Signaling by TGF-beta Receptor Complex	22/709	73/10704	8,60928E-10	2,01912E-08	1,24822E-08
aUC_vs_HC	R-HSA-9006115	Signaling by NTRK2 (TRKB)	13/709	25/10704	1,04937E-09	2,4155E-08	1,49326E-08
aUC_vs_HC	R-HSA-1227986	Signaling by ERBB2	18/709	50/10704	1,17758E-09	2,66132E-08	1,64523E-08
aUC_vs_HC	R-HSA-168643	Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways	19/709	56/10704	1,30179E-09	2,88951E-08	1,78629E-08
aUC_vs_HC	R-HSA-383280	Nuclear Receptor transcription pathway	18/709	52/10704	2,45395E-09	5,32992E-08	3,29495E-08
aUC_vs_HC	R-HSA-450294	MAP kinase activation	20/709	64/10704	2,48701E-09	5,32992E-08	3,29495E-08
aUC_vs_HC	R-HSA-9675126	Diseases of mitotic cell cycle	15/709	36/10704	2,69156E-09	5,57601E-08	3,44708E-08
aUC_vs_HC	R-HSA-9687139	Aberrant regulation of mitotic cell cycle due to RB1 defects	15/709	36/10704	2,69156E-09	5,57601E-08	3,44708E-08
aUC_vs_HC	R-HSA-448424	Interleukin-17 signaling	21/709	72/10704	4,04276E-09	8,23796E-08	5,0927E-08
aUC_vs_HC	R-HSA-8941326	RUNX2 regulates bone development	14/709	32/10704	4,246E-09	8,3345E-08	5,15238E-08
aUC_vs_HC	R-HSA-9673767	Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants	9/709	12/10704	4,2913E-09	8,3345E-08	5,15238E-08
aUC_vs_HC	R-HSA-9673770	Signaling by PDGFRA extracellular domain mutants	9/709	12/10704	4,2913E-09	8,3345E-08	5,15238E-08
aUC_vs_HC	R-HSA-5673001	RAF/MAP kinase cascade	46/709	280/10704	7,37672E-09	1,41066E-07	8,72065E-08
aUC_vs_HC	R-HSA-453279	Mitotic G1 phase and G1/S transition	31/709	149/10704	8,34265E-09	1,5712E-07	9,71313E-08
aUC_vs_HC	R-HSA-177929	Signaling by EGFR	17/709	50/10704	9,3563E-09	1,7358E-07	1,07307E-07
aUC_vs_HC	R-HSA-6802957	Oncogenic MAPK signaling	22/709	84/10704	1,56837E-08	2,86689E-07	1,77231E-07
aUC_vs_HC	R-HSA-2428928	IRS-related events triggered by IGF1R	17/709	52/10704	1,83899E-08	3,31284E-07	2,048E-07
aUC_vs_HC	R-HSA-2990846	SUMOylation	35/709	188/10704	1,9264E-08	3,39822E-07	2,10077E-07
aUC_vs_HC	R-HSA-9617828	FOXO-mediated transcription of cell cycle genes	10/709	17/10704	1,94106E-08	3,39822E-07	2,10077E-07
aUC_vs_HC	R-HSA-6806834	Signaling by MET	21/709	79/10704	2,50417E-08	4,32318E-07	2,67258E-07
aUC_vs_HC	R-HSA-2428924	IGF1R signaling cascade	17/709	53/10704	2,54263E-08	4,32944E-07	2,67645E-07
aUC_vs_HC	R-HSA-3108232	SUMO E3 ligases SUMOylate target proteins	34/709	182/10704	2,8153E-08	4,72843E-07	2,92311E-07
aUC_vs_HC	R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	17/709	54/10704	3,48506E-08	5,77591E-07	3,57066E-07
aUC_vs_HC	R-HSA-1250196	SHC1 events in ERBB2 signaling	11/709	22/10704	3,587E-08	5,86664E-07	3,62675E-07
aUC_vs_HC	R-HSA-8878159	Transcriptional regulation by RUNX3	23/709	96/10704	4,58703E-08	7,40478E-07	4,57762E-07
aUC_vs_HC	R-HSA-2559585	Oncogene Induced Senescence	13/709	33/10704	7,03798E-08	1,10737E-06	6,84574E-07
aUC_vs_HC	R-HSA-389356	CD28 co-stimulation	13/709	33/10704	7,03798E-08	1,10737E-06	6,84574E-07
aUC_vs_HC	R-HSA-933542	TRAF6 mediated NF-kB activation	11/709	24/10704	1,12252E-07	1,74321E-06	1,07765E-06
aUC_vs_HC	R-HSA-186797	Signaling by PDGF	17/709	58/10704	1,13596E-07	1,74321E-06	1,07765E-06
aUC_vs_HC	R-HSA-9671555	Signaling by PDGFR in disease	10/709	20/10704	1,5355E-07	2,32759E-06	1,43891E-06
aUC_vs_HC	R-HSA-1963642	PI3K events in ERBB2 signaling	9/709	16/10704	1,75134E-07	2,62295E-06	1,62151E-06
aUC_vs_HC	R-HSA-400685	Sema4D in semaphorin signaling	11/709	25/10704	1,88516E-07	2,72471E-06	1,68441E-06
aUC_vs_HC	R-HSA-5674400	Constitutive Signaling by AKT1 E17K in Cancer	11/709	25/10704	1,88516E-07	2,72471E-06	1,68441E-06
aUC_vs_HC	R-HSA-9664565	Signaling by ERBB2 KD Mutants	11/709	25/10704	1,88516E-07	2,72471E-06	1,68441E-06
aUC_vs_HC	R-HSA-6802952	Signaling by BRAF and RAF fusions	18/709	67/10704	2,09637E-07	2,9909E-06	1,84897E-06
aUC_vs_HC	R-HSA-195721	Signaling by WNT	48/709	332/10704	2,11745E-07	2,9909E-06	1,84897E-06
aUC_vs_HC	R-HSA-445144	Signal transduction by L1	10/709	21/10704	2,75802E-07	3,85193E-06	2,38126E-06
aUC_vs_HC	R-HSA-1227990	Signaling by ERBB2 in Cancer	11/709	26/10704	3,07314E-07	4,24435E-06	2,62385E-06
aUC_vs_HC	R-HSA-8986944	Transcriptional Regulation by MECP2	17/709	62/10704	3,30966E-07	4,52107E-06	2,79469E-06
aUC_vs_HC	R-HSA-195258	RHO GTPase Effectors	47/709	327/10704	3,38933E-07	4,57928E-06	2,8309E-06
aUC_vs_HC	R-HSA-381340	Transcriptional regulation of white adipocyte differentiation	20/709	84/10704	3,85381E-07	5,15084E-06	3,18424E-06
aUC_vs_HC	R-HSA-2173793	Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	14/709	44/10704	4,90517E-07	6,4863E-06	4,00982E-06
aUC_vs_HC	R-HSA-168928	DDX58/IFIH1-mediated induction of interferon-alpha/beta	19/709	78/10704	5,14655E-07	6,73385E-06	4,16286E-06
aUC_vs_HC	R-HSA-8853884	Transcriptional Regulation by VENTX	13/709	39/10704	6,87699E-07	8,90427E-06	5,50461E-06
aUC_vs_HC	R-HSA-5357801	Programmed Cell Death	32/709	190/10704	8,37522E-07	1,07324E-05	6,63474E-06
aUC_vs_HC	R-HSA-194315	Signaling by Rho GTPases	58/709	455/10704	9,11708E-07	1,15638E-05	7,14873E-06
aUC_vs_HC	R-HSA-109606	Intrinsic Pathway for Apoptosis	15/709	53/10704	1,04537E-06	1,31252E-05	8,114E-06
aUC_vs_HC	R-HSA-5218920	VEGFR2 mediated vascular permeability	11/709	29/10704	1,14495E-06	1,42318E-05	8,79806E-06
aUC_vs_HC	R-HSA-8940973	RUNX2 regulates osteoblast differentiation	10/709	24/10704	1,27748E-06	1,55677E-05	9,62396E-06
aUC_vs_HC	R-HSA-982772	Growth hormone receptor signaling	10/709	24/10704	1,27748E-06	1,55677E-05	9,62396E-06
aUC_vs_HC	R-HSA-8875878	MET promotes cell motility	13/709	41/10704	1,31817E-06	1,59076E-05	9,83409E-06
aUC_vs_HC	R-HSA-74751	Insulin receptor signalling cascade	15/709	54/10704	1,36002E-06	1,62548E-05	1,00487E-05
aUC_vs_HC	R-HSA-198725	Nuclear Events (kinase and transcription factor activation)	16/709	61/10704	1,41077E-06	1,66241E-05	1,0277E-05
aUC_vs_HC	R-HSA-2586552	Signaling by Leptin	7/709	11/10704	1,41767E-06	1,66241E-05	1,0277E-05
aUC_vs_HC	R-HSA-3700989	Transcriptional Regulation by TP53	49/709	365/10704	1,49234E-06	1,72283E-05	1,06505E-05
aUC_vs_HC	R-HSA-5637810	Constitutive Signaling by EGFRvIII	8/709	15/10704	1,51077E-06	1,72283E-05	1,06505E-05
aUC_vs_HC	R-HSA-5637812	Signaling by EGFRvIII in Cancer	8/709	15/10704	1,51077E-06	1,72283E-05	1,06505E-05
aUC_vs_HC	R-HSA-73887	Death Receptor Signalling	26/709	141/10704	1,56837E-06	1,77226E-05	1,09561E-05
aUC_vs_HC	R-HSA-112399	IRS-mediated signalling	14/709	48/10704	1,60529E-06	1,78158E-05	1,10137E-05
aUC_vs_HC	R-HSA-6791312	TP53 Regulates Transcription of Cell Cycle Genes	14/709	48/10704	1,60529E-06	1,78158E-05	1,10137E-05
aUC_vs_HC	R-HSA-4090294	SUMOylation of intracellular receptors	11/709	30/10704	1,70041E-06	1,87045E-05	1,15631E-05
aUC_vs_HC	R-HSA-3928662	EPHB-mediated forward signaling	13/709	42/10704	1,79458E-06	1,95672E-05	1,20964E-05
aUC_vs_HC	R-HSA-109581	Apoptosis	30/709	178/10704	1,81418E-06	1,9609E-05	1,21222E-05
aUC_vs_HC	R-HSA-2559580	Oxidative Stress Induced Senescence	24/709	125/10704	1,87097E-06	2,00484E-05	1,23939E-05
aUC_vs_HC	R-HSA-9006335	Signaling by Erythropoietin	10/709	25/10704	2,00346E-06	2,12846E-05	1,31581E-05
aUC_vs_HC	R-HSA-168638	NOD1/2 Signaling Pathway	12/709	37/10704	2,5813E-06	2,69627E-05	1,66683E-05
aUC_vs_HC	R-HSA-6806003	Regulation of TP53 Expression and Degradation	12/709	37/10704	2,5813E-06	2,69627E-05	1,66683E-05
aUC_vs_HC	R-HSA-373760	L1CAM interactions	23/709	119/10704	2,71524E-06	2,81254E-05	1,73871E-05
aUC_vs_HC	R-HSA-1433559	Regulation of KIT signaling	8/709	16/10704	2,8464E-06	2,87648E-05	1,77824E-05
aUC_vs_HC	R-HSA-1963640	GRB2 events in ERBB2 signaling	8/709	16/10704	2,8464E-06	2,87648E-05	1,77824E-05
aUC_vs_HC	R-HSA-9665348	Signaling by ERBB2 ECD mutants	8/709	16/10704	2,8464E-06	2,87648E-05	1,77824E-05
aUC_vs_HC	R-HSA-202733	Cell surface interactions at the vascular wall	25/709	137/10704	3,0262E-06	3,03352E-05	1,87532E-05
aUC_vs_HC	R-HSA-1474244	Extracellular matrix organization	42/709	301/10704	3,15047E-06	3,13282E-05	1,93671E-05
aUC_vs_HC	R-HSA-5218921	VEGFR2 mediated cell proliferation	9/709	21/10704	3,32722E-06	3,27516E-05	2,0247E-05
aUC_vs_HC	R-HSA-1500931	Cell-Cell communication	24/709	129/10704	3,3463E-06	3,27516E-05	2,0247E-05
aUC_vs_HC	R-HSA-2559582	Senescence-Associated Secretory Phenotype (SASP)	22/709	112/10704	3,37562E-06	3,27804E-05	2,02648E-05
aUC_vs_HC	R-HSA-5655302	Signaling by FGFR1 in disease	12/709	38/10704	3,54756E-06	3,39766E-05	2,10043E-05
aUC_vs_HC	R-HSA-1251985	Nuclear signaling by ERBB4	11/709	32/10704	3,55346E-06	3,39766E-05	2,10043E-05
aUC_vs_HC	R-HSA-201681	TCF dependent signaling in response to WNT	35/709	233/10704	4,00824E-06	3,8019E-05	2,35033E-05
aUC_vs_HC	R-HSA-76002	Platelet activation, signaling and aggregation	38/709	263/10704	4,03741E-06	3,8019E-05	2,35033E-05
aUC_vs_HC	R-HSA-445989	TAK1 activates NFkB by phosphorylation and activation of IKKs complex	11/709	33/10704	4,5993E-06	4,68595E-05	2,89685E-05
aUC_vs_HC	R-HSA-180292	GAB1 signalosome	8/709	17/10704	5,06511E-06	4,69846E-05	2,90458E-05
aUC_vs_HC	R-HSA-389357	CD28 dependent PI3K/Akt signaling	9/709	22/10704	5,30132E-06	4,84525E-05	2,99533E-05
aUC_vs_HC	R-HSA-9665686	Signaling by ERBB2 TMD/JMD mutants	9/709	22/10704	5,30132E-06	4,84525E-05	2,99533E-05
aUC_vs_HC	R-HSA-157118	Signaling by NOTCH	35/709	236/10704	5,3735E-06	4,87537E-05	3,01395E-05
aUC_vs_HC	R-HSA-8853659	RET signaling	12/709	40/10704	6,47329E-06	5,83065E-05	3,6045E-05
aUC_vs_HC	R-HSA-8943724	Regulation of PTEN gene transcription	15/709	61/10704	7,17066E-06	6,2387E-05	3,85676E-05
aUC_vs_HC	R-HSA-6783783	Interleukin-10 signaling	13/709	47/10704	7,26374E-06	6,2387E-05	3,85676E-05

For Review Only

aUC_vs_HC	R-HSA-6802946	Signaling by moderate kinase activity BRAF mutants	13/709	47/10704	7,26374E-06	6,2387E-05	3,85676E-05
aUC_vs_HC	R-HSA-6802949	Signaling by RAS mutants	13/709	47/10704	7,26374E-06	6,2387E-05	3,85676E-05
aUC_vs_HC	R-HSA-6802955	Paradoxical activation of RAF signaling by kinase inactive BRAF	13/709	47/10704	7,26374E-06	6,2387E-05	3,85676E-05
aUC_vs_HC	R-HSA-9649948	Signaling downstream of RAS mutants	13/709	47/10704	7,26374E-06	6,2387E-05	3,85676E-05
aUC_vs_HC	R-HSA-2682334	EPH-Ephrin signaling	19/709	92/10704	7,27765E-06	6,2387E-05	3,85676E-05
aUC_vs_HC	R-HSA-1839117	Signaling by cytosolic FGFR1 fusion mutants	8/709	18/10704	8,58952E-06	7,26311E-05	4,49005E-05
aUC_vs_HC	R-HSA-881907	Gastrin-CREB signalling pathway via PKC and MAPK	8/709	18/10704	8,58952E-06	7,26311E-05	4,49005E-05
aUC_vs_HC	R-HSA-3769402	Deactivation of the beta-catenin transactivating complex	12/709	42/10704	1,13312E-05	9,51667E-05	5,88319E-05
aUC_vs_HC	R-HSA-452723	Transcriptional regulation of pluripotent stem cells	9/709	24/10704	1,23538E-05	0,000101721	6,2884E-05
aUC_vs_HC	R-HSA-6783589	Interleukin-6 family signaling	9/709	24/10704	1,23538E-05	0,000101721	6,2884E-05
aUC_vs_HC	R-HSA-6804116	TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest	7/709	14/10704	1,23571E-05	0,000101721	6,2884E-05
aUC_vs_HC	R-HSA-6804757	Regulation of TP53 Degradation	11/709	36/10704	1,29578E-05	0,000105964	6,55069E-05
aUC_vs_HC	R-HSA-525793	Myogenesis	10/709	30/10704	1,35916E-05	0,00011042	6,82617E-05
aUC_vs_HC	R-HSA-8853334	Signaling by FGFR3 fusions in cancer	6/709	10/10704	1,37939E-05	0,000111337	6,88282E-05
aUC_vs_HC	R-HSA-1236382	Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants	8/709	19/10704	1,39784E-05	0,000111379	6,88545E-05
aUC_vs_HC	R-HSA-5637815	Signaling by Ligand-Responsive EGFR Variants in Cancer	8/709	19/10704	1,39784E-05	0,000111379	6,88545E-05
aUC_vs_HC	R-HSA-1643713	Signaling by EGFR in Cancer	9/709	25/10704	1,81759E-05	0,000143902	8,89601E-05
aUC_vs_HC	R-HSA-109704	PI3K Cascade	12/709	44/10704	1,91146E-05	0,000149431	9,23779E-05
aUC_vs_HC	R-HSA-451927	Interleukin-2 family signaling	12/709	44/10704	1,91146E-05	0,000149431	9,23779E-05
aUC_vs_HC	R-HSA-9616222	Transcriptional regulation of granulopoiesis	18/709	90/10704	2,00588E-05	0,000155832	9,63349E-05
aUC_vs_HC	R-HSA-2454202	Fc epsilon receptor (FCERI) signaling	23/709	134/10704	2,11933E-05	0,000163623	0,000101152
aUC_vs_HC	R-HSA-354194	GRB2:SOS provides linkage to MAPK signaling for Integrins	7/709	15/10704	2,18477E-05	0,000165364	0,000102228
aUC_vs_HC	R-HSA-6785631	ERBB2 Regulates Cell Motility	7/709	15/10704	2,18477E-05	0,000165364	0,000102228
aUC_vs_HC	R-HSA-8866910	TFAP2 (AP-2) family regulates transcription of growth factors and their receptors	7/709	15/10704	2,18477E-05	0,000165364	0,000102228
aUC_vs_HC	R-HSA-8876384	Listeria monocytogenes entry into host cells	8/709	20/10704	2,19511E-05	0,000165364	0,000102228
aUC_vs_HC	R-HSA-114465	Apoptotic cleavage of cellular proteins	11/709	38/10704	2,29702E-05	0,000169952	0,000105064
aUC_vs_HC	R-HSA-5689896	Ovarian tumor domain proteases	11/709	38/10704	2,29702E-05	0,000169952	0,000105064
aUC_vs_HC	R-HSA-8864260	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	11/709	38/10704	2,29702E-05	0,000169952	0,000105064
aUC_vs_HC	R-HSA-75153	Apoptotic execution phase	13/709	52/10704	2,40877E-05	0,000177166	0,000109524
aUC_vs_HC	R-HSA-2173789	TGF-beta receptor signaling activates SMADs	10/709	32/10704	2,58513E-05	0,00018682	0,000115492
aUC_vs_HC	R-HSA-2173796	SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	10/709	32/10704	2,58513E-05	0,00018682	0,000115492
aUC_vs_HC	R-HSA-2871796	FCERI mediated MAPK activation	10/709	32/10704	2,58513E-05	0,00018682	0,000115492
aUC_vs_HC	R-HSA-1059683	Interleukin-6 signaling	6/709	11/10704	2,86454E-05	0,000203464	0,000125781
aUC_vs_HC	R-HSA-5655291	Signaling by FGFR4 in disease	6/709	11/10704	2,86454E-05	0,000203464	0,000125781
aUC_vs_HC	R-HSA-9028731	Activated NTRK2 signals through FRS2 and FRS3	6/709	11/10704	2,86454E-05	0,000203464	0,000125781
aUC_vs_HC	R-HSA-5688426	Deubiquitination	39/709	297/10704	2,95375E-05	0,000208608	0,000128961
aUC_vs_HC	R-HSA-9031628	NGF-stimulated transcription	11/709	39/10704	3,01012E-05	0,000211388	0,00013068
aUC_vs_HC	R-HSA-416572	Sema4D induced cell migration and growth-cone collapse	8/709	21/10704	3,34118E-05	0,00023332	0,000144238
aUC_vs_HC	R-HSA-388841	Costimulation by the CD28 family	15/709	69/10704	3,50631E-05	0,000243483	0,000150521
aUC_vs_HC	R-HSA-74752	Signaling by Insulin receptor	16/709	78/10704	4,1467E-05	0,000286352	0,000177023
aUC_vs_HC	R-HSA-400253	Circadian Clock	15/709	70/10704	4,19423E-05	0,000288034	0,000178062
aUC_vs_HC	R-HSA-9018519	Estrogen-dependent gene expression	24/709	150/10704	4,65365E-05	0,000316198	0,000195473
aUC_vs_HC	R-HSA-4791275	Signaling by WNT in cancer	10/709	34/10704	4,65521E-05	0,000316198	0,000195473
aUC_vs_HC	R-HSA-1834949	Cytosolic sensors of pathogen-associated DNA	14/709	63/10704	4,9144E-05	0,000331979	0,000205229
aUC_vs_HC	R-HSA-512988	Interleukin-3, Interleukin-5 and GM-CSF signaling	12/709	48/10704	4,94096E-05	0,000331979	0,000205229
aUC_vs_HC	R-HSA-8934593	Regulation of RUNX1 Expression and Activity	7/709	17/10704	5,87194E-05	0,00039241	0,000242587
aUC_vs_HC	R-HSA-8863795	Downregulation of ERBB2 signaling	9/709	29/10704	7,00745E-05	0,000463312	0,000286419
aUC_vs_HC	R-HSA-9645723	Diseases of programmed cell death	9/709	29/10704	7,00745E-05	0,000463312	0,000286419
aUC_vs_HC	R-HSA-373755	Semaphorin interactions	14/709	65/10704	7,08564E-05	0,000466003	0,000288082
aUC_vs_HC	R-HSA-2173795	Downregulation of SMAD2/3:SMAD4 transcriptional activity	8/709	23/10704	7,14882E-05	0,000467683	0,000289121
aUC_vs_HC	R-HSA-5654736	Signaling by FGFR1	12/709	50/10704	7,61749E-05	0,000495735	0,000306463
aUC_vs_HC	R-HSA-6802948	Signaling by high-kinase activity BRAF mutants	10/709	36/10704	7,9958E-05	0,000517644	0,000320007
aUC_vs_HC	R-HSA-9656223	Signaling by RAF1 mutants	11/709	43/10704	8,09649E-05	0,000521447	0,000322358
aUC_vs_HC	R-HSA-1980143	Signaling by NOTCH1	15/709	74/10704	8,27561E-05	0,000530236	0,000327791
aUC_vs_HC	R-HSA-6804114	TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest	7/709	18/10704	9,06203E-05	0,000577646	0,0003571
aUC_vs_HC	R-HSA-8874081	MET activates PTK2 signaling	9/709	30/10704	9,42815E-05	0,00059528	0,000368002
aUC_vs_HC	R-HSA-179812	GRB2 events in EGFR signaling	6/709	13/10704	9,48234E-05	0,00059528	0,000368002
aUC_vs_HC	R-HSA-8847993	ERBB2 Activates PTK6 Signaling	6/709	13/10704	9,48234E-05	0,00059528	0,000368002
aUC_vs_HC	R-HSA-3000171	Non-integrin membrane-ECM interactions	13/709	59/10704	9,97967E-05	0,000623353	0,000385356
aUC_vs_HC	R-HSA-5260271	Diseases of Immune System	8/709	24/10704	0,000101055	0,000624935	0,000386334
aUC_vs_HC	R-HSA-5602358	Diseases associated with the TLR signaling cascade	8/709	24/10704	0,000101055	0,000624935	0,000386334
aUC_vs_HC	R-HSA-182971	EGFR downregulation	9/709	31/10704	0,000125126	0,000758692	0,000469023
aUC_vs_HC	R-HSA-1839124	FGFR1 mutant receptor activation	9/709	31/10704	0,000125126	0,000758692	0,000469023
aUC_vs_HC	R-HSA-450282	MAPK targets/ Nuclear events mediated by MAP kinases	9/709	31/10704	0,000125126	0,000758692	0,000469023
aUC_vs_HC	R-HSA-4641262	Disassembly of the destruction complex and recruitment of AXIN to the membrane	9/709	31/10704	0,000125126	0,000758692	0,000469023
aUC_vs_HC	R-HSA-1566948	Elastic fibre formation	11/709	45/10704	0,000126515	0,00076339	0,000471927
aUC_vs_HC	R-HSA-2129379	Molecules associated with elastic fibres	10/709	38/10704	0,000131781	0,000791325	0,000489196
aUC_vs_HC	R-HSA-69206	G1/S Transition	21/709	131/10704	0,000132811	0,000793673	0,000490648
aUC_vs_HC	R-HSA-2029480	Fcgamma receptor (FCGR) dependent phagocytosis	16/709	86/10704	0,000141791	0,000843284	0,000521317
aUC_vs_HC	R-HSA-180336	SHC1 events in EGFR signaling	6/709	14/10704	0,000156673	0,000914294	0,000565216
aUC_vs_HC	R-HSA-198323	AKT phosphorylates targets in the cytosol	6/709	14/10704	0,000156673	0,000914294	0,000565216
aUC_vs_HC	R-HSA-8849471	PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases	6/709	14/10704	0,000156673	0,000914294	0,000565216
aUC_vs_HC	R-HSA-9027284	Erythropoietin activates RAS	6/709	14/10704	0,000156673	0,000914294	0,000565216
aUC_vs_HC	R-HSA-76009	Platelet Aggregation (Plug Formation)	10/709	39/10704	0,000166844	0,000969096	0,000599094
aUC_vs_HC	R-HSA-2173788	Downregulation of TGF-beta receptor signaling	8/709	26/10704	0,000190671	0,001102346	0,000681469
aUC_vs_HC	R-HSA-5625900	RHO GTPases activate CIT	7/709	20/10704	0,000196377	0,001119711	0,000692204
aUC_vs_HC	R-HSA-5627117	RHO GTPases Activate ROCKs	7/709	20/10704	0,000196377	0,001119711	0,000692204
aUC_vs_HC	R-HSA-622312	Inflammasomes	7/709	20/10704	0,000196377	0,001119711	0,000692204
aUC_vs_HC	R-HSA-1226099	Signaling by FGFR in disease	13/709	63/10704	0,000201913	0,001146017	0,000708466
aUC_vs_HC	R-HSA-5674135	MAP2K and MAPK activation	10/709	40/10704	0,000209437	0,001183319	0,000731526
aUC_vs_HC	R-HSA-450341	Activation of the AP-1 family of transcription factors	5/709	10/10704	0,000239393	0,001329758	0,000822055
aUC_vs_HC	R-HSA-74749	Signal attenuation	5/709	10/10704	0,000239393	0,001329758	0,000822055
aUC_vs_HC	R-HSA-9617629	Regulation of FOXO transcriptional activity by acetylation	5/709	10/10704	0,000239393	0,001329758	0,000822055
aUC_vs_HC	R-HSA-9679191	Potential therapeutics for SARS	15/709	81/10704	0,000239635	0,001329758	0,000822055
aUC_vs_HC	R-HSA-2151201	Transcriptional activation of mitochondrial biogenesis	12/709	56/10704	0,000242818	0,001341434	0,000829273
aUC_vs_HC	R-HSA-3772470	Negative regulation of TCF-dependent signaling by WNT ligand antagonists	6/709	15/10704	0,000246557	0,001350088	0,000834623
aUC_vs_HC	R-HSA-844456	The NLRP3 inflammasome	6/709	15/10704	0,000246557	0,001350088	0,000834623
aUC_vs_HC	R-HSA-1538133	G0 and Early G1	8/709	27/10704	0,000255385	0,001374216	0,000849539
aUC_vs_HC	R-HSA-3000170	Syndecan interactions	8/709	27/10704	0,000255385	0,001374216	0,000849539
aUC_vs_HC	R-HSA-354192	Integrin signaling	8/709	27/10704	0,000255385	0,001374216	0,000849539
aUC_vs_HC	R-HSA-912526	Interleukin receptor SHC signaling	8/709	27/10704	0,000255385	0,001374216	0,000849539
aUC_vs_HC	R-HSA-186712	Regulation of beta-cell development	10/709	41/10704	0,000260794	0,001397269	0,00086379
aUC_vs_HC	R-HSA-187687	Signalling to ERKs	9/709	34/10704	0,000272066	0,001451408	0,000897259
aUC_vs_HC	R-HSA-1606322	ZBP1(DAI) mediated induction of type I IFNs	7/709	21/10704	0,00027786	0,001475983	0,000912451
aUC_vs_HC	R-HSA-201451	Signaling by BMP	8/709	28/10704	0,000337013	0,001764791	0,001090991
aUC_vs_HC	R-HSA-6807070	PTEN Regulation	21/709	140/10704	0,000342107	0,001764791	0,001090991
aUC_vs_HC	R-HSA-2644602	Signaling by NOTCH1 PEST Domain Mutants in Cancer	12/709	58/10704	0,000343267	0,001764791	0,001090991
aUC_vs_HC	R-HSA-2644603	Signaling by NOTCH1 in Cancer	12/709	58/10704	0,000343267	0,001764791	0,001090991
aUC_vs_HC	R-HSA-2644606	Constitutive Signaling by NOTCH1 PEST Domain Mutants	12/709	58/10704	0,000343267	0,001764791	0,001090991
aUC_vs_HC	R-HSA-2894858	Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer	12/709	58/10704	0,000343267	0,001764791	0,001090991
aUC_vs_HC	R-HSA-2894862	Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants	12/709	58/10704	0,000343267	0,001764791	0,001090991
aUC_vs_HC	R-HSA-373752	Netrin-1 signaling	11/709	50/10704	0,000343691	0,001764791	0,001090991
aUC_vs_HC	R-HSA-114604	GPVI-mediated activation cascade	9/709	35/10704	0,000345007	0,001764791	0,001090991
aUC_vs_HC	R-HSA-8862803	Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models	7/709	22/10704	0,00038444	0,001950443	0,001205761
aUC_vs_HC	R-HSA-8863678	Neurodegenerative Diseases	7/709	22/10704	0,00038444	0,001950443	0,001205761
aUC_vs_HC	R-HSA-8875555	MET activates RAP1 and RAC1	5/709	11/10704	0,000415017	0,002088525	0,001291124
aUC_vs_HC	R-HSA-9614399	Regulation of localization of FOXO transcription factors	5/709	11/10704	0,000415017	0,002088525	0,001291124
aUC_vs_HC	R-HSA-1266695	Interleukin-7 signaling	9/709	36/10704	0,000433357	0,002172028	0,001342745
aUC_vs_HC	R-HSA-9615017	FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	8/709	29/10704	0,000489908	0,002453148	0,001353854
aUC_vs_HC	R-HSA-75893	TNF signaling	10/709	44/10704	0,000481826	0,00239564	0,001480982
aUC_vs_HC	R-HSA-112409	RAF-independent MAPK1/3 activation	7/709	23/10704	0,000521356	0,002581854	0,001596099
aUC_vs_HC	R-HSA-1810476	RIP-mediated NFkB activation via ZBP1	6/709	17/10704	0,000543676	0,002660588	0,001644772
aUC_vs_HC	R-HSA-196299	Beta-catenin phosphorylation cascade	6/709	17/10704	0,000543676	0,002660588	0,001644772
aUC_vs_HC	R-HSA-9022699	MECP2 regulates neuronal receptors and channels	6/709	17/10704	0,000543676	0,002660588	0,001644772
aUC_vs_HC	R-HSA-114452	Activation of BH3-only proteins	8/709	30/10704	0,000563949	0,002727582	0,001686188
aUC_vs_HC	R-HSA-3000157	Laminin interactions	8/709	30/10704	0,000563949	0,002727582	0,001686188
aUC_vs_HC	R-HSA-5357956	TNFR1-induced NFkappaB signaling pathway	8/709	30/10704	0,000563949	0,002727582	0,001686188
aUC_vs_HC	R-HSA-193704	p75 NTR receptor-mediated signalling	16/709	97/10704	0,000588511	0,002835348	0,001752808
aUC_vs_HC	R-HSA-9679506	SARS-CoV Infections	21/709	147/10704	0,000665707	0,003194878	0,001975069
aUC_vs_HC	R-HSA-933543	NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10	5/709	12/10704	0,000672826	0,003216627	0,001988515
aUC_vs_HC	R-HSA-983231	Factors involved in megakaryocyte development and platelet production	23/709	168/10704	0,000693811	0,003281997	0,002028926
aUC_vs_HC	R-HSA-450302	activated TAK1 mediates p38 MAPK activation	7/709	24/10704	0,000694421	0,003281997	0,002028926
aUC_vs_HC	R-HSA-5668599	RHO GTPases Activate NADPH Oxidases	7/709	24/10704	0,000694421	0,003281997	0,002028926
aUC_vs_HC	R-HSA-111471	Apoptotic factor-mediated response	6/709	18/10704	0,000770204	0,003599111	0,002224966
aUC_vs_HC	R-HSA-1912420	Pre-NOTCH Processing in Golgi	6/709	18/10704	0,000770204	0,003599111	0,002224966
aUC_vs_HC	R-HSA-210993	Tie2 Signaling	6/709	18/10704	0,000770204	0,003599111	0,002224966
aUC_vs_HC	R-HSA-5633007	Regulation of TP53 Activity	22/709	160/10704	0,000847721	0,003946507	0,002439726
aUC_vs_HC	R-HSA-446728	Cell junction organization	15/709	91/10704	0,00087075	0,004038589	0,002496651
aUC_vs_HC	R-HSA-5654741	Signaling by FGFR3	9/709	40/10704	0,00099182	0,00458302	0,002833217
aUC_vs_HC	R-HSA-2122947	NOTCH1 Intracellular Domain Regulates Transcription	10/709	48/10704	0,000998868	0,004598491	0,002842782
aUC_vs_HC	R-HSA-69202	Cyclin E associated events during G1/S transition	14/709	83/10704	0,001015063	0,004655805	0,002878213
aUC_vs_HC	R-HSA-209560	NF-kB is activated and signals survival	5/709	13/10704	0,001034078	0,004725585	0,002921351
aUC_vs_HC	R-HSA-442755	Activation of NMDA receptors and postsynaptic events	15/709	93/10704	0,001096791	0,004993812	0,003087168
aUC_vs_HC	R-HSA-447115	Interleukin-12 family signaling	11/709	57/10704	0,001111568	0,005042623	0,003117343
aUC_vs_HC	R-HSA-9012852	Signaling by NOTCH3	10/709	49/10704	0,001181953	0,005342426	0,003302681
aUC_vs_HC	R-HSA-165159	MTOR signalling	9/709	41/10704	0,001197421	0,005373266	0,003321746
aUC_vs_HC	R-HSA-5654743	Signaling by FGFR4	9/709	41/10704	0,001197421	0,005373266	0,003321746
aUC_vs_HC	R-HSA-216083	Integrin cell surface interactions	14/709	85/10704	0,001290049	0,005747422	0,003553049
aUC_vs_HC	R-HSA-69656	Cyclin A:Cdk2-associated events at S phase entry	14/709	85/10704	0,001290049	0,005747422	0,003553049
aUC_vs_HC	R-HSA-1592230	Mitochondrial biogenesis	15/709	95/10704	0,001370391	0,006083557	0,003760847
aUC_vs_HC	R-HSA-1181150	Signaling by NODAL	6/709	20/10704	0,001434729	0,006324001	0,00390949
aUC_vs_HC	R-HSA-167044	Signalling to RAS	6/709	20/10704	0,001434729	0,006324001	0,00390949
aUC_vs_HC	R-HSA-9664407	Parasite infection	11/709	59/10704	0,001494413	0,006499161	0,004017773
aUC_vs_HC	R-HSA-9664417	Leishmania phagocytosis	11/709	59/10704	0,001494413	0,006499161	0,004017773
aUC_vs_HC	R-HSA-9664422	FCGR3A-mediated phagocytosis	11/709	59/10704	0,001494413	0,006499161	0,004017773
aUC_vs_HC	R-HSA-1250347	SHC1 events in ERBB4 signaling	5/709	14/10704	0,001521525	0,006499161	0,004017773
aUC_vs_HC	R-HSA-162594	Early Phase of HIV Life Cycle	5/709	14/10704	0,001521525	0,006499161	0,004017773
aUC_vs_HC	R-HSA-418885	DCC mediated attractive signaling	5/709	14/10704	0,001521525	0,006499161	0,004017773
aUC_vs_HC	R-HSA-8941856	RUNX3 regulates NOTCH signaling	5/709	14/10704	0,001521525	0,006499161	0,004017773
aUC_vs_HC	R-HSA-8983432	Interleukin-15 signaling	5/709	14/10704	0,001521525	0,006499161	0,004017773
aUC_vs_HC	R-HSA-918233	TRAF3-dependent IRF activation pathway	5/709	14/10704	0,001521525	0,006499161	0,004017773
aUC_vs_HC	R-HSA-1632852	Macroautophagy	19/709	136/10704	0,001543597	0,006570859	0,004062097
aUC_vs_HC	R-HSA-190236	Signaling by FGFR	14/709	87/10704	0,001624749	0,006892708	0,004261063
aUC_vs_HC	R-HSA-5357905	Regulation of TNFR1 signaling	8/709	35/10704	0,001689664	0,007119498	0,004401265
aUC_vs_HC	R-HSA-8953750	Transcriptional Regulation by E2F6	8/709	35/10704	0,001689664	0,007119498	0,004401265
aUC_vs_HC	R-HSA-210745	Regulation of gene expression in beta cells	6/709	21/10704	0,001897477	0,00796812	0,004925882
aUC_vs_HC	R-HSA-2029482	Regulation of actin dynamics for phagocytic cup formation	11/709	61/10704	0,001978996	0,008282465	0,00512021
aUC_vs_HC	R-HSA-5633008	TP53 Regulates Transcription of Cell Death Genes	9/709	44/10704	0,002027793	0,008458209	0,005228854

For Review Only

aUC_vs_HC	R-HSA-5663213	RHO GTPases Activate WASPs and WAVEs	8/709	36/10704	0,002048608	0,008516456	0,005264862
aUC_vs_HC	R-HSA-1912422	Pre-NOTCH Expression and Processing	16/709	109/10704	0,002111109	0,008629096	0,005334496
aUC_vs_HC	R-HSA-438064	Post NMDA receptor activation events	13/709	80/10704	0,002150718	0,008629096	0,005334496
aUC_vs_HC	R-HSA-372708	p130Cas linkage to MAPK signaling for integrins	5/709	15/10704	0,002159009	0,008629096	0,005334496
aUC_vs_HC	R-HSA-4839743	phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex	5/709	15/10704	0,002159009	0,008629096	0,005334496
aUC_vs_HC	R-HSA-5339716	Missspliced GSK3beta mutants stabilize beta-catenin	5/709	15/10704	0,002159009	0,008629096	0,005334496
aUC_vs_HC	R-HSA-5358747	S33 mutants of beta-catenin aren't phosphorylated	5/709	15/10704	0,002159009	0,008629096	0,005334496
aUC_vs_HC	R-HSA-5358749	S37 mutants of beta-catenin aren't phosphorylated	5/709	15/10704	0,002159009	0,008629096	0,005334496
aUC_vs_HC	R-HSA-5358751	S45 mutants of beta-catenin aren't phosphorylated	5/709	15/10704	0,002159009	0,008629096	0,005334496
aUC_vs_HC	R-HSA-5358752	T41 mutants of beta-catenin aren't phosphorylated	5/709	15/10704	0,002159009	0,008629096	0,005334496
aUC_vs_HC	R-HSA-8875360	InlB-mediated entry of Listeria monocytogenes into host cell	5/709	15/10704	0,002159009	0,008629096	0,005334496
aUC_vs_HC	R-HSA-937039	IRAK1 recruits IKK complex	5/709	15/10704	0,002159009	0,008629096	0,005334496
aUC_vs_HC	R-HSA-975144	IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation	5/709	15/10704	0,002159009	0,008629096	0,005334496
aUC_vs_HC	R-HSA-1474228	Degradation of the extracellular matrix	19/709	140/10704	0,002172761	0,008656224	0,005351267
aUC_vs_HC	R-HSA-1660499	Synthesis of PIPs at the plasma membrane	10/709	53/10704	0,002207416	0,008766193	0,00541925
aUC_vs_HC	R-HSA-4086398	Ca2+ pathway	11/709	62/10704	0,002265275	0,008967315	0,005543583
aUC_vs_HC	R-HSA-5655332	Signaling by FGFR3 in disease	6/709	22/10704	0,002464866	0,009665073	0,005974936
aUC_vs_HC	R-HSA-8853338	Signaling by FGFR3 point mutants in cancer	6/709	22/10704	0,002464866	0,009665073	0,005974936
aUC_vs_HC	R-HSA-912631	Regulation of signaling by CBL	6/709	22/10704	0,002464866	0,009665073	0,005974936
aUC_vs_HC	R-HSA-375165	NCAM signaling for neurite out-growth	11/709	63/10704	0,00258422	0,010101212	0,006244557
aUC_vs_HC	R-HSA-5689880	Ub-specific processing proteases	26/709	220/10704	0,002847216	0,011090145	0,006855914
aUC_vs_HC	R-HSA-2424491	DAP12 signaling	7/709	30/10704	0,002884768	0,011090145	0,006855914
aUC_vs_HC	R-HSA-5654696	Downstream signaling of activated FGFR2	7/709	30/10704	0,002884768	0,011090145	0,006855914
aUC_vs_HC	R-HSA-6804758	Regulation of TP53 Activity through Acetylation	7/709	30/10704	0,002884768	0,011090145	0,006855914
aUC_vs_HC	R-HSA-110056	MAPK3 (ERK1) activation	4/709	10/10704	0,002903387	0,011090145	0,006855914
aUC_vs_HC	R-HSA-1250342	PI3K events in ERBB4 signaling	4/709	10/10704	0,002903387	0,011090145	0,006855914
aUC_vs_HC	R-HSA-9020958	Interleukin-21 signaling	4/709	10/10704	0,002903387	0,011090145	0,006855914
aUC_vs_HC	R-HSA-8950505	Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation	8/709	38/10704	0,002944618	0,011090145	0,006855914
aUC_vs_HC	R-HSA-1362300	Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1	5/709	16/10704	0,002971052	0,011090145	0,006855914
aUC_vs_HC	R-HSA-193639	p75NTR signals via NF-kB	5/709	16/10704	0,002971052	0,011090145	0,006855914
aUC_vs_HC	R-HSA-2173791	TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)	5/709	16/10704	0,002971052	0,011090145	0,006855914
aUC_vs_HC	R-HSA-2730905	Role of LAT2/NTAL/LAB on calcium mobilization	5/709	16/10704	0,002971052	0,011090145	0,006855914
aUC_vs_HC	R-HSA-391160	Signal regulatory protein family interactions	5/709	16/10704	0,002971052	0,011090145	0,006855914
aUC_vs_HC	R-HSA-5684264	MAP3K8 (TPL2)-dependent MAPK1/3 activation	5/709	16/10704	0,002971052	0,011090145	0,006855914
aUC_vs_HC	R-HSA-9614657	FOXO-mediated transcription of cell death genes	5/709	16/10704	0,002971052	0,011090145	0,006855914
aUC_vs_HC	R-HSA-450321	JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1	6/709	23/10704	0,00315081	0,01172592	0,007248949
aUC_vs_HC	R-HSA-437239	Recycling pathway of L1	9/709	47/10704	0,003263365	0,012072508	0,007463209
aUC_vs_HC	R-HSA-9020591	Interleukin-12 signaling	9/709	47/10704	0,003263365	0,012072508	0,007463209
aUC_vs_HC	R-HSA-5654687	Downstream signaling of activated FGFR1	7/709	31/10704	0,003517155	0,012972772	0,008019752
aUC_vs_HC	R-HSA-449836	Other interleukin signaling	6/709	24/10704	0,003969607	0,014469857	0,008945248
aUC_vs_HC	R-HSA-5627123	RHO GTPases activate PAKs	6/709	24/10704	0,003969607	0,014469857	0,008945248
aUC_vs_HC	R-HSA-9660826	Purinergic signaling in leishmaniasis infection	6/709	24/10704	0,003969607	0,014469857	0,008945248
aUC_vs_HC	R-HSA-9664424	Cell recruitment (pro-inflammatory response)	6/709	24/10704	0,003969607	0,014469857	0,008945248
aUC_vs_HC	R-HSA-8856825	Cargo recognition for clathrin-mediated endocytosis	15/709	106/10704	0,004100067	0,014901705	0,009212216
aUC_vs_HC	R-HSA-5626467	RHO GTPases activate IQGAPs	7/709	32/10704	0,004249739	0,015400657	0,009520667
aUC_vs_HC	R-HSA-1234158	Regulation of gene expression by Hypoxia-inducible Factor	4/709	11/10704	0,004325312	0,01544932	0,00955075
aUC_vs_HC	R-HSA-351906	Apoptotic cleavage of cell adhesion proteins	4/709	11/10704	0,004325312	0,01544932	0,00955075
aUC_vs_HC	R-HSA-5625970	RHO GTPases activate KTN1	4/709	11/10704	0,004325312	0,01544932	0,00955075
aUC_vs_HC	R-HSA-8851805	MET activates RAS signaling	4/709	11/10704	0,004325312	0,01544932	0,00955075
aUC_vs_HC	R-HSA-9634285	Constitutive Signaling by Overexpressed ERBB2	4/709	11/10704	0,004325312	0,01544932	0,00955075
aUC_vs_HC	R-HSA-1989781	PPARA activates gene expression	16/709	117/10704	0,004356048	0,015514519	0,009591056
aUC_vs_HC	R-HSA-5628897	TP53 Regulates Metabolic Genes	13/709	87/10704	0,004564358	0,016209992	0,010020997
aUC_vs_HC	R-HSA-210991	Basigin interactions	6/709	25/10704	0,004935796	0,017233693	0,010653848
aUC_vs_HC	R-HSA-5654708	Downstream signaling of activated FGFR3	6/709	25/10704	0,004935796	0,017233693	0,010653848
aUC_vs_HC	R-HSA-69273	Cyclin A/B1/B2 associated events during G2/M transition	6/709	25/10704	0,004935796	0,017233693	0,010653848
aUC_vs_HC	R-HSA-8854691	Interleukin-20 family signaling	6/709	25/10704	0,004935796	0,017233693	0,010653848
aUC_vs_HC	R-HSA-9013507	NOTCH3 Activation and Transmission of Signal to the Nucleus	6/709	25/10704	0,004935796	0,017233693	0,010653848
aUC_vs_HC	R-HSA-937041	IKK complex recruitment mediated by RIP1	6/709	25/10704	0,004935796	0,017233693	0,010653848
aUC_vs_HC	R-HSA-446652	Interleukin-1 family signaling	18/709	140/10704	0,005036222	0,017486101	0,010809886
aUC_vs_HC	R-HSA-5663220	RHO GTPases Activate Formins	18/709	140/10704	0,005036222	0,017486101	0,010809886
aUC_vs_HC	R-HSA-1592389	Activation of Matrix Metalloproteinases	7/709	33/10704	0,00509207	0,017554997	0,010852477
aUC_vs_HC	R-HSA-1980145	Signaling by NOTCH2	7/709	33/10704	0,00509207	0,017554997	0,010852477
aUC_vs_HC	R-HSA-9612973	Autophagy	19/709	151/10704	0,005098434	0,017554997	0,010852477
aUC_vs_HC	R-HSA-400206	Regulation of lipid metabolism by PPARalpha	16/709	119/10704	0,005149806	0,017682899	0,010931546
aUC_vs_HC	R-HSA-446353	Cell-extracellular matrix interactions	5/709	18/10704	0,005217942	0,017867499	0,011045666
aUC_vs_HC	R-HSA-3928665	EPH-ephrin mediated repulsion of cells	9/709	51/10704	0,005753713	0,019647982	0,012146358
aUC_vs_HC	R-HSA-5617472	Activation of anterior HOX genes in hindbrain development during early embryogenesis	16/709	121/10704	0,006057396	0,020390356	0,012605293
aUC_vs_HC	R-HSA-5619507	Activation of HOX genes during differentiation	16/709	121/10704	0,006057396	0,020390356	0,012605293
aUC_vs_HC	R-HSA-2559586	DNA Damage/Telomere Stress Induced Senescence	12/709	80/10704	0,00611264	0,020390356	0,012605293
aUC_vs_HC	R-HSA-416482	G alpha (12/13) signalling events	12/709	80/10704	0,00611264	0,020390356	0,012605293
aUC_vs_HC	R-HSA-1474151	Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation	4/709	12/10704	0,006151555	0,020390356	0,012605293
aUC_vs_HC	R-HSA-210990	PECAM1 interactions	4/709	12/10704	0,006151555	0,020390356	0,012605293
aUC_vs_HC	R-HSA-2197563	NOTCH2 intracellular domain regulates transcription	4/709	12/10704	0,006151555	0,020390356	0,012605293
aUC_vs_HC	R-HSA-389359	CD28 dependent Vav1 pathway	4/709	12/10704	0,006151555	0,020390356	0,012605293
aUC_vs_HC	R-HSA-9027276	Erythropoietin activates Phosphoinositide-3-kinase (PI3K)	4/709	12/10704	0,006151555	0,020390356	0,012605293
aUC_vs_HC	R-HSA-9664420	Killing mechanisms	4/709	12/10704	0,006151555	0,020390356	0,012605293
aUC_vs_HC	R-HSA-9673324	WNT5:FZD7-mediated leishmania damping	4/709	12/10704	0,006151555	0,020390356	0,012605293
aUC_vs_HC	R-HSA-3928664	Ephrin signaling	5/709	19/10704	0,00670177	0,022155054	0,013696227
aUC_vs_HC	R-HSA-6798695	Neutrophil degranulation	46/709	480/10704	0,006991877	0,023052793	0,014251208
aUC_vs_HC	R-HSA-5654716	Downstream signaling of activated FGFR4	6/709	27/10704	0,007368922	0,024231666	0,014979986
aUC_vs_HC	R-HSA-9020702	Interleukin-1 signaling	14/709	103/10704	0,00779261	0,025557295	0,015799488
aUC_vs_HC	R-HSA-1912408	Pre-NOTCH Transcription and Translation	13/709	93/10704	0,008051554	0,026337057	0,016281536
aUC_vs_HC	R-HSA-5654738	Signaling by FGFR2	11/709	73/10704	0,008200529	0,026612881	0,01645205
aUC_vs_HC	R-HSA-8939902	Regulation of RUNX2 expression and activity	11/709	73/10704	0,008200529	0,026612881	0,01645205
aUC_vs_HC	R-HSA-5673000	RAF activation	7/709	36/10704	0,008375049	0,026612881	0,01645205
aUC_vs_HC	R-HSA-111461	Cytochrome c-mediated apoptotic response	4/709	13/10704	0,00842599	0,026612881	0,01645205
aUC_vs_HC	R-HSA-1358803	Downregulation of ERBB2:ERBB3 signaling	4/709	13/10704	0,00842599	0,026612881	0,01645205
aUC_vs_HC	R-HSA-1502540	Signaling by Activin	4/709	13/10704	0,00842599	0,026612881	0,01645205
aUC_vs_HC	R-HSA-171007	p38MAPK events	4/709	13/10704	0,00842599	0,026612881	0,01645205
aUC_vs_HC	R-HSA-203615	eNOS activation	4/709	13/10704	0,00842599	0,026612881	0,01645205
aUC_vs_HC	R-HSA-2892247	POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation	4/709	13/10704	0,00842599	0,026612881	0,01645205
aUC_vs_HC	R-HSA-5210891	Uptake and function of anthrax toxins	4/709	13/10704	0,00842599	0,026612881	0,01645205
aUC_vs_HC	R-HSA-168927	TICAM1, RIP1-mediated IKK complex recruitment	5/709	20/10704	0,008457451	0,026612881	0,01645205
aUC_vs_HC	R-HSA-2028269	Signaling by Hippo	5/709	20/10704	0,008457451	0,026612881	0,01645205
aUC_vs_HC	R-HSA-3232118	SUMOylation of transcription factors	5/709	20/10704	0,008457451	0,026612881	0,01645205
aUC_vs_HC	R-HSA-6803204	TP53 Regulates Transcription of Genes Involved in Cytochrome C Release	5/709	20/10704	0,008457451	0,026612881	0,01645205
aUC_vs_HC	R-HSA-9013695	NOTCH4 Intracellular Domain Regulates Transcription	5/709	20/10704	0,008457451	0,026612881	0,01645205
aUC_vs_HC	R-HSA-8878171	Transcriptional regulation by RUNX1	26/709	239/10704	0,00847844	0,026612881	0,01645205
aUC_vs_HC	R-HSA-350054	Notch-HLH transcription pathway	6/709	28/10704	0,008864939	0,027686228	0,017115592
aUC_vs_HC	R-HSA-69205	G1/S-Specific Transcription	6/709	28/10704	0,008864939	0,027686228	0,017115592
aUC_vs_HC	R-HSA-9658195	Leishmania infection	27/709	252/10704	0,008997666	0,028030324	0,017328311
aUC_vs_HC	R-HSA-194840	Rho GTPase cycle	17/709	138/10704	0,009601439	0,02983647	0,018444869
aUC_vs_HC	R-HSA-9029569	NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux	7/709	37/10704	0,00975408	0,030235216	0,018691373
aUC_vs_HC	R-HSA-389513	CTLA4 inhibitory signaling	5/709	21/10704	0,010507442	0,032190807	0,019900317
aUC_vs_HC	R-HSA-5654689	PI-3K cascade:FGFR1	5/709	21/10704	0,010507442	0,032190807	0,019900317
aUC_vs_HC	R-HSA-6807004	Negative regulation of MET activity	5/709	21/10704	0,010507442	0,032190807	0,019900317
aUC_vs_HC	R-HSA-5213460	RIPK1-mediated regulated necrosis	6/709	29/10704	0,01056625	0,032190807	0,019900317
aUC_vs_HC	R-HSA-5218859	Regulated Necrosis	6/709	29/10704	0,01056625	0,032190807	0,019900317
aUC_vs_HC	R-HSA-5675482	Regulation of necroptotic cell death	6/709	29/10704	0,01056625	0,032190807	0,019900317
aUC_vs_HC	R-HSA-933541	TRAF6 mediated IRF7 activation	6/709	29/10704	0,01056625	0,032190807	0,019900317
aUC_vs_HC	R-HSA-69242	S Phase	19/709	162/10704	0,01069126	0,03249202	0,020086526
aUC_vs_HC	R-HSA-204998	Cell death signalling via NRAGE, NRIF and NADE	11/709	76/10704	0,011035126	0,032702764	0,020216808
aUC_vs_HC	R-HSA-3000178	ECM proteoglycans	11/709	76/10704	0,011035126	0,032702764	0,020216808
aUC_vs_HC	R-HSA-189483	Heme degradation	4/709	14/10704	0,011187776	0,032702764	0,020216808
aUC_vs_HC	R-HSA-4839735	AXIN mutants destabilize the destruction complex, activating WNT signaling	4/709	14/10704	0,011187776	0,032702764	0,020216808
aUC_vs_HC	R-HSA-4839744	truncated APC mutants destabilize the destruction complex	4/709	14/10704	0,011187776	0,032702764	0,020216808
aUC_vs_HC	R-HSA-4839748	AMER1 mutants destabilize the destruction complex	4/709	14/10704	0,011187776	0,032702764	0,020216808
aUC_vs_HC	R-HSA-5358565	Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)	4/709	14/10704	0,011187776	0,032702764	0,020216808
aUC_vs_HC	R-HSA-5467337	APC truncation mutants have impaired AXIN binding	4/709	14/10704	0,011187776	0,032702764	0,020216808
aUC_vs_HC	R-HSA-5467340	AXIN missense mutants destabilize the destruction complex	4/709	14/10704	0,011187776	0,032702764	0,020216808
aUC_vs_HC	R-HSA-5467348	Truncations of AMER1 destabilize the destruction complex	4/709	14/10704	0,011187776	0,032702764	0,020216808
aUC_vs_HC	R-HSA-6804759	Regulation of TP53 Activity through Association with Co-factors	4/709	14/10704	0,011187776	0,032702764	0,020216808
aUC_vs_HC	R-HSA-877312	Regulation of IFNG signaling	4/709	14/10704	0,011187776	0,032702764	0,020216808
aUC_vs_HC	R-HSA-9005891	Loss of function of MECP2 in Rett syndrome	4/709	14/10704	0,011187776	0,032702764	0,020216808
aUC_vs_HC	R-HSA-9005895	Pervasive developmental disorders	4/709	14/10704	0,011187776	0,032702764	0,020216808
aUC_vs_HC	R-HSA-9675151	Disorders of Developmental Biology	4/709	14/10704	0,011187776	0,032702764	0,020216808
aUC_vs_HC	R-HSA-9697154	Disorders of Nervous System Development	4/709	14/10704	0,011187776	0,032702764	0,020216808
aUC_vs_HC	R-HSA-9024446	NR1H2 and NR1H3-mediated signaling	8/709	47/10704	0,011207866	0,032702764	0,020216808
aUC_vs_HC	R-HSA-202424	Downstream TCR signaling	13/709	98/10704	0,012327811	0,035886345	0,022184894
aUC_vs_HC	R-HSA-3928663	EPHA-mediated growth cone collapse	6/709	30/10704	0,012486621	0,036263714	0,022418183
aUC_vs_HC	R-HSA-198753	ERK/MAPK targets	5/709	22/10704	0,012872906	0,037298421	0,023057837
aUC_vs_HC	R-HSA-3371556	Cellular response to heat stress	12/709	89/10704	0,014029477	0,040554977	0,025071036
aUC_vs_HC	R-HSA-111447	Activation of BAD and translocation to mitochondria	4/709	15/10704	0,014470964	0,041255522	0,025504112
aUC_vs_HC	R-HSA-2032785	YAP1- and WWTR1 (TAZ)-stimulated gene expression	4/709	15/10704	0,014470964	0,041255522	0,025504112
aUC_vs_HC	R-HSA-2691230	Signaling by NOTCH1 HD Domain Mutants in Cancer	4/709	15/10704	0,014470964	0,041255522	0,025504112
aUC_vs_HC	R-HSA-2691232	Constitutive Signaling by NOTCH1 HD Domain Mutants	4/709	15/10704	0,014470964	0,041255522	0,025504112
aUC_vs_HC	R-HSA-5358508	Mismatch Repair	4/709	15/10704	0,014470964	0,041255522	0,025504112
aUC_vs_HC	R-HSA-71336	Pentose phosphate pathway	4/709	15/10704	0,014470964	0,041255522	0,025504112
aUC_vs_HC	R-HSA-2122948	Activated NOTCH1 Transmits Signal to the Nucleus	6/709	31/10704	0,014639293	0,04163991	0,025741741
aUC_vs_HC	R-HSA-373753	Nephrin family interactions	5/709	23/10704	0,015573488	0,043995105	0,027197719
aUC_vs_HC	R-HSA-5654693	FRS-mediated FGFR1 signaling	5/709	23/10704	0,015573488	0,043995105	0,027197719
aUC_vs_HC	R-HSA-5654695	PI-3K cascade:FGFR2	5/709	23/10704	0,015573488	0,043995105	0,027197719
aUC_vs_HC	R-HSA-983705	Signaling by the B Cell Receptor (BCR)	14/709	112/10704	0,015773056	0,044457843	0,027483783
aUC_vs_HC	R-HSA-3858494	Beta-catenin independent WNT signaling	17/709	146/10704	0,016261756	0,045628358	0,028207394
aUC_vs_HC	R-HSA-8856828	Clathrin-mediated endocytosis	17/709	146/10704	0,016261756	0,045628358	0,028207394
qUC_vs_HC	R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling	18/190	108/10704	4,70976E-13	3,9562E-10	2,64242E-10
qUC_vs_HC	R-HSA-8878166	Transcriptional regulation by RUNX2	18/190	121/10704	3,53299E-12	1,48386E-09	9,91098E-10
qUC_vs_HC	R-HSA-449147	Signaling by Interleukins	32/190	461/10704	2,47598E-11	6,93275E-09	4,63052E-09
qUC_vs_HC	R-HSA-9659787	Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects	8/190	17/10704	1,80375E-10	3,0303E-08	2,024E-08
qUC_vs_HC	R-HSA-9661069	Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	8/190	17/10704	1,80375E-10	3,0303E-08	2,024E-08
qUC_vs_HC	R-HSA-5663202	Diseases of signal transduction by growth factor receptors and second messengers	27/190	387/10704	9,56396E-10	1,33895E-07	8,94314E-08
qUC_vs_HC	R-HSA-9006925	Intracellular signaling by second messengers	22/190	306/10704	2,27692E-08	2,73231E-06	1,82496E-06
qUC_vs_HC	R-HSA-2559583	Cellular Senescence	17/190	197/10704	7,24214E-08	7,53779E-06	5,03464E-06
qUC_vs_HC	R-HSA-2559585	Oncogene Induced Senescence	8/190	33/10704	8,0762E-08	7,53779E-06	5,03464E-06
qUC_vs_HC	R-HSA-69231	Cyclin D associated events in G1	9/190	47/10704	1,10212E-07	8,41622E-06	5,62136E-06
qUC_vs_HC	R-HSA-69236	G1 Phase	9/190	47/10704	1,10212E-07	8,41622E-06	5,62136E-06
qUC_vs_HC	R-HSA-9675126	Diseases of mitotic cell cycle	8/190	36/10704	1,68176E-07	1,08668E-05	7,25813E-06
qUC_vs_HC	R-HSA-9687139	Aberrant regulation of mitotic cell cycle due to RB1 defects	8/190	36/10704	1,68176E-07	1,08668E-05	7,25813E-06

For Review Only

qUC_vs_HC	R-HSA-1257604	PIP3 activates AKT signaling	19/190	264/10704	2,1667E-07	1,30002E-05	8,68308E-06
qUC_vs_HC	R-HSA-8848021	Signaling by PTK6	9/190	54/10704	3,86441E-07	2,02881E-05	1,35509E-05
qUC_vs_HC	R-HSA-9006927	Signaling by Non-Receptor Tyrosine Kinases	9/190	54/10704	3,86441E-07	2,02881E-05	1,35509E-05
qUC_vs_HC	R-HSA-199418	Negative regulation of the PI3K/AKT network	12/190	110/10704	5,32948E-07	2,63339E-05	1,75889E-05
qUC_vs_HC	R-HSA-8941326	RUNX2 regulates bone development	7/190	32/10704	1,14925E-06	5,36314E-05	3,58215E-05
qUC_vs_HC	R-HSA-9006931	Signaling by Nuclear Receptors	19/190	299/10704	1,45254E-06	6,42174E-05	4,28921E-05
qUC_vs_HC	R-HSA-69202	Cyclin E associated events during G1/S transition	10/190	83/10704	1,93804E-06	7,85376E-05	5,24568E-05
qUC_vs_HC	R-HSA-9614085	FOXO-mediated transcription	9/190	65/10704	1,96344E-06	7,85376E-05	5,24568E-05
qUC_vs_HC	R-HSA-8939211	ESR-mediated signaling	16/190	223/10704	2,14333E-06	8,18361E-05	5,46599E-05
qUC_vs_HC	R-HSA-69656	Cyclin A:Cdk2-associated events at S phase entry	10/190	85/10704	2,41785E-06	8,83042E-05	5,89801E-05
qUC_vs_HC	R-HSA-5655302	Signaling by FGFR1 in disease	7/190	38/10704	3,93793E-06	0,000137827	9,20576E-05
qUC_vs_HC	R-HSA-8934593	Regulation of RUNX1 Expression and Activity	5/190	17/10704	8,69872E-06	0,000281036	0,000187709
qUC_vs_HC	R-HSA-9617828	FOXO-mediated transcription of cell cycle genes	5/190	17/10704	8,69872E-06	0,000281036	0,000187709
qUC_vs_HC	R-HSA-5633008	TP53 Regulates Transcription of Cell Death Genes	7/190	44/10704	1,09284E-05	0,000339994	0,000227089
qUC_vs_HC	R-HSA-2219528	PI3K/AKT Signaling in Cancer	10/190	101/10704	1,16134E-05	0,000348401	0,000232704
qUC_vs_HC	R-HSA-453279	Mitotic G1 phase and G1/S transition	12/190	149/10704	1,3157E-05	0,000381099	0,000254544
qUC_vs_HC	R-HSA-9018519	Estrogen-dependent gene expression	12/190	150/10704	1,4082E-05	0,000394296	0,000263358
qUC_vs_HC	R-HSA-3700989	Transcriptional Regulation by TP53	19/190	365/10704	2,57114E-05	0,000696696	0,000465337
qUC_vs_HC	R-HSA-2428928	IRS-related events triggered by IGF1R	7/190	52/10704	3,38454E-05	0,000888441	0,000593408
qUC_vs_HC	R-HSA-109606	Intrinsic Pathway for Apoptosis	7/190	53/10704	3,84166E-05	0,000949117	0,000633934
qUC_vs_HC	R-HSA-2428924	IGF1R signaling cascade	7/190	53/10704	3,84166E-05	0,000949117	0,000633934
qUC_vs_HC	R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	7/190	54/10704	4,34829E-05	0,001043589	0,000697034
qUC_vs_HC	R-HSA-8878159	Transcriptional regulation by RUNX3	9/190	96/10704	4,96315E-05	0,001128997	0,00075408
qUC_vs_HC	R-HSA-8864260	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	6/190	38/10704	4,97296E-05	0,001128997	0,00075408
qUC_vs_HC	R-HSA-452723	Transcriptional regulation of pluripotent stem cells	5/190	24/10704	5,4006E-05	0,001193818	0,000797375
qUC_vs_HC	R-HSA-5688426	Deubiquitination	16/190	297/10704	7,66288E-05	0,001650466	0,001102379
qUC_vs_HC	R-HSA-9006936	Signaling by TGFB family members	9/190	102/10704	8,00239E-05	0,001680502	0,001122441
qUC_vs_HC	R-HSA-6804116	TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest	4/190	14/10704	8,37589E-05	0,001716035	0,001146174
qUC_vs_HC	R-HSA-69206	G1/S Transition	10/190	131/10704	0,000110112	0,002200341	0,001469652
qUC_vs_HC	R-HSA-71336	Pentose phosphate pathway	4/190	15/10704	0,000112637	0,002200341	0,001469652
qUC_vs_HC	R-HSA-2173793	Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	6/190	44/10704	0,000116406	0,002216605	0,001480515
qUC_vs_HC	R-HSA-1226099	Signaling by FGFR in disease	7/190	63/10704	0,000118747	0,002216605	0,001480515
qUC_vs_HC	R-HSA-69242	S Phase	11/190	162/10704	0,000143528	0,002620939	0,001750577
qUC_vs_HC	R-HSA-5689880	Ub-specific processing proteases	13/190	220/10704	0,000147532	0,002636733	0,001761126
qUC_vs_HC	R-HSA-9616222	Transcriptional regulation of granulopoiesis	8/190	90/10704	0,000190242	0,003093557	0,002066248
qUC_vs_HC	R-HSA-112399	IRS-mediated signalling	6/190	48/10704	0,000190803	0,003093557	0,002066248
qUC_vs_HC	R-HSA-6791312	TP53 Regulates Transcription of Cell Cycle Genes	6/190	48/10704	0,000190803	0,003093557	0,002066248
qUC_vs_HC	R-HSA-9034015	Signaling by NTRK3 (TRKC)	4/190	17/10704	0,000191	0,003093557	0,002066248
qUC_vs_HC	R-HSA-1839124	FGFR1 mutant receptor activation	5/190	31/10704	0,000195189	0,003093557	0,002066248
qUC_vs_HC	R-HSA-5654687	Downstream signaling of activated FGFR1	5/190	31/10704	0,000195189	0,003093557	0,002066248
qUC_vs_HC	R-HSA-5683057	MAPK family signaling cascades	16/190	325/10704	0,000217479	0,00338301	0,002259579
qUC_vs_HC	R-HSA-2173789	TGF-beta receptor signaling activates SMADs	5/190	32/10704	0,000228032	0,003420483	0,002284608
qUC_vs_HC	R-HSA-2173796	SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	5/190	32/10704	0,000228032	0,003420483	0,002284608
qUC_vs_HC	R-HSA-1227986	Signaling by ERBB2	6/190	50/10704	0,000239921	0,003474712	0,002320829
qUC_vs_HC	R-HSA-5654736	Signaling by FGFR1	6/190	50/10704	0,000239921	0,003474712	0,002320829
qUC_vs_HC	R-HSA-170834	Signaling by TGF-beta Receptor Complex	7/190	73/10704	0,000301245	0,004288911	0,002864648
qUC_vs_HC	R-HSA-109581	Apoptosis	11/190	178/10704	0,000326636	0,004572909	0,003054336
qUC_vs_HC	R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer	7/190	75/10704	0,000356197	0,004905003	0,003276148
qUC_vs_HC	R-HSA-74751	Insulin receptor signalling cascade	6/190	54/10704	0,000367705	0,004981811	0,00332745
qUC_vs_HC	R-HSA-3108232	SUMO E3 ligases SUMOylate target proteins	11/190	182/10704	0,000395054	0,005267385	0,003518191
qUC_vs_HC	R-HSA-74752	Signaling by Insulin receptor	7/190	78/10704	0,000453404	0,005782477	0,003862231
qUC_vs_HC	R-HSA-5218921	VEGFR2 mediated cell proliferation	4/190	21/10704	0,000454337	0,005782477	0,003862231
qUC_vs_HC	R-HSA-5654689	PI-3K cascade:FGFR1	4/190	21/10704	0,000454337	0,005782477	0,003862231
qUC_vs_HC	R-HSA-6811558	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	8/190	103/10704	0,000479773	0,006015059	0,004017577
qUC_vs_HC	R-HSA-2990846	SUMOylation	11/190	188/10704	0,000520013	0,006348246	0,004240119
qUC_vs_HC	R-HSA-5689896	Ovarian tumor domain proteases	5/190	38/10704	0,000521463	0,006348246	0,004240119
qUC_vs_HC	R-HSA-1250196	SHC1 events in ERBB2 signaling	4/190	22/10704	0,000547648	0,006389228	0,004267492
qUC_vs_HC	R-HSA-5655332	Signaling by FGFR3 in disease	4/190	22/10704	0,000547648	0,006389228	0,004267492
qUC_vs_HC	R-HSA-8853338	Signaling by FGFR3 point mutants in cancer	4/190	22/10704	0,000547648	0,006389228	0,004267492
qUC_vs_HC	R-HSA-5357801	Programmed Cell Death	11/190	190/10704	0,000568388	0,006540354	0,004368432
qUC_vs_HC	R-HSA-8853334	Signaling by FGFR3 fusions in cancer	3/190	10/10704	0,000602601	0,00684033	0,004568792
qUC_vs_HC	R-HSA-166520	Signaling by NTRKs	9/190	134/10704	0,000626916	0,007021455	0,004689769
qUC_vs_HC	R-HSA-2173795	Downregulation of SMAD2/3:SMAD4 transcriptional activity	4/190	23/10704	0,000653811	0,00713248	0,004763925
qUC_vs_HC	R-HSA-5654693	FRS-mediated FGFR1 signaling	4/190	23/10704	0,000653811	0,00713248	0,004763925
qUC_vs_HC	R-HSA-6802957	Oncogenic MAPK signaling	7/190	84/10704	0,000710964	0,007656532	0,00511395
qUC_vs_HC	R-HSA-9607240	FLT3 Signaling	14/190	294/10704	0,000751146	0,007783996	0,005199085
qUC_vs_HC	R-HSA-168142	Toll Like Receptor 10 (TLR10) Cascade	7/190	85/10704	0,000763338	0,007783996	0,005199085
qUC_vs_HC	R-HSA-168176	Toll Like Receptor 5 (TLR5) Cascade	7/190	85/10704	0,000763338	0,007783996	0,005199085
qUC_vs_HC	R-HSA-975871	MyD88 cascade initiated on plasma membrane	7/190	85/10704	0,000763338	0,007783996	0,005199085
qUC_vs_HC	R-HSA-8940973	RUNX2 regulates osteoblast differentiation	4/190	24/10704	0,000773772	0,007783996	0,005199085
qUC_vs_HC	R-HSA-8986944	Transcriptional Regulation by MECP2	6/190	62/10704	0,0007784	0,007783996	0,005199085
qUC_vs_HC	R-HSA-5655291	Signaling by FGFR4 in disease	3/190	11/10704	0,000817779	0,007987604	0,005335079
qUC_vs_HC	R-HSA-9028731	Activated NTRK2 signals through FRS2 and FRS3	3/190	11/10704	0,000817779	0,007987604	0,005335079
qUC_vs_HC	R-HSA-190236	Signaling by FGFR	7/190	87/10704	0,000877229	0,008469794	0,005657143
qUC_vs_HC	R-HSA-5654708	Downstream signaling of activated FGFR3	4/190	25/10704	0,000908482	0,008479166	0,005663403
qUC_vs_HC	R-HSA-9006115	Signaling by NTRK2 (TRKB)	4/190	25/10704	0,000908482	0,008479166	0,005663403
qUC_vs_HC	R-HSA-9664565	Signaling by ERBB2 KD Mutants	4/190	25/10704	0,000908482	0,008479166	0,005663403
qUC_vs_HC	R-HSA-1433557	Signaling by SCF-KIT	5/190	43/10704	0,000930893	0,008592861	0,005739342
qUC_vs_HC	R-HSA-109704	PI3K Cascade	5/190	44/10704	0,001035315	0,00931945	0,006224645
qUC_vs_HC	R-HSA-1227990	Signaling by ERBB2 in Cancer	4/190	26/10704	0,001058896	0,00931945	0,006224645
qUC_vs_HC	R-HSA-2173788	Downregulation of TGF-beta receptor signaling	4/190	26/10704	0,001058896	0,00931945	0,006224645
qUC_vs_HC	R-HSA-6803207	TP53 Regulates Transcription of Caspase Activators and Caspases	3/190	12/10704	0,001076175	0,00931945	0,006224645
qUC_vs_HC	R-HSA-9673767	Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants	3/190	12/10704	0,001076175	0,00931945	0,006224645
qUC_vs_HC	R-HSA-9673770	Signaling by PDGFRA extracellular domain mutants	3/190	12/10704	0,001076175	0,00931945	0,006224645
qUC_vs_HC	R-HSA-975138	TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation	7/190	91/10704	0,001145041	0,009814636	0,00655539
qUC_vs_HC	R-HSA-6802952	Signaling by BRAF and RAF fusions	6/190	67/10704	0,001174513	0,009965566	0,006656199
qUC_vs_HC	R-HSA-975155	MyD88 dependent cascade initiated on endosome	7/190	92/10704	0,001221084	0,00999818	0,006677982
qUC_vs_HC	R-HSA-1538133	G0 and Early G1	4/190	27/10704	0,001225967	0,00999818	0,006677982
qUC_vs_HC	R-HSA-380994	ATF4 activates genes in response to endoplasmic reticulum stress	4/190	27/10704	0,001225967	0,00999818	0,006677982
qUC_vs_HC	R-HSA-5654716	Downstream signaling of activated FGFR4	4/190	27/10704	0,001225967	0,00999818	0,006677982
qUC_vs_HC	R-HSA-69615	G1/S DNA Damage Checkpoints	6/190	68/10704	0,001269488	0,010253555	0,006848553
qUC_vs_HC	R-HSA-168181	Toll Like Receptor 7/8 (TLR7/8) Cascade	7/190	93/10704	0,001301103	0,010408239	0,006951869
qUC_vs_HC	R-HSA-1358803	Downregulation of ERBB2:ERBB3 signaling	3/190	13/10704	0,001380827	0,010673512	0,00712905
qUC_vs_HC	R-HSA-1502540	Signaling by Activin	3/190	13/10704	0,001380827	0,010673512	0,00712905
qUC_vs_HC	R-HSA-5210891	Uptake and function of anthrax toxins	3/190	13/10704	0,001380827	0,010673512	0,00712905
qUC_vs_HC	R-HSA-168164	Toll Like Receptor 3 (TLR3) Cascade	7/190	94/10704	0,001385015	0,010673512	0,00712905
qUC_vs_HC	R-HSA-201451	Signaling by BMP	4/190	28/10704	0,001410648	0,010772223	0,007194981
qUC_vs_HC	R-HSA-5673001	RAF/MAP kinase cascade	13/190	280/10704	0,00145426	0,010951069	0,007314436
qUC_vs_HC	R-HSA-166058	MyD88:MAL(TIRAP) cascade initiated on plasma membrane	7/190	95/10704	0,00147318	0,010951069	0,007314436
qUC_vs_HC	R-HSA-168188	Toll Like Receptor TLR6:TLR2 Cascade	7/190	95/10704	0,00147318	0,010951069	0,007314436
qUC_vs_HC	R-HSA-168138	Toll Like Receptor 9 (TLR9) Cascade	7/190	96/10704	0,001465664	0,011536473	0,007705439
qUC_vs_HC	R-HSA-9615017	FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	4/190	29/10704	0,001613887	0,011788393	0,007873701
qUC_vs_HC	R-HSA-2559580	Oxidative Stress Induced Senescence	8/190	125/10704	0,001705735	0,012349193	0,00824827
qUC_vs_HC	R-HSA-6803205	TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain	3/190	14/10704	0,001734572	0,012349193	0,00824827
qUC_vs_HC	R-HSA-5684996	MAPK1/MAPK3 signaling	13/190	286/10704	0,001757267	0,012349193	0,00824827
qUC_vs_HC	R-HSA-168179	Toll Like Receptor TLR1:TLR2 Cascade	7/190	98/10704	0,00176417	0,012349193	0,00824827
qUC_vs_HC	R-HSA-181438	Toll Like Receptor 2 (TLR2) Cascade	7/190	98/10704	0,00176417	0,012349193	0,00824827
qUC_vs_HC	R-HSA-114452	Activation of BH3-only proteins	4/190	30/10704	0,001836627	0,012645628	0,008446265
qUC_vs_HC	R-HSA-5654696	Downstream signaling of activated FGFR2	4/190	30/10704	0,001836627	0,012645628	0,008446265
qUC_vs_HC	R-HSA-166166	MyD88-independent TLR4 cascade	7/190	99/10704	0,001870485	0,012671027	0,00846323
qUC_vs_HC	R-HSA-937061	TRIF(TICAM1)-mediated TLR4 signaling	7/190	99/10704	0,001870485	0,012671027	0,00846323
qUC_vs_HC	R-HSA-8866910	TFAP2 (AP-2) family regulates transcription of growth factors and their receptors	3/190	15/10704	0,002140056	0,014381179	0,009605474
qUC_vs_HC	R-HSA-383280	Nuclear Receptor transcription pathway	5/190	52/10704	0,002210064	0,01473376	0,00984097
qUC_vs_HC	R-HSA-381042	PERK regulates gene expression	4/190	32/10704	0,002344342	0,015505882	0,010356686
qUC_vs_HC	R-HSA-9009391	Extra-nuclear estrogen signaling	6/190	77/10704	0,002411504	0,015825496	0,010570162
qUC_vs_HC	R-HSA-156711	Polo-like kinase mediated events	3/190	16/10704	0,002599737	0,016543784	0,011049921
qUC_vs_HC	R-HSA-1963642	PI3K events in ERBB2 signaling	3/190	16/10704	0,002599737	0,016543784	0,011049921
qUC_vs_HC	R-HSA-2559584	Formation of Senescence-Associated Heterochromatin Foci (SAHF)	3/190	16/10704	0,002599737	0,016543784	0,011049921
qUC_vs_HC	R-HSA-9665348	Signaling by ERBB2 ECD mutants	3/190	16/10704	0,002599737	0,016543784	0,011049921
qUC_vs_HC	R-HSA-2454202	Fc epsilon receptor (FCERI) signaling	8/190	134/10704	0,002640889	0,016679298	0,011140433
qUC_vs_HC	R-HSA-6806834	Signaling by MET	6/190	79/10704	0,002746011	0,017213803	0,01149744
qUC_vs_HC	R-HSA-2559586	DNA Damage/Telomere Stress Induced Senescence	6/190	80/10704	0,002925753	0,018204684	0,012159269
qUC_vs_HC	R-HSA-194138	Signaling by VEGF	7/190	108/10704	0,003066592	0,018940714	0,012650878
qUC_vs_HC	R-HSA-6807070	PTEN Regulation	8/190	140/10704	0,00345954	0,02121178	0,014167768
qUC_vs_HC	R-HSA-5673000	RAF activation	4/190	36/10704	0,003634253	0,021962393	0,014669117
qUC_vs_HC	R-HSA-6804757	Regulation of TP53 Degradation	4/190	36/10704	0,003634253	0,021962393	0,014669117
qUC_vs_HC	R-HSA-5654710	PI-3K cascade:FGFR3	3/190	18/10704	0,003690639	0,021986784	0,014685408
qUC_vs_HC	R-HSA-6804114	TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest	3/190	18/10704	0,003690639	0,021986784	0,014685408
qUC_vs_HC	R-HSA-6806003	Regulation of TP53 Expression and Degradation	4/190	37/10704	0,004019085	0,023774867	0,015879705
qUC_vs_HC	R-HSA-1362277	Transcription of E2F targets under negative control by DREAM complex	3/190	19/10704	0,00432591	0,025410939	0,016972469
qUC_vs_HC	R-HSA-5628897	TP53 Regulates Metabolic Genes	6/190	87/10704	0,00444083	0,025904843	0,017302358
qUC_vs_HC	R-HSA-9679506	SARS-CoV Infections	8/190	147/10704	0,004649764	0,026936563	0,017991464
qUC_vs_HC	R-HSA-1181150	Signaling by NODAL	3/190	20/10704	0,005023493	0,027761408	0,018542394
qUC_vs_HC	R-HSA-5654706	FRS-mediated FGFR3 signaling	3/190	20/10704	0,005023493	0,027761408	0,018542394
qUC_vs_HC	R-HSA-5654720	PI-3K cascade:FGFR4	3/190	20/10704	0,005023493	0,027761408	0,018542394
qUC_vs_HC	R-HSA-6803204	TP53 Regulates Transcription of Genes Involved in Cytochrome C Release	3/190	20/10704	0,005023493	0,027761408	0,018542394
qUC_vs_HC	R-HSA-9669938	Signaling by KIT in disease	3/190	20/10704	0,005023493	0,027761408	0,018542394
qUC_vs_HC	R-HSA-9670439	Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	3/190	20/10704	0,005023493	0,027761408	0,018542394
qUC_vs_HC	R-HSA-9671555	Signaling by PDGFR in disease	3/190	20/10704	0,005023493	0,027761408	0,018542394
qUC_vs_HC	R-HSA-5654741	Signaling by FGFR3	4/190	40/10704	0,005336785	0,029299996	0,019570047
qUC_vs_HC	R-HSA-450294	MAP kinase activation	5/190	64/10704	0,005466087	0,029815021	0,019914043
qUC_vs_HC	R-HSA-445144	Signal transduction by L1	3/190	21/10704	0,005785019	0,031150101	0,020805769
qUC_vs_HC	R-HSA-5654688	SHC-mediated cascade:FGFR1	3/190	21/10704	0,005785019	0,031150101	0,020805769
qUC_vs_HC	R-HSA-5654743	Signaling by FGFR4	4/190	41/10704	0,005833111	0,031208999	0,020845109
qUC_vs_HC	R-HSA-1912408	Pre-NOTCH Transcription and Translation	6/190	93/10704	0,006144339	0,032666104	0,021818337
qUC_vs_HC	R-HSA-2426168	Activation of gene expression by SREBF (SREBP)	4/190	42/10704	0,006359279	0,033386214	0,022299313
qUC_vs_HC	R-HSA-3769402	Deactivation of the beta-catenin transactivating complex	4/190	42/10704	0,006359279	0,033386214	0,022299313
qUC_vs_HC	R-HSA-381119	Unfolded Protein Response (UPR)	6/190	94/10704	0,006468838	0,033660948	0,022482814
qUC_vs_HC	R-HSA-5654712	FRS-mediated FGFR4 signaling	3/190	22/10704	0,006611972	0,033660948	0,022482814
qUC_vs_HC	R-HSA-8862803	Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models	3/190	22/10704	0,006611972	0,033660948	0,022482814
qUC_vs_HC	R-HSA-8863678	Neurodegenerative Diseases	3/190	22/10704	0,006611972	0,033660948	0,022482814
qUC_vs_HC	R-HSA-9665686	Signaling by ERBB2 TMD/JMD mutants	3/190	22/10704	0,006611972	0,033660948	0,022482814
qUC_vs_HC	R-HSA-5655253	Signaling by FGFR2 in disease	4/190	43/10704	0,006916036	0,034787248	0,023235092
qUC_vs_HC	R-HSA-9656223	Signaling by RAF1 mutants	4/190	43/10704	0,006916036	0,034787248	0,023235092
qUC_vs_HC	R-HSA-450321	JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1	3/190	23/10704	0,007505696	0,037087298	0,024771341
qUC_vs_HC	R-HSA-5654695	PI-3K cascade:FGFR2	3/190	23/10704	0,007505696	0,037087298	0,024771341
qUC_vs_HC	R-HSA-3371453	Regulation of HSF1-mediated heat shock response	5/190	69/10704	0,007505763	0,037087298	0,024771341
qUC_vs_HC	R-HSA-166016	Toll Like Receptor 4 (TLR4) Cascade	7/190	129/10704	0,008066067	0,039392419	0,026310977

For Review Only

qUC_vs_HC	R-HSA-5576891	Cardiac conduction	7/190	129/10704	0,008066067	0,039392419	0,026310977
qUC_vs_HC	R-HSA-3899300	SUMOylation of transcription cofactors	4/190	45/10704	0,008124199	0,039446975	0,026347416
qUC_vs_HC	R-HSA-4420097	VEGFA-VEGFR2 Pathway	6/190	99/10704	0,00828078	0,039976178	0,026700881
qUC_vs_HC	R-HSA-933542	TRAF6 mediated NF-kB activation	3/190	24/10704	0,0084674	0,04041259	0,026992369
qUC_vs_HC	R-HSA-9634638	Estrogen-dependent nuclear events downstream of ESR-membrane signaling	3/190	24/10704	0,0084674	0,04041259	0,026992369
qUC_vs_HC	R-HSA-448424	Interleukin-17 signaling	5/190	72/10704	0,008956068	0,042503372	0,028388843
qUC_vs_HC	R-HSA-6783783	Interleukin-10 signaling	4/190	47/10704	0,009463132	0,042665537	0,028497157
qUC_vs_HC	R-HSA-6802946	Signaling by moderate kinase activity BRAF mutants	4/190	47/10704	0,009463132	0,042665537	0,028497157
qUC_vs_HC	R-HSA-6802949	Signaling by RAS mutants	4/190	47/10704	0,009463132	0,042665537	0,028497157
qUC_vs_HC	R-HSA-6802955	Paradoxical activation of RAF signaling by kinase inactive BRAF	4/190	47/10704	0,009463132	0,042665537	0,028497157
qUC_vs_HC	R-HSA-9024446	NR1H2 and NR1H3-mediated signaling	4/190	47/10704	0,009463132	0,042665537	0,028497157
qUC_vs_HC	R-HSA-9649948	Signaling downstream of RAS mutants	4/190	47/10704	0,009463132	0,042665537	0,028497157
qUC_vs_HC	R-HSA-5654738	Signaling by FGFR2	5/190	73/10704	0,009479645	0,042665537	0,028497157
qUC_vs_HC	R-HSA-2029485	Role of phospholipids in phagocytosis	3/190	25/10704	0,009498161	0,042665537	0,028497157
qUC_vs_HC	R-HSA-400685	Sema4D in semaphorin signaling	3/190	25/10704	0,009498161	0,042665537	0,028497157
qUC_vs_HC	R-HSA-5654700	FRS-mediated FGFR2 signaling	3/190	25/10704	0,009498161	0,042665537	0,028497157
qUC_vs_HC	R-HSA-983231	Factors involved in megakaryocyte development and platelet production	8/190	168/10704	0,01014579	0,045332252	0,030278309
qUC_vs_HC	R-HSA-8878171	Transcriptional regulation by RUNX1	10/190	239/10704	0,010232347	0,0454771	0,030375055

For Review Only

Supplementary Table S4. The list of differentially expressed miRNAs in colonic epithelial cell populations of active (aUC) and quiescent (qUC) UC patients, and Healthy controls (HC)

mir	baseMean	log2FoldChange	lfcSE	stat	pvalue	padj	comparison
hsa-let-7b-5p	4102,037314	-1,290433431	0,398984507	-3,234294584	0,001219436	0,00924739	aUC_CD44+_vs_HC_CD44+
hsa-let-7c-5p	41,3470138	-4,092102762	0,985228677	-4,153454784	3,27493E-05	0,000596037	aUC_CD44+_vs_HC_CD44+
hsa-let-7d-3p	49,35015724	-1,756703232	0,49719175	-3,533250966	0,000410483	0,003735392	aUC_CD44+_vs_HC_CD44+
hsa-let-7e-5p	114,8820552	-3,295229762	0,595852276	-5,530279725	3,19721E-08	5,81891E-06	aUC_CD44+_vs_HC_CD44+
hsa-miR-100-5p	46,30336212	-3,379219905	1,179436696	-2,86511342	0,004168599	0,020593141	aUC_CD44+_vs_HC_CD44+
hsa-miR-10b-5p	600,0771585	-1,535362017	0,364255825	-4,2150651	2,49706E-05	0,000504961	aUC_CD44+_vs_HC_CD44+
hsa-miR-125a-5p	236,4881554	-1,975118993	0,550954338	-3,584905059	0,000337201	0,003230029	aUC_CD44+_vs_HC_CD44+
hsa-miR-1261	44,62962729	11,91305391	3,031064083	3,930320699	8,48326E-05	0,001136094	aUC_CD44+_vs_HC_CD44+
hsa-miR-1275	51,24049769	4,656421378	1,022340043	4,554669859	5,24679E-06	0,000201465	aUC_CD44+_vs_HC_CD44+
hsa-miR-141-3p	120,4713798	1,879837192	0,518174044	3,62781041	0,000285835	0,00289011	aUC_CD44+_vs_HC_CD44+
hsa-miR-142-3p	20,78100957	6,391480659	1,45730493	4,385822436	1,15548E-05	0,000262873	aUC_CD44+_vs_HC_CD44+
hsa-miR-143-3p	1460,473479	-2,95966206	0,660347053	-4,481979659	7,39538E-06	0,000224327	aUC_CD44+_vs_HC_CD44+
hsa-miR-145-5p	9,949487301	-4,278512073	1,489313115	-2,872808969	0,0040684	0,020593141	aUC_CD44+_vs_HC_CD44+
hsa-miR-148a-3p	731,928219	1,076156929	0,349654887	3,07776888	0,002085566	0,013088724	aUC_CD44+_vs_HC_CD44+
hsa-miR-15b-5p	92,85579037	2,103257915	0,524031418	4,013610338	5,9797E-05	0,000906922	aUC_CD44+_vs_HC_CD44+
hsa-miR-182-5p	229,8722431	1,805111225	0,472003574	3,824359231	0,000131113	0,001403676	aUC_CD44+_vs_HC_CD44+
hsa-miR-183-5p	155,9953185	1,963155342	0,59292594	3,310962144	0,000929758	0,007691633	aUC_CD44+_vs_HC_CD44+
hsa-miR-194-3p	154,7450325	-1,580928517	0,551239153	-2,86795397	0,004131356	0,020593141	aUC_CD44+_vs_HC_CD44+
hsa-miR-196a-1-3p	21,30476447	-5,027549535	1,593693456	-3,154652807	0,001606892	0,010444798	aUC_CD44+_vs_HC_CD44+
hsa-miR-197-3p	55,13123525	2,108127721	0,736141103	2,863754942	0,004186518	0,020593141	aUC_CD44+_vs_HC_CD44+
hsa-miR-2110	20,2879364	3,339366961	1,018136338	3,279881915	0,001038505	0,008217739	aUC_CD44+_vs_HC_CD44+
hsa-miR-215-3p	29,8228318	2,257015704	0,678111809	3,328382833	0,000873517	0,007570484	aUC_CD44+_vs_HC_CD44+
hsa-miR-221-3p	160,4347215	2,981531062	0,55723317	5,35059868	8,76637E-08	7,9774E-06	aUC_CD44+_vs_HC_CD44+
hsa-miR-222-3p	143,1615888	1,393298445	0,457825769	3,043294066	0,002340035	0,014196215	aUC_CD44+_vs_HC_CD44+
hsa-miR-223-3p	171,3111872	4,112402164	1,050159785	3,915977572	9,00386E-05	0,001136094	aUC_CD44+_vs_HC_CD44+
hsa-miR-25-3p	135,0667348	1,372412004	0,429062264	3,198631335	0,001380816	0,010052342	aUC_CD44+_vs_HC_CD44+
hsa-miR-30e-5p	266,9515329	-1,072522932	0,418929028	-2,560154248	0,010462571	0,04644361	aUC_CD44+_vs_HC_CD44+
hsa-miR-31-5p	83,18260453	5,774119892	1,298414388	4,447054765	8,70556E-06	0,000226345	aUC_CD44+_vs_HC_CD44+
hsa-miR-3195	75,3779283	-6,165100854	1,231510323	-5,006130067	5,55352E-07	3,36914E-05	aUC_CD44+_vs_HC_CD44+
hsa-miR-340-3p	16,00909324	-4,467159217	1,143513153	-3,906521936	9,36341E-05	0,001136094	aUC_CD44+_vs_HC_CD44+
hsa-miR-34a-5p	39,55171268	6,374871999	1,40309841	4,543424717	5,53476E-06	0,000201465	aUC_CD44+_vs_HC_CD44+
hsa-miR-3960	68,24363582	2,166601973	0,72902931	2,971899678	0,002959634	0,016832917	aUC_CD44+_vs_HC_CD44+
hsa-miR-484	22,9909067	2,712927483	0,708117237	3,831184075	0,000127528	0,001403676	aUC_CD44+_vs_HC_CD44+
hsa-miR-501-3p	22,36904062	3,936285866	0,961493653	4,093928083	4,24126E-05	0,000701736	aUC_CD44+_vs_HC_CD44+
hsa-miR-574-3p	67,27365892	-1,583835852	0,528425759	-2,997272226	0,002724073	0,015992947	aUC_CD44+_vs_HC_CD44+
hsa-miR-598-3p	24,10946306	-5,131274573	1,756858998	-2,92070939	0,003492354	0,019260863	aUC_CD44+_vs_HC_CD44+
hsa-miR-6869-5p	34,23920369	-9,926679987	3,137693664	-3,163686788	0,001557843	0,010444798	aUC_CD44+_vs_HC_CD44+
hsa-miR-7-5p	230,0862854	1,324097316	0,418761477	3,161936779	0,001567236	0,010444798	aUC_CD44+_vs_HC_CD44+
hsa-let-7e-5p	114,8820552	-2,731813942	0,614717742	-4,444013494	8,82961E-06	0,000342883	aUC_CD44+_vs_qUC_CD44+
hsa-miR-100-5p	46,30336212	-4,775206021	1,19799593	-3,985995194	6,71979E-05	0,001423373	aUC_CD44+_vs_qUC_CD44+
hsa-miR-1261	44,62962729	13,34717383	3,131636492	4,26204442	2,02565E-05	0,000589971	aUC_CD44+_vs_qUC_CD44+
hsa-miR-1275	51,24049769	2,926187108	1,009531358	2,898559895	0,003748807	0,034938881	aUC_CD44+_vs_qUC_CD44+
hsa-miR-141-3p	120,4713798	1,948930714	0,53073652	3,672124757	0,000240542	0,003736422	aUC_CD44+_vs_qUC_CD44+
hsa-miR-142-3p	20,78100957	5,918799437	1,496730622	3,95448543	7,66995E-05	0,00148925	aUC_CD44+_vs_qUC_CD44+
hsa-miR-143-3p	1460,473479	-1,952038848	0,6830912	-2,857654802	0,004267844	0,036829913	aUC_CD44+_vs_qUC_CD44+
hsa-miR-148a-3p	731,928219	1,151009639	0,360756036	3,190548532	0,00142003	0,016543348	aUC_CD44+_vs_qUC_CD44+
hsa-miR-181b-5p	36,39010465	-2,512517597	0,808330642	-3,108279541	0,0018818	0,019980693	aUC_CD44+_vs_qUC_CD44+
hsa-miR-182-5p	229,8722431	1,399828415	0,482090707	2,903661892	0,003688262	0,034938881	aUC_CD44+_vs_qUC_CD44+
hsa-miR-184	56,85736686	22,25189642	4,207940023	5,288073571	1,23611E-07	7,20036E-06	aUC_CD44+_vs_qUC_CD44+
hsa-miR-197-3p	55,13123525	2,576427542	0,759541198	3,392083994	0,000693632	0,008978677	aUC_CD44+_vs_qUC_CD44+
hsa-miR-2110	20,2879364	4,597472192	1,053898585	4,362347819	1,28674E-05	0,000428301	aUC_CD44+_vs_qUC_CD44+
hsa-miR-215-3p	29,8228318	2,921581912	0,697804109	4,186822455	2,82887E-05	0,000714417	aUC_CD44+_vs_qUC_CD44+
hsa-miR-221-3p	160,4347215	2,165600932	0,567132637	3,818508744	0,000134261	0,002234484	aUC_CD44+_vs_qUC_CD44+
hsa-miR-224-5p	55,54461285	1,211456182	0,435595437	2,781149841	0,005416673	0,045074457	aUC_CD44+_vs_qUC_CD44+
hsa-miR-23a-5p	8,463931083	-2,908743185	0,939800438	-3,095064726	0,0019677	0,019980693	aUC_CD44+_vs_qUC_CD44+
hsa-miR-296-5p	27,44112461	30	5,426307953	5,528620982	3,22758E-08	2,50675E-06	aUC_CD44+_vs_qUC_CD44+
hsa-miR-31-5p	83,18260453	3,792294458	1,31944405	2,874160869	0,004051026	0,036303422	aUC_CD44+_vs_qUC_CD44+
hsa-miR-3168	59,22086756	27,43309881	3,869986564	7,088680634	1,35397E-12	3,15474E-10	aUC_CD44+_vs_qUC_CD44+
hsa-miR-34a-5p	39,55171268	4,729871518	1,417432517	3,336928891	0,000847096	0,010388074	aUC_CD44+_vs_qUC_CD44+
hsa-miR-3960	68,24363582	2,901232147	0,753321358	3,851254336	0,000117514	0,002106219	aUC_CD44+_vs_qUC_CD44+
hsa-miR-432-5p	34,80484808	30	5,425243348	5,529705872	3,20768E-08	2,50675E-06	aUC_CD44+_vs_qUC_CD44+
hsa-miR-4443	15,28178398	3,560256993	1,150561219	3,094365545	0,001972343	0,019980693	aUC_CD44+_vs_qUC_CD44+
hsa-miR-4488	143,0698439	2,577837646	0,709044564	3,635649683	0,000277281	0,004037904	aUC_CD44+_vs_qUC_CD44+
hsa-miR-484	22,9909067	3,498543617	0,725793587	4,820301091	1,43342E-06	6,67972E-05	aUC_CD44+_vs_qUC_CD44+
hsa-miR-501-3p	22,36904062	4,064012539	0,97493506	4,168495631	3,06617E-05	0,000714417	aUC_CD44+_vs_qUC_CD44+
hsa-miR-99a-5p	59,5387003	5,173941954	1,880806515	2,750916648	0,005942876	0,047747937	aUC_CD44+_vs_qUC_CD44+
hsa-miR-140-5p	5,715811254	4,58486284	1,392480479	3,292586796	0,000992703	0,018479539	qUC_CD44+_vs_HC_CD44+
hsa-miR-15b-5p	92,85579037	1,932393875	0,520292627	3,714052004	0,000203967	0,005484442	qUC_CD44+_vs_HC_CD44+
hsa-miR-184	56,85736686	-28,25850514	4,022653439	-7,024842079	2,14309E-12	2,59313E-10	qUC_CD44+_vs_HC_CD44+
hsa-miR-194-3p	154,7450325	-2,44157383	0,549537205	-4,442963656	8,87282E-06	0,000429444	qUC_CD44+_vs_HC_CD44+
hsa-miR-222-3p	143,1615888	1,904566277	0,457598762	4,162087918	3,15351E-05	0,001271915	qUC_CD44+_vs_HC_CD44+
hsa-miR-223-3p	171,3111872	3,423456106	1,04821034	3,266001083	0,001090778	0,018854882	qUC_CD44+_vs_HC_CD44+
hsa-miR-296-5p	27,44112461	-18,61962506	5,208170267	-3,575079944	0,000350121	0,008472926	qUC_CD44+_vs_HC_CD44+
hsa-miR-3168	59,22086756	-33,79087539	3,703944654	-9,122942848	7,31115E-20	1,7693E-17	qUC_CD44+_vs_HC_CD44+
hsa-miR-3195	75,3779283	-6,722822124	1,229414128	-5,468313704	4,54337E-08	3,66499E-06	qUC_CD44+_vs_HC_CD44+
hsa-miR-374a-5p	11,0930107	2,221796128	0,710938212	3,125160655	0,00177708	0,02867022	qUC_CD44+_vs_HC_CD44+
hsa-miR-432-5p	34,80484808	-18,30623639	5,208152081	-3,514919709	0,000439887	0,009677513	qUC_CD44+_vs_HC_CD44+
hsa-miR-4488	143,0698439	-2,550117423	0,680195978	-3,749092183	0,000177476	0,005484442	qUC_CD44+_vs_HC_CD44+
hsa-miR-5100	92,15853454	3,308809485	0,885198375	3,737929912	0,000185542	0,005484442	qUC_CD44+_vs_HC_CD44+
hsa-miR-574-3p	67,27365892	-1,773167804	0,522290342	-3,394984859	0,000686324	0,013840867	qUC_CD44+_vs_HC_CD44+
hsa-miR-8085	6,309285548	23,26658809	5,201975056	4,472645069	7,7258E-06	0,000429444	qUC_CD44+_vs_HC_CD44+
hsa-let-7c-5p	41,3470138	2,851462254	0,922449444	3,0911854	0,001993591	0,01883561	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-1-3p	97,88744964	-7,210116801	1,306348696	-5,519289624	3,40373E-08	2,45068E-06	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-106b-3p	39,94118164	3,138811072	0,762645653	4,11568736	3,86027E-05	0,000641698	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-10b-5p	600,0771585	-1,030952681	0,352346448	-2,925963028	0,003433917	0,02852793	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-125b-5p	67,32621226	3,479387203	1,124211211	3,094958643	0,001968403	0,01883561	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-1290	75,77449812	-3,38507008	1,15061645	-2,941962181	0,003261398	0,028178475	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-135b-5p	47,88245892	4,465925971	0,783650736	5,69887294	1,20602E-08	1,3025E-06	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-146a-5p	222,0888016	2,269032213	0,49955107	4,542142637	5,56853E-06	0,00015035	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-17-5p	16,53349485	-2,041993446	0,620922216	-3,288646137	0,001006705	0,012791076	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-181b-5p	36,39010465	2,337190965	0,735889625	3,176007496	0,001493171	0,017918051	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-182-5p	229,8722431	2,201183566	0,448370406	4,909297167	9,14034E-07	2,82045E-05	aUC_CD66a+_vs_HC_CD66a+

hsa-miR-183-5p	155,9953185	1,747524702	0,569474099	3,068664064	0,002150182	0,019351641	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-191-3p	12,67245807	6,517847383	1,981499888	3,289350366	0,001004189	0,012791076	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-194-3p	154,7450325	-2,380388528	0,533157242	-4,464702604	8,018E-06	0,000192432	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-196b-5p	187,6678013	-1,581410765	0,46594887	-3,393957722	0,000688903	0,009920207	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-21-5p	6540,11313	1,081145567	0,208603756	5,182771322	2,18613E-07	9,44408E-06	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-221-3p	160,4347215	1,508351149	0,530575322	2,842859599	0,004471076	0,034491159	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-222-3p	143,1615888	1,762577499	0,428269545	4,11557982	3,86207E-05	0,000641698	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-224-5p	55,54461285	1,100861581	0,401592768	2,741238559	0,006120805	0,044069796	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-24-3p	709,3028711	1,482452508	0,349153563	4,245846712	2,17769E-05	0,000461033	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-27a-3p	129,8078549	2,270844167	0,424721051	5,346672033	8,95861E-08	4,83765E-06	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-31-5p	83,18260453	8,334965649	1,225322242	6,802264223	1,02987E-11	2,22453E-09	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-335-5p	73,13769403	-2,738168492	0,555527927	-4,928948411	8,26734E-07	2,82045E-05	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-3960	68,24363582	2,167064445	0,693264828	3,125882574	0,001772723	0,01883561	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-421	6,110488268	3,532279775	1,143356355	3,089395322	0,002005644	0,01883561	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-425-5p	72,57277562	1,284781685	0,410240546	3,131776462	0,001737521	0,01883561	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-5100	92,15853454	-3,57941531	0,846407689	-4,228949425	2,34785E-05	0,000461033	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-552-3p	13,25665175	-4,670823342	1,678529083	-2,782688361	0,005391056	0,040154073	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-574-5p	55,87952961	2,486891752	0,643829669	3,862654788	0,000112161	0,001730491	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-135b-5p	47,88245892	3,241157847	0,830346227	3,903381194	9,48581E-05	0,00355718	aUC_CD66a+_vs_qUC_CD66a+
hsa-miR-181b-5p	36,39010465	2,397593296	0,788757839	3,039707723	0,002368078	0,04440147	aUC_CD66a+_vs_qUC_CD66a+
hsa-miR-182-5p	229,8722431	1,937837861	0,478406407	4,050610174	5,10843E-05	0,002298791	aUC_CD66a+_vs_qUC_CD66a+
hsa-miR-27a-3p	129,8078549	2,455975298	0,455113825	5,396397916	6,79921E-08	7,64911E-06	aUC_CD66a+_vs_qUC_CD66a+
hsa-miR-31-5p	83,18260453	4,748693143	1,286768898	3,690400933	0,000223901	0,006297212	aUC_CD66a+_vs_qUC_CD66a+
hsa-miR-3195	75,3779283	-3,828012441	1,255626035	-3,048688331	0,002298428	0,04440147	aUC_CD66a+_vs_qUC_CD66a+
hsa-miR-4516	5,55272639	3,433220019	1,051241844	3,265870778	0,00109128	0,024553808	aUC_CD66a+_vs_qUC_CD66a+
hsa-miR-574-5p	55,87952961	2,475548954	0,688769126	3,594163648	0,000325435	0,008135881	aUC_CD66a+_vs_qUC_CD66a+
hsa-miR-7977	21,05479651	-3,706488913	0,911829648	-4,064891857	4,80547E-05	0,002298791	aUC_CD66a+_vs_qUC_CD66a+
hsa-miR-8085	6,309285548	-29,33874058	5,425260499	-5,407803106	6,38025E-08	7,64911E-06	aUC_CD66a+_vs_qUC_CD66a+
hsa-miR-99a-5p	59,5387003	-6,960153323	1,865965193	-3,730055281	0,000191438	0,006153357	aUC_CD66a+_vs_qUC_CD66a+
hsa-let-7c-5p	41,3470138	3,263230589	0,913201684	3,573395281	0,000352382	0,011729293	qUC_CD66a+_vs_HC_CD66a+
hsa-miR-1-3p	97,88744964	-4,03851897	1,270340267	-3,179084435	0,00147741	0,034423664	qUC_CD66a+_vs_HC_CD66a+
hsa-miR-106b-3p	39,94118164	2,605461932	0,756698757	3,443195736	0,000574883	0,014883084	qUC_CD66a+_vs_HC_CD66a+
hsa-miR-125b-5p	67,32621226	5,240344711	1,11357634	4,705869299	2,52786E-06	0,000196331	qUC_CD66a+_vs_HC_CD66a+
hsa-miR-1290	75,77449812	-5,682797943	1,151204215	-4,936394316	7,95801E-07	9,27109E-05	qUC_CD66a+_vs_HC_CD66a+
hsa-miR-193a-5p	31,10438134	3,603673501	0,981363401	3,672109128	0,000240557	0,011209952	qUC_CD66a+_vs_HC_CD66a+
hsa-miR-194-3p	154,7450325	-1,550488398	0,525091165	-2,952798488	0,003149075	0,049661554	qUC_CD66a+_vs_HC_CD66a+
hsa-miR-199a-5p	14,52804232	4,026389014	1,316639275	3,058080592	0,002227597	0,039925385	qUC_CD66a+_vs_HC_CD66a+
hsa-miR-335-5p	73,13769403	-1,966378477	0,5432463	-3,619681306	0,000294966	0,011454516	qUC_CD66a+_vs_HC_CD66a+
hsa-miR-4497	12,00241834	3,388216988	1,094002603	3,097083114	0,001954351	0,037946976	qUC_CD66a+_vs_HC_CD66a+
hsa-miR-552-3p	13,25665175	-4,887777941	1,657928633	-2,948123244	0,003197096	0,049661554	qUC_CD66a+_vs_HC_CD66a+
hsa-miR-7704	24,39357806	3,181614078	0,911602334	3,490133756	0,000482779	0,014060934	qUC_CD66a+_vs_HC_CD66a+
hsa-miR-7977	21,05479651	2,585580872	0,833281619	3,102889603	0,001916411	0,037946976	qUC_CD66a+_vs_HC_CD66a+
hsa-miR-8085	6,309285548	28,36852471	5,046058072	5,621918001	1,88849E-08	4,40018E-06	qUC_CD66a+_vs_HC_CD66a+
hsa-miR-99a-5p	59,5387003	7,969518409	1,73359674	4,597100483	4,28411E-06	0,000249549	qUC_CD66a+_vs_HC_CD66a+
hsa-let-7c-5p	41,3470138	3,69754313	0,941151697	3,928742987	8,5391E-05	0,002487014	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-1-3p	97,88744964	-6,038168401	1,286026468	-4,695213165	2,66329E-06	0,000155137	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-106b-3p	39,94118164	3,317500761	0,767622964	4,321784154	1,54773E-05	0,000515172	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-122-5p	37,12961791	6,00845394	1,865337519	3,22110818	0,001276959	0,017697243	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-125b-5p	67,32621226	3,801345078	1,13085706	3,36147265	0,00077528	0,013029354	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-1261	44,62962729	-8,759489086	2,868067327	-3,054143466	0,002257041	0,02629453	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-1275	51,24049769	-4,130337408	0,939134237	-4,398026658	1,0924E-05	0,000424214	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-1290	75,77449812	-3,647378398	1,133456573	-3,217925138	0,001291215	0,017697243	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-135b-5p	47,88245892	2,274617527	0,758445426	2,999052337	0,002708208	0,028682383	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-141-3p	120,4713798	-1,835404247	0,487623458	-3,763978574	0,000167231	0,003896487	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-142-3p	20,78100957	-4,84036017	1,358421953	-3,56322287	0,000366329	0,007112896	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-181b-5p	36,39010465	2,893718185	0,746930011	3,87414904	0,000106998	0,002770057	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-191-3p	12,67245807	5,993391222	1,959306179	3,058935498	0,00222125	0,02629453	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-2110	20,2879364	-4,289528718	0,952842716	-4,501822436	6,73733E-06	0,000313959	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-27a-3p	129,8078549	1,208600419	0,416497269	2,901820751	0,003710008	0,03601799	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-296-5p	27,44112461	-25,11968628	4,992082738	-5,031905038	4,8563E-07	5,65759E-05	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-34a-5p	39,55171268	-4,718893432	1,293958122	-3,646867199	0,000265457	0,005622863	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-421	6,110488268	3,469143115	1,14609228	3,026931753	0,002470497	0,027410756	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-432-5p	34,80484808	-23,50354906	4,991512399	-4,708702931	2,49298E-06	0,000155137	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-484	22,9909067	-2,147360682	0,653085759	-3,288022517	0,001008938	0,015672166	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-501-3p	22,36904062	-4,858698036	0,891884941	-5,447673589	5,10329E-08	1,18907E-05	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-5100	92,15853454	-2,590546002	0,832885799	-3,110325573	0,001868812	0,024190737	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-574-5p	55,87952961	1,882269318	0,635669961	2,961079545	0,003065628	0,03105614	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-99a-5p	59,5387003	-5,787417056	1,723072275	-3,358777888	0,00078288	0,013029354	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-106b-3p	39,94118164	2,922936233	0,788386106	3,707493336	0,000209321	0,007849535	qUC_CD66a+_vs_qUC_CD44+
hsa-miR-1290	75,77449812	-4,899258004	1,174432917	-4,171594591	3,02475E-05	0,002268566	qUC_CD66a+_vs_qUC_CD44+
hsa-miR-184	56,85736686	17,71235803	4,00115842	4,426807481	9,5638E-06	0,001075928	qUC_CD66a+_vs_qUC_CD44+
hsa-miR-193a-5p	31,10438134	3,129197589	1,008236519	3,103634445	0,001911594	0,04778984	qUC_CD66a+_vs_qUC_CD44+
hsa-miR-3168	59,22086756	26,58960094	3,674464708	7,236319587	4,61024E-13	1,0373E-10	qUC_CD66a+_vs_qUC_CD44+
hsa-miR-3195	75,3779283	4,790946922	1,219259218	3,929391595	8,51611E-05	0,003832248	qUC_CD66a+_vs_qUC_CD44+
hsa-miR-660-5p	14,96123124	2,979777877	0,82646905	3,605431901	0,000311634	0,010016814	qUC_CD66a+_vs_qUC_CD44+
hsa-miR-7704	24,39357806	3,782260883	0,952822266	3,969534528	7,20132E-05	0,003832248	qUC_CD66a+_vs_qUC_CD44+
hsa-miR-99a-5p	59,5387003	6,346678222	1,782114779	3,561318437	0,000368997	0,010378047	qUC_CD66a+_vs_qUC_CD44+
hsa-let-7b-5p	4102,03731	-1,0523972	0,38038324	-2,7666762	0,0056631	0,04478995	HC_CD66a+_vs_HC_CD44+
hsa-let-7c-5p	41,3470138	-3,2460219	0,90950246	-3,5690083	0,00035834	0,00725635	HC_CD66a+_vs_HC_CD44+
hsa-let-7d-3p	49,3501572	-1,6833739	0,46724982	-3,6027277	0,0003149	0,00725635	HC_CD66a+_vs_HC_CD44+
hsa-let-7e-5p	114,882055	-2,2046774	0,55821794	-3,9494922	0,000078317	0,00329955	HC_CD66a+_vs_HC_CD44+
hsa-miR-125a-5p	236,488155	-1,8479176	0,52325593	-3,5315752	0,00041309	0,00725635	HC_CD66a+_vs_HC_CD44+
hsa-miR-143-3p	1460,47348	-2,9316605	0,62926979	-4,6588293	3,1801E-06	0,00055334	HC_CD66a+_vs_HC_CD44+
hsa-miR-17-5p	16,5334949	1,83351823	0,63709418	2,87793908	0,00400282	0,03665744	HC_CD66a+_vs_HC_CD44+
hsa-miR-196a-1-3p	21,3047645	-5,4353632	1,50768711	-3,6051003	0,00031203	0,00725635	HC_CD66a+_vs_HC_CD44+
hsa-miR-200a-5p	13,1831738	1,49684288	0,53423353	2,80185127	0,00508103	0,04209996	HC_CD66a+_vs_HC_CD44+
hsa-miR-223-3p	171,311187	3,93347572	1,00768132	3,90349174	0,000094815	0,00329955	HC_CD66a+_vs_HC_CD44+
hsa-miR-23b-3p	294,871966	-1,0154978	0,31104235	-3,2648216	0,00109533	0,01121103	HC_CD66a+_vs_HC_CD44+
hsa-miR-24-3p	709,302871	-1,4516046	0,34426665	-4,2165123	0,000024811	0,00215856	HC_CD66a+_vs_HC_CD44+
hsa-miR-296-5p	27,4411246	-17,671842	5,00751503	-3,5290643	0,00041703	0,00725635	HC_CD66a+_vs_HC_CD44+
hsa-miR-30e-5p	266,951533	-1,3528379	0,39898552	-3,3906943	0,00069716	0,0093312	HC_CD66a+_vs_HC_CD44+
hsa-miR-335-5p	73,137694	1,65482237	0,54757795	3,02207636	0,00251047	0,0242679	HC_CD66a+_vs_HC_CD44+
hsa-miR-340-3p	16,0090932	-4,1957066	1,07027906	-3,9201987	0,000088476	0,00329955	HC_CD66a+_vs_HC_CD44+
hsa-miR-432-5p	34,8048481	-16,987359	5,00751337	-3,3923742	0,0006929	0,0093312	HC_CD66a+_vs_HC_CD44+

hsa-miR-5100	92,1585345	2,93924392	0,85018883	3,45716599	0,00054589	0,00863496	HC_CD66a+_vs_HC_CD44+
hsa-miR-574-3p	67,2736589	-1,6642796	0,49874908	-3,3369075	0,00084716	0,01020122	HC_CD66a+_vs_HC_CD44+
hsa-miR-574-5p	55,8795296	-1,7528987	0,64210026	-2,7299454	0,00633448	0,04792173	HC_CD66a+_vs_HC_CD44+
hsa-miR-598-3p	24,1094631	-5,5456155	1,66709834	-3,3265077	0,00087942	0,01020122	HC_CD66a+_vs_HC_CD44+
hsa-miR-9-5p	25,9280149	-6,8856256	2,08458986	-3,3031081	0,0009562	0,01039862	HC_CD66a+_vs_HC_CD44+

For Review Only

Supplementary Table S5. The list of Reactome pathways significantly enriched with differentially expressed miRNAs in colonic epithelial cell populations of active (aUC) and quiescent (qUC) UC patients, healthy controls (HC)

comparison	ID	Description	GeneRatio	BgRatio	pvalue	p.adjust	qvalue
aUC_CD4+_vs_qUC_CD4+	R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	66/343	439/8290	5.71339352693083e-21	5.75338728161934954e-18	3.69867054638153e-18
aUC_CD4+_vs_qUC_CD4+	R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling	29/343	87/8290	2.74782394845246939e-19	1.38352935804581833e-16	8.89427225420143e-17
aUC_CD4+_vs_qUC_CD4+	R-HSA-5663202	Diseases of signal transduction by growth factor receptors and second messengers	54/343	356/8290	2.31959580896908e-17	7.78611020711086e-15	5.00544376456716e-15
aUC_CD4+_vs_qUC_CD4+	R-HSA-2219528	PI3K/AKT Signaling in Cancer	25/343	83/8290	1.34327810635082e-15	3.38170263278854e-13	2.17398956686896e-13
aUC_CD4+_vs_qUC_CD4+	R-HSA-449147	Signaling by Interleukins	51/343	376/8290	2.19283686442859e-14	4.41637344955198e-12	2.83914667710229e-12
aUC_CD4+_vs_qUC_CD4+	R-HSA-9659787	Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects	12/343	17/8290	1.07083467814682424e-13	1.54047217270838e-11	9.90320792573724e-12
aUC_CD4+_vs_qUC_CD4+	R-HSA-9661069	Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	12/343	17/8290	1.07083467814682424e-13	1.54047217270838e-11	9.90320792573724e-12
aUC_CD4+_vs_qUC_CD4+	R-HSA-109606	Intrinsic Pathway for Apoptosis	18/343	51/8290	6.51923677281232e-13	8.20608928777751e-11	5.27543502010471e-11
aUC_CD4+_vs_qUC_CD4+	R-HSA-2559583	Cellular Senescence	26/343	123/8290	3.43354412686412e-12	3.84175437305797e-10	2.46974226669174044e-10
aUC_CD4+_vs_qUC_CD4+	R-HSA-9006925	Intracellular signaling by second messengers	39/343	273/8290	6.61017600058816754e-12	6.65444723792928474e-10	4.27921920380761044e-10
aUC_CD4+_vs_qUC_CD4+	R-HSA-1257604	PIP3 activates AKT signaling	36/343	237/8290	7.35296573095575e-12	6.73130590097494e-10	4.32734348457211e-10
aUC_CD4+_vs_qUC_CD4+	R-HSA-194138	Signaling by VEGF	22/343	99/8290	9.91053809450861e-11	4.95992655095146e-9	3.18857976151226e-9
aUC_CD4+_vs_qUC_CD4+	R-HSA-4420097	VEGFA-VEGFR2 Pathway	21/343	94/8290	1.46806680163053512e-10	1.13718713018611166e-8	7.31061605670264e-9
aUC_CD4+_vs_qUC_CD4+	R-HSA-9614085	FOXO-mediated transcription	16/343	54/8290	3.58147377191279e-10	2.56171205940134e-8	1.64684894531105e-8
aUC_CD4+_vs_qUC_CD4+	R-HSA-199418	Negative regulation of the PI3K/AKT network	20/343	91/8290	5.55932135521514e-10	3.73215773646776443e-8	2.39928605856653388e-8
aUC_CD4+_vs_qUC_CD4+	R-HSA-8939211	ESR-mediated signaling	26/343	154/8290	6.73510506429535434e-10	4.23890674984088e-8	2.7250589569352904e-8
aUC_CD4+_vs_qUC_CD4+	R-HSA-5683057	MAPK family signaling cascades	36/343	278/8290	7.59140015271463S5e-10	4.49678820810802e-8	2.89084278261293e-8
aUC_CD4+_vs_qUC_CD4+	R-HSA-166520	Signaling by NTRKs	23/343	125/8290	1.18034478140961178e-9	6.60337330488602e-8	4.24509652543809844-8
aUC_CD4+_vs_qUC_CD4+	R-HSA-69231	Cyclin D associated events in G1	14/343	47/8290	3.27087574971213 1e-9	1.61463071831353e-7	1.03799497388054847
aUC_CD4+_vs_qUC_CD4+	R-HSA-69236	G1 Phase	14/343	47/8290	3.27087574971213 1e-9	1.61463071831353e-7	1.03799497388054847
aUC_CD4+_vs_qUC_CD4+	R-HSA-2559585	Oncogene Induced Senescence	12/343	33/8290	3.36715442746169e-9	1.61463071831353e-7	1.03799497388054847
aUC_CD4+_vs_qUC_CD4+	R-HSA-9616222	Transcriptional regulation of granulopoiesis	11/343	27/8290	3.73201096563330e-9	1.70824320108760872-7	1.09817547553324557
aUC_CD4+_vs_qUC_CD4+	R-HSA-9006931	Signaling by Nuclear Receptors	30/343	219/8290	5.69947015397014S5e-9	2.49537671523823a-7	1.60419869322278-7
aUC_CD4+_vs_qUC_CD4+	R-HSA-3700989	Transcriptional Regulation by TP53	39/343	343/8290	6.46094356802709S-9	2.71090423875136844-7	1.74275451505993967
aUC_CD4+_vs_qUC_CD4+	R-HSA-8848021	Signaling by PTK6	14/343	50/8290	8.01837106039723e-9	3.10557679146923477e-7	1.99647700491671858-7
aUC_CD4+_vs_qUC_CD4+	R-HSA-9006927	Signaling by Non-Receptor Tyrosine Kinases	14/343	50/8290	8.01837106039723e-9	3.10557679146923477e-7	1.99647700491671858-7
aUC_CD4+_vs_qUC_CD4+	R-HSA-9675126	Diseases of mitotic cell cycle	12/343	36/8290	1.061436005873e-8	3.81737877826468e-7	2.45407196846577e-7
aUC_CD4+_vs_qUC_CD4+	R-HSA-9687139	Aberrant regulation of mitotic cell cycle due to RB1 defects	12/343	36/8290	1.06143600587S3e-8	3.81737877826468e-7	2.45407196846577e-7
aUC_CD4+_vs_qUC_CD4+	R-HSA-5674400	Constitutive Signaling by AKT1 E17K in Cancer	10/343	25/8290	2.42302754341423e-8	8.41375426282250 1e-7	5.40893652843911756-7
aUC_CD4+_vs_qUC_CD4+	R-HSA-5357801	Programmed Cell Death	25/343	175/8290	3.81933959e125e-8	1.27208921569899644e-6	8.17785885804508e-7
aUC_CD4+_vs_qUC_CD4+	R-HSA-109581	Apoptosis	24/343	161/8290	3.91606411982809e-8	1.27208921569899644e-6	8.17785885804508e-7
aUC_CD4+_vs_qUC_CD4+	R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer	14/343	57/8290	5.05297344749905e-8	1.59010758175987176e-6	1.02222982572763e-6
aUC_CD4+_vs_qUC_CD4+	R-HSA-195721	Signaling by WNT	30/343	241/8290	5.34005380377093a-8	1.62952550921131 2e-6	1.04757036341917836-6
aUC_CD4+_vs_qUC_CD4+	R-HSA-187037	Signaling by NTRK1 (TRKA)	19/343	108/8290	7.23658900901992e-8	2.14330739178913S e-6	1.37786470757562S-6
aUC_CD4+_vs_qUC_CD4+	R-HSA-3928662	EPHB-mediated forward signaling	12/343	42/8290	7.48918691259369S-8	2.15474606313767114-6	1.38521803044966006-6
aUC_CD4+_vs_qUC_CD4+	R-HSA-9009391	Extra-nuclear estrogen signaling	15/343	68/8290	7.91221857446343e-8	2.21322336235207446-6	1.42281234378509e-6
aUC_CD4+_vs_qUC_CD4+	R-HSA-453279	Mitotic G1 phase and G1/S transition	22/343	146/8290	1.20509636430309274-7	3.27981615792765276-6	2.10648997766690174-6
aUC_CD4+_vs_qUC_CD4+	R-HSA-114452	Activation of BH3-only proteins	10/343	29/8290	1.27994978121642247-7	3.30489507735505674-6	2.12461282603184566-6
aUC_CD4+_vs_qUC_CD4+	R-HSA-186763	Downstream signal transduction	10/343	29/8290	1.27994978121642247-7	3.30489507735505674-6	2.12461282603184566-6
aUC_CD4+_vs_qUC_CD4+	R-HSA-452723	Transcriptional regulation of pluripotent stem cells	8/343	17/8290	1.38849562564204e-7	3.49553772980503674-6	2.24717054704469e-6
aUC_CD4+_vs_qUC_CD4+	R-HSA-2559580	Oxidative Stress Induced Senescence	14/343	58/8290	1.58172788680315 7e-7	3.88487825542921e-6	2.49746524547866876-6
aUC_CD4+_vs_qUC_CD4+	R-HSA-6811558	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	16/343	84/8290	2.55276543309109274-7	6.12055902648269 1e-6	3.93471363747123e-6
aUC_CD4+_vs_qUC_CD4+	R-HSA-74751	Insulin receptor signalling cascade	11/343	39/8290	3.06601779748309 1e-7	7.15713485809281e-6	4.60109542437837e-6
aUC_CD4+_vs_qUC_CD4+	R-HSA-8986944	Transcriptional Regulation by MECP2	13/343	56/8290	3.12724859738200997e-07	7.15713485809281e-6	4.60109542437837e-6
aUC_CD4+_vs_qUC_CD4+	R-HSA-1433557	Signaling by SCF-KIT	11/343	41/8290	5.36458155410882327e-7	1.20047413888129 7e-5	7.71746820064778e-6
aUC_CD4+_vs_qUC_CD4+	R-HSA-186797	Signaling by PDGF	12/343	50/8290	6.09422170420228e-7	1.33410462089813940e-5	8.57653265639007e-6
aUC_CD4+_vs_qUC_CD4+	R-HSA-8878159	Transcriptional regulation by RUNX3	16/343	90/8290	6.83913949898883e-7	1.46532016059947e-5	9.42009135918954 4e-6
aUC_CD4+_vs_qUC_CD4+	R-HSA-5684996	MAPK1/MAPK3 signaling	28/343	244/8290	8.27766969693168 9e-7	1.7365861218354607e-5	1.11639624202039 2e-5
aUC_CD4+_vs_qUC_CD4+	R-HSA-6804757	Regulation of TP53 Degradation	10/343	35/8290	9.39204187585145S e-7	1.90013578510072 7e-5	1.22152929575465929e-5
aUC_CD4+_vs_qUC_CD4+	R-HSA-9617828	FOXO-mediated transcription of cell cycle genes	7/343	15/8290	9.43457586159726e-7	1.90013578510072 7e-5	1.22152929575465929e-5
aUC_CD4+_vs_qUC_CD4+	R-HSA-8878166	Transcriptional regulation by RUNX2	17/343	105/8290	1.21111965627670 3e-6	2.34420278904595e-5	1.50701376118389786e-5
aUC_CD4+_vs_qUC_CD4+	R-HSA-2428928	IRS-related events triggered by IGF1R	10/343	36/8290	1.25316322641647376-6	2.34420278904595e-5	1.50701376118389786e-5
aUC_CD4+_vs_qUC_CD4+	R-HSA-6806003	Regulation of TP53 Expression and Degradation	10/343	36/8290	1.25316322641647376-6	2.34420278904595e-5	1.50701376118389786e-5
aUC_CD4+_vs_qUC_CD4+	R-HSA-373760	L1CAM interactions	16/343	94/8290	1.25707001597302 6e-6	2.34420278904595e-5	1.50701376118389786e-5
aUC_CD4+_vs_qUC_CD4+	R-HSA-9607240	FLT3 Signaling	28/343	252/8290	1.59006759022656426-6	2.91126920610572746-5	1.87156280954897e-5
aUC_CD4+_vs_qUC_CD4+	R-HSA-2428924	IGF1R signaling cascade	10/343	37/8290	1.65488676192780666e-6	2.97584101653803e-5	1.91307398230376 1e-5
aUC_CD4+_vs_qUC_CD4+	R-HSA-2682334	EPH-Ephrin signaling	15/343	89/8290	1.97020634022043e-6	3.48069788562267 3e-5	2.23763047972935 2e-5
aUC_CD4+_vs_qUC_CD4+	R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	10/343	38/8290	2.16431651407958e-6	3.63244454946356 3e-5	2.33518360729638 9e-5
aUC_CD4+_vs_qUC_CD4+	R-HSA-3769402	Deactivation of the beta-catenin transactivating complex	10/343	38/8290	2.16431651407958e-6	3.63244454946356 3e-5	2.33518360729638 9e-5
aUC_CD4+_vs_qUC_CD4+	R-HSA-5654736	Signaling by FGFR1	10/343	38/8290	2.16431651407958e-6	3.63244454946356 3e-5	2.33518360729638 9e-5
aUC_CD4+_vs_qUC_CD4+	R-HSA-9634638	Estrogen-dependent nuclear events downstream of ESR-membrane signaling	8/343	17/8290	2.25028123765438644-6	3.71148063494745 7e-5	2.38613290613880336-5
aUC_CD4+_vs_qUC_CD4+	R-HSA-445144	Signal transduction by L1	7/343	17/8290	2.65333523352837e-6	4.30952996800484 7e-5	2.77046038814925055-5
aUC_CD4+_vs_qUC_CD4+	R-HSA-6802957	Oncogenic MAPK signaling	14/343	78/8290	3.04971746909852 13e-6	4.87470721291781126e-5	3.13379489305863055-5
aUC_CD4+_vs_qUC_CD4+	R-HSA-389356	CD28 co-stimulation	9/343	32/8290	3.85788210392411 6e-6	6.07013637289310 15e-5	3.90229850972558737-5
aUC_CD4+_vs_qUC_CD4+	R-HSA-1912408	Pre-NOTCH Transcription and Translation	9/343	33/8290	5.11335124190692 2e-6	7.92176107784689 4e-5	5.09264941501667965-5
aUC_CD4+_vs_qUC_CD4+	R-HSA-5673001	RAF/MAP kinase cascade	26/343	239/8290	5.61532775155635 65e-6	8.56762885729886 5e-5	5.50785736396676044-5
aUC_CD4+_vs_qUC_CD4+	R-HSA-2559586	DNA Damage/Telomere Stress Induced Senescence	8/343	26/8290	6.42848543674354e-6	9.53862834037169 3e-5	6.13208219236731 3e-5
aUC_CD4+_vs_qUC_CD4+	R-HSA-6804116	TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest	6/343	13/8290	6.44117901832448e-6	9.53862834037169 3e-5	6.13208219236731 3e-5
aUC_CD4+_vs_qUC_CD4+	R-HSA-112399	IRS-mediated signalling	8/343	28/8290	6.70353511825219e-6	9.78327515953619 3e-5	6.28935798523647 5e-5
aUC_CD4+_vs_qUC_CD4+	R-HSA-422475	Axon guidance	41/343	483/8290	7.53877462750578 1e-6	1.08450657855690 31e-4	6.97194946754294e-5
aUC_CD4+_vs_qUC_CD4+	R-HSA-9669938	Signaling by KIT in disease	7/343	20/8290	9.49527977607336e-6	1.32802038000702e-4	8.53472260705922 7e-5
aUC_CD4+_vs_qUC_CD4+	R-HSA-9670439	Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	7/343	20/8290	9.49527977607336e-6	1.32802038000702e-4	8.53472260705922 7e-5
aUC_CD4+_vs_qUC_CD4+	R-HSA-198323	AKT phosphorylates targets in the cytosol	5/343	14/8290	1.08808416534839 55e-5	1.48067669527814 54e-4	9.51880173099476e-5
aUC_CD4+_vs_qUC_CD4+	R-HSA-8849471	PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases	6/343	14/8290	1.08808416534839 55e-5	1.48067669527814 54e-4	9.51880173099476e-5
aUC_CD4+_vs_qUC_CD4+	R-HSA-73887	Death Receptor Signalling	18/343	136/8290	1.13784786912456 8e-5	1.52774975816112 54e-4	9.82141955019173 1e-5
aUC_CD4+_vs_qUC_CD4+	R-HSA-6563007	Regulation of TP53 Activity	19/343	152/8290	1.50069256919008574e-5	1.98841764196837 4e-4	1.27829075184729574-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-5688426	Deubiquitination	24/343	224/8290	1.67828632849438e-5	2.19484978281652 5e-4	1.41099944225386764-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-8878171	Transcriptional regulation by RUNX1	19/343	155/8290	1.98853197899643e-5	2.56724577288412 77e-4	1.65040103519964254-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-2559582	Senescence-Associated Secretory Phenotype (SASP)	10/343	49/8290	2.50580790077070374-5	3.19411209629885 9e-4	2.05339354958911e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-1368108	BMAL1:CLOCK,NPAS2 activates circadian gene expression	7/343	23/8290	2.69644099231418 16e-5	3.35224207316096 4e-4	2.15505005748178 4e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-9006115	Signaling by NTRK2 (TRKB)	7/343	23/8290	2.69644099231418 16e-5	3.35224207316096 4e-4	2.15505005748178 4e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-9006936	Signaling by TGFB family members	14/343	94/8290	2.84677958178540 87e-5	3.48368366479351 53e-4	2.23954994391680554-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-74752	Signaling by Insulin receptor	11/343	60/8290	2.87135793622504 26e-5	3.48368366479351 53e-4	2.23954994391680554-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-5633008	TP53 Regulates Transcription of Cell Death Genes	9/343	41/8290	3.44427190696718 3e-5	4.12350308598551 14e-4	2.65089595928777 4e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-5654741	Signaling by FGFR3	8/343	32/8290	3.48061332724695 56e-5	4.12350308298551 1e-4	2.65086959288777 4e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-190236	Signaling by FGFR	12/343	73/8290	3.91115807761460 66e-5	4.51353267639990 5e-4	2.90160727119212e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-6802952	Signaling by BRAF and RAF fusions	11/343	62/8290	3.95419623114652 75e-5	4.51353267639990 5e-4	2.90160727119212e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-111471	Apoptotic factor-mediated response	6/343	17/8290	4.03394181604758 2e-5	4.51353267639990 5e-4	2.90160727119212e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-8934593	Regulation of RUNX1 Expression and Activity	6/343	17/8290	4.03394181604758 2e-5	4.51353267639990 5e-4	2.90160727119212e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-9034015	Signaling by NTRK3 (TRKC)	6/343	17/8290	4.03394181604758 2e-5	4.51353267639990 5e-4	2.90160727119212e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-9614399	Regulation of localization of FOXO transcription factors	5/343	11/8290	4.42818905994208 4-5	4.84978024857668 5e-4	3.11777019063885 5e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-5654743	Signaling by FGFR4	8/343	33/8290	4.43078235222497 6e-5	4.84978024857668 5e-4	3.11777019063885 5e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-400685	Sema4D in semaphorin signaling	7/343	25/8290	4.92151553017664 04e-5	5.32899584266534 4e-4	3.42584272898543 7e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-6802948	Signaling by high-kinase activity BRAF mutants	8/343	34/8290	5.59783738023801 45e-5	5.98611940627625 6e-4	3.84828666164208 1e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-6803204	TP53 Regulates Transcription of Genes Involved in Cytochrome C Release	6/343	18/8290	5.84148898217992 85e-5	6.19197832110724e-4	3.98062684104227 7e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-168164	Toll Like Receptor 3 (TLR3) Cascade	13/343	89/8290	6.75893231834287 6e-5	7.01674726244615e-4	4.51084468343013 3e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-9018519	Estrogen-dependent gene expression	13/343	89/8290	6.75893231834287 6e-5	7.01674726244615e-4	4.51084468343013 3e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-9673367	Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants	5/343	12/8290	7.33452985107508 5e-5	7.46047632326526 3e-4	4.79610404934734 3e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-9673770	Signaling by PDGFRA extracellular domain mutants	5/343	12/8290	7.33452985107508 5e-5	7.46047632326526 3e-4	4.79610404934734 3e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-166016	Toll Like Receptor 4 (TLR4) Cascade	15/343	116/8290	8.05153128423507 1e-5	8.10789203524602e-4	5.21230709453 1E8e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-5693565	Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks	8/343	36/8290	8.66223534587971e-5	8.63649596363258 1e-4	5.55212984647889 6e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-6791312	TP53 Regulates Transcription of Cell Cycle Genes	9/343	46/8290	9.07531490048770 4e-5	8.95767461254031 2e-4	5.75860543219807 8e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-166166	MyD88-independent TLR4 cascade	13/343	92/8290	9.59580376979599e-5	9.29132153479283 9e-4	5.97309647631886 4e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-937061	TRIF(TICAM1)-mediated TLR4 signaling	13/343	92/8290	9.59580376979598e-5	9.29132153479283 9e-4	5.97309647631886 4e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-69473	G2/M DNA damage checkpoint	10/343	57/8290	9.80583665135464e-5	9.38297220117953 5e-4	6.03201578814134 e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-69202	Cyclin E associated events during G1/S transition	12/343	80/8290	9.87681284346879e-5	9.38297220117953 5e-4	6.03201578814134 e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-3108232	SUMO E3 ligases SUMOylate target proteins	8/343	40/8290	1.02867935823810 54e-4	9.88112539490309e-4	6.23368720199275 4e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-5693606	DNA Double Strand Break Response	8/343	37/8290	1.05589031680358 4e-4	9.79006775828954 e-4	6.29372463424245 3e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-1227986	Signaling by ERBB2	9/343	47/8290	1.08196612853837 6e-4	9.79006775828954 e-4	6.29372463424245 3e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-383280	Nuclear Receptor transcription pathway	9/343	47/8290	1.08196612853837 6e-4	9.79006775828954 e-4	6.29372463424245 3e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-5218920	VEGFR2 mediated vascular permeability	8/343	28/8290	1.08886553021690 56e-4	9.79006775828954 e-4	6.29372463424245 3e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-8941326	RUNX2 regulates bone development	7/343	28/8290	1.08886553021690 56e-4	9.79006775828954 e-4	6.29372463424245 3e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-5218921	VEGFR2 mediated cell proliferation	6/343	20/8290	1.13677517793567 89e-4	9.99711170740275 e-4	6.42682663465436 e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-111461	Cytochrome c-mediated apoptotic response	5/343	13/8290	1.15160373193517 27e-4	9.99711170740275 e-4	6.42682663465436 e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-5357786	TNFR1-induced proapoptotic signaling	5/343	13/8290	1.15160373193517 27e-4	9.99711170740275 e-4	6.42682663465436 e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-75035	Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	5/343	13/8290	1.15160373193517 27e-4	9.99711170740275 e-4	6.42682663465436 e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-69656	Cyclin A:Cdk2-associated events at S phase entry	12/343	82/8290	1.26087891401240 35e-4	0.00108521800547905 14	6.97652300600549 e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-1236394	Signaling by ERBB4	9/343	48/8290	1.28389569511468 6e-4	0.00109566535083684 22	7.04367398175337 4e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-5674135	MAPK and MAPK activation	8/343	38/8290	1.30215139919426744e-4	0.00110190455356515 8	7.08379534099268e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-373755	Semaphorin interactions	10/343	59/8290	1.32547567820984 9e-4	0.00111229508189776 6	7.15059295798162 8e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-5357956	TNFR1-induced NFkappaB signaling pathway	7/343	29/8290	1.38493218114125 7e-4	0.00114313660828626 5	7.34886332001887e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-9645723	Diseases of programmed cell death	7/343	29/8290	1.38493218114125 7e-4	0.00114313660828626 5	7.34886332001887e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-1912422	Pre-NOTCH Expression and Processing	8/343	40/8290	1.51639155045921 08e-4	0.00123782256722981 78	7.95756942294818 3e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-8949693	RUNX2 regulates osteoblast differentiation	6/343	21/8290	1.53652255117901934-4	0.00123782256722981 78	7.95756942294818 3e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-982772	Growth hormone receptor signaling	6/343	21/8290	1.53652255117901934-4	0.00123782256722981 78	7.95756942294818 3e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-170834	Signaling by TGF-beta Receptor Complex	11/343	72/8290	1.62364746341178854-4	0.00129762936163148 5	8.34204837091269 7e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-2990846	SUMOylation	18/343	166/8290	1.65148976655203924-4	0.00130948342495047 8	8.41828600438876 1e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-5655332	Signaling by FGFR3 in disease	5/343	14/8290	1.73093446271313 5e-4	0.00132973601521522 74	8.54845188228310 9e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-8853338	Signaling by FGFR3 point mutants in cancer	5/343	14/8290	1.73093446271313 5e-4	0.00132973601521522 74	8.54845188228310 9e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-109704	PI3K Cascade	7/343	30/8290	1.74305018868016 58e-4	0.00132973601521522 74	8.54845188228310 9e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-2871796	FCERI mediated MAPK activation	7/343	30/8290	1.74305018868016 58e-4	0.00132973601521522 74	8.54845188228310 9e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-5655302	Signaling by FGFR1 in disease	7/343	30/8290	1.74305018868016 58e-4	0.00132973601521522 174	8.54845188228310 9e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-8862803	Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models	6/343	22/8290	2.03980831318084 9e-4	0.00153290072490530 98	9.85453348473073e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-8863678	Neurodegenerative Diseases	6/343	22/8290	2.03980831318084 9e-4	0.00153290072490530 98	9.85453348473073e-4
aUC_CD4+_vs_qUC_CD4+	R-HSA-187687	Signalling to ERKs	6/343	23/8290	2.17248837147755698-4	0.00159685824093272 9	0.00102656961080192 48
aUC_CD4+_vs_qUC_CD4+	R-HSA-2173796	SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	7/343	31/8290	2.17248837147755698-4	0.00159685824093272 9	0.00102656961080192 48
aUC_CD4+_vs_qUC_CD4+	R-HSA-9022692	Regulation of MECP2 expression and activity	7/343	31/8290	2.17248837147755698-4	0.00159685824093272 9	0.00102656961080192 48
aUC_CD4+_vs_qUC_CD4+	R-HSA-69206	G1/S Transition	15/343	128/8290	2.46401490105077e-4	0.00179800688444642 09	0.01155881705884532 8
aUC_CD4+_vs_qUC_CD4+	R-HSA-6804756	Regulation of TP53 Activity through Phosphorylation	12/343	88/8290	2.50110865022135 1e-4	0.00181954253246040 4	0.01164848027176168 7
aUC_CD4+_vs_qUC_CD4+	R-HSA-166058	MyD88:MAL(TIRAP) cascade initiated on plasma membrane	12/343	89/8290	2.78555780633362474-4	0.00198940192267940 43	0.01278923516905695 3
aUC_CD4+_vs_qUC_CD4+	R-HSA-168188	Toll Like Receptor TLR6:TLR2 Cascade	12/343	89/8290	2.78555780633362474-4	0.00198940192267940 43	0.01278923516905695 3
aUC_CD4+_vs_qUC_CD4+	R-HSA-168179	Toll Like Receptor TLR1:TLR2 Cascade	12/343	90/8290	3.09702189047559 9e-4	0.00218090982077541 77	0.01402037881959840 7
aUC_CD4+_vs_qUC_CD4+	R-HSA-181438	Toll Like Receptor 2 (TLR2) Cascade	12/343	90/8290	3.09702189047559 9e-4	0.00218090982077541 77	0.01402037881959840 7
aUC_CD4+_vs_qUC_CD4+	R-HSA-2173793	Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	8/343	43/8290	3.22299531347481544-4	0.00223831467632354 44	0.01438941646306 36
aUC_CD4+_vs_qUC_CD4+	R-HSA-75893	TNF signaling	8/343	43/8290	3.22299531347481544-4	0.00223831467632354 44	0.01438941646306 36
aUC_CD4+_vs_qUC_CD4+	R-HSA-69273	Cyclin A/B1/B2 associated events during G2/M transition	6/343	24/8290	3.43033883496529434-4	0.00236599597726715 85	0.01521022626895207
aUC_CD4+_vs_qUC_CD4+	R-HSA-9614657	FOXO-mediated transcription of cell death genes	5/343	16/8290	3.52636759728441 6e-4	0.00241568174861923	0.01552965322123634
aUC_CD4+_vs_qUC_CD4+	R-HSA-2029480	Fcgamma receptor (FCGR) dependent phagocytosis	11/343	79/8290	3.74863313422648 3e-4	0.00251725593

aUC_CD44+_vs_cUC_CD44+	R-HSA-437239	Recycling pathway of L1	7/343	39/8290	9.55805141187253e-4	0.005147036241580556	0.00330886665805239
aUC_CD44+_vs_cUC_CD44+	R-HSA-109582	Hemostasis	34/343	470/8290	9.73403312275899e-4	0.005213920933306488	0.00335186470912416
aUC_CD44+_vs_cUC_CD44+	R-HSA-8953897	Cellular responses to external stimuli	35/343	490/8290	0.001026712863183270	0.005470369593785998	0.00351672743446233
aUC_CD44+_vs_cUC_CD44+	R-HSA-1226099	Signaling by FGFR in disease	8/343	51/8290	0.001061003313162970	0.005566078322010954	0.00357825545595338366
aUC_CD44+_vs_cUC_CD44+	R-HSA-1266695	Interleukin-7 signaling	5/343	20/8290	0.001091757629249913	0.005566078322010954	0.00357825545595338366
aUC_CD44+_vs_cUC_CD44+	R-HSA-5627117	RHO GTPases Activate ROCKs	5/343	20/8290	0.001091757629249913	0.005566078322010954	0.00357825545595338366
aUC_CD44+_vs_cUC_CD44+	R-HSA-5654687	Downstream signaling of activated FGFR1	5/343	20/8290	0.001091757629249913	0.005566078322010954	0.00357825545595338366
aUC_CD44+_vs_cUC_CD44+	R-HSA-1502540	Signaling by Activin	4/343	12/8290	0.001094422549988078	0.005566078322010954	0.00357825545595338366
aUC_CD44+_vs_cUC_CD44+	R-HSA-418885	DCC mediated attractive signaling	4/343	12/8290	0.001094422549988078	0.005566078322010954	0.00357825545595338366
aUC_CD44+_vs_cUC_CD44+	R-HSA-5654706	FRS-mediated FGFR3 signaling	4/343	12/8290	0.001094422549988078	0.005566078322010954	0.00357825545595338366
aUC_CD44+_vs_cUC_CD44+	R-HSA-5654719	SHC-mediated cascade:FGFR4	4/343	12/8290	0.001094422549988078	0.005566078322010954	0.00357825545595338366
aUC_CD44+_vs_cUC_CD44+	R-HSA-6804759	Regulation of TP53 Activity through Association with Co-factors	4/343	12/8290	0.001094422549988078	0.005566078322010954	0.00357825545595338366
aUC_CD44+_vs_cUC_CD44+	R-HSA-9656223	Signaling by RAF1 mutants	7/343	40/8290	0.001118144943675246	0.005658150544125491	0.0036374458627890832
aUC_CD44+_vs_cUC_CD44+	R-HSA-69620	Cell Cycle Checkpoints	21/343	244/8290	0.001151808346043697	0.005799355022326856	0.00372822171565748
aUC_CD44+_vs_cUC_CD44+	R-HSA-400253	Circadian Clock	9/343	64/8290	0.001177697257030113	0.005900208015835845	0.00379305694845431 76
aUC_CD44+_vs_cUC_CD44+	R-HSA-6804757	MAPK targets/ Nuclear events mediated by MAP kinases	3/343	3/8290	0.001226874570769839	0.006086023110663242	0.00391251159462269 36
aUC_CD44+_vs_cUC_CD44+	R-HSA-8864260	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	6/343	30/8290	0.001226874570769839	0.006086023110663242	0.00391251159462269 36
aUC_CD44+_vs_cUC_CD44+	R-HSA-389357	CD28 dependent PI3K/Akt signaling	5/343	21/8290	0.001384915558666171	0.006737246220177944	0.00433116231161878 4
aUC_CD44+_vs_cUC_CD44+	R-HSA-416572	Sema4D induced cell migration and growth-cone collapse	5/343	21/8290	0.001384915558666171	0.006737246220177944	0.00433116231161878 4
aUC_CD44+_vs_cUC_CD44+	R-HSA-5654732	Negative regulation of FGFR3 signaling	5/343	21/8290	0.001384915558666171	0.006737246220177944	0.00433116231161878 4
aUC_CD44+_vs_cUC_CD44+	R-HSA-9615017	FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	5/343	21/8290	0.001384915558666171	0.006737246220177944	0.00433116231161878 4
aUC_CD44+_vs_cUC_CD44+	R-HSA-114604	GPVI-mediated activation cascade	6/343	31/8290	0.001469184768382034	0.007092804091739593	0.00455973689690485
aUC_CD44+_vs_cUC_CD44+	R-HSA-448424	Interleukin-17 signaling	9/343	66/8290	0.001472090668096967	0.007092804091739593	0.00455973689690485
aUC_CD44+_vs_cUC_CD44+	R-HSA-373752	Netrin-1 signaling	7/343	50/8290	0.001507229643315062	0.007227520038986336	0.00464634720074569
aUC_CD44+_vs_cUC_CD44+	R-HSA-171007	p38MAPK events	4/343	13/8290	0.001529650184004879	0.007265838374021375	0.00467097747349930 5
aUC_CD44+_vs_cUC_CD44+	R-HSA-5654693	FRS-mediated FGFR1 signaling	4/343	13/8290	0.001529650184004879	0.007265838374021375	0.00467097747349930 5
aUC_CD44+_vs_cUC_CD44+	R-HSA-168142	Toll Like Receptor 10 (TLR10) Cascade	10/343	80/8290	0.001608930977140067	0.007535783692934525	0.00484451677327364
aUC_CD44+_vs_cUC_CD44+	R-HSA-168176	Toll Like Receptor 5 (TLR5) Cascade	10/343	80/8290	0.001608930977140067	0.007535783692934525	0.00484451677327364
aUC_CD44+_vs_cUC_CD44+	R-HSA-975871	MyD88 cascade initiated on plasma membrane	10/343	80/8290	0.001608930977140067	0.007535783692934525	0.00484451677327364
aUC_CD44+_vs_cUC_CD44+	R-HSA-5689880	Ub-specific processing proteases	15/343	154/8290	0.001731581143611553	0.008001720399623236	0.00514405273168691 8
aUC_CD44+_vs_cUC_CD44+	R-HSA-5654726	Negative regulation of FGFR1 signaling	5/343	22/8290	0.001732249302003838	0.008001720399623236	0.00514405273168691 8
aUC_CD44+_vs_cUC_CD44+	R-HSA-5668599	RHO GTPases Activate NADPH Oxidases	5/343	22/8290	0.001732249302003838	0.008001720399623236	0.00514405273168691 8
aUC_CD44+_vs_cUC_CD44+	R-HSA-69242	S Phase	15/343	156/8290	0.001968476888481334	0.009051398295437	0.00581885742089307
aUC_CD44+_vs_cUC_CD44+	R-HSA-4086398	Ca2+ pathway	8/343	56/8290	0.001978048110320625	0.009054065668602292	0.00582057190655375
aUC_CD44+_vs_cUC_CD44+	R-HSA-75153	Apoptotic execution phase	7/343	44/8290	0.001994489123866693	0.009088011528207556	0.00584239409159399
aUC_CD44+_vs_cUC_CD44+	R-HSA-162658	Golgi Cisternae Pericentricular Stack Reorganization	4/343	9/8290	0.002072272879097759	0.009357752416176909	0.00601580278803456
aUC_CD44+_vs_cUC_CD44+	R-HSA-5654712	FRS-mediated FGFR4 signaling	4/343	14/8290	0.002072272879097759	0.009357752416176909	0.00601580278803456
aUC_CD44+_vs_cUC_CD44+	R-HSA-1839124	FGFR1 mutant receptor activation	5/343	23/8290	0.002139413770521606	0.009532697641218018	0.00612826953632029
aUC_CD44+_vs_cUC_CD44+	R-HSA-2173795	Downregulation of SMAD2/3:SMAD4 transcriptional activity	5/343	23/8290	0.002139413770521606	0.009532697641218018	0.00612826953632029
aUC_CD44+_vs_cUC_CD44+	R-HSA-5654733	Negative regulation of FGFR4 signaling	5/343	23/8290	0.002139413770521606	0.009532697641218018	0.00612826953632029
aUC_CD44+_vs_cUC_CD44+	R-HSA-2029482	Regulation of actin dynamics for phagocytic cup formation	8/343	57/8290	0.002219997697277219	0.009848183617436827	0.00633108548029440 95
aUC_CD44+_vs_cUC_CD44+	R-HSA-2644602	Signaling by NOTCH1 PEST Domain Mutants in Cancer	8/343	58/8290	0.002484597033494485	0.010784436261762368	0.00693297266605744 5
aUC_CD44+_vs_cUC_CD44+	R-HSA-2644603	Signaling by NOTCH1 in Cancer	8/343	58/8290	0.002484597033494485	0.010784436261762368	0.00693297266605744 5
aUC_CD44+_vs_cUC_CD44+	R-HSA-2644606	Constitutive Signaling by NOTCH1 PEST Domain Mutants	8/343	58/8290	0.002484597033494485	0.010784436261762368	0.00693297266605744 5
aUC_CD44+_vs_cUC_CD44+	R-HSA-2894858	Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer	8/343	58/8290	0.002484597033494485	0.010784436261762368	0.00693297266605744 5
aUC_CD44+_vs_cUC_CD44+	R-HSA-2894862	Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants	8/343	58/8290	0.002484597033494485	0.010784436261762368	0.00693297266605744 5
aUC_CD44+_vs_cUC_CD44+	R-HSA-1980143	Signaling by NOTCH1	8/343	58/8290	0.002724279491920705	0.011668377444665139	0.00750123046918527 2
aUC_CD44+_vs_cUC_CD44+	R-HSA-111447	Activation of BAD and translocation to mitochondria	4/343	15/8290	0.002734594912506241	0.011668377444665139	0.00750123046918527 2
aUC_CD44+_vs_cUC_CD44+	R-HSA-399954	Sema3A PAK dependent Axon repulsion	4/343	15/8290	0.002734594912506241	0.011668377444665139	0.00750123046918527 2
aUC_CD44+_vs_cUC_CD44+	R-HSA-9665348	Signaling by ERBB2 ECD mutants	4/343	15/8290	0.002734594912506241	0.011668377444665139	0.00750123046918527 2
aUC_CD44+_vs_cUC_CD44+	R-HSA-168638	NOD1/2 Signaling Pathway	5/343	28/8290	0.002817973566617984	0.011873219169680883	0.00763291672966333
aUC_CD44+_vs_cUC_CD44+	R-HSA-5673000	RAF activation	6/343	35/8290	0.002817973566617984	0.011873219169680883	0.00763291672966333
aUC_CD44+_vs_cUC_CD44+	R-HSA-6783783	Interleukin-10 signaling	6/343	35/8290	0.002817973566617984	0.011873219169680883	0.00763291672966333
aUC_CD44+_vs_cUC_CD44+	R-HSA-69563	p53-Dependent G1 DNA Damage Response	8/343	60/8290	0.003087468425290858	0.012900749810240225	0.00829348364950372 2
aUC_CD44+_vs_cUC_CD44+	R-HSA-69580	p53-Dependent G1/S DNA damage checkpoint	8/343	60/8290	0.003087468425290858	0.012900749810240225	0.00829348364950372 2
aUC_CD44+_vs_cUC_CD44+	R-HSA-6807070	PTEN Regulation	13/343	132/8290	0.003192972847321616	0.013021395691127549	0.00837104306699779 8
aUC_CD44+_vs_cUC_CD44+	R-HSA-111465	Apoptotic cleavage of cellular proteins	6/343	36/8290	0.003266145146247868	0.013424523111312665	0.00863020092349060 6
aUC_CD44+_vs_cUC_CD44+	R-HSA-5689896	Ovarian tumor domain proteases	6/343	36/8290	0.003266145146247868	0.013424523111312665	0.00863020092349060 6
aUC_CD44+_vs_cUC_CD44+	R-HSA-8853659	RET signaling	6/343	36/8290	0.003266145146247868	0.013424523111312665	0.00863020092349060 6
aUC_CD44+_vs_cUC_CD44+	R-HSA-177929	Signaling by EGFR	7/343	48/8290	0.003326924186652676	0.013618750633398057	0.00875506364908598 9
aUC_CD44+_vs_cUC_CD44+	R-HSA-168928	DDX58/IFIH1-mediated induction of interferon-alpha/beta	8/343	61/8290	0.003428688229929814	0.013946713125835486	0.00896590035267738 8
aUC_CD44+_vs_cUC_CD44+	R-HSA-194315	Signaling by Rho GTPases	27/343	375/8290	0.003437416635622644	0.013946713125835486	0.00896590035267738 8
aUC_CD44+_vs_cUC_CD44+	R-HSA-156711	Polo-like kinase mediated events	4/343	16/8290	0.003525880643321647	0.014156498128191992	0.09100076448945599
aUC_CD44+_vs_cUC_CD44+	R-HSA-881907	Gastrin-CREB signalling pathway via PKC and MAPK	4/343	16/8290	0.003525880643321647	0.014156498128191992	0.09100076448945599
aUC_CD44+_vs_cUC_CD44+	R-HSA-9022699	MECP2 regulates neuronal receptors and channels	4/343	16/8290	0.003525880643321647	0.014156498128191992	0.09100076448945599
aUC_CD44+_vs_cUC_CD44+	R-HSA-1181150	Signaling by NODAL	4/343	17/8290	0.004465756443857793	0.017767621700464267	0.01142224151548165 2
aUC_CD44+_vs_cUC_CD44+	R-HSA-2424491	DAP12 signaling	5/343	27/8290	0.004481604679163774	0.017767621700464267	0.01142224151548165 2
aUC_CD44+_vs_cUC_CD44+	R-HSA-397795	G-protein beta:gamma signalling	5/343	27/8290	0.004481604679163774	0.017767621700464267	0.01142224151548165 2
aUC_CD44+_vs_cUC_CD44+	R-HSA-193704	p75 NTR receptor-mediated signalling	10/343	93/8290	0.004917594844958166	0.019419678466168613	0.01248429651042011
aUC_CD44+_vs_cUC_CD44+	R-HSA-168643	Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways	7/343	52/8290	0.005250032444998704	0.020571388019988 1	0.01322453390814742
aUC_CD44+_vs_cUC_CD44+	R-HSA-375165	NCAM signaling for neurite out-growth	7/343	52/8290	0.005250032444998704	0.020571388019988 1	0.01322453390814742
aUC_CD44+_vs_cUC_CD44+	R-HSA-350054	Notch-HLH transcription pathway	5/343	28/8290	0.005274402889283244	0.020585652600584842	0.01323442585438268
aUC_CD44+_vs_cUC_CD44+	R-HSA-167044	Signalling to RAS	4/343	18/8290	0.005557123839075309	0.021295900055571595	0.01369045997405167
aUC_CD44+_vs_cUC_CD44+	R-HSA-3232118	SUMOylation of transcription factors	4/343	18/8290	0.005557123839075309	0.021295900055571595	0.01369045997405167
aUC_CD44+_vs_cUC_CD44+	R-HSA-5654696	Downstream signaling of activated FGFR2	4/343	18/8290	0.005557123839075309	0.021295900055571595	0.01369045997405167
aUC_CD44+_vs_cUC_CD44+	R-HSA-6804114	TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest	4/343	18/8290	0.005557123839075309	0.021295900055571595	0.01369045997405167
aUC_CD44+_vs_cUC_CD44+	R-HSA-5687128	MAPK6/MAPK4 signaling	9/343	80/8290	0.005561888495149284 5	0.021295900055571595	0.01369045997405167
aUC_CD44+_vs_cUC_CD44+	R-HSA-2454202	Fc epsilon receptor (FCERI) signaling	12/343	126/8290	0.005826502046344195	0.022140707776140794	0.01423356011321421 9
aUC_CD44+_vs_cUC_CD44+	R-HSA-69481	G2/M Checkpoints	12/343	126/8290	0.005826502046344195	0.022140707776140794	0.01423356011321421 9
aUC_CD44+_vs_cUC_CD44+	R-HSA-5628897	TP53 Regulates Metabolic Genes	9/343	81/8290	0.006035906360737609	0.022850216937078 09	0.01468968109162496 4
aUC_CD44+_vs_cUC_CD44+	R-HSA-201722	Formation of the beta-catenin:TCF transactivating complex	5/343	29/8290	0.006161495020302908	0.022980094390537144	0.01477317519487831 4
aUC_CD44+_vs_cUC_CD44+	R-HSA-2172127	DAP12 interactions	5/343	29/8290	0.006161495020302908	0.022980094390537144	0.01477317519487831 4
aUC_CD44+_vs_cUC_CD44+	R-HSA-3214858	RMTs methylate histone arginines	5/343	29/8290	0.006161495020302908	0.022980094390537144	0.01477317519487831 4
aUC_CD44+_vs_cUC_CD44+	R-HSA-6804758	Regulation of TP53 Activity through Acetylation	5/343	29/8290	0.006161495020302908	0.022980094390537144	0.01477317519487831 4
aUC_CD44+_vs_cUC_CD44+	R-HSA-1059683	Interleukin-6 signaling	3/343	10/8290	0.006781513422847072	0.024072930375355708	0.01547572485323136
aUC_CD44+_vs_cUC_CD44+	R-HSA-170968	Frs2-mediated activation	3/343	10/8290	0.006781513422847072	0.024072930375355708	0.01547572485323136
aUC_CD44+_vs_cUC_CD44+	R-HSA-2032785	YAP1- and WWTR1 (TAZ)-stimulated gene expression	3/343	10/8290	0.006781513422847072	0.024072930375355708	0.01547572485323136
aUC_CD44+_vs_cUC_CD44+	R-HSA-430116	GP1b-IX-V activation signalling	3/343	10/8290	0.006781513422847072	0.024072930375355708	0.01547572485323136
aUC_CD44+_vs_cUC_CD44+	R-HSA-5625970	RHO GTPases activate KTN1	3/343	10/8290	0.006781513422847072	0.024072930375355708	0.01547572485323136
aUC_CD44+_vs_cUC_CD44+	R-HSA-5654710	PI-3K cascade:FGFR3	3/343	10/8290	0.006781513422847072	0.024072930375355708	0.01547572485323136
aUC_CD44+_vs_cUC_CD44+	R-HSA-6803207	TP53 Regulates Transcription of Caspase Activators and Caspases	3/343	10/8290	0.006781513422847072	0.024072930375355708	0.01547572485323136
aUC_CD44+_vs_cUC_CD44+	R-HSA-8851805	MET activates RAS signaling	3/343	10/8290	0.006781513422847072	0.024072930375355708	0.01547572485323136
aUC_CD44+_vs_cUC_CD44+	R-HSA-8875555	MET activates PAK1 and RAC1	3/343	10/8290	0.006781513422847072	0.024072930375355708	0.01547572485323136
aUC_CD44+_vs_cUC_CD44+	R-HSA-8028731	Activated NTRK2 signals through FRS2 and FRS3	3/343	10/8290	0.006781513422847072	0.024072930375355708	0.01547572485323136
aUC_CD44+_vs_cUC_CD44+	R-HSA-9634285	Constitutive Signaling by Overexpressed ERBB2	3/343	10/8290	0.006781513422847072	0.024072930375355708	0.01547572485323136
aUC_CD44+_vs_cUC_CD44+	R-HSA-1362277	Transcription of E2F targets under negative control by DREAM complex	4/343	19/8290	0.006813093502459163	0.024072930375355708	0.01547572485323136
aUC_CD44+_vs_cUC_CD44+	R-HSA-2028269	Signaling by Hippo	4/343	19/8290	0.006813093502459163	0.024072930375355708	0.01547572485323136
aUC_CD44+_vs_cUC_CD44+	R-HSA-5621575	CD209 (DC-SIGN) signaling	4/343	19/8290	0.006813093502459163	0.024072930375355708	0.01547572485323136
aUC_CD44+_vs_cUC_CD44+	R-HSA-8876384	Listeria monocytogenes entry into host cells	4/343	19/8290	0.006813093502459163	0.024072930375355708	0.01547572485323136
aUC_CD44+_vs_cUC_CD44+	R-HSA-5675221	Negative regulation of MAPK pathway	6/343	42/8290	0.007146293684244642	0.025161950139986026	0.01617582118443028
aUC_CD44+_vs_cUC_CD44+	R-HSA-9664407	Parasite infection	7/343	56/8290	0.007907253166878547	0.027552627648674621	0.01771247750019325
aUC_CD44+_vs_cUC_CD44+	R-HSA-9664417	Leishmania phagocytosis	7/343	56/8290	0.007907253166878547	0.027552627648674621	0.01771247750019325
aUC_CD44+_vs_cUC_CD44+	R-HSA-9664422	FCGR3A-mediated phagocytosis	7/343	56/8290	0.007907253166878547	0.027552627648674621	0.01771247750019325
aUC_CD44+_vs_cUC_CD44+	R-HSA-1250196	SHC1 events in ERBB2 signaling	4/343	20/8290	0.008243427470761469	0.028562624958958075	0.01833860696154206
aUC_CD44+_vs_cUC_CD44+	R-HSA-449836	Other interleukin signaling	4/343	20/8290	0.008243427470761469	0.028562624958958075	0.01833860696154206
aUC_CD44+_vs_cUC_CD44+	R-HSA-9679191	Potential therapeutics for SARS	8/343	71/8290	0.008673327647624258	0.029911099135533	0.01922889874409266
aUC_CD44+_vs_cUC_CD44+	R-HSA-111458	Formation of apoptosome	3/343	11/8290	0.009041807156623668	0.030451838818461615	0.01957652315199280 2
aUC_CD44+_vs_cUC_CD44+	R-HSA-389359	CD28 dependent Vav1 pathway	3/343	11/8290	0.009041807156623668	0.030451838818461615	0.01957652315199280 2
aUC_CD44+_vs_cUC_CD44+	R-HSA-5654689	PI-3K cascade:FGFR1	3/343	11/8290	0.009041807156623668	0.030451838818461615	0.01957652315199280 2
aUC_CD44+_vs_cUC_CD44+	R-HSA-5654699	SHC-mediated cascade:FGFR2	3/343	11/8290	0.009041807156623668	0.030451838818461615	0.01957652315199280 2
aUC_CD44+_vs_cUC_CD44+	R-HSA-5655291	Signaling by FGFR4 in disease	3/343	11/8290	0.009041807156623668	0.030451838818461615	0.01957652315199280 2
aUC_CD44+_vs_cUC_CD44+	R-HSA-68689	CDC6 association with the ORC:origin complex	3/343	11/8290	0.009041807156623668	0.030451838818461615	0.01957652315199280 2
aUC_CD44+_vs_cUC_CD44+	R-HSA-9627069	Regulation of the apoptosome activity	3/343	11/8290	0.009041807156623668	0.030451838818461615	0.01957652315199280 2
aUC_CD44+_vs_cUC_CD44+	R-HSA-8943724	Regulation of PTEN gene transcription	7/343	58/8290	0.009557039585444292	0.032079792608474 67	0.02062308542122189 4
aUC_CD44+_vs_cUC_CD44+	R-HSA-112409	RAF-independent MAPK1/3 activation	4/343	21/8290	0.009857194979489784	0.032977393170585422	0.02120012209262534
aUC_CD44+_vs_cUC_CD44+	R-HSA-3928665	EPH-ephrin mediated repulsion of cells	6/343	45/8290	0.010005382989051851	0.033363220099255674	0.02144757942932 05
aUC_CD44+_vs_cUC_CD44+	R-HSA-983231	Factors involved in megakaryocyte development and platelet production	11/343	119/8290	0.010087739913438826	0.033529210984617 3	0.02155275332518645
aUC_CD44+_vs_cUC_CD44+	R-HSA-9679506	SARS-CoV Infections	12/343	136/8290	0.010515845861403123	0.034842693103397 85	0.02239926436898518
aUC_CD44+_vs_cUC_CD44+	R-HSA-198753	ERK/MAPK targets	4/343	22/8290	0.011662738463375554	0.037373879067853846	0.04202648369490412
aUC_CD44+_vs_cUC_CD44+	R-HSA-5654727	Negative regulation of FGFR2 signaling	4/343	22/8290	0.011662738463375554	0.037373879067853846	0.04202648369490412
aUC_CD44+_vs_cUC_CD44+	R-HSA-912446	Meiotic recombination	4/343	22/8290	0.011662738463375554	0.037373879067853846	0.04202648369490412
aUC_CD44+_vs_cUC_CD44+	R-HSA-9664565	Signaling by ERBB2 KD Mutants	4/343	22/8290	0.011662738463375554	0.037373879067853846	0.04202648369490412
aUC_CD44+_vs_cUC_CD44+	R-HSA-1358803	Downregulation of ERBB2:ERBB3 signaling	3/343	12/8290	0.011690935358861928	0.037373879067853846	0.04202648369490412
aUC_CD44+_vs_cUC_CD44+	R-HSA-162594	Early Phase of HIV Life Cycle	3/343	12/8290	0.011690935358861928	0.037373879067853846	0.04202648369490412
aUC_CD44+_vs_cUC_CD44+	R-HSA-169893	Prolonged ERK activation events	3/343	12/8290	0.011690935358861928	0.037373879067853846	0.04202648369490412
aUC_CD44+_vs_cUC_CD44+	R-HSA-2299718	Condensation of Prophase Chromosomes	3/343	12/8290	0.011690935358861928	0.037373879067853846	0.04202648369490412
aUC_CD44+_vs_cUC_CD44+	R-HSA-264642	Acetylcholine Neurotransmitter Release Cycle	3/343	12/8290	0.011690935358861928	0.037373879067853846	0.04202648369490412
aUC_CD44+_vs_cUC_CD44+	R-HSA-264870	Caspase-mediated cleavage of cytoskeletal proteins	3/343	12/8290	0.011690935358861928	0.037373879067853846	0.04202648369490412
aUC_CD44+_vs_cUC_CD44+	R-HSA-5654720	PI-3K cascade:FGFR4	3/343	12/8290	0.011690935358861928	0.037373879067853846	0.04202648369490412
aUC_CD44+_vs_cUC_CD44+	R-HSA-5625740	RHO GTPases activate PKNs	5/343	34/8290	0.012200026964364475	0.038755290703832886	0.02491454950384908 5
aUC_CD44+_vs_cUC_CD44+	R-HSA-936440	Negative regulators of DDX58/IFIH1 signaling	5/343	34/8290	0.012200026964364475	0.038755290703832886	0.02491454950384908 5
aUC_CD44+_vs_cUC_CD44+	R-HSA-5654738	Signaling by FGFR2	7/343	61/8290	0.012484515908887547	0.039534300378141389	0.02541535016208473
aUC_CD44+_vs_cUC_CD44+	R-HSA-2122947	NOTCH1 Intracellular Domain Regulates Transcription	6/343	48/8290	0.013596612578034534	0.042876393979763894	0.02756387633675303
aUC_CD44+_vs_cUC_CD44+	R-HSA-1227990	Signaling by ERBB2 in Cancer	4/343	23/8290	0.013667648925029006	0.042876393979763894	0.02756387633675303
aUC_CD44+_vs_cUC_CD44+	R-HSA-9006335	Signaling by Erythropoietin	4/343	23/8290	0.013667648925029006	0.042876393979763894	0.02756387633675303
aUC_CD44+_vs_cUC_CD44+	R-HSA-5693532	DNA Double-Strand Break Repair	11/343	125/8290	0.014264639004309031	0.044610221979314274	0.02867849946927117
aUC_CD44+_vs_cUC_CD44+	R-HSA-5654700	FRS-mediated FGFR2 signaling	5/343	35/8290	0.014733920911319213	0.045810173326229775	0.02944991020292846
aUC_CD44+_vs_cUC_CD44+	R-HSA-6803205	TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain	3/343	13/8290	0.014733920911319213	0.045810173326229775	0.02944991020292846
aUC_CD44+_vs_cUC_CD44+	R-HSA-451927	Interleukin-2 family signaling	5/343	36/8290	0.015456859474954727	0.047455673194108 6	0.03069411373170718 3
aUC_CD44+_vs_cUC_CD44+	R-HSA-8875878	MET promotes cell motility	5/343	36/8290	0.015456859474954727	0.047455673194108 6	0.03069411373170718 3
aUC_CD44+_vs_cUC_CD44+	R-HSA-2203927	MicroRNA (miRNA) biogenesis	4/343	24/8290	0.015878749646087063	0.048454245131215053	0.03114970026265828 8
aUC_CD44+_vs_cUC_CD44+	R-HSA-3928663	EPHA-mediated growth cone collapse	4/343	24/8290	0.015878749646087063	0.048454245131215053	0.03114970026265828 8
aUC_CD44+_vs_cUC_CD44+	R-HSA-5357769	Caspase activation via extrinsic apoptotic signalling pathway	4/343	24/8290	0.015878749646087063	0.048454245131215053	0.03114970026265828 8
aUC_CD44+_vs_cUC_CD44+	R-HSA-5627123	RHO GTPases activate PAKs	4/343	24/8290	0.015878749646087063	0.048454245131215053	0.03114970026265828 8
aUC_CD44+_vs_cUC_CD44+	R-HSA-5663202	Diseases of signal transduction by growth factor receptors and second messengers	79/475	358/8290	4.43504385350233e-27	5.06482008315605e-24	3.07185142841196 65e-24
aUC_cD44+_vs_HC_CD44+	R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	86/475	439/8290	2.03036992770049 57e-25	1.15934122871693e-22	7.03149164435224e-23
aUC_cD44+_vs_HC_CD44+	R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling	36/475	87/8290	1.31392602800118644e-22	5.0016784132578496e-20	3.03355553131502e-20
aUC_cD44+_vs_HC_CD44+	R-HSA-449147	Signaling by Interleukins	72/475	376/8290	1.16205916565553344e-20	3.31767891794661254e-18	2.01219718684567 35e-18
aUC_cD44+_vs_HC_CD44+	R-HSA-2219528	PI3K/AKT Signaling in Cancer	33/475	83/8290	3.68072072436700440e-20	8.40676613445423e-18	5.09876681396524e-18
aUC_cD44+_vs_HC_CD44+	R-HSA-9659787	Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects	15/475	17/8290	2.33157275510398354e-17	3.80379440904107e-15	2.30702988399762644e-15
aUC_cD44+_vs_HC_CD44+	R-HSA-9661069	Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	15/475	17/8290	2.33157275510398354e-17	3.80379440904107e-15	2.30702988399762644e-15
aUC_cD44+_vs_HC_CD44+	R-HSA-1257604	PIP3 activates AKT signaling	50/475	237/8290	2.46567446266155e-16	3.51975026690155590e-14	2.13476497998943e-14
aUC_cD44+_vs_HC_CD44+	R-HSA-2559583	Cellular Senescence	34/475	123/8290	4.08679163607216e-15	5.18568449821601e-13	3.14515660413506866-13
aUC_cD44+_vs_HC_CD44+	R-HSA-9006925	Intracellular signaling by second messengers	52/475	273/8290	5.43924316699934e-15	5.77598080728663e-13	3.50317575001807e-13
aUC_cD44+_vs_HC_CD44+	R-HSA-8939211	ESR-mediated signaling	38/475	154/8290	5.56355419265788e-15	5.77598080728663e-13	3.50317575001807e-13
aUC_cD44+_vs_HC_CD44+	R-HSA-199418	Negative regulation of the PI3K/AKT network	29/475	91/8290	7.40215633372624e-15	7.04590811059294e-13	4.27338619943778844e-13
aUC_cD44+_vs_HC_CD44+	R-HSA-9616222	Transcriptional regulation of granulopoiesis	16/475	27/8290	7.66874926149187e-14	5.87395084274622e-12	3.56259531249609422e-12
aUC_cD44+_vs_HC_CD44+	R-HSA-8848021	Signaling by PTK6	21/475	50/8290	7.71534699134792e-14	5.87395084274622e-12	3.56259531249609422e-12
aUC_cD44+_vs_HC_CD44+	R-HSA-9006927	Signaling by Non-Receptor Tyrosine Kinases	21/475	50/8290	7.71534699134792e-14	5.87395084274622e-12	3.56259531249609422e-12
aUC_cD44+_vs_HC_CD44+	R-HSA-9006931	Signaling by Nuclear Receptors	44/475	219/8290	1.09027175644907e-13	7.78181466165526e-12	4.71929305094402756e-12
aUC_cD44+_vs_HC_CD44+	R-HSA-9009391	Extra-nuclear estrogen signa

aUC_CD44+_vs_HC_CD44+	R-HSA-9607240	FLT3 Signaling	40/475	252/8290	2.83519558219534070e-9	7.19509634414906e-8	4.36387998382347270e-8
aUC_CD44+_vs_HC_CD44+	R-HSA-6804116	TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest	9/475	13/8290	3.59835571925157480e-9	8.93330919866369e-8	5.41811913791198e-8
aUC_CD44+_vs_HC_CD44+	R-HSA-157118	Signaling by NOTCH	31/475	168/8290	4.84492821581856680e-9	1.17721447284852e-7	7.13989421278526e-8
aUC_CD44+_vs_HC_CD44+	R-HSA-5673001	RAF/MAP kinase cascade	38/475	239/8290	6.86226162432161e-9	1.63264641145318340e-7	9.90212313334127e-8
aUC_CD44+_vs_HC_CD44+	R-HSA-389356	CD28 co-stimulation	13/475	32/8290	7.76794166623156e-9	1.81040599649723330e-7	1.09802483703129830e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-2990846	SUMOylation	30/475	166/8290	1.42841730762279670e-8	3.26250513061046e-8	1.97873387034905340e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-422475	Axon guidance	59/475	483/8290	1.58020014694919780e-8	3.53840895650192e-7	2.14607161340056619e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-186763	Downstream signal transduction	12/475	29/8290	2.31620306697999355e-8	5.03901156746433e-7	3.05619836979586634e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-3108232	SUMO E3 ligases SUMOylate target proteins	29/475	160/8290	2.33859556108239670e-8	5.03901156746433e-7	3.05619836979586634e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-1227986	Signaling by ERBB2	15/475	47/8290	2.59511010777580806e-8	5.48817730199993e-7	3.32862076202042e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-109581	Apoptosis	29/475	161/8290	2.70279078289774485e-8	5.61197649830706e-7	3.40370590458644e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-5357801	Programmed Cell Death	30/475	173/8290	3.81461713519896444e-8	7.77909422928074570e-7	4.71807908827240464e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-3928662	EPHB-mediated forward signaling	14/475	42/8290	4.07314395374672e-8	8.16057964066449e-7	4.94945285607835e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-2428928	IRS-related events triggered by IGF1R	13/475	36/8290	4.18002888644674706e-8	8.23033273848652e-7	4.99175863390555e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-5688426	Deubiquitination	35/475	224/8290	4.36133014678490e-8	8.28958174812878570e-7	5.02769360334769e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-8957367	Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants	8/475	2/8290	4.42788511924695570e-8	8.28958174812878570e-7	5.02769360334769e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-9673770	Signaling by PDGFRA extracellular domain mutants	8/475	12/8290	4.42788511924695570e-8	8.28958174812878570e-7	5.02769360334769e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-2559582	Senescence-Associated Secretory Phenotype (SASP)	15/475	49/8290	4.89996885697939e-8	9.00700715269431e-7	5.46281750066829e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-9006936	Signaling by TGFB family members	21/475	94/8290	5.11740044918382240e-8	9.27630367137765e-7	5.62614786226058e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-2428924	IGF1R signaling cascade	13/475	37/8290	6.11168827790353e-8	1.00055080831878730e-6	6.61427257695420e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-186797	Signaling by PDGF	15/475	50/8290	6.62317794664592e-8	1.16364141770302250e-6	7.05757261359133e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-2559586	DNA Damage/Telomere Stress Induced Senescence	11/475	26/8290	6.86793511033602e-8	1.18836089333390666e-6	7.20749809027293e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-170834	Signaling by TGF-beta Receptor Complex	18/475	72/8290	7.43654210051916e-8	1.26754195205868627e-6	7.68773715968857e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	13/475	34/8290	8.81045849916940e-8	1.45819472551470410e-6	8.84406055294198e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-5654736	Signaling by FGFR1	13/475	38/8290	8.81045849916940e-8	1.45819472551470410e-6	8.84406055294198e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-452723	Transcriptional regulation of pluripotent stem cells	9/475	17/8290	9.94306330621955e-8	1.59929271770461036e-6	9.69983047155625e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-9034015	Signaling by NTRK3 (TRKC)	9/475	17/8290	9.94306330621955e-8	1.59929271770461036e-6	9.69983047155625e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-5633007	Regulation of TP53 Activity	27/475	152/8290	1.11152600222833337e-7	1.76300374242327370e-6	1.0692750138363575e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-6791312	TP53 Regulates Transcription of Cell Cycle Genes	14/475	46/8290	1.49445409081387480e-7	2.33789941330060944e-6	1.41795355696543586e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-112399	IRS-mediated signalling	12/475	34/8290	1.87984704559740880e-7	2.90106125144897460e-6	1.75951544239416086e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-198323	AKT phosphorylates targets in the cytosol	8/475	14/8290	2.42436495028467667e-7	3.64292733319092e-6	2.20946279402675456e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-8849471	PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases	8/475	14/8290	2.42436495028467667e-7	3.64292733319092e-6	2.20946279402675456e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-2559580	Oxidative Stress Induced Senescence	16/475	62/8290	2.47390579328652477e-7	3.66909144926391e-6	2.22533152697539e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-114452	Activation of BH3-only proteins	11/475	29/8290	2.62733815363722667e-7	3.84669252750479e-6	2.33304791105661266e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-1236394	Signaling by ERBB4	14/475	48/8290	2.70210133378310050e-7	3.96607559896240e-6	2.39806419404301117e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-8986944	Transcriptional Regulation by MECP2	23/475	128/8290	3.47450676583469167e-7	4.95985840622302e-6	3.00819138410424e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-8864260	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	11/475	30/8290	3.93642863302517006e-7	5.54987839372190706e-6	3.36604293766154956e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-9617828	FOXO-mediated transcription of cell cycle genes	8/475	15/8290	4.93556516143913327e-7	6.87367733458962026e-6	4.16893693995753e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-2644602	Signaling by NOTCH1 PEST Domain Mutants in Cancer	15/475	58/8290	5.71810878445655657e-7	7.50583934695333e-6	4.55234794939119186e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-2644603	Signaling by NOTCH1 in Cancer	15/475	58/8290	5.71810878445655657e-7	7.50583934695333e-6	4.55234794939119186e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-2644606	Constitutive Signaling by NOTCH1 PEST Domain Mutants	15/475	58/8290	5.71810878445655657e-7	7.50583934695333e-6	4.55234794939119186e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-2894858	Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer	15/475	58/8290	5.71810878445655657e-7	7.50583934695333e-6	4.55234794939119186e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-2894862	Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants	15/475	58/8290	5.71810878445655657e-7	7.50583934695333e-6	4.55234794939119186e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-975138	TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation	18/475	82/8290	6.14851415174169e-7	7.97909450146479e-6	4.83938075579695e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-168181	Toll Like Receptor 7/8 (TLR7/8) Cascade	18/475	83/8290	7.44209265492624667e-7	9.44318867991752e-6	5.72736473615754e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-975155	MyD88 dependent cascade initiated on endosome	18/475	83/8290	7.44209265492624667e-7	9.44318867991752e-6	5.72736473615754e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-69206	G1/S Transition	23/475	128/8290	7.95381572748177447e-7	9.98101029323522e-6	6.04142757207761e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-1538133	G0 and Early G1	10/475	26/8290	8.02463159872085e-7	9.98101029323522e-6	6.04142757207761e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-195721	Signaling by WNT	34/475	241/8290	8.25785255921627e-7	1.01402877662634225e-5	6.15016070624145e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-5654741	Signaling by FGFR3	11/475	32/8290	8.37192204904252e-7	1.01709946595814949e-5	6.16878466771554e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-74752	Signaling by Insulin receptor	15/475	60/8290	9.19138096533240e-7	1.10490074701797738e-5	6.67306003162751e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-389357	CD28 dependent PI3K/Akt signaling	9/475	21/8290	9.77434730030887e-7	1.15075305329409699e-5	6.97940371525039956e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-982772	Growth hormone receptor signaling	9/475	21/8290	9.77434730030887e-7	1.15075305329409699e-5	6.97940371525039956e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-373760	L1CAM interactions	19/475	94/8290	1.15476602653506686e-6	1.34565592071739425e-5	8.16150424769145e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-5654743	Signaling by FGFR4	11/475	33/8290	1.19167615744654854e-6	1.37464057757975504e-5	8.33729835889508674e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-168138	Toll Like Receptor 9 (TLR9) Cascade	18/475	86/8290	1.29437495115332624e-6	1.46354078635360037e-5	8.87648481353739e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-2682334	EPH-Ephrin signaling	18/475	86/8290	1.29437495115332624e-6	1.46354078635360037e-5	8.87648481353739e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-69615	G1/S DNA Damage Checkpoints	15/475	62/8290	1.44561745021235474e-6	1.61852463543393322e-5	9.81647350926003e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-186712	Regulation of beta-cell development	11/475	34/8290	1.67170250447937746e-6	1.81328230552807072e-5	1.09976934006587799e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-210745	Regulation of gene expression in beta cells	8/475	17/8290	1.68308164961449666e-6	1.81328230552807072e-5	1.09976934006587799e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-445144	Signal transduction by L1	8/475	17/8290	1.68308164961449666e-6	1.81328230552807072e-5	1.09976934006587799e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-8934593	Regulation of RUNX1 Expression and Activity	8/475	17/8290	1.68308164961449666e-6	1.81328230552807072e-5	1.09976934006587799e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-8941326	RUNX2 regulates bone development	10/475	29/8290	1.78645300375276854e-6	1.90666292550059439e-5	1.15640538757429e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-381340	Transcriptional regulation of white adipocyte differentiation	17/475	80/8290	2.04403679581561e-6	2.14155047781783135e-5	1.29886645258008385e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-69202	Cyclin E associated events during G1/S transition	17/475	80/8290	2.04403679581561e-6	2.14155047781783135e-5	1.29886645258008385e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-8878171	Transcriptional regulation by RUNX1	25/475	155/8290	2.13675803668459e-6	2.19446069295605055e-5	1.33095689553422557e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-1980143	Signaling by NOTCH1	16/475	72/8290	2.18585890866898386e-6	2.19446069295605055e-5	1.33095689553422557e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-6806834	Signaling by MET	16/475	72/8290	2.18585890866898386e-6	2.19446069295605055e-5	1.33095689553422557e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-166058	MyD88:MAL(TIRAP) cascade initiated on plasma membrane	18/475	89/8290	2.19061750435319246e-6	2.19446069295605055e-5	1.33095689553422557e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-168188	Toll Like Receptor TLR6:TLR2 Cascade	18/475	89/8290	2.19061750435319246e-6	2.19446069295605055e-5	1.33095689553422557e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-73887	Death Receptor Signalling	23/475	128/8290	2.37928739928694113e-6	2.36273583477018205e-5	1.43501703316321106e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-9006115	Signaling by NTRK2 (TRKB)	9/475	23/8290	2.45068640206022446e-6	2.41265850961446222e-5	1.46329551048605045e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-168179	Toll Like Receptor TLR1:TLR2 Cascade	18/475	90/8290	2.59570530894463e-6	2.51211478899556575e-5	1.52361649713253066e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-181438	Toll Like Receptor 2 (TLR2) Cascade	18/475	90/8290	2.59570530894463e-6	2.51211478899556575e-5	1.52361649713253066e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-3232118	SUMOylation of transcription factors	8/475	18/8290	2.87848644450942856e-6	2.76237942826030854e-5	1.67540387482285255e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-69656	Cyclin A:Cdk2-associated events at S phase entry	17/475	82/8290	2.93312485492457e-6	2.79135715362022383e-5	1.69297908294071e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-2173793	Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	12/475	43/8290	3.27343477184246246e-6	3.08947314830092e-5	1.87378867322511296e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-166166	MyD88-independent TLR4 cascade	18/475	92/8290	3.61489836841940846e-6	3.35627149328045846e-5	2.03560387370130144e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-937061	TRIF(TICAM1)-mediated TLR4 signaling	18/475	92/8290	3.61489836841940846e-6	3.35627149328045846e-5	2.03560387370130144e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-69273	Cyclin A/B1/B2 associated events during G2/M transition	9/475	24/8290	3.72379006415956566e-6	3.42949052683090e-5	2.08001167586635655e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-373755	Semaphorin interactions	14/475	59/8290	4.15726660014933366e-6	3.79011220347059e-5	2.29873152535458785e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-69278	Cell Cycle, Mitotic	52/475	477/8290	4.18173500558051446e-6	3.79011220347059e-5	2.29873152535458785e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-5655332	Signaling by FGFR3 in disease	7/475	14/8290	4.68318285133494246e-6	4.15000146806720e-5	2.51700706078186e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-8853338	Signaling by FGFR3 point mutants in cancer	7/475	14/8290	4.68318285133494246e-6	4.15000146806720e-5	2.51700706078186e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-5621575	CD209 (DC-SIGN) signaling	8/475	19/8290	4.72416979727440466e-6	4.15000146806720e-5	2.51700706078186e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-9671555	Signaling by PDGFR in disease	8/475	19/8290	4.72416979727440466e-6	4.15000146806720e-5	2.51700706078186e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-2173796	SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	10/475	31/8290	5.16523162439852446e-6	4.50282024050619456e-5	2.73099430201223474e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-400685	Sema4D in semaphorin signaling	9/475	25/8290	5.52578774702480646e-6	4.78064364174418945e-5	2.89949628193167685e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-8853334	Signaling by FGFR3 fusions in cancer	6/475	10/8290	5.91269582539666686e-6	5.07691626511503356e-5	3.07918785366917945e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-450294	MAP kinase activation	14/475	61/8290	6.33041888814340606e-6	5.39502864336072296e-5	2.27212540080317115e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-6802957	Oncogenic MAPK signaling	16/475	78/8290	6.63510935444794646e-6	5.61281102428111515e-5	3.40421205085906356e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-388841	Costimulation by the CD28 family	14/475	62/8290	7.75515265426911e-6	6.51204730234796e-5	3.94960560875315445e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-9665348	Signaling by ERBB2 ECD mutants	7/475	15/8290	8.34910589427095e-6	6.95961965814909e-5	4.22106164813392e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-69620	Cell Cycle Checkpoints	32/475	244/8290	8.50192741968264e-6	7.03565298663998e-5	4.26717636079035e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-168142	Toll Like Receptor 10 (TLR10) Cascade	16/475	80/8290	9.35022838880452576e-6	7.57302185816650255e-5	4.59309464713204805e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-168176	Toll Like Receptor 5 (TLR5) Cascade	16/475	80/8290	9.35022838880452576e-6	7.57302185816650255e-5	4.59309464713204805e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-975871	MyD88 cascade initiated on plasma membrane	16/475	80/8290	9.35022838880452576e-6	7.57302185816650255e-5	4.59309464713204805e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-168164	Toll Like Receptor 3 (TLR3) Cascade	17/475	89/8290	9.44416572589263535e-6	7.59523750631502446e-5	4.60656804622589945e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-1912408	Pre-NOTCH Transcription and Translation	10/475	33/8290	9.71549884013474846e-6	7.75881096184187656e-5	4.70577713419852056e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-400253	Circadian Clock	14/475	64/8290	1.14806935117065656e-5	8.98269184018837e-5	5.44807008069627e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-8940973	RUNX2 regulates osteoblast differentiation	8/475	21/8290	1.14840018272110515e-5	8.98269184018837e-5	5.44807008069627e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-9615017	FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	8/475	21/8290	1.14840018272110515e-5	8.98269184018837e-5	5.44807008069627e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-9614399	Regulation of localization of FOXO transcription factors	6/475	11/8290	1.23791497905792580e-5	9.61699936111688455e-5	5.83278235746604e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-190236	Signaling by FGFR	15/475	73/8290	1.25956474595032585e-5	9.71907391807616336e-5	5.89469134306767006e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-6802948	Signaling by high-kinase activity BRAF mutants	10/475	34/8290	1.30670806466578336e-5	1.00151737817667774e-4	6.07427698021961e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-881907	Gastrin-CREB signalling pathway via PKC and MAPK	7/475	16/8290	1.41134283910435e-5	1.07450023482698450e-4	6.51693746096353e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-1912422	Pre-NOTCH Expression and Processing	12/475	49/8290	1.43655985042274145e-5	1.08545784714090754e-4	6.58948459938402e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-350054	Notch-HLH transcription pathway	9/475	28/8290	1.60048491348455566e-5	1.19481030797334398e-4	7.24540125953104e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-5218920	VEGFR2 mediated vascular permeability	9/475	28/8290	1.60048491348455566e-5	1.19481030797334398e-4	7.24540125953104e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-448424	Interleukin-17 signaling	14/475	66/8290	1.67075230011699157e-5	1.23896047265874284e-4	7.51438834019005e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-9664565	Signaling by ERBB2 KD Mutants	8/475	22/8290	1.71486865527573636e-5	1.26347097053218754e-4	7.66304635090957e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-5654708	Downstream signaling of activated FGFR3	7/475	17/8290	2.28146711150731145e-5	1.66082543672284e-4	1.00730310384699239e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-8863659	RET signaling	10/475	36/8290	2.28327139724588165e-5	1.66082543672284e-4	1.00730310384699239e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-1227990	Signaling by ERBB2 in Cancer	8/475	23/8290	2.49876199664626045e-5	1.78349137510626844e-4	1.08170091696923366e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-1368108	BMAL1:CLOCK,NPAS2 activates circadian gene expression	8/475	23/8290	2.49876199664626045e-5	1.78349137510626844e-4	1.08170091696923366e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-9006335	Signaling by Erythropoietin	8/475	23/8290	2.49876199664626045e-5	1.78349137510626844e-4	1.08170091696923366e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-69563	p53-Dependent G1 DNA Damage Response	13/475	68/8290	2.62991377847920435e-5	1.85392687347114227e-4	1.12442057585400669e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-69580	p53-Dependent G1/S DNA damage checkpoint	13/475	60/8290	2.62991377847920435e-5	1.85392687347114227e-4	1.12442057585400669e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-109582	Hemostasis	49/475	470/8290	2.70120121185853725e-5	1.89249803161714694e-4	1.14781427305726516e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-168643	Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways	12/475	52/8290	2.74533652677189955e-5	1.90010564459000516e-4	1.15242834744236688e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-375165	NCAM signaling for neurite out-growth	12/475	52/8290	2.74533652677189955e-5	1.90010564459000516e-4	1.15242834744236688e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-166016	Toll Like Receptor 4 (TLR4) Cascade	19/475	116/8290	2.86398262977031955e-5	1.97028202602271384e-4	1.19499084996123688e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-109704	PI3K Cascade	9/475	30/8290	2.90092975011831075e-5	2.02108980747639764e-4	1.22580615109177744e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-450282	MAPK targets/ Nuclear events mediated by MAP kinases	9/475	30/8290	2.90092975011831075e-5	2.02108980747639764e-4	1.22580615109177744e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-5655302	Signaling by FGFR1 in disease	9/475	30/8290	2.90092975011831075e-5	2.02108980747639764e-4	1.22580615109177744e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-2029480	Fcgamma receptor (FCGR) dependent phagocytosis	15/475	79/8290	3.39720940571771675e-5	2.28212533725272524e-4	1.38412618511594924e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-9018519	Estrogen-dependent gene expression	16/475	89/8290	3.79394594224054755e-5	2.53373465862231746e-4	1.53672910440914846e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-5674135	MAPK6 and MAPK activation	10/475	38/8290	3.82810451031808665e-5	2.54168334347863674e-4	1.54155004148672024e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-114604	GPVI-mediated activation cascade	9/475	28/8290	4.00316699053223445e-5	2.64256620693511164e-4	1.60273562478461984e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-75035	Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	6/475	13/8290	4.16483721370929936e-5	2.73347361957242134e-4	1.6578722847072674e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-383280	Nuclear Receptor transcription pathway	11/475	47/8290	5.15963339474875545e-5	3.36702933531604544e-4	2.04212585871108666e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-2173789	TGF-beta receptor signaling activates SMADs	9/475	32/8290	5.29055276758135325e-5	3.43284730714652324e-4	2.08204768006490254e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-5654716	Downstream signaling of activated FGFR4	7/475	19/8290	5.34546799138304845e-5	3.44888368788669e-4	2.09177397462387534e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-5689880	Ub-specific processing proteases	22/475	154/8290	6.09022806037636745e-5	3.90732609266843334e-4	2.36982262786969204e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-9656223	Signaling by RAF1 mutants	10/475	40/8290	6.18861758340508e-5	3.94826887164726264e-4	2.39456743089123344e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-177929	Signaling by EGFR	11/475	48/8290	6.35370055741095545e-5	4.00879891522834884e-4	2.43136665703774824e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-2122947	NOTCH1 Intracellular Domain Regulates Transcription	11/475	48/8290	6.35370055741095545e-5	4.00879891522834884e-4	2.43136665703774824e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-193704	p75 NTR receptor-mediated signalling	16/475	93/8290	6.61926129229822665e-5	4.15340461307943664e-4	2.51907109909325244e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-2173788	Downregulation of TGF-beta receptor signaling	8/475	26/8290	6.83390436024767445e-5	4.26465507071193764e-4	2.58654533738451e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-69473	G2/M DNA damage checkpoint	12/475	57/8290	7.23997791212777e-5	4.49350803024451884e-4	2.72534378533223e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-69242	S Phase	22/475	156/8290	7.42311052979429898e-5	4.58226606758159214e-4	2.79178792947431e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-5633008	TP53 Regulates Transcription of Cell Death Genes	10/475	41/8290	7.77202173775820745e-5	4.70080071912997964e-4	2.85107094956911e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-1250196	SHC1 events in ERBB2 signaling	7/475	20/8290	7.82094690573282925e-5	4.70080071912997964e-4	2.85107094956911e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-1266695	Interleukin-7 signaling	7/475	20/8290	7.82094690573282925e-5	4.70080071912997964e-4	2.85107094956911e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-5627117	RHO GTPases Activate ROCKs	7/475	20/8290	7.82094690573282925e-5	4.70080071912997964e-4	2.85107094956911e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-5654687	Downstream signaling of activated FGFR1	7/475	20/8290	7.82094690573282925e-5	4.70080071912997964e-4	2.85107094956911e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-2262752	Cellular responses to stress	48/475	479/8290	8.91898836884427426e-5	5.33271451139351e-4	3.23433141164801564e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-2454202	Fc epsilon receptor (FCERI) signaling	19/475	126/8290	9.20598132127481e-5	5.47564097338325e-4	3.32101738455883924e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-168898	Toll-like Receptor Cascades	20/475	137/8290	9.62940716731841945e-5	5.69781501817494e-4	3.45576761172376e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-210993	Tie2 Signaling	6/475	15/8290	1.10054369572600784e-4	6.41235153326072e-4	3.88913937587386626e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-5637810	Constitutive Signaling by EGFRvIII	6/475	15/8290	1.10054369572600784e-4	6.41235153326072e-4	3.88913937587386626e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-5

aUC_CD44+_vs_HC_CD44+	R-HSA-1236382	Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants	6/475	19/8290	4.90015151141712e-4	0.00236795424676904	0.00143618203924257e-36
aUC_CD44+_vs_HC_CD44+	R-HSA-389513	CTLA4 inhibitory signaling	6/475	19/8290	4.90015151141712e-4	0.00236795424676904	0.00143618203924257e-36
aUC_CD44+_vs_HC_CD44+	R-HSA-5637815	Signaling by Ligand-Responsive EGFR Variants in Cancer	6/475	19/8290	4.90015151141712e-4	0.00236795424676904	0.00143618203924257e-36
aUC_CD44+_vs_HC_CD44+	R-HSA-9665686	Signaling by ERBB2 TMD/JMD mutants	6/475	19/8290	4.90015151141712e-4	0.00236795424676904	0.00143618203924257e-36
aUC_CD44+_vs_HC_CD44+	R-HSA-1251985	Nuclear signaling by ERBB4	7/475	26/8290	4.91423079233230e-4	0.00236795424676904	0.00143618203924257e-36
aUC_CD44+_vs_HC_CD44+	R-HSA-1226099	Signaling by FGFR in disease	10/475	51/8290	5.28610462614984e-4	0.00252136377558557	0.00152922607092252e-8
aUC_CD44+_vs_HC_CD44+	R-HSA-171007	p38/MAPK events	5/475	13/8290	5.29883805729994e-4	0.00252136377558557	0.00152922607092252e-8
aUC_CD44+_vs_HC_CD44+	R-HSA-5654693	FRS-mediated FGFR1 signaling	5/475	13/8290	5.29883805729994e-4	0.00252136377558557	0.00152922607092252e-8
aUC_CD44+_vs_HC_CD44+	R-HSA-202733	Cell surface interactions at the vascular wall	15/475	101/8290	5.86061613950133e-4	0.00277715237629482	0.00168433518882847e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-168928	DDX58/IFIH1-mediated induction of interferon-alpha/beta	11/475	61/8290	5.98329463603153e-4	0.00282352168361488	0.00171248711200925e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-2424491	DAP12 signaling	7/475	27/8290	6.31116581123605e-4	0.00296598821523287	0.00179889413203089
aUC_CD44+_vs_HC_CD44+	R-HSA-168638	NOD1/2 Signaling Pathway	8/475	36/8290	6.52313151164012e-4	0.00304057803744087	0.00184413342117808
aUC_CD44+_vs_HC_CD44+	R-HSA-8934659	RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function	8/475	35/8290	6.52313151164012e-4	0.00304057803744087	0.00184413342117808
aUC_CD44+_vs_HC_CD44+	R-HSA-5218921	VEGFR2 mediated cell proliferation	6/475	20/8290	6.66503300606449e-4	0.00309409255809987	0.00187659039790234
aUC_CD44+_vs_HC_CD44+	R-HSA-5693532	DNA Double-Strand Break Repair	17/475	125/8290	7.34847118602763e-4	0.00339755226495690057	0.00206040097183302 06
aUC_CD44+_vs_HC_CD44+	R-HSA-194315	Signaling by Rho GTPases	37/475	375/8290	7.80489971217841e-4	0.00357488563877470083	0.00216819495219613
aUC_CD44+_vs_HC_CD44+	R-HSA-1963640	GRB2 events in ERBB2 signaling	5/475	14/8290	7.85723551079240e-4	0.00357488563877470083	0.00216819495219613
aUC_CD44+_vs_HC_CD44+	R-HSA-1963642	PI3K events in ERBB2 signaling	5/475	14/8290	7.85723551079240e-4	0.00357488563877470083	0.00216819495219613
aUC_CD44+_vs_HC_CD44+	R-HSA-5654712	FRS-mediated FGFR4 signaling	5/475	14/8290	7.85723551079240e-4	0.00357488563877470083	0.00216819495219613
aUC_CD44+_vs_HC_CD44+	R-HSA-5688896	Ovarian tumor domain proteases	6/475	36/8290	7.97371550502353e-4	0.00358503271926859 4	0.00217434927576618 6
aUC_CD44+_vs_HC_CD44+	R-HSA-5693565	Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks	8/475	36/8290	7.97371550502353e-4	0.00358503271926859 4	0.00217434927576618 6
aUC_CD44+_vs_HC_CD44+	R-HSA-8875878	MET promotes cell motility	8/475	36/8290	7.97371550502353e-4	0.00358503271926859 4	0.00217434927576618 6
aUC_CD44+_vs_HC_CD44+	R-HSA-5654732	Negative regulation of FGFR3 signaling	6/475	21/8290	8.88475397800711e-4	0.00397897762677976 94	0.00241327982156981 17
aUC_CD44+_vs_HC_CD44+	R-HSA-5693606	DNA Double Strand Break Response	6/475	37/8290	9.67255790867286e-4	0.00429807826136358 5	0.00260681675359686 64
aUC_CD44+_vs_HC_CD44+	R-HSA-8853884	Transcriptional Regulation by VENTX	6/475	37/8290	9.67255790867286e-4	0.00429807826136358 5	0.00260681675359686 64
aUC_CD44+_vs_HC_CD44+	R-HSA-2172127	DAP12 interactions	7/475	29/8290	9.01003977458899445	0.00437611548790711	0.00265414691826399 5
aUC_CD44+_vs_HC_CD44+	R-HSA-3214858	RMTs methylate histone arginines	7/475	29/8290	9.01003977458899445	0.00437611548790711	0.00265414691826399 5
aUC_CD44+_vs_HC_CD44+	R-HSA-5357956	TNFR1-induced NFkappaB signaling pathway	7/475	29/8290	9.01003977458899445	0.00437611548790711	0.00265414691826399 5
aUC_CD44+_vs_HC_CD44+	R-HSA-6804758	Regulation of TP53 Activity through Acetylation	7/475	29/8290	9.01003977458899445	0.00437611548790711	0.00265414691826399 5
aUC_CD44+_vs_HC_CD44+	R-HSA-9645723	Diseases of programmed cell death	7/475	29/8290	9.01003977458899445	0.00437611548790711	0.00265414691826399 5
aUC_CD44+_vs_HC_CD44+	R-HSA-111447	Activation of BAD and translocation to mitochondria	5/475	15/8290	9.01123558141832511 9	0.00483082798144983 2	0.00292993346095865 05
aUC_CD44+_vs_HC_CD44+	R-HSA-2691230	Signaling by NOTCH1 HD Domain Mutants in Cancer	5/475	15/8290	9.01123558141832511 9	0.00483082798144983 2	0.00292993346095865 05
aUC_CD44+_vs_HC_CD44+	R-HSA-2691232	Constitutive Signaling by NOTCH1 HD Domain Mutants	5/475	15/8290	9.01123558141832511 9	0.00483082798144983 2	0.00292993346095865 05
aUC_CD44+_vs_HC_CD44+	R-HSA-9664407	Parasite infection	10/475	56/8290	9.01139808891174535	0.00483082798144983 2	0.00292993346095865 05
aUC_CD44+_vs_HC_CD44+	R-HSA-9664417	Leishmania phagocytosis	10/475	56/8290	9.01139808891174535	0.00483082798144983 2	0.00292993346095865 05
aUC_CD44+_vs_HC_CD44+	R-HSA-9664422	FCGR3A-mediated phagocytosis	10/475	56/8290	9.01139808891174535	0.00483082798144983 2	0.00292993346095865 05
aUC_CD44+_vs_HC_CD44+	R-HSA-198753	ERK/MAPK targets	6/475	22/8290	9.01163290450874522	0.00483082798144983 2	0.00292993346095865 05
aUC_CD44+_vs_HC_CD44+	R-HSA-3000170	Syndecan interactions	6/475	22/8290	9.01163290450874522	0.00483082798144983 2	0.00292993346095865 05
aUC_CD44+_vs_HC_CD44+	R-HSA-5654726	Negative regulation of FGFR1 signaling	6/475	22/8290	9.01163290450874522	0.00483082798144983 2	0.00292993346095865 05
aUC_CD44+_vs_HC_CD44+	R-HSA-8862803	Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models	6/475	22/8290	9.01163290450874522	0.00483082798144983 2	0.00292993346095865 05
aUC_CD44+_vs_HC_CD44+	R-HSA-8863678	Neurodegenerative Diseases	6/475	22/8290	9.01163290450874522	0.00483082798144983 2	0.00292993346095865 05
aUC_CD44+_vs_HC_CD44+	R-HSA-912446	Meiotic recombination	6/475	22/8290	9.01163290450874522	0.00483082798144983 2	0.00292993346095865 05
aUC_CD44+_vs_HC_CD44+	R-HSA-933542	TRAF6 mediated NF-kB activation	6/475	22/8290	9.01163290450874522	0.00483082798144983 2	0.00292993346095865 05
aUC_CD44+_vs_HC_CD44+	R-HSA-2029482	Regulation of actin dynamics for phagocytic cup formation	10/475	57/8290	9.00131230811610129 8	0.00542991256734643 5	0.00329328276255972
aUC_CD44+_vs_HC_CD44+	R-HSA-6807070	PTEN Regulation	17/475	132/8290	9.01364757568093058	0.00562654564174455	0.00341254219952798 8
aUC_CD44+_vs_HC_CD44+	R-HSA-437239	Recycling pathway of L1	8/475	39/8290	9.01393513775623688	0.00572443428691425	0.00347119239818377 4
aUC_CD44+_vs_HC_CD44+	R-HSA-1839124	FGFR1 mutant receptor activation	6/475	23/8290	9.01498759292476178 8	0.06007881794125635	0.03688648747970149
aUC_CD44+_vs_HC_CD44+	R-HSA-5654733	Negative regulation of FGFR4 signaling	6/475	23/8290	9.01498759292476178 8	0.06007881794125635	0.03688648747970149
aUC_CD44+_vs_HC_CD44+	R-HSA-5617472	Activation of anterior HOX genes in hindbrain development during early embryogenesis	10/475	58/8290	9.01050639709172815 4	0.06007881794125635	0.03688648747970149
aUC_CD44+_vs_HC_CD44+	R-HSA-5619507	Activation of HOX genes during differentiation	10/475	58/8290	9.01050639709172815 4	0.06007881794125635	0.03688648747970149
aUC_CD44+_vs_HC_CD44+	R-HSA-8943724	Regulation of PTEN gene transcription	10/475	58/8290	9.01050639709172815 4	0.06007881794125635	0.03688648747970149
aUC_CD44+_vs_HC_CD44+	R-HSA-1362300	Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1	5/475	16/8290	9.01558075963468253	0.06019973083712987 6	0.03376018332641826
aUC_CD44+_vs_HC_CD44+	R-HSA-180292	GAB1 signalosome	5/475	16/8290	9.01558075963468253	0.06019973083712987 6	0.03376018332641826
aUC_CD44+_vs_HC_CD44+	R-HSA-2173791	TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)	5/475	16/8290	9.01558075963468253	0.06019973083712987 6	0.03376018332641826
aUC_CD44+_vs_HC_CD44+	R-HSA-9022699	MECP2 regulates neuronal receptors and channels	5/475	16/8290	9.01558075963468253	0.06019973083712987 6	0.03376018332641826
aUC_CD44+_vs_HC_CD44+	R-HSA-1059683	Interleukin-6 signaling	4/475	10/8290	9.01693987557909132 8	0.06553558713220348	0.03963882692404728
aUC_CD44+_vs_HC_CD44+	R-HSA-2559584	Formation of Senescence-Associated Heterochromatin Foci (SAHF)	4/475	10/8290	9.01693987557909132 8	0.06553558713220348	0.03963882692404728
aUC_CD44+_vs_HC_CD44+	R-HSA-430116	GP1b-IX-V activation signalling	4/475	10/8290	9.01693987557909132 8	0.06553558713220348	0.03963882692404728
aUC_CD44+_vs_HC_CD44+	R-HSA-5654710	PI-3K cascade:FGFR3	4/475	10/8290	9.01693987557909132 8	0.06553558713220348	0.03963882692404728
aUC_CD44+_vs_HC_CD44+	R-HSA-6803207	TP53 Regulates Transcription of Caspase Activators and Caspases	4/475	10/8290	9.01693987557909132 8	0.06553558713220348	0.03963882692404728
aUC_CD44+_vs_HC_CD44+	R-HSA-8851805	MET activates RAS signaling	4/475	10/8290	9.01693987557909132 8	0.06553558713220348	0.03963882692404728
aUC_CD44+_vs_HC_CD44+	R-HSA-9027276	Erythropoietin activates Phosphoinositide-3-kinase (PI3K)	4/475	10/8290	9.01693987557909132 8	0.06553558713220348	0.03963882692404728
aUC_CD44+_vs_HC_CD44+	R-HSA-2029731	Activated NTRK2 signals through FRS2 and FRS3	4/475	10/8290	9.01693987557909132 8	0.06553558713220348	0.03963882692404728
aUC_CD44+_vs_HC_CD44+	R-HSA-9634285	Constitutive Signaling by Overexpressed ERBB2	4/475	10/8290	9.01693987557909132 8	0.06553558713220348	0.03963882692404728
aUC_CD44+_vs_HC_CD44+	R-HSA-1643713	Signaling by EGFR in Cancer	6/475	24/8290	9.01903095667462595	0.07293073116259485	0.04423302540417311
aUC_CD44+_vs_HC_CD44+	R-HSA-3928663	EPHA-mediated growth cone collapse	6/475	24/8290	9.01903095667462595	0.07293073116259485	0.04423302540417311
aUC_CD44+_vs_HC_CD44+	R-HSA-1181150	Signaling by NODAL	7/475	28/8290	9.02104522909121322	0.08033801091720256	0.04875114006061714
aUC_CD44+_vs_HC_CD44+	R-HSA-69481	G2/M Checkpoints	16/475	126/8290	9.02167170098610247 5	0.08249694175376342	0.05000350149082467
aUC_CD44+_vs_HC_CD44+	R-HSA-5654738	Signaling by FGFR2	10/475	61/8290	9.02223235955804326	0.08649661666207777	0.05153688613111546 9
aUC_CD44+_vs_HC_CD44+	R-HSA-5675221	Negative regulation of MAPK pathway	8/475	42/8290	9.02229875809912085	0.08869275958526495	0.05527222399066267
aUC_CD44+_vs_HC_CD44+	R-HSA-8874081	MET activates PTK2 signaling	8/475	42/8290	9.02238457715600245	0.08988473645681451	0.05451576779435335
aUC_CD44+_vs_HC_CD44+	R-HSA-9658195	Leishmania infection	20/475	176/8290	9.02528410410562955	0.09045716099943492	0.05753583919036608
aUC_CD44+_vs_HC_CD44+	R-HSA-4641265	Repression of WNT target genes	4/475	11/8290	9.02542336625942655	0.09045716099943492	0.05753583919036608
aUC_CD44+_vs_HC_CD44+	R-HSA-5654689	PI-3K cascade:FGFR1	4/475	11/8290	9.02542336625942655	0.09045716099943492	0.05753583919036608
aUC_CD44+_vs_HC_CD44+	R-HSA-5654699	SHC-mediated cascade:FGFR2	4/475	11/8290	9.02542336625942655	0.09045716099943492	0.05753583919036608
aUC_CD44+_vs_HC_CD44+	R-HSA-75893	TNF signaling	8/475	43/8290	9.02685838678370823	0.09995853172305026	0.06003992430064252 2
aUC_CD44+_vs_HC_CD44+	R-HSA-5625740	RHO GTPases activate PKNs	7/475	34/8290	9.02699204833538711 5	0.09975862781643393	0.06065043571787386 3
aUC_CD44+_vs_HC_CD44+	R-HSA-1368082	RORA activates gene expression	8/475	48/8290	9.02778511095050209	0.10107006304663297	0.06168219637463817
aUC_CD44+_vs_HC_CD44+	R-HSA-167044	Signalling to RAS	8/475	48/8290	9.02778511095050209	0.10107006304663297	0.06168219637463817
aUC_CD44+_vs_HC_CD44+	R-HSA-1839117	Signaling by cytosolic FGFR1 fusion mutants	5/475	18/8290	9.02778511095050209	0.10107006304663297	0.06168219637463817
aUC_CD44+_vs_HC_CD44+	R-HSA-2151201	Transcriptional activation of mitochondrial biogenesis	9/475	53/8290	9.02286008355831792 04	0.10435193044664238	0.06632902297418258 5
aUC_CD44+_vs_HC_CD44+	R-HSA-8863795	Downregulation of ERBB2 signaling	6/475	26/8290	9.02952888110410673	0.10739484783727178	0.06651357819862581 85
aUC_CD44+_vs_HC_CD44+	R-HSA-6783589	Interleukin-6 family signaling	5/475	19/8290	9.03595831075020078	0.11287827554086478	0.07871077085988406
aUC_CD44+_vs_HC_CD44+	R-HSA-9013695	NOTCH4 Intracellular Domain Regulates Transcription	5/475	19/8290	9.03595831075020078	0.11287827554086478	0.07871077085988406
aUC_CD44+_vs_HC_CD44+	R-HSA-3928665	EPH-ephrin mediated repulsion of cells	8/475	45/8290	9.03061124557050839	0.11287827554086478	0.07871077085988406
aUC_CD44+_vs_HC_CD44+	R-HSA-397795	G-protein beta:gamma signalling	6/475	29/8290	9.03641625140492278	0.11287827554086478	0.07871077085988406
aUC_CD44+_vs_HC_CD44+	R-HSA-179812	GRB2 events in EGFR signaling	4/475	12/8290	9.03642454465586097 3	0.11287827554086478	0.07871077085988406
aUC_CD44+_vs_HC_CD44+	R-HSA-2299718	Condensation of Prophase Chromosomes	4/475	12/8290	9.03642454465586097 3	0.11287827554086478	0.07871077085988406
aUC_CD44+_vs_HC_CD44+	R-HSA-418885	DCC mediated attractive signaling	4/475	12/8290	9.03642454465586097 3	0.11287827554086478	0.07871077085988406
aUC_CD44+_vs_HC_CD44+	R-HSA-5654720	PI-3K cascade:FGFR4	4/475	12/8290	9.03642454465586097 3	0.11287827554086478	0.07871077085988406
aUC_CD44+_vs_HC_CD44+	R-HSA-6804759	Regulation of TP53 Activity through Association with Co-factors	4/475	12/8290	9.03642454465586097 3	0.11287827554086478	0.07871077085988406
aUC_CD44+_vs_HC_CD44+	R-HSA-451927	Interleukin-2 family signaling	7/475	36/8290	9.03793577789459942	0.11333004872481013	0.08084774689764023
aUC_CD44+_vs_HC_CD44+	R-HSA-8939243	RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known	7/475	36/8290	9.03793577789459942	0.11333004872481013	0.08084774689764023
aUC_CD44+_vs_HC_CD44+	R-HSA-176187	Activation of ATR in response to replication stress	7/475	37/8290	9.04453052922484895	0.11559934490016843	0.09461119867555399
aUC_CD44+_vs_HC_CD44+	R-HSA-392451	G beta:gamma signalling through PI3Kgamma	5/475	20/8290	9.04572273666491298	0.11591931868028372 7	0.09965518636890653
aUC_CD44+_vs_HC_CD44+	R-HSA-5625900	RHO GTPases activate CIT	5/475	20/8290	9.04572273666491298	0.11591931868028372 7	0.09965518636890653
aUC_CD44+_vs_HC_CD44+	R-HSA-3858494	Beta-catenin independent WNT signaling	16/475	136/8290	9.04691383110177685	0.16284375415875137	0.09876596021426714
aUC_CD44+_vs_HC_CD44+	R-HSA-187577	SCF(Skp2)-mediated degradation of p27/p21	8/475	57/8290	9.04747135218492617	0.16404795210858324	0.09965154621888812
aUC_CD44+_vs_HC_CD44+	R-HSA-9012852	Signaling by NOTCH3	8/475	47/8290	9.04765999925915781	0.16444319683975 29	0.09973057564803893
aUC_CD44+_vs_HC_CD44+	R-HSA-180336	SHC1 events in EGFR signaling	4/475	13/8290	9.05002581920329991	0.17108180213712025	0.10360241341013578
aUC_CD44+_vs_HC_CD44+	R-HSA-5357786	TNFR1-induced proapoptotic signaling	4/475	13/8290	9.05002581920329991	0.17108180213712025	0.10360241341013578
aUC_CD44+_vs_HC_CD44+	R-HSA-5654700	FRS-mediated FGFR2 signaling	4/475	13/8290	9.05002581920329991	0.17108180213712025	0.10360241341013578
aUC_CD44+_vs_HC_CD44+	R-HSA-6785631	ERBB2 Regulates Cell Motility	4/475	13/8290	9.05002581920329991	0.17108180213712025	0.10360241341013578
aUC_CD44+_vs_HC_CD44+	R-HSA-9027284	Erythropoietin activates RAS	4/475	13/8290	9.05002581920329991	0.17108180213712025	0.10360241341013578
aUC_CD44+_vs_HC_CD44+	R-HSA-5693616	Presynaptic phase of homologous DNA pairing and strand exchange	7/475	38/8290	9.05195533372001033	0.17160622999481245 2	0.10678310753605489
aUC_CD44+_vs_HC_CD44+	R-HSA-201722	Formation of the beta-catenin:TCF transactivating complex	6/475	29/8290	9.05265995324402333	0.17163555879315972	0.10696908890127 29
aUC_CD44+_vs_HC_CD44+	R-HSA-2122948	Activated NOTCH1 Transmits Signal to the Nucleus	6/475	29/8290	9.05265995324402333	0.17163555879315972	0.10696908890127 29
aUC_CD44+_vs_HC_CD44+	R-HSA-4090294	SUMOylation of intracellular receptors	6/475	29/8290	9.05265995324402333	0.17163555879315972	0.10696908890127 29
aUC_CD44+_vs_HC_CD44+	R-HSA-445989	TAK1 activates NFkB by phosphorylation and activation of IKKs complex	6/475	29/8290	9.05265995324402333	0.17163555879315972	0.10696908890127 29
aUC_CD44+_vs_HC_CD44+	R-HSA-5693607	Processing of DNA double-strand break ends	9/475	59/8290	9.05985754162154547	0.19198751828415348	0.12122579989835926
aUC_CD44+_vs_HC_CD44+	R-HSA-1500620	Meiosis	8/475	49/8290	9.06018460413452981	0.20054241981314412	0.12459131937507284
aUC_CD44+_vs_HC_CD44+	R-HSA-5628897	TP53 Regulates Metabolic Genes	11/475	81/8290	9.06018790929572817 64	0.20054241981314412	0.12459131937507284
aUC_CD44+_vs_HC_CD44+	R-HSA-162658	Golgi Cisternae Pericentriolar Stack Reorganization	7/475	44/8290	9.06672185746418820 65	0.22005850926466359 7	0.13378651577240898
aUC_CD44+_vs_HC_CD44+	R-HSA-877312	Regulation of IFNG signaling	7/475	44/8290	9.06672185746418820 65	0.22005850926466359 7	0.13378651577240898
aUC_CD44+_vs_HC_CD44+	R-HSA-8941856	RUNX3 regulates NOTCH signaling	7/475	44/8290	9.06672185746418820 65	0.22005850926466359 7	0.13378651577240898
aUC_CD44+_vs_HC_CD44+	R-HSA-975163	IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation	7/475	44/8290	9.06672185746418820 65	0.22005850926466359 7	0.13378651577240898
aUC_CD44+_vs_HC_CD44+	R-HSA-388396	GPCR downstream signaling	41/475	483/8290	9.06687609007984479	0.22520037489681078	0.13649464928122545
aUC_CD44+_vs_HC_CD44+	R-HSA-201451	Signaling by BMP	5/475	22/8290	9.07064687009092668 5	0.22920092512454054	0.13901208289422779
aUC_CD44+_vs_HC_CD44+	R-HSA-5654727	Negative regulation of FGFR2 signaling	5/475	22/8290	9.07064687009092668 5	0.22920092512454054	0.13901208289422779
aUC_CD44+_vs_HC_CD44+	R-HSA-937041	IKK complex recruitment mediated by RIP1	5/475	22/8290	9.07064687009092668 5	0.22920092512454054	0.13901208289422779
aUC_CD44+_vs_HC_CD44+	R-HSA-1980145	Signaling by NOTCH2	6/475	31/8290	9.07408492259380993	0.23899712316986142	0.14499535505994224
aUC_CD44+_vs_HC_CD44+	R-HSA-5655253	Signaling by FGFR2 in disease	6/475	31/8290	9.07408492259380993	0.23899712316986142	0.14499535505994224
aUC_CD44+_vs_HC_CD44+	R-HSA-1592230	Mitochondrial biogenesis	10/475	72/8290	9.07572044690006813	0.24235852833768548	0.14177363042326153
aUC_CD44+_vs_HC_CD44+	R-HSA-5693579	Homologous DNA Pairing and Strand Exchange	7/475	41/8290	9.07798280217048307	0.25609286538958335	0.15533224668296237
aUC_CD44+_vs_HC_CD44+	R-HSA-5260271	Diseases of Immune System	6/475	28/8290	9.08061077804148616	0.27487900903288825	0.16659488242569852
aUC_CD44+_vs_HC_CD44+	R-HSA-5602358	Diseases associated with the TLR signaling cascade	6/475	28/8290	9.08061077804148616	0.27487900903288825	0.16659488242569852
aUC_CD44+_vs_HC_CD44+	R-HSA-399954	Sema3A PAK dependent Axon repulsion	4/475	15/8290	9.08075760267231752	0.27781061810518454	0.16849422685331611
aUC_CD44+_vs_HC_CD44+	R-HSA-937072	TRAF6-mediated induction of TAK1 complex within TLR4 complex	4/475	15/8290	9.08075760267231752	0.27781061810518454	0.16849422685331611
aUC_CD44+_vs_HC_CD44+	R-HSA-373752	Netrin-1 signaling	7/475	45/8290	9.09120179096475553	0.28885108283159120	0.17486404565857701
aUC_CD44+_vs_HC_CD44+	R-HSA-204998	Cell death signalling via NRAGE, NRIF and NADE	10/475	74/8290	9.09016445945248501	0.28891108479765675	0.17534790116009058
aUC_CD44+_vs_HC_CD44+	R-HSA-416476	G alpha (q) signalling events	16/475	146/8290	9.09226822790854641	0.29002763533651790 7	0.17605478893308076
aUC_CD44+_vs_HC_CD44+	R-HSA-8941858	Regulation of RUNX3 expression and activity	8/475	53/8290	9.09956527941577656	0.31237323876172865	0.18945619969803641
aUC_CD44+_vs_HC_CD44+	R-HSA-4791275	Signaling by WNT in cancer	8/475	53/8290	9.10101781588664807	0.31656288705621198	0.19199777515254188
aUC_CD44+_vs_HC_CD44+	R-HSA-212165	Epigenetic regulation of gene expression	11/475	87/8290	9.10151340477028292	0.32280423230810476	0.19896013327249402
aUC_CD44+_vs_HC_CD44+	R-HSA-1500931	Cell-Cell communication	12/475	99/8290	9.10169318443066486	0.33318374018726276	0.20126188087464185
aUC_CD44+_vs_HC_CD44+	R-HSA-5693538	Homology Directed Repair	12/475	99/8290	9.10169318443066486	0.33318374018726276	0.20126188087464185
aUC_CD44+_vs_HC_CD44+	R-HSA-9679506	SARS-CoV Infections	15/475	136/8290	9.10187310051533791	0.33565062543474802	0.20403937212230822
aUC_CD44+_vs_HC_CD44+	R-HSA-447115	Interleukin-12 family signaling	8/475	54/8290	9.11120720748328271	0.34316032730719306	0.20071849513154770 7
aUC_CD44+_vs_HC_CD44+	R-HSA-1295596	Spry regulation of FGF signaling	4/475	16/8290	9.1115744908607796	0.34316032730719306	0.20071849513154770 7
aUC_CD44+_vs_HC_CD44+	R-HSA-1433559	Regulation of KIT signaling	4/475	16/8290	9.1115744908607796	0.34316032730719306	0.20071849513154770 7
aUC_CD44+_vs_HC_CD44+	R-HSA-4655427	SUMOylation of DNA methylation proteins	4/475	16/8290	9.1115744908607796	0.34316032730719306	0.20071849513154770 7
aUC_CD44+_vs_HC_CD44+	R-HSA-5357905	Regulation of TNFR1 signaling	6/475	34/8290	9.11170758993249997	0.35653526720472399	0.21622397439460631 4
aUC_CD44+_vs_HC_CD44+	R-HSA-8953750	Transcriptional Regulation by E2F6	6/475	34/8290	9.11170758993249997	0.35653526720472399	0.21622397439460631 4
aUC_CD44+_vs_HC_CD44+	R-HSA-75153	Apoptotic execution phase	7/475	44/8290	9.11174279538361086	0.35686561789384054	0.21633146618033621 4
aUC_CD44+_vs_HC_CD44+	R-HSA-9029569	NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux	6/475	35/8290	9.11346541103083424	0.40789123506735536	0.24738906565875313
aUC_CD44+_vs_HC_CD44+	R-HSA-4086398	Ca2+ pathway	8/475	56/8290	9.11374621591375684	0.41529575294579437	0.25187997970626503
aUC_CD44+_vs_HC_CD44+	R-HSA-1810476	RIP-mediated NFkB activation via ZBP1	4/475	17/8290	9.11394295934229517	0.41792282333075956	0.25343733187541694
aUC_CD44+_vs_HC_CD44+	R-HSA-5689901	Metalloprotease DUBs	4/475	17/8290	9.11394295934229517	0.41792282333075956	0.25343733187541694
aUC_CD44+_vs_HC_CD44+	R-HSA-8854691	Interleukin-20 family signaling	4/475	17/8290	9.11394295934229517	0.41792282333075956	0.25343733187541694
aUC_CD44+_vs_HC_CD44+	R-HSA-1168372	Downstream signaling events of B Cell Receptor (BCR)	10/475	79/8290	9.11426319520340988 2	0.42528900580840231	0.25794097668178838
aUC_CD44+_vs_HC_CD44+	R-HSA-9013694	Signaling by NOTCH4	10/475	79/8290	9.11426319520340988 2	0.42528900580840231	0.25794097668178838
aUC_CD44+_vs_HC_CD44+	R-HSA-5663220	RHO GTPases Activate Formins	14/475	128/8290	9.11457597090358315	0.43424449504972069 4	0.26222811110518126
aUC_CD44+_vs_HC_CD44+	R-HSA-392518	Signal amplification	5/475	26/8290	9.11461679079614027	0.43424449504972069 4	0.26222811110518126
aUC_CD44+_vs_HC_CD44+	R-HSA-442742	CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling	5/475	26/8290	9.11461679079614027	0.43424449504972069 4	0.26222811110518126
aUC_CD44+_vs_HC_CD44+	R-HSA-5687128	MAPK6/MAPK4 signaling	10/475	80/8290	9.01549664817647619	0.04572912717708162	0.02773505919584857
aUC_CD44+_vs_HC_CD44+	R-HSA-1234158	Regulation of gene expression by Hypoxia-inducible Factor	3/475	10/8290	9.01657604324290410 5	0.04816753532708616	0.02921397202043900 6
aUC_CD44+_vs_HC_CD44+	R-HSA-170968	Frs2-mediated activation	3/475	10/8290	9.01657604324290410 5	0.04816753532708616	0.02921397202043900 6
aUC_CD44+_vs_HC_CD44+	R-HSA-2032785	YAP1- and WWTR1 (TAZ)-stimulated gene expression	3/475	10/8290	9.01657604324290410 5	0.04816753532708616	0.02921397202043900 6
aUC_CD44+_vs_HC_CD44+	R-HSA-8875555	MET activates RAP1 and RAC1	3/475	10/8290	9.01657604324290410 5	0.04816753532708616	0.02921397202043900 6
aUC_CD44+_vs_HC_CD44+	R-HSA-9683610	Maturation of nucleoprotein	3/475	10/8290	9.01657604324290410 5	0.04816753532708616	0.02921397202043900 6
aUC_CD44+_vs_HC_CD44+	R-HSA-9694631	Maturation of nucleoprotein	3/475	10/8290	9.01657604324290

qUC_CD44+_vs_HC_CD44+	R-HSA-9614399	Regulation of localization of FOXO transcription factors	5/137	11/8290	4.88809081886577e-7	1.77304385157142e-5	1.34013207617784442e-5	
qUC_CD44+_vs_HC_CD44+	R-HSA-69202	Cyclin E associated events during G1/S transition	10/137	80/8290	6.72720031783935e-7	2.33404602331990018e-5	1.76415825268738l+5	
qUC_CD44+_vs_HC_CD44+	R-HSA-453279	Mitotic G1 phase and G1/S transition	13/137	146/8290	7.54208285364719l8e-7	2.50774254883769934e-5	1.89544406640283e-5	
qUC_CD44+_vs_HC_CD44+	R-HSA-69231	Cyclin D associated events in G1	8/137	47/8290	8.28167515326114e-7	2.51188732591656723e-5	1.89857728235086e-5	
qUC_CD44+_vs_HC_CD44+	R-HSA-69236	G1 Phase	8/137	47/8290	8.28167515326114e-7	2.51188732591656723e-5	1.89857728235086e-5	
qUC_CD44+_vs_HC_CD44+	R-HSA-69656	Cyclin A:Cdk2-associated events at S phase entry	10/137	82/8290	8.49886689219891e-7	2.51188732591656723e-5	1.89857728235086e-5	
qUC_CD44+_vs_HC_CD44+	R-HSA-186712	Regulation of beta-cell development	7/137	34/8290	1.07021305949643456e-6	3.0501072194878885e-5	2.30538377096235335e-5	
qUC_CD44+_vs_HC_CD44+	R-HSA-8878166	Transcriptional regulation by RUNX2	11/137	105/8290	1.11130058121493557e-6	3.06268495894891 7e-5	2.31489049133062 0e-5	
qUC_CD44+_vs_HC_CD44+	R-HSA-109606	Intrinsic Pathway for Apoptosis	8/137	51/8290	1.58631741735511944e-6	4.21960433027101 8e-5	3.18933291286802e-5	
qUC_CD44+_vs_HC_CD44+	R-HSA-198323	AKT phosphorylates targets in the cytosol	5/137	14/8290	2.03508279474287836e-6	5.23869700066606874e-5	3.95960081965218e-5	
qUC_CD44+_vs_HC_CD44+	R-HSA-9617828	FOXO-mediated transcription of cell cycle genes	5/137	15/8290	3.01219886425577604e-6	7.51167091774279e-5	5.67559851717005 6e-5	
qUC_CD44+_vs_HC_CD44+	R-HSA-3700989	Transcriptional Regulation by TP53	19/137	343/8290	3.21459833978993033e-6	7.77348325803746 9e-5	5.87548596076437 06e-5	
qUC_CD44+_vs_HC_CD44+	R-HSA-9616222	Transcriptional regulation of granulopoiesis	6/137	27/8290	4.06122642723798e-6	9.53193689792824e-5	7.20459021568775l+5	
qUC_CD44+_vs_HC_CD44+	R-HSA-2559583	Cellular Senescence	11/137	123/8290	5.3462072664368696e-6	1.21893525674760 63e-4	9.21316199002485e-5	
qUC_CD44+_vs_HC_CD44+	R-HSA-6791312	TP53 Regulates Transcription of Cell Cycle Genes	7/137	46/8290	9.02610766315255e-6	1.96357349028881 16e-4	1.48414141925272 3e-4	
qUC_CD44+_vs_HC_CD44+	R-HSA-8881158	PIGF, PPZA and IER3 Regulate PI3K/AKT Signaling	5/137	19/8290	9.10428811286792e-6	1.96357349028881 16e-4	1.48414141925272 3e-4	
qUC_CD44+_vs_HC_CD44+	R-HSA-8848021	Signaling by PTK6	7/137	50/8290	1.59421361716725 34e-5	3.26200632435761 06e-4	2.46554494638822e-4	
qUC_CD44+_vs_HC_CD44+	R-HSA-9006927	Signaling by Non-Receptor Tyrosine Kinases	7/137	50/8290	1.59421361716725 34e-5	3.26200632435761 06e-4	2.46554494638822e-4	
qUC_CD44+_vs_HC_CD44+	R-HSA-170834	Signaling by TGF-beta Receptor Complex	8/137	72/8290	2.22772045149416 8e-5	4.44430203073865e-4	3.35916794396357e-4	
qUC_CD44+_vs_HC_CD44+	R-HSA-6806003	Regulation of TP53 Expression and Degradation	4/137	36/8290	2.36487627213441 7e-5	4.60285674430694e-4	3.47900925271639e-4	
qUC_CD44+_vs_HC_CD44+	R-HSA-6804759	Regulation of TP53 Activity through Association with Co-factors	4/137	12/8290	3.18835757742945 4e-5	6.05387290950324 1e-4	4.57574090112829 1e-4	
qUC_CD44+_vs_HC_CD44+	R-HSA-3769402	Deactivation of the beta-catenin transactivating complex	6/137	38/8290	3.26211968779942e-5	6.05387290950324 1e-4	4.57574090112829 1e-4	
qUC_CD44+_vs_HC_CD44+	R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer	7/137	57/8290	3.83265312472144e-5	6.95103941671084 3e-4	5.25385250728837e-4	
qUC_CD44+_vs_HC_CD44+	R-HSA-201681	TCF dependent signaling in response to WNT	11/137	154/8290	4.50782556180914 5e-5	7.88715373869202e-4	5.96140230775234 5e-4	
qUC_CD44+_vs_HC_CD44+	R-HSA-6804116	TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest	4/137	13/8290	4.54647959596470 26e-5	7.88715373869202e-4	5.96140230775234 5e-4	
qUC_CD44+_vs_HC_CD44+	R-HSA-69206	G1/S Transition	10/137	128/8290	4.73028751819075 e-5	8.03142433993612e-4	6.07044736376992 5e-4	
qUC_CD44+_vs_HC_CD44+	R-HSA-69242	S Phase	11/137	156/8290	5.07574465129428 06e-5	8.30783344617328 2e-4	6.00062793675829802035	
qUC_CD44+_vs_HC_CD44+	R-HSA-1433557	Signaling by SCF-KIT	5/137	41/8290	5.10130123887833 2e-5	8.30783344617328 2e-4	6.00062793675829802035	
qUC_CD44+_vs_HC_CD44+	R-HSA-2559586	DNA Damage/Telomere Stress Induced Senescence	5/137	26/8290	5.69967156986288 35e-5	9.09667582550116 3e-4	6.87560380953985 7e-4	
qUC_CD44+_vs_HC_CD44+	R-HSA-111447	Activation of BAD and translocation to mitochondria	4/137	15/8290	8.45910384479184 9e-5	0.00132360095435380188	0.00100042652280584l	
qUC_CD44+_vs_HC_CD44+	R-HSA-6804758	Regulation of TP53 Activity through Acetylation	5/137	29/8290	9.85796956295879 1e-5	0.00149812568180000887	0.00113233876226276 8	
qUC_CD44+_vs_HC_CD44+	R-HSA-157118	Signaling by NOTCH	11/137	168/8290	9.94995753576448e-5	0.00149812568180000887	0.00113233876226276 8	
qUC_CD44+_vs_HC_CD44+	R-HSA-9018519	Estrogen-dependent gene expression	8/137	89/8290	1.03863628102642 78e-4	0.00153487361529461	0.00116011420863185 8	
qUC_CD44+_vs_HC_CD44+	R-HSA-9614657	FOXO-mediated transcription of cell death genes	4/137	16/8290	1.11346926137351044e-4	0.00160212088823886 62	0.00121094218303768 8	
qUC_CD44+_vs_HC_CD44+	R-HSA-8878159	Transcriptional regulation by RUNX3	8/137	90/8290	1.12429538016762544e-4	0.00160212088823886 62	0.00121094218303768 8	
qUC_CD44+_vs_HC_CD44+	R-HSA-8864260	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	5/137	32/8290	1.17091418297821294e-4	0.00163927985617138	0.00123928304427392 2	
qUC_CD44+_vs_HC_CD44+	R-HSA-9006936	Signaling by TGFB family members	8/137	94/8290	1.52758553018908765e-4	0.00210174698808774 47	0.00158857805589536 7	
qUC_CD44+_vs_HC_CD44+	R-HSA-2173789	TGF-beta receptor signaling activates SMADs	5/137	32/8290	1.61130773927337798e-4	0.00217936199318910 3	0.00164724345412993 7	
qUC_CD44+_vs_HC_CD44+	R-HSA-5633007	Regulation of TP53 Activity	10/137	152/8290	1.99829597150984184e-4	0.00265773364210809 6	0.00200881351872831 5	
qUC_CD44+_vs_HC_CD44+	R-HSA-6804757	Regulation of TP53 Degradation	5/137	35/8290	2.49628514743323 6e-4	0.00326563204533069 24	0.00246828540030309	
qUC_CD44+_vs_HC_CD44+	R-HSA-5625900	RHO GTPases activate CIT	4/137	20/8290	2.81570626701882e-4	0.00362408645338616 4	0.00273921849068763 3	
qUC_CD44+_vs_HC_CD44+	R-HSA-381340	Transcriptional regulation of white adipocyte differentiation	7/137	80/8290	3.35933638781974866-4	0.00425515924457168 1	0.00321260767286075	
qUC_CD44+_vs_HC_CD44+	R-HSA-9615017	FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	4/137	21/8290	3.43388695223056e-4	0.00428162779356247	0.00323821538862005	
qUC_CD44+_vs_HC_CD44+	R-HSA-74751	Insulin receptor signalling cascade	5/137	39/8290	4.19898430574414434-4	0.00515506073228211	0.00389638543674719 75	
qUC_CD44+_vs_HC_CD44+	R-HSA-9617629	Regulation of FOXO transcriptional activity by acetylation	3/137	10/8290	4.86693917129087374-4	0.00588457190706238	0.00444777694601223 4	
qUC_CD44+_vs_HC_CD44+	R-HSA-1839124	FGFR1 mutant receptor activation	4/137	23/8290	4.95193496615097 5e-4	0.00589797627311731	0.00445790846127968	
qUC_CD44+_vs_HC_CD44+	R-HSA-69273	Cyclin A/B1/B2 associated events during G2/M transition	7/137	82/8290	5.86668073466290 5e-4	0.00688472239156203 05	0.00520372648547748	
qUC_CD44+_vs_HC_CD44+	R-HSA-4086400	PCP/CE pathway	7/137	88/8290	6.01739072009302e-4	0.00695924318053249 64	0.00526005321520264	
qUC_CD44+_vs_HC_CD44+	R-HSA-5683057	MAPK family signaling cascades	13/137	278/8290	6.63707140020657 4e-4	0.00748388155889701	0.00565659429263730 6	
qUC_CD44+_vs_HC_CD44+	R-HSA-2173793	Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	5/137	43/8290	6.65859138192652 6e-4	0.00748388155889701	0.00565659429263730 6	
qUC_CD44+_vs_HC_CD44+	R-HSA-1538133	G0 and Early G1	5/137	8/8290	8.04534112872754e-4	0.00867592191989807	0.00655758245627436 7	
qUC_CD44+_vs_HC_CD44+	R-HSA-2173788	Downregulation of TGF-beta receptor signaling	4/137	26/8290	8.04534112872754e-4	0.00867592191989807	0.00655758245627436 7	
qUC_CD44+_vs_HC_CD44+	R-HSA-8863795	Downregulation of ERBB2 signaling	4/137	26/8290	8.04534112872754e-4	0.00867592191989807	0.00655758245627436 7	
qUC_CD44+_vs_HC_CD44+	R-HSA-69278	Cell Cycle, Mitotic	18/137	477/8290	8.25659699444791e-4	0.00878497951489257	0.00664001221742968 9	
qUC_CD44+_vs_HC_CD44+	R-HSA-1358803	Downregulation of ERBB2:ERBB3 signaling	3/137	12/8290	8.70878655585287054-4	0.00914225883362014	0.00691154390095469	
qUC_CD44+_vs_HC_CD44+	R-HSA-8878171	Transcriptional regulation by RUNX1	9/137	155/8290	0.00103370324245798 33	0.01071292451274632	0.00809722430524162	
qUC_CD44+_vs_HC_CD44+	R-HSA-5218920	VEGFR2 mediated vascular permeability	4/137	28/8290	0.00107403552246 1307	0.01098820957950293	0.00830529493077361	
qUC_CD44+_vs_HC_CD44+	R-HSA-2122947	NOTCH1 Intracellular Domain Regulates Transcription	5/137	48/8290	0.00110879694906149	0.01120025272559629	0.00846556498084555	
qUC_CD44+_vs_HC_CD44+	R-HSA-5688426	Deubiquitination	11/137	24/8290	0.00116983032788798	0.01166913437079051	0.00881999306300791	
qUC_CD44+_vs_HC_CD44+	R-HSA-2559582	Senescence-Associated Secretory Phenotype (SASP)	5/137	49/8290	0.00121861921482626 57	0.01197058832797559	0.00904781310108169	
qUC_CD44+_vs_HC_CD44+	R-HSA-186763	Downstream signal transduction	4/137	29/8290	0.00123006045475434	0.01197058832797559	0.00904781310108169	
qUC_CD44+_vs_HC_CD44+	R-HSA-5655302	Signaling by FGFR1 in disease	4/137	30/8290	0.00140128546036372	0.01347260958276707	0.01018309628139545 8	
qUC_CD44+_vs_HC_CD44+	R-HSA-2173796	SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	4/137	20/8290	0.00158847421257292 6	0.01509050501644429	0.01140950944861156	
qUC_CD44+_vs_HC_CD44+	R-HSA-5099900	WNT5A-dependent internalization of FZD4	3/137	15/8290	0.00173686993867220 78	0.01636011549828494	0.01232476477844179 9	
qUC_CD44+_vs_HC_CD44+	R-HSA-389356	CD28 co-stimulation	4/137	32/8290	0.00179238041773300 2	0.01659247941199139 6	0.01254120921127960 8	
qUC_CD44+_vs_HC_CD44+	R-HSA-3858494	Beta-catenin independent WNT signaling	8/137	136/8290	0.00180895452235999643	0.01659247941199139 6	0.01254120921127960 8	
qUC_CD44+_vs_HC_CD44+	R-HSA-1912408	Pre-NOTCH Transcription and Translation	3/137	9/8290	0.00201375661014653 7	0.01805995685195415	0.01365038290278324	
qUC_CD44+_vs_HC_CD44+	R-HSA-5687128	MAPK6/MAPK4 signaling	6/137	80/8290	0.00201420571453808 5	0.01805995685195415	0.01365038290278324	
qUC_CD44+_vs_HC_CD44+	R-HSA-156711	Polo-like kinase mediated events	3/137	16/8290	0.00211198694156868 8	0.01852050087218237	0.01399847909215349 8	
qUC_CD44+_vs_HC_CD44+	R-HSA-2173791	TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)	3/137	16/8290	0.00211198694156868 8	0.01852050087218237	0.01399847909215349 8	
qUC_CD44+_vs_HC_CD44+	R-HSA-8986944	Transcriptional Regulation by MECP2	5/137	66/8290	0.00222612681507761 84	0.01930923654773849	0.01459463003477606	
qUC_CD44+_vs_HC_CD44+	R-HSA-6783783	Interleukin-10 signaling	4/137	35/8290	0.00251189246466144 7	0.02055105907407596	0.01553325003224578 3	
qUC_CD44+_vs_HC_CD44+	R-HSA-445144	Signal transduction by L1	3/137	17/8290	0.00253375244776967 6	0.02055105907407596	0.01553325003224578 3	
qUC_CD44+_vs_HC_CD44+	R-HSA-8934593	Regulation of RUNX1 Expression and Activity	3/137	17/8290	0.00253375244776967 6	0.02055105907407596	0.01553325003224578 3	
qUC_CD44+_vs_HC_CD44+	R-HSA-76002	Platelet activation, signaling and aggregation	10/137	211/8290	0.00253960605402342 6	0.02055105907407596	0.01553325003224578 3	
qUC_CD44+_vs_HC_CD44+	R-HSA-2644602	Signaling by NOTCH1 PEST Domain Mutants in Cancer	5/137	58/8290	0.00260107389283417 57	0.02055105907407596	0.01553325003224578 3	
qUC_CD44+_vs_HC_CD44+	R-HSA-2644603	Signaling by NOTCH1 in Cancer	5/137	58/8290	0.00260107389283417 57	0.02055105907407596	0.01553325003224578 3	
qUC_CD44+_vs_HC_CD44+	R-HSA-2644606	Constitutive Signaling by NOTCH1 PEST Domain Mutants	5/137	58/8290	0.00260107389283417 57	0.02055105907407596	0.01553325003224578 3	
qUC_CD44+_vs_HC_CD44+	R-HSA-2894858	Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer	5/137	58/8290	0.00260107389283417 57	0.02055105907407596	0.01553325003224578 3	
qUC_CD44+_vs_HC_CD44+	R-HSA-2894862	Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants	5/137	58/8290	0.00260107389283417 57	0.02055105907407596	0.01553325003224578 3	
qUC_CD44+_vs_HC_CD44+	R-HSA-2428928	IRS-related events triggered by IGF1R	4/137	36/8290	0.00279011941479395 6	0.02182858130397624 3	0.01649884851877575	
qUC_CD44+_vs_HC_CD44+	R-HSA-1368082	RORA activates gene expression	3/137	18/8290	0.00300401104590027	0.02295093631939223	0.01734716955694164	
qUC_CD44+_vs_HC_CD44+	R-HSA-6804114	TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest	3/137	18/8290	0.00300401104590027	0.02295093631939223	0.01734716955694164	
qUC_CD44+_vs_HC_CD44+	R-HSA-74752	Signaling by Insulin receptor	5/137	60/8290	0.00301986004202592 6	0.02295093631939223	0.01734716955694164	
qUC_CD44+_vs_HC_CD44+	R-HSA-2428924	IGF1R signaling cascade	4/137	37/8290	0.00308874898022058 3	0.02325303477562926	0.01757550313472093 5	
qUC_CD44+_vs_HC_CD44+	R-HSA-168928	DDX58/IFIH1-mediated induction of interferon-alpha/beta	5/137	62/8290	0.00324657440646144 3	0.02421276856068407	0.01830090683339947	
qUC_CD44+_vs_HC_CD44+	R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	4/137	38/8290	0.00340849105845516 87	0.02518496170969526	0.01903572491710343 2	
qUC_CD44+_vs_HC_CD44+	R-HSA-69615	G1/S DNA Damage Checkpoints	5/137	62/8290	0.00348530665422108	0.02551628174374792 6	0.01928614884470065 3	
qUC_CD44+_vs_HC_CD44+	R-HSA-389513	CTLA4 inhibitory signaling	3/137	19/8290	0.00352448191516224 84	0.02556851425726794 7	0.01932562810975774	
qUC_CD44+_vs_HC_CD44+	R-HSA-6689480	Ub-specific processing proteases	8/137	154/8290	0.00391402280353974 2	0.02814210188199168	0.02127204075765891 7	
qUC_CD44+_vs_HC_CD44+	R-HSA-392451	G beta:gamma signalling through PI3Kgamma	3/137	20/8290	0.00409676037783132	0.02867732264481918 2	0.02167538039240389 5	
qUC_CD44+_vs_HC_CD44+	R-HSA-9669938	Signaling by KIT in disease	3/137	20/8290	0.00409676037783132	0.02867732264481918 2	0.02167538039240389 5	
qUC_CD44+_vs_HC_CD44+	R-HSA-9670439	Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	3/137	20/8290	0.00409676037783132	0.02867732264481918 2	0.02167538039240389 5	
qUC_CD44+_vs_HC_CD44+	R-HSA-373760	L1CAM interactions	6/137	84/8290	0.00432365584735135	0.03111963246712370	0.02352136842588297 6	
qUC_CD44+_vs_HC_CD44+	R-HSA-4420097	VEGFA-VEGFR2 Pathway	6/137	94/8290	0.00452365584735135	0.03111963246712370	0.02352136842588297 6	
qUC_CD44+_vs_HC_CD44+	R-HSA-1445148	Translocation of SLC2A4 (GLUT4) to the plasma membrane	5/137	66/8290	0.00456744928376552 5	0.03115234639696485	0.02354609482319 07	
qUC_CD44+_vs_HC_CD44+	R-HSA-389357	CD28 dependent PI3K/Akt signaling	3/137	21/8290	0.00472232232493263	0.03193570521437533	0.02413816370976214	
qUC_CD44+_vs_HC_CD44+	R-HSA-3108232	SUMO E3 ligases SUMOylate target proteins	8/137	160/8290	0.00492929035420506	0.03305524119757916	0.02498437304605326	
qUC_CD44+_vs_HC_CD44+	R-HSA-109581	Apoptosis	8/137	161/8290	0.00511640165057097	0.03402407067794704	0.02571665017604826	
qUC_CD44+_vs_HC_CD44+	R-HSA-201451	Signaling by BMP	3/137	22/8290	0.00540252851821683 2	0.03533785047161501 5	0.02670965350248704	
qUC_CD44+_vs_HC_CD44+	R-HSA-5668599	RHO GTPases Activate NADPH Oxidases	3/137	22/8290	0.00540252851821683 2	0.03533785047161501 5	0.02670965350248704	
qUC_CD44+_vs_HC_CD44+	R-HSA-194138	Signaling by VEGF	6/137	99/8290	0.00582286487457537	0.03777761138274 08	0.02855371479025047	
qUC_CD44+_vs_HC_CD44+	R-HSA-2990846	SUMOylation	8/137	166/8290	0.00613497474154043 2	0.03887798221922822	0.02938541592351638	
qUC_CD44+_vs_HC_CD44+	R-HSA-6807070	PTEN Regulation	7/137	132/8290	0.00613668451815772 2	0.03887798221922822	0.02938541592351638	
qUC_CD44+_vs_HC_CD44+	R-HSA-73980	RNA Polymerase III Transcription Termination	3/137	23/8290	0.00613862677114570 7	0.03887798221922822	0.02938541592351638	
qUC_CD44+_vs_HC_CD44+	R-HSA-1980143	Signaling by NOTCH1	5/137	72/8290	0.00661056335131390 4	0.04153724058412123	0.03139338168506313	
qUC_CD44+_vs_HC_CD44+	R-HSA-1227986	Signaling by ERBB2	4/137	47/8290	0.00734733470518051 5	0.04580603980260978	0.03462189791147	
qUC_CD44+_vs_HC_CD44+	R-HSA-400685	Sema4D in semaphorin signaling	3/137	25/8290	0.00778298023964980 8	0.04795271225769289	0.03624443229607971	
qUC_CD44+_vs_HC_CD44+	R-HSA-5357801	Programmed Cell Death	8/137	173/8290	0.00781184535528352	0.04795271225769289	0.03624443229607971	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-5663202	Diseases of signal transduction by growth factor receptors and second messengers	61/368	356/8290	9.63738349616773e-21	9.83031116609109 2e-18	6.28966080802526e-18	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	66/368	439/8290	2.96467484412846 05e-19	1.51198410750551 5e-16	9.67420212294550 3e-17	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling	27/368	87/8290	2.38430337308117e-16	8.10663146847600 3e-14	5.18690583545017 6e-14	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-2219528	PI3K/AKT Signaling in Cancer	26/368	84/8290	6.73526638520144 9e-16	1.71749282226336950 3e-13	1.09831188390102 9e-13	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-9616222	Transcriptional regulation of granulopoiesis	16/368	27/8290	1.37834215349948 86e-15	2.47981727580868 24e-13	1.58667359236468 4e-13	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-449147	Signaling by Interleukins	55/368	376/8290	1.45871604459334 27e-15	2.47981727580868 24e-13	1.58667359236468 4e-13	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-1257604	PIP3 activates AKT signaling	42/368	237/8290	5.27724138341284e-15	7.68969458725846e-13	4.92013482363047e-13	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-8006925	Intracellular signaling by second messengers	45/368	273/8290	8.50396659818 3e-15	1.04258291260063 0e-12	6.93374525109059e-13	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-199418	Negative regulation of the PI3K/AKT network	24/368	91/8290	6.37993111198462e-13	7.23058859358568e-11	4.62638279465551 34e-11	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-109606	Intrinsic Pathway for Apoptosis	18/368	51/8290	2.16359805354269372e-12	2.20687001461354 5e-10	1.41203241389102 1e-10	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-2559583	Cellular Senescence	27/368	123/8290	2.65481442248728 08e-12	2.46173700994275 16e-10	1.57510520760010 93e-10	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-6986944	Transcriptional Regulation by MECP2	18/368	56/8290	1.34203241403092e-11	1.40727551926268 4e-9	7.29872778092 3e-10	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-9006931	Signaling by Nuclear Receptors	34/368	219/8290	1.09667800339370 78e-10	8.60470433431986 3e-9	5.50558997655140 7e-9	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-166520	Signaling by NTRKs	25/368	125/8290	1.50388579774533e-10	1.09568822407 16e-8	7.01059548136139e-9	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer	17/368	57/8290	1.91907133353539632e-10	1.30496850681695 8e-8	8.34964369686366e-9	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-6811558	PIGF, PPZA and IER3 Regulate PI3K/AKT Signaling	20/368	84/8290	4.17915144432505 0e-10	2.66421076707527 19e-8	1.70649491955838 3e-8	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-8939211	ESR-mediated signaling	27/368	154/8290	6.26469052875792e-10	3.75881431725479 5e-8	2.40502051258207 6e-8	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-9614085	FOXO-mediated transcription	16/368	55/8290	1.00278475015513 56e-9	5.68244691754576 9e-8	3.63582774910491 5e-8	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-5683057	MAPK family signaling cascades	37/368	278/8290	1.44792284050376 95e-9	7.77305945954655 2e-8	4.97347457679652 e-8	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-8006936	Signaling by TGFB family members	20/368	94/8290	3.49330423591830604e-9	1.78158516031833e-7	1.13920329615447 5e-7	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-2559580	Oxidative Stress Induced Senescence	16/368	62/8290	6.92553722159533e-9	3.36383236477891 6e-7	2.15229728190606 6e-7	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-2559585	Oncogene Induced Senescence	12/368	33/8290	7.47100863208881e-9	3.46383127487754 7e-7	2.21628007267706 7e-7	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-9607240	FLT3 Signaling	33/368	252/8290	1.77399392608105 24e-8	7.86727741122726 e-7	5.03375850873159 e-7	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-5684996	MAPK1/MAPK3 signaling	28/368	206/8290	2.84768706754669 13e-8	1.21026700707548 36e-6	7.74371046837494 e-7	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-187037	Signaling by NTRK1 (TRKA)	20/368	108/8290	4.28007889126833 1e-8	1.74627218763747 88e-6	1.11732585793110 11e-6	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-5673001	RAF/MAP kinase cascade	31/368	239/8290	6.13981857962577e-8	2.40869805816087 98e-6	1.54116903618136 7e-6	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-157118	Signaling by NOTCH	25/368	168/8290	8.40746706946788 e-8	3.17615422624334 57e-6	2.03221426245434 6e-6	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-8848021	Signaling by PTK6	13/368	29/8290	1.67555546585582 37e-7	5.89333301783725 6e-6	3.77070003205303 44e-6	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-9006927	Signaling by Non-Receptor Tyrosine Kinases	13/368	50/8290	1.67555546585582 37e-7	5.89333301783725 6e-6	3.77070003205303 44e-6	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-9009391	Extra-nuclear estrogen signaling	15/368	68/8290	1.98849782615914 17e-7	6.76086526089420 2e-6	4.32583742183117 2e-6	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-452723	Transcriptional regulation of pluripotent stem cells	8/368	17/8290	2.39090888117985 7e-7	7.61605796237467 95e-6	4.87301954248947 55e-6	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-114452	Activation of BHG-only proteins	10/368	29/8290	2.47318546038823 9e-7	7.61605796237467 95e-6	4.87301954248947 55e-6	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-2428928	IRS-related events triggered by IGF1R	11/368	36/8290	2.50869903907774 7e-7	7.61605796237467 95e-6	4.87301954248947 55e-6	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-195721	Signaling by WNT	30/368	241/8290	2.53865987458226 5e-7	7.61605796237467 95e-6	4.87301954248947 55e-6	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-2428924	IGF1R signaling cascade	11/368	37/8290	3.42965386071085 97e-7	9.99499125121450 6e-6	6.39514040142761 e-6	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	13/368	50/8290	4.63711060169415 95e-7	1.31384800381345 2e-5	8.40645781593871 e-6	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-383280	Nuclear Receptor transcription pathway	12/368	47/8290	6.25532832811635 8e-7	1.72444186342667 17e-5	1.10335805030418 5e-5	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-1912408	Pre-NOTCH Transcription and Translation	10/368	33/8290	9.74342035257594e-7	2.61533914727038 38e-5	1.67338521290777 93e-05	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-8878159	Transcriptional regulation by RUNX3	16/368	99/8290	1.73862888437776 52e-6	4.54718323694415 5e-5	2.90944644610854 3e-5	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-6806003	Regulation of TP53 Expression and Degradation	10/368	36/8290	2.37421099266965 13e-6	6.05423803130761 1e-5	3.87371267250484e-5	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-9022699	MECP2 regulates neuronal receptors and channels	7/368	16/8290	2.59421329230764 93e-6	6.45389424427756 7e-5	4.12942665784529 5e-5	
uUC_CD66a+_vs_dUC_CD44+	R-HSA-186763	Downstream signal transduction	9/368	29/8290	2.75891520832113 65e-6	6.51273999505006 4e-5	4.16711272789065e-5	
uUC_CD66a+_vs

aUC_CD66a-_vs_aUC_CD44+	R-HSA-8853334	Signaling by FGFR3 mutations	5/368	10/8290	3.51508530101215394e-5	4.42640371239749945e-4	2.83216749400046074e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-9617629	Regulation of FOXO transcriptional activity by acetylation	5/368	10/8290	3.51508530101215394e-5	4.42640371239749945e-4	2.83216749400046074e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-74751	Insulin receptor signalling cascade	9/368	39/8290	3.93415746758802e-5	4.62098292847061e-4	2.95666606362413e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-2644602	Signaling by NOTCH1 PEST Domain Mutants in Cancer	11/368	58/8290	3.94142661546023 1e-5	4.62098292847061e-4	2.95666606362413e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-2644603	Signaling by NOTCH1 in Cancer	11/368	58/8290	3.94142661546023 1e-5	4.62098292847061e-4	2.95666606362413e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-2644606	Constitutive Signaling by NOTCH1 PEST Domain Mutants	11/368	58/8290	3.94142661546023 1e-5	4.62098292847061e-4	2.95666606362413e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-2894858	Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer	11/368	58/8290	3.94142661546023 1e-5	4.62098292847061e-4	2.95666606362413e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-2894862	Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants	11/368	58/8290	3.94142661546023 1e-5	4.62098292847061e-4	2.95666606362413e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-5633007	Regulation of TP53 Activity	19/368	152/8290	3.99313308154766e-5	4.6284042536120677e-4	2.96141446631525e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-1839124	FGFR1 mutant receptor activation	7/368	23/8290	4.24244337873794e-5	4.80810249590304e-4	3.07639168984508e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-9006335	Signaling by Erythropoietin	7/368	23/8290	4.24244337873794e-5	4.80810249590304e-4	3.07639168984508e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-168142	Toll Like Receptor 10 (TLR10) Cascade	13/368	80/8290	4.43406391106039e-5	4.86316687019527 1e-4	3.11162379723536144e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-168176	Toll Like Receptor 5 (TLR5) Cascade	13/368	80/8290	4.43406391106039e-5	4.86316687019527 1e-4	3.11162379723536144e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-975871	MyD88 cascade initiated on plasma membrane	13/368	80/8290	4.43406391106039e-5	4.86316687019527 1e-4	3.11162379723536144e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-9022692	Regulation of MECP2 expression and activity	8/368	31/8290	4.48540409663511e-5	4.86437255810503 8e-4	3.11239523841602034e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-1912422	Pre-NOTCH Expression and Processing	10/368	49/8290	4.57823299586365655e-5	4.86437255810503 8e-4	3.11239523841602034e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-2559582	Senescence-Associated Secretory Phenotype (SASP)	10/368	49/8290	4.57823299586365655e-5	4.86437255810503 8e-4	3.11239523841602034e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-186797	Signaling by PDGF	10/368	50/8290	5.5002598331600485e-5	5.78377838126108 2e-4	3.70066315416058 8e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-389356	CD28 co-stimulation	8/368	32/8290	5.75177214646308e-5	5.96701471440614 7e-4	3.81790415632416e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-975138	TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation	6/368	17/8290	5.79151428162949454e-5	5.96701471440614 7e-4	3.81790415632416e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-445144	Signal transduction by L1	6/368	17/8290	5.99287050186609 7e-5	5.99287050186609 7e-4	3.83444758633313e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-8934593	Regulation of RUNX1 Expression and Activity	6/368	17/8290	5.99287050186609 7e-5	5.99287050186609 7e-4	3.83444758633313e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-9034015	Signaling by NTRK3 (TRKC)	6/368	17/8290	5.99287050186609 7e-5	5.99287050186609 7e-4	3.83444758633313e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-450294	MAP kinase activation	11/368	61/8290	6.42099678380170 1e-5	6.35865898784209e-4	4.06849182008896e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-168181	Toll Like Receptor 7/8 (TLR7/8) Cascade	13/368	83/8290	6.59632646915419e-5	6.40785999806092 7e-4	4.09997234172992 25e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-975155	MyD88 dependent cascade initiated on endosome	13/368	83/8290	6.59632646915419e-5	6.40785999806092 7e-4	4.09997234172992 25e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-170834	Signaling by TGF-beta Receptor Complex	12/368	72/8290	6.73645198891254e-5	6.48224625348188 1e-4	4.14756726228974 97e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-2262752	Cellular responses to stress	40/368	479/8290	7.34147714529745 8e-5	6.99841746561066 1e-4	4.47783160854345 73e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-190236	Signaling by FGFR	12/368	73/8290	7.74509718318412e-5	7.31481400634054 1e-4	4.68027315163119 4e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-168138	Toll Like Receptor 9 (TLR9) Cascade	13/368	86/8290	9.62047591717763 6e-5	9.00264718855155e-4	5.7602076954126e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-9673767	Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants	5/368	12/8290	1.02596925806913 14e-4	9.42782561468931 5e-4	6.03225168328934 5e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-9673770	Signaling by PDGFRA extracellular domain mutants	5/368	12/8290	1.02596925806913 14e-4	9.42782561468931 5e-4	6.03225168328934 5e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-8953897	Cellular responses to external stimuli	40/368	490/8290	1.20621641098384 38e-4	0.00109851851714600 7	7.02870465046976 7e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-448424	Interleukin-17 signaling	11/368	66/8290	1.35156647317414 61e-4	0.00121999805543153 02	7.80597311008222 e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-166058	MyD88:MAL(TIRAP) cascade initiated on plasma membrane	13/368	89/8290	1.37761043830250 27e-4	0.00122188056268308 8	7.81801804803251e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-168188	Toll Like Receptor TLR6:TLR2 Cascade	13/368	89/8290	1.37761043830250 27e-4	0.00122188056268308 8	7.81801804803251e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-9675126	Diseases of mitotic cell cycle	8/368	36/8290	1.41598945751859 8e-4	0.00123445234758031 61	7.89845671310419e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-9687139	Aberrant regulation of mitotic cell cycle due to RB1 defects	8/368	36/8290	1.41598945751859 8e-4	0.00123445234758031 61	7.89845671310419e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-6802957	Oncogenic MAPK signaling	12/368	82/8290	1.49775597662232996e-4	0.00129462720031316 2	8.28247840950799e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-168179	Toll Like Receptor TLR1:TLR2 Cascade	13/368	90/8290	1.54679984539202 87e-4	0.00131477913685327 5	8.41241552995008 4e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-181438	Toll Like Receptor 2 (TLR2) Cascade	13/368	90/8290	1.54679984539202 87e-4	0.00131477913685327 5	8.41241552995008 4e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-76002	Platelet activation, signaling and aggregation	22/368	211/8290	1.61333822052654844e-4	0.00136000411978271 02	8.70178074577127e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-1250196	SHC1 events in ERBB2 signaling	5/368	20/8290	0.00016755249168380861	0.00140084870962990 2	8.96311823392611e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-350054	Notch-HLH transcription pathway	7/368	28/8290	1.69036753790901 16e-4	0.00140178820218448 7	8.96900191273929e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-8853884	Transcriptional Regulation by VENTX	8/368	37/8290	1.73767196772979 39e-4	0.00142935732829386 29	9.14564193541966e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-166016	Toll Like Receptor 4 (TLR4) Cascade	15/368	116/8290	1.76272271584815 72e-4	0.00143838173613209 63	9.20326807432301e-4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-8878166	Transcriptional regulation by RUNX2	14/368	105/8290	2.08145292740528e-4	0.00168498570313761 6	0.00107811927394552
aUC_CD66a-_vs_aUC_CD44+	R-HSA-5654736	Signaling by FGFR1	8/368	38/8290	2.11710765561938 1e-4	0.00170035418010376 85	0.00108794591503027 52
aUC_CD66a-_vs_aUC_CD44+	R-HSA-5628897	TP53 Regulates Metabolic Genes	12/368	81/8290	2.16319120092323 2e-4	0.00172379298235706	0.00110292428094674 4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-177929	Signaling by EGFR	9/368	48/8290	2.18562118854327 2e-4	0.00172816559094119 19	0.00110574062578280 6
aUC_CD66a-_vs_aUC_CD44+	R-HSA-9615017	FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	8/368	42/8290	2.25879242625060 1e-4	0.00177228583829151 1	0.00113968667429552 1
aUC_CD66a-_vs_aUC_CD44+	R-HSA-6807070	PTEN Regulation	16/368	132/8290	2.31953011475972 5e-4	0.00180604634889685 3	0.00115557145130657 26
aUC_CD66a-_vs_aUC_CD44+	R-HSA-1963642	PI3K events in ERBB2 signaling	5/368	14/8290	2.40887947501965 54e-4	0.00183624675014961 7	0.00117321702635362 5
aUC_CD66a-_vs_aUC_CD44+	R-HSA-5655332	Signaling by FGFR3 in disease	5/368	14/8290	2.40887947501965 54e-4	0.00183624675014961 7	0.00117321702635362 5
aUC_CD66a-_vs_aUC_CD44+	R-HSA-8853338	Signaling by FGFR3 point mutants in cancer	5/368	14/8290	2.40887947501965 54e-4	0.00183624675014961 7	0.00117321702635362 5
aUC_CD66a-_vs_aUC_CD44+	R-HSA-3108232	SUMO E3 ligases SUMOylate target proteins	18/368	160/8290	2.48170091244925e-4	0.00187506291162833 3	0.00119973065531094
aUC_CD66a-_vs_aUC_CD44+	R-HSA-8864260	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	7/368	30/8290	2.69154290596744 1e-4	0.00201865717947558 08	0.00129160727885744 08
aUC_CD66a-_vs_aUC_CD44+	R-HSA-74752	Signaling by Insulin receptor	10/368	60/8290	2.71726838580385 1e-4	0.00202307573249629 8	0.00129443442105681 8
aUC_CD66a-_vs_aUC_CD44+	R-HSA-198753	ERK/MAPK targets	6/368	22/8290	2.99081730936432 83e-4	0.00215170212606953	0.00137673047447121 4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-201451	Signaling by BMP	6/368	22/8290	2.99081730936432 83e-4	0.00215170212606953	0.00137673047447121 4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-9664565	Signaling by ERBB2 KD Mutants	6/368	22/8290	2.99081730936432 83e-4	0.00215170212606953	0.00137673047447121 4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-1592230	Mitochondrial biogenesis	11/368	72/8290	2.99550688139089 05e-4	0.00215170212606953	0.00137673047447121 4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-6806834	Signaling by MET	11/368	72/8290	2.99550688139089 05e-4	0.00215170212606953	0.00137673047447121 4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-187687	Signalling to ERKs	7/368	31/8290	3.34575196738942 2e-4	0.00236990764356750 7	0.00151634957586362 7
aUC_CD66a-_vs_aUC_CD44+	R-HSA-2173796	SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	7/368	31/8290	3.34575196738942 2e-4	0.00236990764356750 7	0.00151634957586362 7
aUC_CD66a-_vs_aUC_CD44+	R-HSA-111447	Activation of BAD and translocation to mitochondria	5/368	15/8290	3.48259614152246e-4	0.00238405910359255 07	0.00152540417360927 53
aUC_CD66a-_vs_aUC_CD44+	R-HSA-2644603	Signaling by NOTCH1 HD Domain Mutants in Cancer	5/368	15/8290	3.48259614152246e-4	0.00238405910359255 07	0.00152540417360927 53
aUC_CD66a-_vs_aUC_CD44+	R-HSA-2691232	Constitutive Signaling by NOTCH1 HD Domain Mutants	5/368	15/8290	3.48259614152246e-4	0.00238405910359255 07	0.00152540417360927 53
aUC_CD66a-_vs_aUC_CD44+	R-HSA-9617828	FOXO-mediated transcription of cell cycle genes	5/368	15/8290	3.48259614152246e-4	0.00238405910359255 07	0.00152540417360927 53
aUC_CD66a-_vs_aUC_CD44+	R-HSA-9665348	Signaling by ERBB2 ECD mutants	5/368	15/8290	3.48259614152246e-4	0.00238405910359255 07	0.00152540417360927 53
aUC_CD66a-_vs_aUC_CD44+	R-HSA-388841	Costimulation by the CD28 family	10/368	62/8290	3.58071857232575 8e-4	0.00243488626318511	0.00155792567708284
aUC_CD66a-_vs_aUC_CD44+	R-HSA-1227990	Signaling by ERBB2 in Cancer	6/368	23/8290	3.89666559341980854e-4	0.00261085114407391 5	0.00167051363191522
aUC_CD66a-_vs_aUC_CD44+	R-HSA-1368108	BMAL1:CLOCK,NPAS2 activates circadian gene expression	6/368	23/8290	3.89666559341980854e-4	0.00261085114407391 5	0.00167051363191522
aUC_CD66a-_vs_aUC_CD44+	R-HSA-2990846	SUMOylation	18/368	166/8290	3.91627671611092 7e-4	0.00261085114407391 5	0.00167051363191522
aUC_CD66a-_vs_aUC_CD44+	R-HSA-5654741	Signaling by FGFR3	7/368	32/8290	4.12151289815796 9e-4	0.00272983321826043	0.00174664251323167 51
aUC_CD66a-_vs_aUC_CD44+	R-HSA-881907	Gastrin-CREB signalling pathway via PKC and MAPK	5/368	16/8290	4.88252686363787e-4	0.00319242141084015 7	0.00204622257453162 6
aUC_CD66a-_vs_aUC_CD44+	R-HSA-9614657	FOXO-mediated transcription of cell death genes	5/368	16/8290	4.88252686363787e-4	0.00319242141084015 7	0.00204622257453162 6
aUC_CD66a-_vs_aUC_CD44+	R-HSA-8878171	Transcriptional regulation by RUNX1	17/368	155/8290	4.94826086602415e-4	0.00321481006803493	0.00205694791897043
aUC_CD66a-_vs_aUC_CD44+	R-HSA-4791275	Signaling by WNT in cancer	7/368	33/8290	0.00050345570802514685	0.00322971586280829	0.00206648465776836
aUC_CD66a-_vs_aUC_CD44+	R-HSA-5654743	Signaling by FGFR4	7/368	33/8290	0.00050345570802514685	0.00322971586280829	0.00206648465776836
aUC_CD66a-_vs_aUC_CD44+	R-HSA-2173793	Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	8/368	43/8290	5.17004785801117 4e-4	0.00327543404669039	0.00209573695453869 1
aUC_CD66a-_vs_aUC_CD44+	R-HSA-75893	TNF signaling	8/368	43/8290	5.17004785801117 4e-4	0.00327543404669039	0.00209573695453869 1
aUC_CD66a-_vs_aUC_CD44+	R-HSA-6802946	Signaling by moderate kinase activity BRAF mutants	8/368	44/8290	6.07871330989308 6e-4	0.00374924374661286	0.00239889692766018 32
aUC_CD66a-_vs_aUC_CD44+	R-HSA-6802949	Signaling by RAS mutants	8/368	44/8290	6.07871330989308 6e-4	0.00374924374661286	0.00239889692766018 32
aUC_CD66a-_vs_aUC_CD44+	R-HSA-6802955	Paradoxical activation of RAF signaling by kinase inactive BRAF	8/368	44/8290	6.07871330989308 6e-4	0.00374924374661286	0.00239889692766018 32
aUC_CD66a-_vs_aUC_CD44+	R-HSA-9649948	Signaling downstream of RAS mutants	8/368	44/8290	6.07871330989308 6e-4	0.00374924374661286	0.00239889692766018 32
aUC_CD66a-_vs_aUC_CD44+	R-HSA-186712	Regulation of beta-catenin expression	7/368	34/8290	6.10171041161466e-4	0.00374924374661286	0.00239889692766018 32
aUC_CD66a-_vs_aUC_CD44+	R-HSA-354192	Integrin signaling	6/368	25/8290	6.34028102207088e-4	0.00386655211149235 7	0.00247395491324795
aUC_CD66a-_vs_aUC_CD44+	R-HSA-5654710	PI-3K cascade:FGFR3	4/368	10/8290	6.48216089265666e-4	0.00386655211149235 7	0.00247395491324795
aUC_CD66a-_vs_aUC_CD44+	R-HSA-6875555	MET activates PAK1 and RAC1	4/368	10/8290	6.48216089265666e-4	0.00386655211149235 7	0.00247395491324795
aUC_CD66a-_vs_aUC_CD44+	R-HSA-9027276	Erythropoietin activates Phosphoinositide-3-kinase (PI3K)	4/368	10/8290	6.48216089265666e-4	0.00386655211149235 7	0.00247395491324795
aUC_CD66a-_vs_aUC_CD44+	R-HSA-9028731	Activated NTRK2 signals through FRS2 and FRS3	4/368	10/8290	6.48216089265666e-4	0.00386655211149235 7	0.00247395491324795
aUC_CD66a-_vs_aUC_CD44+	R-HSA-111471	Apoptotic factor-mediated response	5/368	17/8290	6.66721011924253 6e-4	0.00388603104929935	0.00248641820988293 7
aUC_CD66a-_vs_aUC_CD44+	R-HSA-1181150	Signaling by NODAL	5/368	17/8290	6.66721011924253 6e-4	0.00388603104929935	0.00248641820988293 7
aUC_CD66a-_vs_aUC_CD44+	R-HSA-210745	Regulation of gene expression in beta cells	5/368	17/8290	6.66721011924253 6e-4	0.00388603104929935	0.00248641820988293 7
aUC_CD66a-_vs_aUC_CD44+	R-HSA-5654708	Downstream signaling of activated FGFR3	5/368	17/8290	6.66721011924253 6e-4	0.00388603104929935	0.00248641820988293 7
aUC_CD66a-_vs_aUC_CD44+	R-HSA-453279	Mitotic G1 phase and G1/S transition	16/368	146/8290	7.26002935258569e-4	0.00420751701115725 7	0.00269211614789675
aUC_CD66a-_vs_aUC_CD44+	R-HSA-381340	Transcriptional regulation of white adipocyte differentiation	11/368	80/8290	7.59343536407462e-4	0.00435623921654487	0.00278726977443237 42
aUC_CD66a-_vs_aUC_CD44+	R-HSA-1251985	Nuclear signaling by ERBB4	6/368	26/8290	7.93812187712910e-4	0.00454881141273690 35	0.00291048821041989 7
aUC_CD66a-_vs_aUC_CD44+	R-HSA-373760	L1CAM interactions	12/368	94/8290	8.69465901254468e-4	0.00490626850044641 5	0.00313920172371071 06
aUC_CD66a-_vs_aUC_CD44+	R-HSA-451927	Interleukin-2 family signaling	7/368	36/8290	8.77102391536779e-4	0.00490626850044641 5	0.00313920172371071 06
aUC_CD66a-_vs_aUC_CD44+	R-HSA-8853659	RET signaling	7/368	36/8290	8.77102391536779e-4	0.00490626850044641 5	0.00313920172371071 06
aUC_CD66a-_vs_aUC_CD44+	R-HSA-167044	Signalling to RAS	5/368	18/8290	8.89862424100253 7e-4	0.00490626850044641 5	0.00313920172371071 06
aUC_CD66a-_vs_aUC_CD44+	R-HSA-1839117	Signaling by cytosolic FGFR1 fusion mutants	5/368	18/8290	8.89862424100253 7e-4	0.00490626850044641 5	0.00313920172371071 06
aUC_CD66a-_vs_aUC_CD44+	R-HSA-5654696	Downstream signaling of activated FGFR2	5/368	18/8290	8.89862424100253 7e-4	0.00490626850044641 5	0.00313920172371071 06
aUC_CD66a-_vs_aUC_CD44+	R-HSA-6803204	TP53 Regulates Transcription of Genes Involved in Cytochrome C Release	5/368	18/8290	8.89862424100253 7e-4	0.00490626850044641 5	0.00313920172371071 06
aUC_CD66a-_vs_aUC_CD44+	R-HSA-5688426	Deubiquitination	21/368	224/8290	9.41876243510013e-4	0.00516512778699393	0.00330482892459653 66
aUC_CD66a-_vs_aUC_CD44+	R-HSA-4641265	Repression of WNT target genes	4/368	11/8290	9.83138408810493e-4	0.00527657349303050 9	0.00337613577469444
aUC_CD66a-_vs_aUC_CD44+	R-HSA-5654689	PI-3K cascade:FGFR1	4/368	11/8290	9.83138408810493e-4	0.00527657349303050 9	0.00337613577469444
aUC_CD66a-_vs_aUC_CD44+	R-HSA-5654695	PI-3K cascade:FGFR2	4/368	11/8290	9.83138408810493e-4	0.00527657349303050 9	0.00337613577469444
aUC_CD66a-_vs_aUC_CD44+	R-HSA-5655291	Signaling by FGFR4 in disease	4/368	11/8290	9.83138408810493e-4	0.00527657349303050 9	0.00337613577469444
aUC_CD66a-_vs_aUC_CD44+	R-HSA-73887	Death Receptor Signalling	15/368	136/8290	9.80642521263013e-4	0.00527657349303050 9	0.00337613577469444
aUC_CD66a-_vs_aUC_CD44+	R-HSA-168898	Toll-like Receptor Cascades	15/368	137/8290	0.00106577221415614 5	0.00566191488769703	0.00362269640415672 5
aUC_CD66a-_vs_aUC_CD44+	R-HSA-2122947	NOTCH1 Intracellular Domain Regulates Transcription	8/368	48/8290	0.00110859406403259	0.00585889060378245	0.00374872257147917
aUC_CD66a-_vs_aUC_CD44+	R-HSA-389513	CTLA4 inhibitory signaling	5/368	19/8290	0.00116418669957182 3	0.00599723254220366	0.00383723857189509
aUC_CD66a-_vs_aUC_CD44+	R-HSA-5654716	Downstream signaling of activated FGFR4	5/368	19/8290	0.00116418669957182 3	0.00599723254220366	0.00383723857189509
aUC_CD66a-_vs_aUC_CD44+	R-HSA-8876384	Listeria monocytogenes entry into host cells	5/368	19/8290	0.00116418669957182 3	0.00599723254220366	0.00383723857189509
aUC_CD66a-_vs_aUC_CD44+	R-HSA-9665686	Signaling by ERBB2 TMD/JMD mutants	5/368	19/8290	0.00116418669957182 3	0.00599723254220366	0.00383723857189509
aUC_CD66a-_vs_aUC_CD44+	R-HSA-9671555	Signaling by PDGFR in disease	5/368	19/8290	0.00116418669957182 3	0.00599723254220366	0.00383723857189509
aUC_CD66a-_vs_aUC_CD44+	R-HSA-5218920	VEGFR2 mediated vascular permeability	6/368	28/8290	0.00120495734283651 22	0.00617161636479016 4	0.00395172468954522 8
aUC_CD66a-_vs_aUC_CD44+	R-HSA-6689480	Ub-specific processing proteases	16/368	154/8290	0.00129214731255369	0.00658995129403406	0.00421648070412230 4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-1358803	Downregulation of ERBB2:ERBB3 signaling	4/368	12/8290	0.00142349150311622 8	0.00715210509023574	0.00457616631160594 3
aUC_CD66a-_vs_aUC_CD44+	R-HSA-5654706	FRS-mediated FGFR3 signaling	4/368	12/8290	0.00142349150311622 8	0.00715210509023574	0.00457616631160594 3
aUC_CD66a-_vs_aUC_CD44+	R-HSA-5654720	PI-3K cascade:FGFR4	4/368	12/8290	0.00142349150311622 8	0.00715210509023574	0.00457616631160594 3
aUC_CD66a-_vs_aUC_CD44+	R-HSA-2122948	Activated NOTCH1 Transmits Signal to the Nucleus	5/368	19/8290	0.00146335690879465 29	0.00724574780827892	0.00463608218424245
aUC_CD66a-_vs_aUC_CD44+	R-HSA-5339562	Uptake and actions of bacterial toxins	6/368	29/8290	0.00146335690879465 29	0.00724574780827892	0.00463608218424245
aUC_CD66a-_vs_aUC_CD44+	R-HSA-9645723	Diseases of programmed cell death	6/368	29/8290	0.00146335690879465 29	0.00724574780827892	0.00463608218424245
aUC_CD66a-_vs_aUC_CD44+	R-HSA-5218921	VEGFR2 mediated cell proliferation	5/368	20/8290	0.00149637406271496 54	0.00733798819215927	0.00469510080405174 5
aUC_CD66a-_vs_aUC_CD44+	R-HSA-5654687	Downstream signaling of activated FGFR1	5/368	20/8290	0.00149637406271496 54	0.00733798819215927	0.00469510080405174 5
aUC_CD66a-_vs_aUC_CD44+	R-HSA-6804756	Regulation of TP53 Activity through Phosphorylation	11/368	88/8290	0.00168230446314486 87	0.00821028972443907 2	0.00525322975144708 4
aUC_CD66a-_vs_aUC_CD44+	R-HSA-389357	CD28 dependent PI3K/Akt signaling	5/368	21/8290	0.00189430639930636	0.00907179877091504	0.00580445328995560 5
aUC_CD66a-_vs_aUC_CD44+	R-HSA-525793	Myogenesis	5/368	21/8290	0.00189430639930636	0.00907179877091504	0.00580445328995560 5
aUC_CD66a-_vs_aUC_CD44+	R-HSA-5654732	Negative regulation of FGFR3 signaling	5/368	21/8290	0.00189430639930636	0.00907179877091504	0.00580445328995560 5
aUC_CD66a-_vs_aUC_CD44+	R-HSA-168643	Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways	8/368	52/8290	0.00189450037457879	0.00907179877091504	0.00580445328995560 5
aUC_CD66a-_vs_aUC_CD44+	R-HSA-171007	p38/MAPK events	4/368	13/8290	0.00198424040904965	0.00915980326571213	0.00586076163543958
aUC_CD66a-_vs_aUC_CD44+	R-HSA-354194	GRB2:SOS provides linkage to MAPK signaling for Integrins	4/368	13/8290	0.00198424040904965	0.00915980326571213	0.00586076163543958
aUC_CD66a-_vs_aUC_CD44+	R-HSA-5357786	TNFR1-induced proapoptotic signaling	4/368	13/8290	0.00198424040904965	0.00915980326571213	0.00586076163543958
aUC_CD66a-_vs_aUC_CD44+	R-HSA-5654693	FRS-mediated FGFR1 signaling	4/368	13/8290	0.00198424040904965	0.00915980326571213	0.00586076163543958
aUC_CD66a-_vs_aUC_CD44+	R-HSA-5654700	FRS-mediated FGFR2 signaling	4/368	13/8290	0.00198424040904965	0.00915980326571213	0.00586076163543958
aUC_CD66a-_vs_aUC_CD44+	R-HSA-6785631	ERBB2 Regulates Cell Motility	4/368	13/8290	0.00198424040904965	0.00915980326571213	0.00586076163543958
aUC_CD66a-_vs_aUC_CD44+	R-HSA-6804116	TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest	4/368	13/8290	0.00198424040904965	0.00915980326571213	0.00586076163543958
aUC_CD66a-_vs_aUC_CD44+	R-HSA-75035	Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	4/368	13/8290	0.00198424040904965	0.00915980326571213	0.00586076163543958
aUC_CD66a-_vs_aUC_CD44+	R-HSA-983231	Factors involved in megakaryocyte development and platelet production	13/368	119/8290	0.00230275445612727	0.01058022317680084	0.00676959584067759 5
aUC_CD66a-_vs_aUC_CD44+	R-HSA-5654726	Negative regulation of FGFR1 signaling	5/368	22/8290	0.00236321918421488 7	0.01075700159281237	0.00688270483750621 8
aUC_CD66a-_vs_aUC_CD44+	R-HSA-5654727	Negative regulation of FGFR2 signaling	5/368	22/8290	0.00236321918421488 7	0.01075700159281237	0.00688270483750621 8
aUC_CD66a-_vs_aUC_CD44+	R-HSA-1445148	Translocation of SLC2A4 (GLUT4) to the plasma membrane	9/368	66/8290	0.00238708315412383 25	0.01082144363202804 1	0.00692393710202006
aUC_CD66a-_vs_aUC_CD44+	R-HSA-76009	Platelet Aggregation (Plug Formation)	6/368	32/8290	0.00249500180244789 7	0.01126062760396834	0.00720494232658519
aUC_CD66a-_vs_aUC_CD44+	R-HSA-438064	Post NMDA receptor activation events	9/368	67/8290	0.00256227725459444 195	0.01135170476278134	0.00726321666968425
aUC_CD66a-_vs_aUC_CD44+	R-HSA-1963640	GRB2 events in ERBB2 signaling	4/368	14/8290	0.00268211847826494	0.01135170476278134	0.00726321666968425
aUC_CD66a-_vs_aUC_CD44+	R-HSA-4839735	AXIN mutants destabilize the destruction complex, activating WNT signaling	4/368	14/8290	0.00268211847826494	0.01135170476278134	0.00726321666968425
aUC_CD66a-_vs_aUC_CD44+	R-HSA-4839744	truncated APC mutants destabilize the destruction complex	4/368	14/

aUC_CD66a+_vs_aUC_CD4+	R-HSA-5654738	Signaling by FGFR2	8/368	61/8290	0.00524386809143685	0.119958005109042746
aUC_CD66a+_vs_aUC_CD4+	R-HSA-8950505	Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation	6/368	37/8290	0.00531150690758309	0.120140286415367865
aUC_CD66a+_vs_aUC_CD4+	R-HSA-196299	Beta-catenin phosphorylation cascade	4/368	17/8290	0.00573828393206716	0.121597969043204816
aUC_CD66a+_vs_aUC_CD4+	R-HSA-450604	KSRP (KHSRP) binds and destabilizes mRNA	4/368	17/8290	0.00573828393206716	0.121597969043204816
aUC_CD66a+_vs_aUC_CD4+	R-HSA-9031628	NGF-stimulated transcription	6/368	38/8290	0.00607706674561873	0.122789000292607021
aUC_CD66a+_vs_aUC_CD4+	R-HSA-442755	Activation of NMDA receptors and postsynaptic events	9/368	77/8290	0.00678939797377474	0.125366981440475681
aUC_CD66a+_vs_aUC_CD4+	R-HSA-8941326	RUNX2 regulates bone development	5/368	28/8290	0.00708621688538794 5	0.126379347529546363
aUC_CD66a+_vs_aUC_CD4+	R-HSA-69278	Cell Cycle, Mitotic	33/368	477/8290	0.00711383513421321	0.126385661225081724
aUC_CD66a+_vs_aUC_CD4+	R-HSA-3858494	Beta-catenin independent WNT signaling	13/368	136/8290	0.00725431198403998	0.126809413854006795
aUC_CD66a+_vs_aUC_CD4+	R-HSA-375165	NCAM signaling for neurite out-growth	7/368	52/8290	0.00765381477586616	0.128183722279362593
aUC_CD66a+_vs_aUC_CD4+	R-HSA-165159	MTOR signalling	6/368	40/8290	0.00784436476320225	0.128678322789536304
aUC_CD66a+_vs_aUC_CD4+	R-HSA-9656223	Signaling by RAF1 mutants	6/368	40/8290	0.00784436476320225	0.128678322789536304
aUC_CD66a+_vs_aUC_CD4+	R-HSA-2032785	YAP1- and WWTR1 (TAZ)-stimulated gene expression	3/368	10/8290	0.00824590596824515	0.129044134373283372
aUC_CD66a+_vs_aUC_CD4+	R-HSA-2559584	Formation of Senescence-Associated Heterochromatin Foci (SAHF)	3/368	10/8290	0.00824590596824515	0.129044134373283372
aUC_CD66a+_vs_aUC_CD4+	R-HSA-5625970	RHO GTPases activate KTN1	3/368	10/8290	0.00824590596824515	0.129044134373283372
aUC_CD66a+_vs_aUC_CD4+	R-HSA-5654704	SHC-mediated cascade:FGFR3	3/368	10/8290	0.00824590596824515	0.129044134373283372
aUC_CD66a+_vs_aUC_CD4+	R-HSA-8851805	MET activates RAS signaling	3/368	10/8290	0.00824590596824515	0.129044134373283372
aUC_CD66a+_vs_aUC_CD4+	R-HSA-9634285	Constitutive Signaling by Overexpressed ERBB2	3/368	10/8290	0.00824590596824515	0.129044134373283372
aUC_CD66a+_vs_aUC_CD4+	R-HSA-201722	Formation of the beta-catenin:TCF transactivating complex	5/368	29/8290	0.00825764604717825	0.129044134373283372
aUC_CD66a+_vs_aUC_CD4+	R-HSA-4641262	Disassembly of the destruction complex and recruitment of AXIN to the membrane	5/368	29/8290	0.00825764604717825	0.129044134373283372
aUC_CD66a+_vs_aUC_CD4+	R-HSA-5357956	TNFR1-induced NFkappaB signaling pathway	5/368	29/8290	0.00825764604717825	0.129044134373283372
aUC_CD66a+_vs_aUC_CD4+	R-HSA-6804758	Regulation of TP53 Activity through Acetylation	5/368	29/8290	0.00825764604717825	0.129044134373283372
aUC_CD66a+_vs_aUC_CD4+	R-HSA-8979227	Triglyceride metabolism	5/368	29/8290	0.00825764604717825	0.129044134373283372
aUC_CD66a+_vs_aUC_CD4+	R-HSA-2151201	Transcriptional activation of mitochondrial biogenesis	7/368	52/8290	0.00849184029273441 5	0.129276521339721414
aUC_CD66a+_vs_aUC_CD4+	R-HSA-422475	Axon guidance	33/368	483/8290	0.00852647107866027	0.129784248289189 55
aUC_CD66a+_vs_aUC_CD4+	R-HSA-69202	Cyclin E associated events during G1/S transition	9/368	80/8290	0.00869112303425608 6	0.129822044069699
aUC_CD66a+_vs_aUC_CD4+	R-HSA-1236382	Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants	4/368	19/8290	0.00871271483341755	0.129822044069699
aUC_CD66a+_vs_aUC_CD4+	R-HSA-1362277	Transcription of E2F targets under negative control by DREAM complex	4/368	19/8290	0.00871271483341755	0.129822044069699
aUC_CD66a+_vs_aUC_CD4+	R-HSA-2028269	Signaling by Hippo	4/368	19/8290	0.00871271483341755	0.129822044069699
aUC_CD66a+_vs_aUC_CD4+	R-HSA-5637815	Signaling by Ligand-Responsive EGFR Variants in Cancer	4/368	19/8290	0.00871271483341755	0.129822044069699
aUC_CD66a+_vs_aUC_CD4+	R-HSA-6807004	Negative regulation of MET activity	4/368	19/8290	0.00871271483341755	0.129822044069699
aUC_CD66a+_vs_aUC_CD4+	R-HSA-5633008	TP53 Regulates Transcription of Cell Death Genes	6/368	41/8290	0.00885445376698165	0.130205931452216 8
aUC_CD66a+_vs_aUC_CD4+	R-HSA-447115	Interleukin-12 family signaling	7/368	54/8290	0.00939543129094254 2	0.131944663892046 4
aUC_CD66a+_vs_aUC_CD4+	R-HSA-2871796	FCERI mediated MAPK activation	5/368	30/8290	0.00955679374394505	0.132385148235295 43
aUC_CD66a+_vs_aUC_CD4+	R-HSA-5675221	Negative regulation of MAPK pathway	6/368	42/8290	0.00995441121606386	0.133620862451614 95
aUC_CD66a+_vs_aUC_CD4+	R-HSA-69656	Cyclin A:Cdk2-associated events at S phase entry	9/368	82/8290	0.01016699919693262	0.134225541851052366
aUC_CD66a+_vs_aUC_CD4+	R-HSA-392451	G beta:gamma signaling through PI3Kgamma	4/368	20/8290	0.01051680002609365	0.135170937792181 76
aUC_CD66a+_vs_aUC_CD4+	R-HSA-449836	Other interleukin signaling	4/368	20/8290	0.01051680002609365	0.135170937792181 76
aUC_CD66a+_vs_aUC_CD4+	R-HSA-5654688	SHC-mediated cascade:FGFR1	3/368	11/8290	0.01096944380033298	0.135928628549526914
aUC_CD66a+_vs_aUC_CD4+	R-HSA-5654699	SHC-mediated cascade:FGFR2	3/368	11/8290	0.01096944380033298	0.135928628549526914
aUC_CD66a+_vs_aUC_CD4+	R-HSA-68689	CDC6 association with the ORC:origin complex	3/368	11/8290	0.01096944380033298	0.135928628549526914
aUC_CD66a+_vs_aUC_CD4+	R-HSA-8847993	ERBB2 Activates PTK6 Signaling	3/368	11/8290	0.01096944380033298	0.135928628549526914
aUC_CD66a+_vs_aUC_CD4+	R-HSA-9013700	NOTCH4 Activation and Transmission of Signal to the Nucleus	3/368	11/8290	0.01096944380033298	0.135928628549526914
aUC_CD66a+_vs_aUC_CD4+	R-HSA-1980145	Signaling by NOTCH2	5/368	31/8290	0.01098993343867821	0.135928628549526914
aUC_CD66a+_vs_aUC_CD4+	R-HSA-5655253	Signaling by FGFR2 in disease	5/368	31/8290	0.01098993343867821	0.135928628549526914
aUC_CD66a+_vs_aUC_CD4+	R-HSA-512988	Interleukin-3, Interleukin-5 and GM-CSF signaling	6/368	43/8290	0.01114180734817046	0.136213835508004 42
aUC_CD66a+_vs_aUC_CD4+	R-HSA-8024446	NR1H2 and NR1H3-mediated signaling	6/368	43/8290	0.01114180734817046	0.136213835508004 42
aUC_CD66a+_vs_aUC_CD4+	R-HSA-114608	Platelet degranulation	10/368	98/8290	0.01137674073774535	0.136838970007093732
aUC_CD66a+_vs_aUC_CD4+	R-HSA-450531	Regulation of mRNA stability by proteins that bind AU-rich elements	9/368	84/8290	0.01182413785750865	0.138166520932455636
aUC_CD66a+_vs_aUC_CD4+	R-HSA-112409	RAF-independent MAPK1/3 activation	4/368	21/8290	0.01254583445717656	0.140044782204397285
aUC_CD66a+_vs_aUC_CD4+	R-HSA-2979096	NOTCH2 Activation and Transmission of Signal to the Nucleus	4/368	21/8290	0.01254583445717656	0.140044782204397285
aUC_CD66a+_vs_aUC_CD4+	R-HSA-982772	Growth hormone receptor signaling	4/368	21/8290	0.01254583445717656	0.140044782204397285
aUC_CD66a+_vs_aUC_CD4+	R-HSA-2173789	TGF-beta receptor signaling activates SMADs	5/368	32/8290	0.01256306892686936	0.140044782204397285
aUC_CD66a+_vs_aUC_CD4+	R-HSA-8943724	Regulation of PTEN gene transcription	7/368	58/8290	0.01372153340327842	0.143601134178641 14
aUC_CD66a+_vs_aUC_CD4+	R-HSA-9020591	Interleukin-12 signaling	6/368	45/8290	0.01383829247125295	0.143818479256762688
aUC_CD66a+_vs_aUC_CD4+	R-HSA-179812	GRB2 events in EGFR signaling	3/368	12/8290	0.01415145533594052	0.144412154315043924
aUC_CD66a+_vs_aUC_CD4+	R-HSA-2299718	Condensation of Prophase Chromosomes	3/368	12/8290	0.01415145533594052	0.144412154315043924
aUC_CD66a+_vs_aUC_CD4+	R-HSA-264642	Acetylcholine Neurotransmitter Release Cycle	3/368	12/8290	0.01415145533594052	0.144412154315043924
aUC_CD66a+_vs_aUC_CD4+	R-HSA-5654719	SHC-mediated cascade:FGFR4	3/368	12/8290	0.01415145533594052	0.144412154315043924
aUC_CD66a+_vs_aUC_CD4+	R-HSA-6804759	Regulation of TP53 Activity through Association with Co-factors	3/368	12/8290	0.01415145533594052	0.144412154315043924
aUC_CD66a+_vs_aUC_CD4+	R-HSA-5668599	RHO GTPases Activate NADPH Oxidases	4/368	22/8290	0.01480883724356952	0.145634483487530 85
aUC_CD66a+_vs_aUC_CD4+	R-HSA-8862803	Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models	4/368	22/8290	0.01480883724356952	0.145634483487530 85
aUC_CD66a+_vs_aUC_CD4+	R-HSA-8863678	Neurodegenerative Diseases	4/368	22/8290	0.01480883724356952	0.145634483487530 85
aUC_CD66a+_vs_aUC_CD4+	R-HSA-912526	Interleukin receptor SHC signaling	4/368	22/8290	0.01480883724356952	0.145634483487530 85
aUC_CD66a+_vs_aUC_CD4+	R-HSA-76005	Response to elevated platelet cytosolic Ca2+	10/368	103/8290	0.01578234037310792	0.148487913194488 18
aUC_CD66a+_vs_aUC_CD4+	R-HSA-5357905	Regulation of TNFR1 signaling	5/368	34/8290	0.01615184172754978	0.148886880006233785
aUC_CD66a+_vs_aUC_CD4+	R-HSA-5625740	RHO GTPases activate PKNs	5/368	34/8290	0.01615184172754978	0.148886880006233785
aUC_CD66a+_vs_aUC_CD4+	R-HSA-6802948	Signaling by high-kinase activity BRAF mutants	5/368	34/8290	0.01615184172754978	0.148886880006233785
aUC_CD66a+_vs_aUC_CD4+	R-HSA-936440	Negative regulators of DDX58/IFIH1 signaling	5/368	34/8290	0.01615184172754978	0.148886880006233785
aUC_CD66a+_vs_aUC_CD4+	R-HSA-9664323	FCGR3A-mediated IL10 synthesis	5/368	34/8290	0.01615184172754978	0.148886880006233785
aUC_CD66a+_vs_aUC_CD4+	R-HSA-2980736	Peptide hormone metabolism	7/368	60/8290	0.01634983846452494	0.149339746218560186
qUC_CD66a+_vs_qUC_CD4+	R-HSA-2219528	PI3K/AKT Signaling in Cancer	8/34	83/8290	1.05264394253704079 e-9	2.77898000829769 2e-7
qUC_CD66a+_vs_qUC_CD4+	R-HSA-8939211	ESR-mediated signaling	9/34	154/8290	7.35439107193448 2e-9	9.70779621495316e-7
qUC_CD66a+_vs_qUC_CD4+	R-HSA-199418	Negative regulation of the PI3K/AKT network	7/34	91/8290	6.42833198624350 4e-8	5.56593214789429 4e-6
qUC_CD66a+_vs_qUC_CD4+	R-HSA-6804759	Regulation of TP53 Activity through Association with Co-factors	9/34	12/8290	1.14058801374211 1e-7	7.52788089069793 3e-6
qUC_CD66a+_vs_qUC_CD4+	R-HSA-9006931	Signaling by Nuclear Receptors	9/34	219/8290	1.57054446435852 8e-7	8.29247679281317e-6
qUC_CD66a+_vs_qUC_CD4+	R-HSA-1257604	PIP3 activates AKT signaling	9/34	237/8290	3.08105923274397e-7	1.35566062407346 8e-5
qUC_CD66a+_vs_qUC_CD4+	R-HSA-5663202	Diseases of signal transduction by growth factor receptors and second messengers	10/34	356/8290	9.79601114323541e-7	3.35312512664374 9e-5
qUC_CD66a+_vs_qUC_CD4+	R-HSA-9006925	Intracellular signaling by second messengers	9/34	273/8290	1.01609852322529 67e-6	3.35312512664374 9e-5
qUC_CD66a+_vs_qUC_CD4+	R-HSA-389357	CD28 dependent PI3K/Akt signaling	4/34	21/8290	1.34354732923209 84e-6	3.94107246993415 5e-5
qUC_CD66a+_vs_qUC_CD4+	R-HSA-114452	Activation of BHB-only proteins	4/34	29/8290	5.20951544101739 6e-6	1.37531207642859 24e-4
qUC_CD66a+_vs_qUC_CD4+	R-HSA-9009391	Extra-nuclear estrogen signaling	5/34	68/8290	7.40365645992561 2e-6	1.72020713289741 72e-4
qUC_CD66a+_vs_qUC_CD4+	R-HSA-389356	CD28 co-stimulation	4/34	32/8290	7.81912333135189 7e-6	1.72020713289741 72e-4
qUC_CD66a+_vs_qUC_CD4+	R-HSA-1358803	Downregulation of ERBB2:ERBB3 signaling	3/34	12/8290	1.35232666790354 48e-5	2.74626338712719 86e-4
qUC_CD66a+_vs_qUC_CD4+	R-HSA-5628897	TP53 Regulates Metabolic Genes	5/34	81/8290	1.75186453740666 28e-5	3.30351598482399 27e-4
qUC_CD66a+_vs_qUC_CD4+	R-HSA-6811558	PIP2, PIP3 and IER3 Regulate PI3K/AKT Signaling	5/34	84/8290	2.09241772718134 e-5	3.68265519985115e-4
qUC_CD66a+_vs_qUC_CD4+	R-HSA-111447	Activation of BAD and translocation to mitochondria	3/34	15/8290	2.77340435577216 48e-5	4.57611718702407 2e-4
qUC_CD66a+_vs_qUC_CD4+	R-HSA-5633007	Regulation of TP53 Activity	6/34	152/8290	3.02892740235973 05e-5	4.70374608366452 3e-4
qUC_CD66a+_vs_qUC_CD4+	R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	9/34	439/8290	4.83067714866260 56e-5	7.02470984942083 e-4
qUC_CD66a+_vs_qUC_CD4+	R-HSA-109606	Intrinsic Pathway for Apoptosis	4/34	51/8290	5.14268293525323 e-5	7.02470984942083 e-4
qUC_CD66a+_vs_qUC_CD4+	R-HSA-1660499	Synthesis of PIPs at the plasma membrane	9/34	52/8290	5.55512066204174 7e-5	7.02470984942083 e-4
qUC_CD66a+_vs_qUC_CD4+	R-HSA-3700989	Transcriptional Regulation by TP53	8/34	343/8290	5.58783738230209 6e-5	7.02470984942083 e-4
qUC_CD66a+_vs_qUC_CD4+	R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer	4/34	57/8290	7.98880975596666 5e-5	9.58656837016e-4
qUC_CD66a+_vs_qUC_CD4+	R-HSA-9634638	Estrogen-dependent nuclear events downstream of ESR-membrane signaling	4/34	63/8290	1.05553593957871 88e-4	1.32255809196384 7e-4
qUC_CD66a+_vs_qUC_CD4+	R-HSA-388841	Costimulation by the CD28 family	4/34	62/8290	1.11197988323623 16e-4	1.00122317787154 89539
qUC_CD66a+_vs_qUC_CD4+	R-HSA-5674400	Constitutive Signaling by AKT1 E17K in Cancer	3/34	25/8290	1.36315932643159 78e-4	1.00143946248711 7673
qUC_CD66a+_vs_qUC_CD4+	R-HSA-8863795	Downregulation of ERBB2 signaling	3/34	26/8290	1.53664824780907e-4	1.00150288990074 671
qUC_CD66a+_vs_qUC_CD4+	R-HSA-6807070	PTEN Regulation	5/34	132/8290	1.82177847206455 4e-4	2.00178129467288 543
qUC_CD66a+_vs_qUC_CD4+	R-HSA-5218920	VEGFR2 mediated vascular permeability	3/34	28/8290	1.92535149906408 4e-4	2.00181533143398 136
qUC_CD66a+_vs_qUC_CD4+	R-HSA-6804758	Regulation of TP53 Activity through Acetylation	3/34	29/8290	2.14149646190466 9e-4	2.00194950227389 781
qUC_CD66a+_vs_qUC_CD4+	R-HSA-8864260	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	3/34	30/8290	2.32278098167870 74e-4	2.00208047263877 257
qUC_CD66a+_vs_qUC_CD4+	R-HSA-1483255	PI Metabolism	4/34	78/8290	2.71461838072813 53e-4	2.00231180404362247
qUC_CD66a+_vs_qUC_CD4+	R-HSA-6804757	Regulation of TP53 Degradation	3/34	35/8290	3.77187281334914 2e-4	3.00308060005842575
qUC_CD66a+_vs_qUC_CD4+	R-HSA-195721	Signaling by WNT	6/34	241/8290	3.85007500730307 2e-4	3.00308060005842575
qUC_CD66a+_vs_qUC_CD4+	R-HSA-2428928	IRS-related events triggered by IGF1R	3/34	36/8290	4.10326068940256 1e-4	3.00309503092006503
qUC_CD66a+_vs_qUC_CD4+	R-HSA-6806003	Regulation of TP53 Expression and Degradation	3/34	36/8290	4.10326068940256 1e-4	3.00309503092006503
qUC_CD66a+_vs_qUC_CD4+	R-HSA-2428924	IGF1R signaling cascade	3/34	37/8290	4.45282414588122 43e-4	3.00321152806197437 8
qUC_CD66a+_vs_qUC_CD4+	R-HSA-9018519	Estrogen-dependent gene expression	4/34	89/8290	4.50100523837318 24e-4	3.00321152806197437 8
qUC_CD66a+_vs_qUC_CD4+	R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	3/34	38/8290	4.82097459281550 85e-4	3.00328342895136517
qUC_CD66a+_vs_qUC_CD4+	R-HSA-3769402	Deactivation of the beta-catenin transactivating complex	3/34	38/8290	4.82097459281550 85e-4	3.00328342895136517
qUC_CD66a+_vs_qUC_CD4+	R-HSA-4420097	VEGFA-VEGFR2 Pathway	4/34	94/8290	5.54082683766640 7e-4	3.00361528997742094 65
qUC_CD66a+_vs_qUC_CD4+	R-HSA-165159	MTOR signalling	3/34	40/8290	5.61465488917847e-4	3.00361528997742094 65
qUC_CD66a+_vs_qUC_CD4+	R-HSA-194138	Signaling by VEGF	4/34	98/8290	6.74147929736189 4e-4	3.00423750127267148
qUC_CD66a+_vs_qUC_CD4+	R-HSA-9614399	Regulation of localization of FOXO transcription factors	2/34	11/8290	8.77474339859288 1e-4	3.00538728431913609 4
qUC_CD66a+_vs_qUC_CD4+	R-HSA-1227986	Signaling by ERBB2	3/34	47/8290	9.03596078458677e-4	3.00542157646107520 6
qUC_CD66a+_vs_qUC_CD4+	R-HSA-198323	AKT phosphorylates targets in the cytosol	2/34	14/8290	1.00144065082006998	3.00845190181444047 8
qUC_CD66a+_vs_qUC_CD4+	R-HSA-8986944	Transcriptional Regulation by MECP2	3/34	56/8290	1.01506328021259079 8	3.00665031298498568
qUC_CD66a+_vs_qUC_CD4+	R-HSA-76002	Platelet activation, signaling and aggregation	5/34	211/8290	1.00155290195274624 73	3.00872268330904275 2
qUC_CD66a+_vs_qUC_CD4+	R-HSA-210745	Regulation of gene expression in beta cells	2/34	17/8290	1.00213654882767754	3.01175101855228197
qUC_CD66a+_vs_qUC_CD4+	R-HSA-8948751	Regulation of PTEN stability and activity	3/34	64/8290	1.00221400800656038	3.01192853293304902
qUC_CD66a+_vs_qUC_CD4+	R-HSA-389513	CTLA4 inhibitory signaling	2/34	19/8290	1.00267263426393113 3	3.01141150891359853
qUC_CD66a+_vs_qUC_CD4+	R-HSA-392451	G beta:gamma signaling through PI3Kgamma	2/34	20/8290	1.00296198035726579	3.01533260420231801
qUC_CD66a+_vs_qUC_CD4+	R-HSA-201681	TCF dependent signaling in response to WNT	4/34	154/8290	1.00344219502483396	3.01747575935684748 6
qUC_CD66a+_vs_qUC_CD4+	R-HSA-8878171	Transcriptional regulation by RUNX1	4/34	155/8290	1.00352319033956664	3.01751547103017872
qUC_CD66a+_vs_qUC_CD4+	R-HSA-912526	Interleukin receptor SHC signaling	2/34	22/8290	1.00358270998445474	3.01751547103017872
qUC_CD66a+_vs_qUC_CD4+	R-HSA-109581	Apoptosis	4/34	161/8290	1.00403668711750761 9	3.01937609816403657
qUC_CD66a+_vs_qUC_CD4+	R-HSA-69202	Cyclin E associated events during G1/S transition	3/34	80/8290	1.00417529009235718	3.01968351043539789
qUC_CD66a+_vs_qUC_CD4+	R-HSA-69656	Cyclin A:Cdk2-associated events at S phase entry	3/34	82/8290	1.00447550595018235	3.02072865913768653
qUC_CD66a+_vs_qUC_CD4+	R-HSA-1855204	Synthesis of IP3 and IP4 in the cytosol	2/34	26/8290	1.00498917134472691	3.02270933501755603
qUC_CD66a+_vs_qUC_CD4+	R-HSA-5683057	MAPK family signaling cascades	5/34	278/8290	1.00512590961088658	3.02286188541258492
qUC_CD66a+_vs_qUC_CD4+	R-HSA-5357801	Programmed Cell Death	4/34	173/8290	1.00521198104018165	3.02286188541258492
qUC_CD66a+_vs_qUC_CD4+	R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling	3/34	87/8290	1.00528248109119994	3.02286188541258492
qUC_CD66a+_vs_qUC_CD4+	R-HSA-397795	G-protein beta:gamma signalling	2/34	27/8290	1.00537451414081048	3.02288502735441774
qUC_CD66a+_vs_qUC_CD4+	R-HSA-1483257	Phospholipid metabolism	4/34	182/8290	1.00623135361738605	3.02611233896809407
qUC_CD66a+_vs_qUC_CD4+	R-HSA-109704	PI3K Cascade	2/34	30/8290	1.00660973450404845	3.02726515482916576
qUC_CD66a+_vs_qUC_CD4+	R-HSA-2173796	SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	2/34	31/8290	1.00704751167117316	3.02862373971061101
qUC_CD66a+_vs_qUC_CD4+	R-HSA-76005	Response to elevated platelet cytosolic Ca2+	3/34	103/8290	1.00849274931205577	3.03275718856722244
qUC_CD66a+_vs_qUC_CD4+	R-HSA-112399	IRS-mediated signalling	2/34	34/8290	1.00843745761254266	3.03275718856722244
qUC_CD66a+_vs_qUC_CD4+	R-HSA-186712	Regulation of beta-cell development	2/34	34/8290	1.00843745761254266	3.03275718856722244
qUC_CD66a+_vs_qUC_CD4+	R-HSA-451927	Interleukin-2 family signaling	2/34	36/8290	1.00942687847448682	3.03608056577194957
qUC_CD66a+_vs_qUC_CD4+	R-HSA-74751	Insulin receptor signalling cascade	3/34	91/8290	1.01100311165585209	3.04144610916442812
qUC_CD66a+_vs_qUC_CD4+	R-HSA-109582	Hemostasis	6/34	470/8290	1.01114649147982726	3.04144610916442812
qUC_CD66a+_vs_qUC_CD4+	R-HSA-2173793	Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	2/34	43/8290	1.01327238000029007	3.04799874410969394
qUC_CD66a+_vs_qUC_CD4+	R-HSA-512988	Interleukin-3, Interleukin-5 and GM-CSF signaling	2/34	43/8290	1.01327238000029007	3.04799874410969394
qUC_CD66a+_vs_qUC_CD4+	R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling	33/337	87/8290	3.89267184406113374 e-24	3.38998864542268e-21
HC_CD66a+_vs_HC_CD4+	R-HSA-5663202	Diseases of signal transduction by growth factor receptors and second messengers	57/337	356/8290	7.88418732292687e-20	4.00464603000022e-17
HC_CD66a+_vs_HC_CD4+	R-HSA-449147	Signaling by Interleukins	56/337	376/8290	5.59009674385209 3e-18	1.99094972081613e-15
HC_CD66a+_vs_HC_CD4+	R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	59/337	439/8290	9.48692241670043e-17	2.43102386928041e-14
HC_CD66a+_vs_HC_CD4+	R-HSA-2559583	Cellular Senescence	29/337	123/8290	5.54340694966725e-15	1.13639842468167886e-12
HC_CD66a+_vs_HC_CD4+	R-HSA-2219528	PI3K/AKT Signaling in Cancer	24/337	83/8290	9.53124029314105e-15	1.62825355007826e-12
HC_CD66a+_vs_HC_CD4+	R-HSA-8939211	ESR-mediated signaling	29/337	154/8290	2.58746925048306 16e-12	3.78879425963594 1e-10
HC_CD66a+_vs_HC_CD4+	R-HSA-9659787	Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects	11/337	17/8290	4.24528560070181 8e-12	4.83490860079929e-10
HC_CD66a+_vs_HC_CD4+	R-HSA-9661069	Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	11/337	17/8290	4.24528560070181 8e-12	4.83490860079929e-10
HC_CD66a+_vs_HC_CD4+	R-HSA-1257604	PIP3 activates AKT signaling	35/337	237/8290	2.01434051093848222e-11	2.06469902371194 43e-9
HC_CD66a+_vs_HC_CD4+	R-HSA-5674400	Constitutive Signaling by AKT1 E17K in Cancer	12/337	25/8290	5.42117009983842 7e-11	4.30981238904559e-9
HC_CD66a+_vs_HC_CD4+	R-HSA-8848021	Signaling by PTK6	16/337	50/8290	5.46610351781391 1e-11	4.30981238904559e-9
HC_CD66a+_vs_HC_CD4+	R-HSA-9006927	Signaling by Non-Receptor Tyrosine Kinases	16/337	50/8290	5.46610351781391 1e-11	4.30981238904559e-9
HC_CD66a+_vs_HC_CD4+	R-HSA-166520	Signaling by NTRKs	24/337	125/8290	1.40443217051705 87e-10	1.02824498198570 37e-8
HC_CD66a+_vs_HC_CD4+	R-HSA-9616222	Transcriptional regulation of granulopoiesis	12/337	27/8290	1.68345180093275 94e-10	1.15035730637385 4e-8
HC_CD66a+_vs_HC_CD4+	R-HSA-9006931	Signaling by Nuclear Receptors	32/337	219/8290	2.05104910577382 85e-10	1.31395333384535 89e-8
HC_CD66a+_vs_HC_CD4+	R-HSA-69231	Cyclin D associated events in G1	15/337	47/8290	2.31319500686791 32e-10	1.31723604557756 17e-8
HC_CD66a+_vs_HC_CD4+	R-HSA-69236	G1 Phase	15/337	47/8290	2.31319500686791 32e-10	1.31723604557756 17e-8
HC_CD66a+_vs_HC_CD4+	R-HSA-9614085	FOXO-mediated transcription	16/337	55/8290	2.74266691402238 10e-10	1.42204970876380 36e-8
HC_CD66a+_vs_HC_CD4+	R-HSA-9006925	Intracellular signaling by second messengers	36/337	273/8290	2.77473139051324e-10	1.42204970876380 36e-8
HC_CD66a+_vs_HC_CD4+	R-HSA-8878159	Transcriptional regulation by RUNX3	20/337	90/8290	3.29401701932103 63e-10	1.60779402135302 8e-8
HC_CD66a+_vs_HC_CD4+	R-HSA-9675126	Diseases of mitotic cell cycle	13/337	36/8290	6.52478161381189 9e-10	2.81866887722020 06e-8
HC_CD66a+_vs_HC_CD4+	R-HSA-9687139	Aberrant regulation of mitotic cell cycle due to RB1 defects	13/337	36/8290	6.52478161381189 9e-10	2.81866887722020 06e-8
HC_CD66a+_vs_HC_CD4+	R-HSA-157118	Signaling by NOTCH	27/337	168/8290	6.59981005397900 6e-10	2.81866887722020 06e-8
HC_CD66a+_vs_HC_CD4+	R-HSA-8878166	Transcriptional regulation by RUNX2	21/337	105/8290	9.40303654325010 e-10	3.85524498273254 1e-8
HC_CD66a+_vs_HC_CD4+	R-HSA-9009391	Extra-nuclear estrogen signaling	17/337	68/8290	1.02782143685271 43e-9	4.05198835682301 e-8
HC_CD66a+_vs_HC_CD4+	R-HSA-2559585	Oncogene Induced Senescence	12/337	33/8290	2.75473530670224 3e-9	1.04577914421103 66e-7
HC_CD66a+_vs_HC_CD4+	R-HSA-186763	Downstream signal transduction	11/337	29/8290	7.64072631273625 8e-9	2.72381407771559 06e-7
HC_CD66a+_vs_HC_CD4+	R-HSA-9634638	Estrogen-dependent nuclear events downstream of ESR-membrane signaling	10/337	23/8290	7.70640080524411e-9	2.72381407771559 06e-7
HC_CD66a+_vs_HC_CD4+	R-HSA-187037	Signaling by NTRK1 (TRKA)	20/337	108/8290	9.70302784147443 5e-9	3.31520117917043 2e-7
HC_CD66a+_vs_HC_CD4+	R-HSA-194138	Signaling by VEGF	19/337	99/8290	1.24100103620419 8e-8	4.10333996481394 e-7
HC_CD66a+_vs_HC_CD4+	R-H

HC_CD66a-_vs_HC_CD44+	R-HSA-1433557	Signaling by SCF-KIT	11/337	41/8290	4.49659765452025e-7	9.87883307265660e-6	5.99577955937609e-6	
HC_CD66a-_vs_HC_CD44+	R-HSA-8953897	Cellular responses to external stimuli	44/337	490/8290	4.50512319740164e-7	9.87883307265660e-6	5.99577955937609e-6	
HC_CD66a-_vs_HC_CD44+	R-HSA-2559586	DNA Damage/Telomere Stress Induced Senescence	9/337	26/8290	4.61499673799510046e-7	9.87883307265660e-6	5.99577955937609e-6	
HC_CD66a-_vs_HC_CD44+	R-HSA-198323	AKT phosphorylates targets in the cytosol	7/337	14/8290	4.62618324378063e-7	9.87883307265660e-6	5.99577955937609e-6	
HC_CD66a-_vs_HC_CD44+	R-HSA-9669938	Signaling by KIT in disease	8/337	20/8290	5.63648628826359e-7	1.15547968990403e-5	7.01297557129278e-6	
HC_CD66a-_vs_HC_CD44+	R-HSA-9670439	Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	8/337	20/8290	5.63648628826359e-7	1.15547968990403e-5	7.01297557129278e-6	
HC_CD66a-_vs_HC_CD44+	R-HSA-186712	Regulation of beta-cell development	10/337	34/8290	5.91723576938440e-7	1.1892483645154933e-5	7.21792846172587e-6	
HC_CD66a-_vs_HC_CD44+	R-HSA-2262752	Cellular responses to stress	43/337	479/8290	6.22658498062413ⁿ-7	1.22735569329610430e-5	7.44921401028110ⁿ6e-6	
HC_CD66a-_vs_HC_CD44+	R-HSA-6804757	Regulation of TP53 Degradation	10/337	35/8290	7.98828887874810ⁿ3e-7	1.54490492466354ⁿ8e-5	9.37652180265796e-6	
HC_CD66a-_vs_HC_CD44+	R-HSA-9617828	FOXO-mediated transcription of cell cycle genes	7/337	15/8290	8.37272569689256ⁿ6-7	1.58825695636107740e-5	9.63963913950ⁿ6e-6	
HC_CD66a-_vs_HC_CD44+	R-HSA-5683057	MAPK family signaling cascades	30/337	278/8290	8.52235439998627e-7	1.58825695636107740e-5	9.63963913950ⁿ6e-6	
HC_CD66a-_vs_HC_CD44+	R-HSA-2559580	Oxidative Stress Induced Senescence	13/337	89/8290	8.98892585309450833e-7	1.64540428155691258e-5	9.98648452722825e-6	
HC_CD66a-_vs_HC_CD44+	R-HSA-8941326	RUNX2 regulates bone development	9/337	28/8290	9.49068373237316e-7	1.70665803959341934e-5	1.03582515943220ⁿ2e-5	
HC_CD66a-_vs_HC_CD44+	R-HSA-69242	S Phase	21/337	156/8290	1.19776481851312ⁿ6e-6	2.11673954995834ⁿ3e-5	1.28471689245221ⁿ3e-5	
HC_CD66a-_vs_HC_CD44+	R-HSA-8819507	Gastrin-CREB signalling pathway via PKC and MAPK	7/337	16/8290	1.43679450120937ⁿ6e-6	2.45452393956601ⁿ5e-5	1.48972903546445ⁿ6e-5	
HC_CD66a-_vs_HC_CD44+	R-HSA-9661651	FOXO-mediated transcription of cell death genes	7/337	16/8290	1.43679450120937ⁿ6e-6	2.45452393956601ⁿ5e-5	1.48972903546445ⁿ6e-5	
HC_CD66a-_vs_HC_CD44+	R-HSA-6791312	TP53 Regulates Transcription of Cell Cycle Genes	11/337	46/8290	1.58152358865600ⁿ4e-6	2.65747816126623ⁿ6e-5	1.61290843985452ⁿ7e-5	
HC_CD66a-_vs_HC_CD44+	R-HSA-109581	Apoptosis	21/337	161/8290	2.01899310157213ⁿ7e-6	3.33785149856683ⁿ5e-5	2.02584876575404ⁿ36e-05	
HC_CD66a-_vs_HC_CD44+	R-HSA-9673767	Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants	6/337	12/8290	3.24200752739850ⁿ52e-6	5.19227768059916ⁿ85e-5	3.15135929061269ⁿ5e-5	
HC_CD66a-_vs_HC_CD44+	R-HSA-9673770	Signaling by PDGFRA extracellular domain mutants	6/337	12/8290	3.24200752739850ⁿ52e-6	5.19227768059916ⁿ85e-5	3.15135929061269ⁿ5e-5	
HC_CD66a-_vs_HC_CD44+	R-HSA-381340	Transcriptional regulation of white adipocyte differentiation	14/337	80/8290	3.39160554609418ⁿ6e-6	5.26726618909090ⁿ24e-5	3.19687221330408ⁿ5e-5	
HC_CD66a-_vs_HC_CD44+	R-HSA-69202	Cyclin E associated events during G1/S transition	14/337	80/8290	3.39160554609418ⁿ6e-6	5.26726618909090ⁿ24e-5	3.19687221330408ⁿ5e-5	
HC_CD66a-_vs_HC_CD44+	R-HSA-166166	MyD88-independent TLR4 cascade	15/337	92/8290	3.80637726191136ⁿ22e-6	5.73755396096933ⁿ5e-5	3.48230489441116ⁿ85e-05	
HC_CD66a-_vs_HC_CD44+	R-HSA-937061	TRIF(TICAM1)-mediated TLR4 signaling	15/337	95/8290	3.80637726191136ⁿ22e-6	5.73755396096933ⁿ5e-5	3.48230489441116ⁿ85e-05	
HC_CD66a-_vs_HC_CD44+	R-HSA-69656	Cyclin A:Cdk2-associated events at S phase entry	14/337	82/8290	4.59277821552815ⁿ95e-6	6.82260532016864ⁿ3e-5	4.14085724952161e-5	
HC_CD66a-_vs_HC_CD44+	R-HSA-1980143	Signaling by NOTCH1	13/337	72/8290	5.30968050643783ⁿ1e-6	7.77488931299825ⁿ2e-5	4.71882884105978ⁿ7e-5	
HC_CD66a-_vs_HC_CD44+	R-HSA-1538133	G0 and Early G1	8/337	26/8290	5.64072109044413ⁿ6e-6	8.07638691187882ⁿ5e-5	4.90181737090668ⁿ5e-5	
HC_CD66a-_vs_HC_CD44+	R-HSA-5621575	CD209 (DC-SIGN) signaling	7/337	19/8290	5.69237941696038ⁿ6e-6	8.07638691187882ⁿ5e-5	4.90181737090668ⁿ5e-5	
HC_CD66a-_vs_HC_CD44+	R-HSA-375165	NCAM signaling for neurite out-growth	11/337	52/8290	5.75196336163007724e-6	8.07638691187882ⁿ5e-5	4.90181737090668ⁿ5e-5	
HC_CD66a-_vs_HC_CD44+	R-HSA-6811558	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	14/337	84/8290	6.15812591104579ⁿ9e-6	8.52983656597ⁿ56e-5	5.17703046068374ⁿ5	
HC_CD66a-_vs_HC_CD44+	R-HSA-5357801	Programmed Cell Death	21/337	173/8290	6.45026188422399ⁿ8	8.81535788110612ⁿ5	5.35032247264053ⁿ5	
HC_CD66a-_vs_HC_CD44+	R-HSA-6783783	Interleukin-10 signaling	9/337	35/8290	7.53752279953418ⁿ6	1.01657379682183ⁿ4	6.16991132205748ⁿ5	
HC_CD66a-_vs_HC_CD44+	R-HSA-3700989	Transcriptional Regulation by TP53	32/337	343/8290	8.59801361048623ⁿ6	1.14454077282446ⁿ57e-4	6.94658379193077ⁿ5e-5	
HC_CD66a-_vs_HC_CD44+	R-HSA-2428928	IRS-related events triggered by IGF1R	9/337	36/8290	9.69450348347114ⁿ6	1.27395718853306ⁿ4e-4	7.73205338560248ⁿ5e-5	
HC_CD66a-_vs_HC_CD44+	R-HSA-8940973	RUNX2 regulates osteoblast differentiation	7/337	21/8290	1.22417557531429ⁿ4e-5	1.54469495823672ⁿ3e-4	9.37524744870769ⁿ5	
HC_CD66a-_vs_HC_CD44+	R-HSA-168164	Toll Like Receptor 3 (TLR3) Cascade	14/337	84/8290	1.23168608978667ⁿ2e-5	1.54469495823672ⁿ3e-4	9.37524744870769ⁿ5	
HC_CD66a-_vs_HC_CD44+	R-HSA-9018519	Estrogen-dependent gene expression	14/337	89/8290	1.23168608978667ⁿ2e-5	1.54469495823672ⁿ3e-4	9.37524744870769ⁿ5	
HC_CD66a-_vs_HC_CD44+	R-HSA-2428924	IGF1R signaling cascade	9/337	37/8290	1.23575596658893786e-5	1.54469495823672ⁿ3e-4	9.37524744870769ⁿ5	
HC_CD66a-_vs_HC_CD44+	R-HSA-1227986	Signaling by ERBB2	10/337	47/8290	1.45746899353228444e-5	1.76557555759218ⁿ25e-4	1.07158420859542ⁿ8e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-9012852	Signaling by NOTCH3	10/337	47/8290	1.45746899353228444e-5	1.76557555759218ⁿ25e-4	1.07158420859542ⁿ8e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer	11/337	57/8290	1.46413582247175ⁿ8e-5	1.76557555759218ⁿ25e-4	1.07158420859542ⁿ8e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	9/337	38/8290	1.56202171283457ⁿ25e-5	1.86171192518074ⁿ05e-4	1.12993247525732ⁿ2e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-2644602	Signaling by NOTCH1 PEST Domain Mutants In Cancer	11/337	58/8290	1.74214571832223ⁿ3e-5	1.96230699041791ⁿ2e-4	1.19098683577618ⁿ2e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-2644603	Signaling by NOTCH1 in Cancer	11/337	58/8290	1.74214571832223ⁿ3e-5	1.96230699041791ⁿ2e-4	1.19098683577618ⁿ2e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-2644606	Constitutive Signaling by NOTCH1 PEST Domain Mutants	11/337	58/8290	1.74214571832223ⁿ3e-5	1.96230699041791ⁿ2e-4	1.19098683577618ⁿ2e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-2894858	Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer	11/337	58/8290	1.74214571832223ⁿ3e-5	1.96230699041791ⁿ2e-4	1.19098683577618ⁿ2e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-2894862	Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants	11/337	58/8290	1.74214571832223ⁿ3e-5	1.96230699041791ⁿ2e-4	1.19098683577618ⁿ2e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-1236394	Signaling by ERBB4	10/337	48/8290	1.77548962149307ⁿ8e-5	1.97812702394609ⁿ3e-4	1.20058851979686ⁿ6e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-8864260	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	8/337	30/8290	1.83217773442259ⁿ7e-5	2.01933567503565ⁿ8e-4	1.22559936733871ⁿ5e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-9617629	Regulation of FOXO transcriptional activity by acetylation	5/337	10/8290	2.29476627779963ⁿ7e-5	2.49577966743876ⁿ7e-4	1.51478845541048ⁿ4e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-975138	TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation	13/337	98/8290	2.31316164290203ⁿ58e-5	2.49577966743876ⁿ7e-4	1.51478845541048ⁿ4e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-187687	Signalling to ERKs	8/337	31/8290	2.38298976884142ⁿ3e-5	2.51810774542521ⁿ7e-4	1.52832007963676ⁿ7e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-2173796	SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	8/337	31/8290	2.38298976884142ⁿ3e-5	2.51810774542521ⁿ7e-4	1.52832007963676ⁿ7e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-198725	Nuclear Events (kinase and transcription factor activation)	11/337	60/8290	2.43785248976080ⁿ8e-5	2.53173549609023ⁿ7e-4	1.53659119713559ⁿ4	
HC_CD66a-_vs_HC_CD44+	R-HSA-3108232	SUMO E3 ligases SUMOylate target proteins	13/337	100/8290	2.44528599134568ⁿ5e-5	2.53173549609023ⁿ7e-4	1.53659119713559ⁿ4	
HC_CD66a-_vs_HC_CD44+	R-HSA-168181	Toll Like Receptor 7/8 (TLR7/8) Cascade	13/337	83/8290	2.64386385098936ⁿ1e-5	2.68312915570702ⁿ7e-4	1.62847684829047ⁿ6e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-975155	MyD88 dependent cascade initiated on endosome	13/337	83/8290	2.64386385098936ⁿ1e-5	2.68312915570702ⁿ7e-4	1.62847684829047ⁿ6e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-6806834	Signaling by MET	12/337	72/8290	2.85011833853311ⁿ62e-5	2.82645365585518ⁿ8e-4	1.71546506866281ⁿ52e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-168928	DDX58/IFIH1-mediated induction of interferon-alpha/beta	11/337	61/8290	2.86781639228233ⁿ73e-5	2.82645365585518ⁿ8e-4	1.71546506866281ⁿ52e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-450294	MAP kinase activation	11/337	61/8290	2.86781639228233ⁿ73e-5	2.82645365585518ⁿ8e-4	1.71546506866281ⁿ52e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-2173789	TGF-beta receptor signaling activates SMADs	8/337	32/8290	3.06611384773101ⁿ75e-5	2.99311113707075ⁿ7e-4	1.81661482108168ⁿ5e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-9607240	FLT3 Signaling	25/337	252/8290	3.10563952751887ⁿ5e-5	3.00309482618534ⁿ6e-4	1.82267424107612ⁿ2e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-210745	Regulation of gene expression in beta cells	6/337	17/8290	3.65133449553406ⁿ5e-5	3.40237987085683ⁿ4e-4	2.06501309748522ⁿ7e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-452723	Transcriptional regulation of pluripotent stem cells	6/337	17/8290	3.65133449553406ⁿ5e-5	3.40237987085683ⁿ4e-4	2.06501309748522ⁿ7e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-8934593	Regulation of RUNX1 Expression and Activity	6/337	17/8290	3.65133449553406ⁿ5e-5	3.40237987085683ⁿ4e-4	2.06501309748522ⁿ7e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-9034015	Signaling by NTRK3 (TRKC)	6/337	17/8290	3.65133449553406ⁿ5e-5	3.40237987085683ⁿ4e-4	2.06501309748522ⁿ7e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-168898	Toll-like Receptor Cascades	17/337	137/8290	3.71791692487535ⁿ5e-5	3.43321574598854ⁿ7e-4	2.08372584399272ⁿ7e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-5688426	Deubiquitination	23/337	224/8290	3.76893996821499664e-5	3.44925309591104ⁿ54e-4	2.09346195602919ⁿ54e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-168138	Toll Like Receptor 9 (TLR9) Cascade	13/337	86/8290	3.89670156605392ⁿ5	3.53461867717280ⁿ6e-4	2.14527305592716e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-2990846	SUMOylation	19/337	166/8290	4.10662496541624ⁿ5e-5	3.69236016627337ⁿ6e-4	2.24101140772022ⁿ3e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-5633007	Regulation of TP53 Activity	18/337	152/8290	4.15348706011168ⁿ5	3.70202107531709ⁿ7e-4	2.24687492222069ⁿ4e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-400685	Sema4D in semaphorin signaling	7/337	25/8290	4.39597159072979ⁿ6e-5	3.88437144870521e-4	2.35754919248757ⁿ5e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-2173793	Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	9/337	43/8290	4.51452696156413e-5	3.95503430393438ⁿ8e-4	2.40043673997661e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-400253	Circadian Clock	11/337	64/8290	4.57287320565679ⁿ5e-5	3.97219918288400ⁿ3e-4	2.41054651688915ⁿ4e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-69278	Cell Cycle, Mitotic	38/337	477/8290	4.61571322990648ⁿ5e-5	3.97571937870096e-4	2.41299117105239ⁿ4e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-6802948	Signaling by high-kinase activity BRAF mutants	8/337	34/8290	4.92881645485092ⁿ3e-5	4.21003072185183e-4	2.55520221475166ⁿ24e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-166058	MyD88:MAL(TIRAP) cascade initiated on plasma membrane	13/337	89/8290	5.63873930727207ⁿ3e-5	4.73748540160153ⁿ6e-4	2.87531918084365ⁿ6e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-168188	Toll Like Receptor TLR6:TLR2 Cascade	13/337	89/8290	5.63873930727207ⁿ3e-5	4.73748540160153ⁿ6e-4	2.87531918084365ⁿ6e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-69206	G1/S Transition	16/337	128/8290	5.74685096975081ⁿ24e-5	4.78904247479234ⁿ4e-4	2.90662295515756ⁿ6e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-422475	Axon guidance	38/337	483/8290	6.05285665656060ⁿ24e-5	5.00336859455340ⁿ7e-4	3.03670432799082ⁿ4e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-448424	Interleukin-17 signaling	11/337	66/8290	6.14175639687032ⁿ8e-5	5.01588834868195e-4	3.04430296955364e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-168638	NOD1/2 Signaling Pathway	6/337	18/8290	6.16587250667244ⁿ7e-5	5.01588834868195e-4	3.04430296955364e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-168179	Toll Like Receptor TLR1:TLR2 Cascade	13/337	90/8290	6.35339478770941ⁿ3e-5	5.08767941984529e-4	3.08787526277653e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-181438	Toll Like Receptor 2 (TLR2) Cascade	13/337	90/8290	6.35339478770941ⁿ3e-5	5.08767941984529e-4	3.08787526277653e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-166016	Toll Like Receptor 4 (TLR4) Cascade	15/337	116/8290	6.59188833793648ⁿ6e-5	5.23774073363169ⁿ4	3.17895227068172ⁿ4e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-9665686	Signaling by ERBB2 TMD/JMD mutants	6/337	18/8290	7.46996130773399ⁿ5e-5	5.84481705376133ⁿ2e-4	3.54740629399018ⁿ4e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-9671555	Signaling by PDGFR in disease	6/337	19/8290	7.46996130773399ⁿ5e-5	5.84481705376133ⁿ2e-4	3.54740629399018ⁿ4e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-168142	Toll Like Receptor 10 (TLR10) Cascade	12/337	80/8290	8.34313292196849ⁿ5e-5	6.38186717911765ⁿ6e-4	3.87335918136948ⁿ5e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-168176	Toll Like Receptor 5 (TLR5) Cascade	12/337	80/8290	8.34313292196849ⁿ5e-5	6.38186717911765ⁿ6e-4	3.87335918136948ⁿ5e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-975871	MyD88 cascade initiated on plasma membrane	12/337	80/8290	8.34313292196849ⁿ5e-5	6.38186717911765ⁿ6e-4	3.87335918136948ⁿ5e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-8853884	Transcriptional Regulation by VENTX	8/337	37/8290	9.42016692027209ⁿ5	7.15234895798436ⁿ4e-4	4.34098920066877ⁿ5e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-5218920	VEGFR2 mediated vascular permeability	7/337	28/8290	9.74465885363614ⁿ5e-5	7.34432007832871ⁿ2e-4	4.45750260979950ⁿ6e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-1250196	SHC1 events in ERBB2 signaling	6/337	20/8290	1.03090588530130ⁿ54e-4	7.61598920631764ⁿ4	4.62238728722333ⁿ4e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-5218921	VEGFR2 mediated cell proliferation	6/337	20/8290	1.03090588530130ⁿ54e-4	7.61598920631764ⁿ4e-4	4.62238728722333ⁿ4e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-5673001	RAF/MAP kinase cascade	23/337	239/8290	1.03280243871039ⁿ21e-4	7.61598920631764ⁿ4	4.62238728722333ⁿ4e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-171007	p38MAPK events	5/337	13/8290	1.05903233098740ⁿ4e-4	7.69863928554671ⁿ9e-4	4.67255026213926ⁿ7e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-9027284	Erythropoietin activates RAS	5/337	13/8290	1.05903233098740ⁿ4e-4	7.69863928554671ⁿ9e-4	4.67255026213926ⁿ7e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-2122947	NOTCH1 Intracellular Domain Regulates Transcription	9/337	48/8290	1.12206426057530ⁿ13e-4	8.09940751471608ⁿ5e-4	5.01578931060408ⁿ4e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-5674135	MAP2K and MAPK activation	8/337	38/8290	1.15156723089220ⁿ7e-4	8.25424064101059ⁿ4e-4	5.00976248404339ⁿ4e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-73887	Death Receptor Signalling	16/337	136/8290	1.19766812237956ⁿ92e-4	8.52506823221583e-4	5.17413640589419ⁿ4e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-114452	Activation of BH3-only proteins	7/337	29/8290	1.24022050373406ⁿ8e-4	8.76707597467185ⁿ9e-4	5.32101864033999ⁿ4e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-147424	Extracellular matrix organization	21/337	212/8290	1.37431350815ⁿ4e-4	9.64843875767824e-4	5.85594292228823ⁿ2e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-74751	Insulin receptor signalling cascade	8/337	39/8290	1.39819451553187ⁿ57e-4	9.74931549945695ⁿ6e-4	5.91717120429117ⁿ9e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-5684996	MAPK1/MAPK3 signaling	23/337	244/8290	1.41266167636149ⁿ32e-4	9.78363660093608ⁿ4	5.93800178328335ⁿ4e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-5655302	Signaling by FGFR1 in disease	7/337	30/8290	1.56191698686635ⁿ4	0.00107407319046948	6.51889351031719ⁿ4e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-1963640	GRB2 events in ERBB2 signaling	5/337	14/8290	1.59277195074434ⁿ3e-4	0.00107407319046948	6.51889351031719ⁿ4e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-8849471	PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases	5/337	14/8290	1.59277195074434ⁿ3e-4	0.00107407319046948	6.51889351031719ⁿ4e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-8941856	RUNX3 regulates NOTCH signaling	5/337	14/8290	1.59277195074434ⁿ3e-4	0.00107407319046948	6.51889351031719ⁿ4e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-9656223	Signaling by RAF1 mutants	7/337	31/8290	1.68678632488718044e-4	0.00112714352325074ⁿ2	6.84099432340115ⁿ4e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-2682334	EPH-Ephrin signaling	12/337	86/8290	1.70103650439997424e-4	0.00112714352325074ⁿ2	6.84099432340115ⁿ4e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-5621481	C-type lectin receptors (CLRs)	15/337	126/8290	1.70446093759868802e-4	0.00112714352325074ⁿ2	6.84099432340115ⁿ4e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-6802952	Signaling by BRAF and RAF fusions	10/337	62/8290	1.75920181358797ⁿ4	0.00115588580700490ⁿ75	7.01544043070501e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-9664565	Signaling by ERBB2 KD Mutants	7/337	22/8290	1.85216490392156ⁿ4	0.00120921632364197ⁿ8	7.33912038989759ⁿ4	
HC_CD66a-_vs_HC_CD44+	R-HSA-1980145	Signaling by NOTCH2	7/337	31/8290	1.94797223977835e-4	0.00126371616821034ⁿ4	7.69989735981824e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-5633008	TP53 Regulates Transcription of Cell Death Genes	8/337	41/8290	2.02264649501087e-4	0.00130390614197391ⁿ3	7.91382315693733e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-9665348	Signaling by ERBB2 ECD mutants	5/337	15/8290	2.31003132180555e-4	0.00147986381554609ⁿ8	9.98176652105513e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-389356	CD28 co-stimulation	7/337	34/8290	2.40755327917915777e-4	0.00150393867441567ⁿ7	9.12788453483609e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-5654741	Signaling by FGFR3	7/337	32/8290	2.40755327917915777e-4	0.00150393867441567ⁿ7	9.12788453483609e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-3928662	EPHB-mediated forward signaling	8/337	42/8290	2.41149718481242235e-4	0.00150393867441567ⁿ7	9.12788453483609e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-1227990	Signaling by ERBB2 in Cancer	6/337	23/8290	2.42097445149840ⁿ7e-4	0.00150393867441567ⁿ7	9.12788453483609e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-9006335	Signaling by Erythropoietin	6/337	23/8290	2.42097445149840ⁿ7e-4	0.00150393867441567ⁿ7	9.12788453483609e-4	
HC_CD66a-_vs_HC_CD44+	R-HSA-6802957	Oncogenic MAPK signaling	11/337	78/8290	2.87683690638825434e-4	0.00177636013798069ⁿ4	0.00107812974716270ⁿ3	
HC_CD66a-_vs_HC_CD44+	R-HSA-69273	Cyclin A/B1/B2 associated events during G2/M transition	6/337	24/8290	3.11868531028637ⁿ4e-4	0.00191416313995470ⁿ56	0.00116176679380979ⁿ4	
HC_CD66a-_vs_HC_CD44+	R-HSA-9013694	Signaling by NOTCH4	11/337	79/8290	3.22322439545372e-4	0.00195887801061826ⁿ4	0.00118890567833159ⁿ5	
HC_CD66a-_vs_HC_CD44+	R-HSA-1362300	Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1	5/337	19/8290	3.24887084687906644e-4	0.00195887801061826ⁿ4	0.00118890567833159ⁿ5	
HC_CD66a-_vs_HC_CD44+	R-HSA-156711	Polo-like kinase mediated events	5/337	16/8290	3.24887084687906644e-4	0.00195887801061826ⁿ4	0.00118890567833159ⁿ5	
HC_CD66a-_vs_HC_CD44+	R-HSA-6802946	Signaling by moderate kinase activity BRAF mutants	8/337	44/8290	3.37328278115757666e-4	0.00197577991467809ⁿ3	0.00119916398415887ⁿ8	
HC_CD66a-_vs_HC_CD44+	R-HSA-6802949	Signaling by RAS mutants	8/337	44/8290	3.37328278115757666e-4	0.00197577991467809ⁿ3	0.00119916398415887ⁿ8	
HC_CD66a-_vs_HC_CD44+	R-HSA-6802955	Paradoxical activation of RAF signaling by kinase inactive BRAF	8/337	44/8290	3.37328278115757666e-4	0.00197577991467809ⁿ3	0.00119916398415887ⁿ8	
HC_CD66a-_vs_HC_CD44+	R-HSA-75153	Apoptotic execution phase	8/337	44/8290	3.37328278115757666e-4	0.00197577991467809ⁿ3	0.00119916398415887ⁿ8	
HC_CD66a-_vs_HC_CD44+	R-HSA-9649948	Signaling downstream of RAS mutants	8/337	44/8290	3.37328278115757666e-4	0.00197577991467809ⁿ3	0.00119916398415887ⁿ8	
HC_CD66a-_vs_HC_CD44+	R-HSA-109582	Hemostasis	35/337	470/8290	3.47524156962115e-4	0.00202393330048959	0.00122838981318546ⁿ6	
HC_CD66a-_vs_HC_CD44+	R-HSA-112399	IRS-mediated signalling	7/337	34/8290	3.58777067860655e-4	0.00207663974152309	0.00126100067915872ⁿ8	
HC_CD66a-_vs_HC_CD44+	R-HSA-1181150	Signaling by NODAL	5/337	17/8290	4.45042809576395ⁿ1e-4	0.00254829496177681ⁿ5	0.00154672331937459ⁿ8	
HC_CD66a-_vs_HC_CD44+	R-HSA-445144	Signal transduction by L1	5/337	17/8290	4.45042809576395ⁿ1e-4	0.00254829496177681ⁿ5	0.00154672331937459ⁿ8	
HC_CD66a-_vs_HC_CD44+	R-HSA-1234158	Regulation of gene expression by Hypoxia-induc

HC_CD66a-_vs_HC_CD44+	R-HSA-9013508	NOTCH3 Intracellular Domain Regulates Transcription	5/337	23/8290	0.001979439514306484	0.008705121397091994	0.005283416426887157
HC_CD66a-_vs_HC_CD44+	R-HSA-174824	Plasma lipoprotein assembly, remodeling, and clearance	8/337	57/8290	0.001987315518458797	0.008705121397091994	0.005283416426887157
HC_CD66a-_vs_HC_CD44+	R-HSA-3928665	EPH-ephrin mediated repulsion of cells	7/337	45/8290	0.002062323379064365	0.008995240270387124	0.005459498844466023
HC_CD66a-_vs_HC_CD44+	R-HSA-5617472	Activation of anterior HOX genes in hindbrain development during early embryogenesis	8/337	58/8290	0.002225587810846803	0.009625432515265711	0.005841982661383347
HC_CD66a-_vs_HC_CD44+	R-HSA-5619507	Activation of HOX genes during differentiation	8/337	58/8290	0.002225587810846803	0.009625432515265711	0.005841982661383347
HC_CD66a-_vs_HC_CD44+	R-HSA-210744	Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells	4/337	15/8290	0.002564005255245086	0.010905001604257817	0.006618594041711291
HC_CD66a-_vs_HC_CD44+	R-HSA-5637810	Constitutive Signaling by EGFRvIII	4/337	15/8290	0.002564005255245086	0.010905001604257817	0.006618594041711291
HC_CD66a-_vs_HC_CD44+	R-HSA-5637812	Signaling by EGFRvIII in Cancer	4/337	15/8290	0.002564005255245086	0.010905001604257817	0.006618594041711291
HC_CD66a-_vs_HC_CD44+	R-HSA-937072	TRAF6-mediated induction of TAK1 complex within TLR4 complex	4/337	15/8290	0.002564005255245086	0.010905001604257817	0.006618594041711291
HC_CD66a-_vs_HC_CD44+	R-HSA-5673000	RAF activation	6/337	35/8290	0.002579457574069553	0.010925388485211195	0.006630967491409685
HC_CD66a-_vs_HC_CD44+	R-HSA-6807070	PTEN Regulation	13/337	132/8290	0.002686547446486529	0.011332144578801202	0.006877840766183836
HC_CD66a-_vs_HC_CD44+	R-HSA-74752	Signaling by Insulin receptor	8/337	62/8290	0.002769102480370037	0.011632500173693887	0.007060136177307395
HC_CD66a-_vs_HC_CD44+	R-HSA-9013507	NOTCH3 Activation and Transmission of Signal to the Nucleus	5/337	25/8290	0.002923724650799865	0.012231909253346374	0.007423936707294178
HC_CD66a-_vs_HC_CD44+	R-HSA-111465	Apoptotic cleavage of cellular proteins	6/337	36/8290	0.002991524941910109	0.012414222937076363	0.007534588709434794
HC_CD66a-_vs_HC_CD44+	R-HSA-8875878	MET promotes cell motility	6/337	36/8290	0.002991524941910109	0.012414222937076363	0.007534588709434794
HC_CD66a-_vs_HC_CD44+	R-HSA-1474029	Laminin interactions	7/337	49/8290	0.003015202825442147	0.012462052042421827	0.007563516632105768
HC_CD66a-_vs_HC_CD44+	R-HSA-2173791	TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)	4/337	16/8290	0.003310377978764027	0.013572549171923574	0.008237614254524418
HC_CD66a-_vs_HC_CD44+	R-HSA-4655427	SUMOylation of DNA methylation proteins	4/337	16/8290	0.003310377978764027	0.013572549171923574	0.008237614254524418
HC_CD66a-_vs_HC_CD44+	R-HSA-69615	G1/S DNA Damage Checkpoints	8/337	62/8290	0.003411059931781977	0.013929611127520529	0.008454326240169907
HC_CD66a-_vs_HC_CD44+	R-HSA-1251985	Nuclear signaling by ERBB4	5/337	26/8290	0.003501280630256394	0.014129183645717197	0.008575453180611139
HC_CD66a-_vs_HC_CD44+	R-HSA-442742	CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling	5/337	26/8290	0.003501280630256394	0.014129183645717197	0.008575453180611139
HC_CD66a-_vs_HC_CD44+	R-HSA-8863795	Downregulation of ERBB2 signaling	5/337	26/8290	0.003501280630256394	0.014129183645717197	0.008575453180611139
HC_CD66a-_vs_HC_CD44+	R-HSA-1632852	Macroautophagy	12/337	122/8290	0.003907747554472248	0.015707612718957077	0.009533452238155207
HC_CD66a-_vs_HC_CD44+	R-HSA-3769402	Deactivation of the beta-catenin transactivating complex	6/337	38/8290	0.003960675611904667	0.015858173836727767	0.009624832593074251
HC_CD66a-_vs_HC_CD44+	R-HSA-5626467	RHO GTPases activate IQGAPs	5/337	27/8290	0.004156425204506659	0.016400076559219077	0.009953706767635316
HC_CD66a-_vs_HC_CD44+	R-HSA-1474165	Reproduction	8/337	64/8290	0.004162847418478876	0.016400076559219077	0.009953706767635316
HC_CD66a-_vs_HC_CD44+	R-HSA-1592389	Activation of Matrix Metalloproteinases	4/337	17/8290	0.004192019569283315	0.016400076559219077	0.009953706767635316
HC_CD66a-_vs_HC_CD44+	R-HSA-5654708	Downstream signaling of activated FGFR3	4/337	17/8290	0.004192019569283315	0.016400076559219077	0.009953706767635316
HC_CD66a-_vs_HC_CD44+	R-HSA-5689901	Metalloprotease DUBs	4/337	17/8290	0.004192019569283315	0.016400076559219077	0.009953706767635316
HC_CD66a-_vs_HC_CD44+	R-HSA-8854691	Interleukin-20 family signaling	4/337	17/8290	0.004192019569283315	0.016400076559219077	0.009953706767635316
HC_CD66a-_vs_HC_CD44+	R-HSA-373760	L1CAM interactions	10/337	94/8290	0.004691929208179579	0.018286035887391895	0.011098379675942089
HC_CD66a-_vs_HC_CD44+	R-HSA-350054	Notch-HLH transcription pathway	5/337	28/8290	0.004984609024116929	0.019003682106606952	0.011533942104941805
HC_CD66a-_vs_HC_CD44+	R-HSA-1368082	RORA activates gene expression	4/337	18/8290	0.005219492604529577	0.019888401188826326	0.012070906395135906
HC_CD66a-_vs_HC_CD44+	R-HSA-1912420	Pre-NOTCH Processing in Golgi	4/337	18/8290	0.005219492604529577	0.019888401188826326	0.012070906395135906
HC_CD66a-_vs_HC_CD44+	R-HSA-3232118	SUMOylation of transcription factors	4/337	18/8290	0.005219492604529577	0.019888401188826326	0.012070906395135906
HC_CD66a-_vs_HC_CD44+	R-HSA-6803204	TP53 Regulates Transcription of Genes Involved in Cytochrome C Release	4/337	18/8290	0.005219492604529577	0.019888401188826326	0.012070906395135906
HC_CD66a-_vs_HC_CD44+	R-HSA-6804760	Regulation of TP53 Activity through Methylation	4/337	18/8290	0.005219492604529577	0.019888401188826326	0.012070906395135906
HC_CD66a-_vs_HC_CD44+	R-HSA-2151201	Transcriptional activation of mitochondrial biogenesis	7/337	53/8290	0.005309021499920177	0.020154618657104356	0.012232482286365776
HC_CD66a-_vs_HC_CD44+	R-HSA-438064	Post NMDA receptor activation events	8/337	67/8290	0.005522435552468864	0.020887412939194047	0.012677293081029708
HC_CD66a-_vs_HC_CD44+	R-HSA-2122948	Activated NOTCH1 Transmits Signal to the Nucleus	5/337	29/8290	0.005721211964873259	0.021402344029179163	0.012989766697042243
HC_CD66a-_vs_HC_CD44+	R-HSA-5357956	TNFR1-induced NFkappaB signaling pathway	5/337	29/8290	0.005721211964873259	0.021402344029179163	0.012989766697042243
HC_CD66a-_vs_HC_CD44+	R-HSA-6804758	Regulation of TP53 Activity through Acetylation	5/337	29/8290	0.005721211964873259	0.021402344029179163	0.012989766697042243
HC_CD66a-_vs_HC_CD44+	R-HSA-1442490	Collagen degradation	6/337	41/8290	0.005825259805728287	0.021713330031169607	0.013177908306992829
HC_CD66a-_vs_HC_CD44+	R-HSA-3000178	ECM proteoglycans	7/337	54/8290	0.005892588095622074	0.021883698363236483	0.013281916027889057
HC_CD66a-_vs_HC_CD44+	R-HSA-1236382	Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants	4/337	19/8290	0.006402825548458973	0.022793328491683737	0.013801225302783124
HC_CD66a-_vs_HC_CD44+	R-HSA-389513	CTLA4 inhibitory signaling	4/337	19/8290	0.006402825548458973	0.022793328491683737	0.013801225302783124
HC_CD66a-_vs_HC_CD44+	R-HSA-5637815	Signaling by Ligand-Responsive EGFR Variants in Cancer	4/337	19/8290	0.006402825548458973	0.022793328491683737	0.013801225302783124
HC_CD66a-_vs_HC_CD44+	R-HSA-6783589	Interleukin-6 family signaling	4/337	19/8290	0.006402825548458973	0.022793328491683737	0.013801225302783124
HC_CD66a-_vs_HC_CD44+	R-HSA-1059683	Interleukin-6 signaling	3/337	10/8290	0.006455750820565812	0.022793328491683737	0.013801225302783124
HC_CD66a-_vs_HC_CD44+	R-HSA-170968	Frs2-mediated activation	3/337	10/8290	0.006455750820565812	0.022793328491683737	0.013801225302783124
HC_CD66a-_vs_HC_CD44+	R-HSA-351906	Apoptotic cleavage of cell adhesion proteins	3/337	10/8290	0.006455750820565812	0.022793328491683737	0.013801225302783124
HC_CD66a-_vs_HC_CD44+	R-HSA-430116	GP1b-IX-V activation signalling	3/337	10/8290	0.006455750820565812	0.022793328491683737	0.013801225302783124
HC_CD66a-_vs_HC_CD44+	R-HSA-6803207	TP53 Regulates Transcription of Caspase Activators and Caspases	3/337	10/8290	0.006455750820565812	0.022793328491683737	0.013801225302783124
HC_CD66a-_vs_HC_CD44+	R-HSA-75205	Dissolution of Fibrin Clot	3/337	10/8290	0.006455750820565812	0.022793328491683737	0.013801225302783124
HC_CD66a-_vs_HC_CD44+	R-HSA-8875555	MET activates PAK1 and RAC1	3/337	10/8290	0.006455750820565812	0.022793328491683737	0.013801225302783124
HC_CD66a-_vs_HC_CD44+	R-HSA-9020558	Interleukin-2 signaling	3/337	10/8290	0.006455750820565812	0.022793328491683737	0.013801225302783124
HC_CD66a-_vs_HC_CD44+	R-HSA-9020956	Interleukin-27 signaling	3/337	10/8290	0.006455750820565812	0.022793328491683737	0.013801225302783124
HC_CD66a-_vs_HC_CD44+	R-HSA-9028731	Activated NTRK2 signals through FRS2 and FRS3	3/337	10/8290	0.006455750820565812	0.022793328491683737	0.013801225302783124
HC_CD66a-_vs_HC_CD44+	R-HSA-9037042	IRAK2 mediated activation of TAK1 complex	3/337	10/8290	0.006455750820565812	0.022793328491683737	0.013801225302783124
HC_CD66a-_vs_HC_CD44+	R-HSA-5675221	Negative regulation of MAPK pathway	6/337	42/8290	0.006569319170140342 5	0.023060110100663875	0.013995917914754658
HC_CD66a-_vs_HC_CD44+	R-HSA-9663891	Selective autophagy	8/337	69/8290	0.006601245062538138	0.023093092795568572	0.014015936166553044
HC_CD66a-_vs_HC_CD44+	R-HSA-1474228	Degradation of the extracellular matrix	10/337	99/8290	0.006765449560335075	0.023587026528379088	0.014315720337121479
HC_CD66a-_vs_HC_CD44+	R-HSA-8986944	Transcriptional Regulation by MECP2	8/337	74/8290	0.007202181785605467 6	0.025023268420564385	0.015187419635783456
HC_CD66a-_vs_HC_CD44+	R-HSA-75893	TNF signaling	6/337	43/8290	0.007380032186557526	0.025469808051250466	0.015458440624687061
HC_CD66a-_vs_HC_CD44+	R-HSA-977225	Amyloid fiber formation	6/337	43/8290	0.007380032186557526	0.025469808051250466	0.015458440624687061
HC_CD66a-_vs_HC_CD44+	R-HSA-1266695	Interleukin-7 signaling	4/337	20/8290	0.007751458129686459	0.026308756897114635	0.015967625495450302
HC_CD66a-_vs_HC_CD44+	R-HSA-450321	JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1	4/337	20/8290	0.007751458129686459	0.026308756897114635	0.015967625495450302
HC_CD66a-_vs_HC_CD44+	R-HSA-5625900	RHO GTPases activate CIT	4/337	20/8290	0.007751458129686459	0.026308756897114635	0.015967625495450302
HC_CD66a-_vs_HC_CD44+	R-HSA-5627117	RHO GTPases Activate ROCKs	4/337	20/8290	0.007751458129686459	0.026308756897114635	0.015967625495450302
HC_CD66a-_vs_HC_CD44+	R-HSA-5654687	Downstream signaling of activated FGFR1	4/337	20/8290	0.007751458129686459	0.026308756897114635	0.015967625495450302
HC_CD66a-_vs_HC_CD44+	R-HSA-1592230	Mitochondrial biogenesis	8/337	75/8290	0.008509368354248554	0.028202701846727008	0.017117121223533417
HC_CD66a-_vs_HC_CD44+	R-HSA-190873	Gap junction degradation	3/337	11/8290	0.008612412124902980	0.028202701846727008	0.017117121223533417
HC_CD66a-_vs_HC_CD44+	R-HSA-2586552	Signaling by Leptin	3/337	11/8290	0.008612412124902980	0.028202701846727008	0.017117121223533417
HC_CD66a-_vs_HC_CD44+	R-HSA-5654689	SHC-mediated cascade:FGFR2	3/337	11/8290	0.008612412124902980	0.028202701846727008	0.017117121223533417
HC_CD66a-_vs_HC_CD44+	R-HSA-5655291	Signaling by FGFR4 in disease	3/337	11/8290	0.008612412124902980	0.028202701846727008	0.017117121223533417
HC_CD66a-_vs_HC_CD44+	R-HSA-68689	CDC6 association with the ORC:origin complex	3/337	11/8290	0.008612412124902980	0.028202701846727008	0.017117121223533417
HC_CD66a-_vs_HC_CD44+	R-HSA-8847993	ERBB2 Activates PTK6 Signaling	3/337	11/8290	0.008612412124902980	0.028202701846727008	0.017117121223533417
HC_CD66a-_vs_HC_CD44+	R-HSA-8924903	Receptor Mediated Mitophagy	3/337	11/8290	0.008612412124902980	0.028202701846727008	0.017117121223533417
HC_CD66a-_vs_HC_CD44+	R-HSA-9013700	NOTCH4 Activation and Transmission of Signal to the Nucleus	3/337	11/8290	0.008612412124902980	0.028202701846727008	0.017117121223533417
HC_CD66a-_vs_HC_CD44+	R-HSA-9014325	TICAM1,TRAF6-dependent induction of TAK1 complex	3/337	11/8290	0.008612412124902980	0.028202701846727008	0.017117121223533417
HC_CD66a-_vs_HC_CD44+	R-HSA-9645460	Alpha-protein kinase 1 signaling pathway	3/337	11/8290	0.008612412124902980	0.028202701846727008	0.017117121223533417
HC_CD66a-_vs_HC_CD44+	R-HSA-9679506	SARS-CoV Infections	12/337	136/8290	0.009217628372739242	0.029795376015365 15	0.018086291844753 45
HC_CD66a-_vs_HC_CD44+	R-HSA-190236	Signaling by FGFR	8/337	73/8290	0.009229059914702614	0.029795376015365 15	0.018086291844753 45
HC_CD66a-_vs_HC_CD44+	R-HSA-2979096	NOTCH2 Activation and Transmission of Signal to the Nucleus	4/337	21/8290	0.009274197555990276	0.029795376015365 15	0.018086291844753 45
HC_CD66a-_vs_HC_CD44+	R-HSA-389357	CD28 dependent PI3K/Akt signaling	4/337	21/8290	0.009274197555990276	0.029795376015365 15	0.018086291844753 45
HC_CD66a-_vs_HC_CD44+	R-HSA-5654732	Negative regulation of FGFR3 signaling	4/337	21/8290	0.009274197555990276	0.029795376015365 15	0.018086291844753 45
HC_CD66a-_vs_HC_CD44+	R-HSA-9615017	FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	4/337	21/8290	0.009274197555990276	0.029795376015365 15	0.018086291844753 45
HC_CD66a-_vs_HC_CD44+	R-HSA-9612973	Autophagy	12/337	137/8290	0.009745669967625532	0.031216599115050533	0.018946351812061477
HC_CD66a-_vs_HC_CD44+	R-HSA-201681	TCF dependent signaling in response to WNT	13/337	154/8290	0.009822235531683347	0.031383836199300 4	0.019035714704787206
HC_CD66a-_vs_HC_CD44+	R-HSA-204998	Cell death signalling via NRAGE, NRIF and NADE	8/337	74/8290	0.009993197226635786	0.031810643344845007	0.019306898624418246
HC_CD66a-_vs_HC_CD44+	R-HSA-69563	p53-Dependent G1 DNA Damage Response	7/337	60/8290	0.010449692334322516	0.033058440255186937	0.020064224077224516
HC_CD66a-_vs_HC_CD44+	R-HSA-69580	p53-Dependent G1/S DNA damage checkpoint	7/337	60/8290	0.010449692334322516	0.033058440255186937	0.020064224077224516
HC_CD66a-_vs_HC_CD44+	R-HSA-198753	ERK/MAPK targets	4/337	22/8290	0.010979184467144949	0.033391634250987914	0.020264505159007812
HC_CD66a-_vs_HC_CD44+	R-HSA-201451	Signaling by BMP	4/337	22/8290	0.010979184467144949	0.033391634250987914	0.020264505159007812
HC_CD66a-_vs_HC_CD44+	R-HSA-3000170	Syndecan interactions	4/337	22/8290	0.010979184467144949	0.033391634250987914	0.020264505159007812
HC_CD66a-_vs_HC_CD44+	R-HSA-450302	activated TAK1 mediates p38 MAPK activation	4/337	22/8290	0.010979184467144949	0.033391634250987914	0.020264505159007812
HC_CD66a-_vs_HC_CD44+	R-HSA-5654726	Negative regulation of FGFR1 signaling	4/337	22/8290	0.010979184467144949	0.033391634250987914	0.020264505159007812
HC_CD66a-_vs_HC_CD44+	R-HSA-933542	TRAF6 mediated NF-kB activation	4/337	22/8290	0.010979184467144949	0.033391634250987914	0.020264505159007812
HC_CD66a-_vs_HC_CD44+	R-HSA-1250347	SHC1 events in ERBB4 signaling	3/337	12/8290	0.011141403818378408	0.033391634250987914	0.020264505159007812
HC_CD66a-_vs_HC_CD44+	R-HSA-1474151	Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation	3/337	12/8290	0.011141403818378408	0.033391634250987914	0.020264505159007812
HC_CD66a-_vs_HC_CD44+	R-HSA-1502540	Signaling by Activin	3/337	12/8290	0.011141403818378408	0.033391634250987914	0.020264505159007812
HC_CD66a-_vs_HC_CD44+	R-HSA-162594	Early Phase of HIV Life Cycle	3/337	12/8290	0.011141403818378408	0.033391634250987914	0.020264505159007812
HC_CD66a-_vs_HC_CD44+	R-HSA-169893	Prolonged ERK activation events	3/337	12/8290	0.011141403818378408	0.033391634250987914	0.020264505159007812
HC_CD66a-_vs_HC_CD44+	R-HSA-209560	NF-kB is activated and signals survival	3/337	12/8290	0.011141403818378408	0.033391634250987914	0.020264505159007812
HC_CD66a-_vs_HC_CD44+	R-HSA-264870	Caspase-mediated cleavage of cytoskeletal proteins	3/337	12/8290	0.011141403818378408	0.033391634250987914	0.020264505159007812
HC_CD66a-_vs_HC_CD44+	R-HSA-391160	Signal regulatory protein family interactions	3/337	12/8290	0.011141403818378408	0.033391634250987914	0.020264505159007812
HC_CD66a-_vs_HC_CD44+	R-HSA-5654719	SHC-mediated cascade:FGFR4	3/337	12/8290	0.011141403818378408	0.033391634250987914	0.020264505159007812
HC_CD66a-_vs_HC_CD44+	R-HSA-6804759	Regulation of TP53 Activity through Association with Co-factors	3/337	12/8290	0.011141403818378408	0.033391634250987914	0.020264505159007812
HC_CD66a-_vs_HC_CD44+	R-HSA-68884	Mitotic Telophase/Cytokinesis	3/337	12/8290	0.011141403818378408	0.033391634250987914	0.020264505159007812
HC_CD66a-_vs_HC_CD44+	R-HSA-8984722	Interleukin-35 Signaling	3/337	12/8290	0.011141403818378408	0.033391634250987914	0.020264505159007812
HC_CD66a-_vs_HC_CD44+	R-HSA-936440	Negative regulators of DDX58/IFIH1 signaling	5/337	34/8290	0.011361599023786565	0.033853601742387295	0.020546832995893084
HC_CD66a-_vs_HC_CD44+	R-HSA-9664323	FCGR3A-mediated IL10 synthesis	5/337	34/8290	0.011361599023786565	0.033853601742387295	0.020546832995893084
HC_CD66a-_vs_HC_CD44+	R-HSA-76002	Platelet activation, signaling and aggregation	16/337	211/8290	0.012000202666081047	0.035458195115168328	0.021462006491812048
HC_CD66a-_vs_HC_CD44+	R-HSA-388841	Costimulation by the CD28 family	7/337	62/8290	0.012422864547027651	0.036801838614749546	0.022336212191339643
HC_CD66a-_vs_HC_CD44+	R-HSA-442755	Activation of NMDA receptors and postsynaptic events	8/337	77/8290	0.012568134235547888	0.037124892194341744	0.022532283734897015
HC_CD66a-_vs_HC_CD44+	R-HSA-8936459	RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function	5/337	35/8290	0.012825289265460676	0.037720040872824866	0.022882573715881382
HC_CD66a-_vs_HC_CD44+	R-HSA-1839124	FGFR1 mutant receptor activation	3/337	13/8290	0.012873867615111093	0.037720040872824866	0.022882573715881382
HC_CD66a-_vs_HC_CD44+	R-HSA-2173795	Downregulation of SMAD2/3:SMAD4 transcriptional activity	3/337	23/8290	0.012873867615111093	0.037720040872824866	0.022882573715881382
HC_CD66a-_vs_HC_CD44+	R-HSA-193704	p75 NTR receptor-mediated signalling	9/337	93/8290	0.013013368874636378	0.038002003123938144	0.023064630394092366
HC_CD66a-_vs_HC_CD44+	R-HSA-212300	PRC2 methylates histones and DNA	3/337	13/8290	0.014054057342365188	0.040464631393045844	0.024559278206202916
HC_CD66a-_vs_HC_CD44+	R-HSA-5357786	TNFR1-induced proapoptotic signaling	3/337	13/8290	0.014054057342365188	0.040464631393045844	0.024559278206202916
HC_CD66a-_vs_HC_CD44+	R-HSA-5654700	FRS-mediated FGFR2 signaling	3/337	13/8290	0.014054057342365188	0.040464631393045844	0.024559278206202916
HC_CD66a-_vs_HC_CD44+	R-HSA-6785631	ERBB2 Regulates Cell Motility	3/337	13/8290	0.014054057342365188	0.040464631393045844	0.024559278206202916
HC_CD66a-_vs_HC_CD44+	R-HSA-6803205	TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain	3/337	13/8290	0.014054057342365188	0.040464631393045844	0.024559278206202916
HC_CD66a-_vs_HC_CD44+	R-HSA-451927	Interleukin-2 family signaling	5/337	37/8290	0.014411382082532746	0.041372123038036969	0.025115125730729963
HC_CD66a-_vs_HC_CD44+	R-HSA-1643713	Signaling by EGFR in Cancer	4/337	24/8290	0.014964863414151125	0.042608641666529175	0.025860546572445433
HC_CD66a-_vs_HC_CD44+	R-HSA-3928663	EPHA-mediated growth cone collapse	4/337	24/8290	0.014964863414151125	0.042608641666529175	0.025860546572445433
HC_CD66a-_vs_HC_CD44+	R-HSA-5357769	Caspase activation via extrinsic apoptotic signalling pathway	4/337	24/8290	0.014964863414151125	0.042608641666529175	0.025860546572445433
HC_CD66a-_vs_HC_CD44+	R-HSA-5607764	CLEC7A (Dectin-1) signaling	5/337	37/8290	0.015786099147211427	0.044827705334480094	0.027207367243400404
HC_CD66a-_vs_HC_CD44+	R-HSA-8939902	Regulation of RUNX2 expression and activity	7/337	65/8290	0.015866410744460317	0.044925610533347586	0.027267789037441255
HC_CD66a-_vs_HC_CD44+	R-HSA-5205647	Mitophagy	4/337	25/8290	0.017258559996770338	0.049755027788081966	0.029105439207873115
HC_CD66a-_vs_HC_CD44+	R-HSA-8874081	MET activates PTK2 signaling	4/337	25/8290	0.017258559996770338	0.049755027788081966	0.029105439207873115
HC_CD66a-_vs_HC_CD44+	R-HSA-8648002	RAB processing	4/337	25/8290	0.017258559996770338	0.049755027788081966	0.029105439207873115
HC_CD66a-_vs_HC_CD44+	R-HSA-1963642	PI3K events in ERBB2 signaling	3/337	14/8290	0.017357380793256987	0.049755027788081966	0.029105439207873115
HC_CD66a-_vs_HC_CD44+	R-HSA-5654712	FRS-mediated FGFR4 signaling	3/337	14/8290	0.017357380793256987	0.049755027788081966	0.029105439207873115
HC_CD66a-_vs_HC_CD44+	R-HSA-844456	The NLRP3 inflammasome	3/337	14/8290	0.017357380793256987	0.049755027788081966	0.029105439207873115
HC_CD66a-_vs_HC_CD44+	R-HSA-877312	Regulation of IFNG signaling	3/337	14/8290	0.017357380793256987	0.049755027788081966	0.029105439207873115
HC_CD66a-_vs_HC_CD44+	R-HSA-8963898	Plasma lipoprotein assembly	3/337	14/8290	0.017357380793256987	0.049755027788081966	0.029105439207873115
HC_CD66a-_vs_HC_CD44+	R-HSA-8983432	Interleukin-15 signaling	3/337	14/8290	0.017357380793256987	0.049755027788081966	0.029105439207873115
HC_CD66a-_vs_HC_CD44+	R-HSA-194315	Signaling by Rho GTPases	24/337	375/8290	0.018123808099099093	0.049937892239984406	0.030308903018054651
aUC_CD66a-_vs_aUC_CD66a-	R-HSA-5663202	Diseases of signal transduction by growth factor receptors and second messengers	31/757	356/8290	5.0366757076406E-06	4.0192672149704240E-10	2.3751092284452813e-10
aUC_CD66a-_vs_aUC_CD66a-	R-HSA-9614085	FOXO-mediated transcription	13/757	55/8290	1.7878501354494444-11	7.1335220404432815e-9	4.2155624246386899-9
aUC_CD66a-_vs_aUC_CD66a-	R-HSA-9006925	Intracellular signaling by second messengers	25/757	273/8290	4.0546163531063294-11	1.0785279499282835e-8	6.3735723726023e-9
aUC_CD66a-_vs_aUC_CD66a-	R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	31/757	439/8290	1.2013653257562879e-10	2.3967202472488379e-8	1.4163443752470757e-8
aUC_CD66a-_vs_aUC_CD66a-	R-HSA-2219528	PI3K/AKT Signaling in Cancer	14/757	8/8290	3.6552063643105176e-10	5.8337093574385647e-8	3.4474367393916e-8
aUC_CD66a-_vs_aUC_CD66a-	R-HSA-1257604	PIP3 activates AKT signaling	22/757	237/8290	5.2159977387555011e-10	6.9372769925441640e-8	4.0995912051969218e-8
aUC_CD66a-_vs_aUC_CD66a-	R-HSA-9617828	FOXO-mediated transcription of cell cycle genes	7/157	15/8290	4.3320374628326e-9	4.5343195455442086e-7	2.6795609502754336-7
aUC_CD66a-_vs_aUC_CD66a-	R-HSA-9006931	Signaling by Nuclear Receptors	20/157	219/8290	4.5456837549315137e-9	4.5343195455442086e-7	2.6795609502754336-7
aUC_CD66a-_vs_aUC_CD66a-	R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling	13/157	87/8290	7.4809512346018754e-9	6.6331100946803e-7	3.9198345332920047e-7
aUC_CD66a-_vs_aUC_CD66a-	R-HSA-8848021	Signaling by PTK6	10/157	50/8290	2.3873614118279408e-8	1.7319221878533607e-6	1.0234812559798254e-6
aUC_CD66a-_vs_aUC_CD66a-	R-HSA-9006927	Signaling by Non-Receptor Tyrosine Kinases	10/157	50/8290	2.3873614118279408e-8	1.7319221878533607e-6	1.0234812559798254e-6
aUC_CD66a-_vs_aUC_CD66a-	R-HSA-2559583	Cellular Senescence	14/157	123/8290	6.946669639491732e-8	4.6195353105200206e-6	2.7299192969230673e-6
aUC_CD66a-_vs_aUC_CD66a-	R-HSA-9634638	Estrogen-dependent nuclear events downstream of ESR-membrane signaling	7/157	23/8290	1.4527489945584977e-7	8.9176438281360 1e-6	5.2698910895725266-6
aUC_CD66a-_vs_aUC_CD66a-	R-HSA-8939211	ESR-mediated signaling	15/157	154/8290	1.8806112644494218e-7	1.0719484207361705e-5	6.3346905749875265e-6
aUC_CD66a-_vs_aUC_CD66a-	R-HSA-5674400	Constitutive Signaling by AKT1 E17K in Cancer	7/157	25/8290	2.7591960685031234e-7	1.4678923084436617e-5	8.6745251837852586-6
aUC_CD66a-_vs_aUC_CD66a-	R-HSA-9659787	Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects	6/157	17/8290	4.3828359583327047e-7	2.0505154320055875e-5	1.1175427202826492e-5
aUC_CD66a-_vs_aUC_CD66a-	R-HSA-9661069	Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	6/157	17/8290	4.3828259583327047e-7	2.0505154322055875e-5	1.1217542720328492e-5
aUC_CD66a-_vs_aUC_CD66a-	R-HSA-9009391	Extra-nuclear estrogen signaling	10/157	68/8290	5.0442657149946827e-7	2.2362911334259756e-5	1.3215386199377888e-5
aUC_CD66a-_vs_aUC_CD66a-	R-HSA-449147	Signaling by Interleukins	23/157	376/8290	5.4795075814483847e-7	2.3013931842083215e-5	1.3600107459772167e-5
aUC_CD66a-_vs_aUC_CD66a-	R-HSA-69473	G2/M DNA damage checkpoint	9/157	57/8290	1.0305601813049503e-6	4.1121442340467924e-5	2.4301748012995915e-5
aUC_CD66a-_vs_aUC_CD66a-	R-HSA-3700989	Transcriptional Regulation by TP53	21/157	343/8290	1.7710506182300424e-6	6.7299923492741615e-5	3.9770961251481656e-5
aUC_CD66a-_vs_aUC_CD66a-	R-HSA-76002	Platelet activation, signaling

aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5654732	Negative regulation of FGFR3 signaling	5/157	21/8290	3.63987914114247e-5	5.87962340199871e-4	3.47456969277855546e-4	3.47456969277855546e-4
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-9614399	Regulation of localization of FOXO transcription factors	4/157	11/8290	3.68397456265583e-5	5.87962340199871e-4	3.47456969277855546e-4	3.47456969277855546e-4
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-186797	Signaling by PDGF	7/157	50/8290	3.8533094800936876e-5	6.02929602411113e-4	3.56301888774813 7e-4	3.56301888774813 7e-4
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-2428928	IRS-related events triggered by IGF1R	6/157	36/8290	5.10449308199511344e-5	7.83343361429250 2e-4	4.62917591241662 1e-4	4.62917591241662 1e-4
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5654706	FRS-mediated FGFR3 signaling	4/157	12/8290	5.44463653501672e-5	8.19777349989227e-4	4.84448295469164 8e-4	4.84448295469164 8e-4
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5684996	MAPK1/MAPK3 signaling	15/157	244/8290	5.61619588907928 5e-5	8.29948940529075e-4	4.90459212145762 5e-4	4.90459212145762 5e-4
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-9006115	Signaling by NTRK2 (TRKB)	5/157	23/8290	5.83730604157289844e-5	8.46940040213668 7e-4	5.00500116100413 1e-4	5.00500116100413 1e-4
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-2428924	IGF1R signaling cascade	6/157	37/8290	5.99796321731011 9e-5	8.54709758466692e-4	5.05091639352431 1e-4	5.05091639352431 1e-4
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-190236	Signaling by FGFR	8/157	73/8290	6.55370107528021 2e-5	9.17518150539229 7e-4	5.42208325341742 4e-4	5.42208325341742 4e-4
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-9006936	Signaling by TGFB family members	9/157	94/8290	6.70704830174491 6e-5	9.22797335309042e-4	5.45328055187256 6e-4	5.45328055187256 6e-4
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	6/157	38/8290	7.01213653437639e-5	9.48421178717343e-4	5.60470502658448 6e-4	5.60470502658448 6e-4
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-6804116	TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest	4/157	13/8290	7.74879672273104 1e-5	0.00101369504687855	5.99044164242192 6e-4	5.99044164242192 6e-4
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-75035	Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	4/157	13/8290	7.74879672273104 1e-5	0.00101369504687855	5.99044164242192 6e-4	5.99044164242192 6e-4
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-8986944	Transcriptional Regulation by MECP2	7/157	56/8290	8.13521910741155 4e-5	0.00104708142705013	6.18773881174936 6e-4	6.18773881174936 6e-4
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5688426	Deubiquitination	14/157	224/8290	8.39903560837637e-5	0.00106387784372783 9	6.28699741458114 e-4	6.28699741458114 e-4
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-198323	AKT phosphorylates targets in the cytosol	4/157	14/8290	1.06888349702234054e-4	0.00127308810408698	7.52332767739212e-4	7.52332767739212e-4
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5655332	Signaling by FGFR3 in disease	4/157	14/8290	1.06888349702234054e-4	0.00127308810408698	7.52332767739212e-4	7.52332767739212e-4
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-8849471	PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases	4/157	14/8290	1.06888349702234054e-4	0.00127308810408698	7.52332767739212e-4	7.52332767739212e-4
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-8853338	Signaling by FGFR3 point mutants in cancer	4/157	14/8290	1.06888349702234054e-4	0.00127308810408698	7.52332767739212e-4	7.52332767739212e-4
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-69481	G2/M Checkpoints	10/157	126/8290	1.30552989055029863e-4	0.00153207724501888 8	9.05382958154393 1e-4	9.05382958154393 1e-4
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5633007	Regulation of TP53 Activity	11/157	152/8290	1.37909508527528 65e-4	0.00159495344648806	9.42539432804674 e-4	9.42539432804674 e-4
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-2559580	Oxidative Stress Induced Senescence	7/157	62/8290	1.56880507718396 6e-4	0.00178843778989724	0.00105687920989235 3	0.00105687920989235 3
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5673001	RAF/MAP kinase cascade	14/157	239/8290	1.67300058415927 26e-4	0.00188035840304009 8	0.01111199794984209	0.01111199794984209
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-6811558	PIP3, PP2A and IER3 Regulate PI3K/AKT Signaling	8/157	84/8290	1.78272144128425 9e-4	0.00197584959723872	0.01167630417683257 6	0.01167630417683257 6
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-195721	Signaling by WNT	14/157	241/8290	1.82561979566436844e-4	0.00199567753005022	0.01179347755265134	0.01179347755265134
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-9614657	FOXO-mediated transcription of cell death genes	4/157	16/8290	1.88675056141264 3e-4	0.00203463101082066 1	0.01202367356348128	0.01202367356348128
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-400253	Circadian Clock	7/157	64/8290	1.91993672811486 32e-4	0.00204281267814215	0.01207202321677837	0.01207202321677837
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-187037	Signaling by NTRK1 (TRKA)	5/157	28/8290	1.96871128382262 3e-4	0.00206714684001093	0.01221585262466193 4	0.01221585262466193 4
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-69620	Cell Cycle Checkpoints	14/157	244/8290	2.0770864293699758e-4	0.00214834561341741 3	0.01269566499777206 3	0.01269566499777206 3
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-6791312	TP53 Regulates Transcription of Cell Cycle Genes	5/157	29/8290	2.09988566146185 25e-4	0.00214834561341741 3	0.01269566499777206 3	0.01269566499777206 3
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-1181150	Signaling by NODAL	4/157	17/8290	2.43107761788929e-4	0.00236585358428660 17	0.01398103668723366	0.01398103668723366
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-452723	Transcriptional regulation of pluripotent stem cells	4/157	17/8290	2.43107761788929e-4	0.00236585358428660 17	0.01398103668723366	0.01398103668723366
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5654708	Downstream signaling of activated FGFR3	4/157	17/8290	2.43107761788929e-4	0.00236585358428660 17	0.01398103668723366	0.01398103668723366
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-8934593	Regulation of RUNX1 Expression and Activity	4/157	17/8290	2.43107761788929e-4	0.00236585358428660 17	0.01398103668723366	0.01398103668723366
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-1236394	Signaling by ERBB4	6/157	48/8290	2.66662865444887145e-4	0.00253329722176427 87	0.01497054683221744	0.01497054683221744
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-177929	Signaling by EGFR	6/157	48/8290	2.66662865444887145e-4	0.00253329722176427 87	0.01497054683221744	0.01497054683221744
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-9607240	FLT3 Signaling	14/157	252/8290	2.89885987002797 2e-4	0.00272151785444979	0.01608283865972175 1	0.01608283865972175 1
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-157118	Signaling by NOTCH	11/157	168/8290	3.31603748408284e-4	0.00307697428322105 4	0.01818314122000136 13	0.01818314122000136 13
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-1912408	Pre-NOTCH Transcription and Translation	5/157	33/8290	3.53375458933668834e-4	0.00318847017043908	0.01872410812066582	0.01872410812066582
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-2559585	Oncogene Induced Senescence	5/157	33/8290	3.53375458933668834e-4	0.00318847017043908	0.01872410812066582	0.01872410812066582
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5654743	Signaling by FGFR4	5/157	33/8290	3.53375458933668834e-4	0.00318847017043908	0.01872410812066582	0.01872410812066582
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5673000	RAF activation	5/157	35/8290	4.68836921689087 4e-4	0.00406250156419854	0.02240073961316334 3	0.02240073961316334 3
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-1250196	SHC1 events in ERBB2 signaling	4/157	20/8290	4.73449430408441 7e-4	0.00406250156419854	0.02240073961316334 3	0.02240073961316334 3
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-9669938	Signaling by KIT in disease	4/157	20/8290	4.73449430408441 7e-4	0.00406250156419854	0.02240073961316334 3	0.02240073961316334 3
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-9670439	Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	4/157	20/8290	4.73449430408441 7e-4	0.00406250156419854	0.02240073961316334 3	0.02240073961316334 3
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5689896	Ovarian tumor domain proteases	5/157	36/8290	5.36222726667979 4e-4	0.00455218867958561 2	0.02269102734011811 7	0.02269102734011811 7
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-9615017	FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	4/157	21/8290	5.76284874878327 3e-4	0.00484078294897794	0.02286087173346804	0.02286087173346804
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5693532	DNA Double-Strand Break Repair	9/157	125/8290	5.85638866934270 4e-4	0.00486812308139112 3	0.02287682250423852 2	0.02287682250423852 2
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-2262752	Cellular responses to stress	20/157	479/8290	6.82158588297317 4e-4	0.00545400365318948	0.03322304925026892 06	0.03322304925026892 06
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer	6/157	57/8290	6.85487629304873 1e-4	0.00545400365318948	0.03322304925026892 06	0.03322304925026892 06
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-3769402	Deactivation of the beta-catenin transactivating complex	6/157	58/8290	6.92531823037203 4e-4	0.00545400365318948	0.03322304925026892 06	0.03322304925026892 06
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5654726	Negative regulation of FGFR1 signaling	4/157	22/8290	6.9403968745589e-4	0.00545400365318948	0.03322304925026892 06	0.03322304925026892 06
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5654727	Negative regulation of FGFR2 signaling	4/157	22/8290	6.9403968745589e-4	0.00545400365318948	0.03322304925026892 06	0.03322304925026892 06
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5654710	PI-3K cascade:FGFR3	3/157	10/8290	7.25223238857785e-4	0.00545400365318948	0.03322304925026892 06	0.03322304925026892 06
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-8851805	MET activates RAS signaling	3/157	10/8290	7.25223238857785e-4	0.00545400365318948	0.03322304925026892 06	0.03322304925026892 06
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-8853334	Signaling by FGFR3 fusions in cancer	3/157	10/8290	7.25223238857785e-4	0.00545400365318948	0.03322304925026892 06	0.03322304925026892 06
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-8875555	MET activates PAP1 and RAC1	3/157	10/8290	7.25223238857785e-4	0.00545400365318948	0.03322304925026892 06	0.03322304925026892 06
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-9028731	Activated NTRK2 signals through FRS2 and FRS3	3/157	10/8290	7.25223238857785e-4	0.00545400365318948	0.03322304925026892 06	0.03322304925026892 06
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-69242	S Phase	10/157	156/8290	7.31301241718383e-4	0.00545400365318948	0.03322304925026892 06	0.03322304925026892 06
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5617472	Activation of anterior HOX genes in hindbrain development during early embryogenesis	6/157	58/8290	7.52792086751172e-4	0.00551126683785624 2	0.03256888990053621 4	0.03256888990053621 4
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5619507	Activation of HOX genes during differentiation	6/157	58/8290	7.52792086751172e-4	0.00551126683785624 2	0.03256888990053621 4	0.03256888990053621 4
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5628897	TP53 Regulates Metabolic Genes	7/157	81/8290	8.21711561014663 7e-4	0.00589532713683459	0.03485744417059779 7	0.03485744417059779 7
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-1368108	BMAL1:CLOCK,NPAS2 activates circadian gene expression	4/157	23/8290	8.27864240516976 8e-4	0.00589532713683459	0.03485744417059779 7	0.03485744417059779 7
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5654733	Negative regulation of FGFR4 signaling	4/157	23/8290	8.27864240516976 8e-4	0.00589532713683459	0.03485744417059779 7	0.03485744417059779 7
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-6807070	PTEN Regulation	9/157	132/8290	8.68495624052913 6e-4	0.00613269982249779	0.03652446240871639 7	0.03652446240871639 7
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-8953897	Cellular responses to external stimuli	20/157	490/8290	9.05637287621095e-4	0.00633946101334764	0.03774631121749077 15	0.03774631121749077 15
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-109581	Apoptosis	10/157	161/8290	9.33546631702875 2e-4	0.00647802356172936	0.03852819437073582 14	0.03852819437073582 14
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5654688	SHC-mediated cascade:FGFR1	3/157	11/8290	9.83367048194972e-4	0.00670706756374323 8	0.03996354898795634	0.03996354898795634
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5654699	SHC-mediated cascade:FGFR2	3/157	11/8290	9.83367048194972e-4	0.00670706756374323 8	0.03996354898795634	0.03996354898795634
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-6802952	Signaling by BRAF and RAF fusions	6/157	62/8290	0.01017449037688605	0.00726648881860914	0.04429412721274367 521	0.04429412721274367 521
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-3928662	EPHB-mediated forward signaling	5/157	45/8290	0.01104395135765228 5	0.00740594385192882 7	0.04376550038322205	0.04376550038322205
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-354192	Integrin signaling	4/157	25/8290	0.01148347517373277	0.00763651099053196 5	0.04512804278800053	0.04512804278800053
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-1502540	Signaling by Activin	3/157	12/8290	0.01129300727664261 5	0.00825455845408643 2	0.04878040083670652	0.04878040083670652
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-179812	GRB2 events in EGFR signaling	3/157	12/8290	0.01129300727664261 5	0.00825455845408643 2	0.04878040083670652	0.04878040083670652
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5654719	SHC-mediated cascade:FGFR4	3/157	12/8290	0.01129300727664261 5	0.00825455845408643 2	0.04878040083670652	0.04878040083670652
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-9673367	Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants	3/157	12/8290	0.01129300727664261 5	0.00825455845408643 2	0.04878040083670652	0.04878040083670652
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-9673770	Signaling by PDGFRA extracellular domain mutants	3/157	12/8290	0.01129300727664261 5	0.00825455845408643 2	0.04878040083670652	0.04878040083670652
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-2559585	DNA Damage/Telomere Stress Induced Senescence	4/157	26/8290	0.01033732111955854 1	0.00833171247584906 3	0.04923634334375849	0.04923634334375849
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-6804756	Regulation of TP53 Activity through Phosphorylation	7/157	88/8290	0.01034362850869412 08	0.00833171247584906 3	0.04923634334375849	0.04923634334375849
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-6802946	Signaling by moderate kinase activity BRAF mutants	5/157	44/8290	0.01036773726107296 66	0.00833171247584906 3	0.04923634334375849	0.04923634334375849
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-6802949	Signaling by RAS mutants	5/157	44/8290	0.01036773726107296 66	0.00833171247584906 3	0.04923634334375849	0.04923634334375849
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-6802955	Paradoxical activation of RAF signaling by kinase inactive BRAF	5/157	44/8290	0.01036773726107296 66	0.00833171247584906 3	0.04923634334375849	0.04923634334375849
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-9649948	Signaling downstream of RAS mutants	5/157	44/8290	0.01036773726107296 66	0.00833171247584906 3	0.04923634334375849	0.04923634334375849
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-9018519	Estrogen-dependent gene expression	7/157	89/8290	0.01043556622831684 97	0.00867865038027913 8	0.05128657657782684	0.05128657657782684
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5357801	Programmed Cell Death	10/157	173/8290	0.01061103698905374 35	0.00965558488638559 9	0.05705097814153904 3	0.05705097814153904 3
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-180336	SHC1 events in EGFR signaling	3/157	13/8290	0.01065766306946720 17	0.00965558488638559 9	0.05705097814153904 3	0.05705097814153904 3
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-354194	GRB2:SOS provides linkage to MAPK signaling for Integrins	3/157	13/8290	0.01065766306946720 17	0.00965558488638559 9	0.05705097814153904 3	0.05705097814153904 3
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5654693	FRS-mediated FGFR1 signaling	3/157	13/8290	0.01065766306946720 17	0.00965558488638559 9	0.05705097814153904 3	0.05705097814153904 3
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5654700	FRS-mediated FGFR2 signaling	3/157	13/8290	0.01065766306946720 17	0.00965558488638559 9	0.05705097814153904 3	0.05705097814153904 3
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-8941326	RUNX2 regulates bone development	4/157	24/8290	0.01077496636558467 26	0.01028435011690262 8	0.06607754762158667	0.06607754762158667
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-383280	Nuclear Receptor transcription pathway	5/157	47/8290	0.01084589129154788 8	0.01059727518456989 4	0.06626247102319199	0.06626247102319199
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-4420097	VEGFA-VEGFR2 Pathway	7/157	94/8290	0.01097140068835910 5	0.01099549735273956	0.06497800836373195	0.06497800836373195
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-182971	EGFR downregulation	4/157	29/8290	0.02023398416440567 94	0.01099549735273956	0.06497800836373195	0.06497800836373195
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-3214858	RMTs methylate histone arginines	4/157	29/8290	0.02023398416440567 94	0.01099549735273956	0.06497800836373195	0.06497800836373195
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-4090294	SUMOylation of intracellular receptors	4/157	29/8290	0.02023398416440567 94	0.01099549735273956	0.06497800836373195	0.06497800836373195
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-1963640	GRB2 events in ERBB2 signaling	3/157	14/8290	0.02008060162940309 96	0.01099549735273956	0.06497800836373195	0.06497800836373195
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-4839735	AXIN mutants destabilize the destruction complex, activating WNT signaling	3/157	14/8290	0.02008060162940309 96	0.01099549735273956	0.06497800836373195	0.06497800836373195
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-4839744	truncated APC mutants destabilize the destruction complex	3/157	14/8290	0.02008060162940309 96	0.01099549735273956	0.06497800836373195	0.06497800836373195
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-4839748	AMER1 mutants destabilize the destruction complex	3/157	14/8290	0.02008060162940309 96	0.01099549735273956	0.06497800836373195	0.06497800836373195
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5467337	APC truncation mutants have impaired AXIN binding	3/157	14/8290	0.02008060162940309 96	0.01099549735273956	0.06497800836373195	0.06497800836373195
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5467340	AXIN missense mutants destabilize the destruction complex	3/157	14/8290	0.02008060162940309 96	0.01099549735273956	0.06497800836373195	0.06497800836373195
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5467348	Truncations of AMER1 destabilize the destruction complex	3/157	14/8290	0.02008060162940309 96	0.01099549735273956	0.06497800836373195	0.06497800836373195
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5654712	FRS-mediated FGFR4 signaling	3/157	14/8290	0.02008060162940309 96	0.01099549735273956	0.06497800836373195	0.06497800836373195
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-1912422	Pre-NOTCH Expression and Processing	5/157	49/8290	0.02222615304472552 43	0.01161091588033312 7	0.06861483068710251	0.06861483068710251
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-2559582	Senescence-Associated Secretory Phenotype (SASP)	5/157	49/8290	0.02222615304472552 43	0.01161091588033312 7	0.06861483068710251	0.06861483068710251
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-2871796	FCERI mediated MAPK activation	7/157	96/8290	0.02311578492674783 2	0.01188778648588872	0.07025089409943165	0.07025089409943165
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5655302	Signaling by FGFR1 in disease	4/157	30/8290	0.02311578492674783 2	0.01188778648588872	0.07025089409943165	0.07025089409943165
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-170834	Signaling by TGF-beta Receptor Complex	6/157	72/8290	0.02333882161940406 93	0.01188778648588872	0.07025089409943165	0.07025089409943165
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-6806834	Signaling by MET	6/157	72/8290	0.02333882161940406 93	0.01188778648588872	0.07025089409943165	0.07025089409943165
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-114608	Platelet degranulation	7/157	98/8290	0.02502248928209917	0.01218302906259306 8	0.07199573961273836	0.07199573961273836
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-111447	Activation of BAD and translocation to mitochondria	3/157	15/8290	0.02256484822370380 35	0.01218302906259306 8	0.07199573961273836	0.07199573961273836
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-4839743	phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex	3/157	15/8290	0.02256484822370380 35	0.01218302906259306 8	0.07199573961273836	0.07199573961273836
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5339716	Misspliced GSK3beta mutants stabilize beta-catenin	3/157	15/8290	0.02256484822370380 35	0.01218302906259306 8	0.07199573961273836	0.07199573961273836
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5358747	S33 mutants of beta-catenin aren't phosphorylated	3/157	15/8290	0.02256484822370380 35	0.01218302906259306 8	0.07199573961273836	0.07199573961273836
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5358749	S37 mutants of beta-catenin aren't phosphorylated	3/157	15/8290	0.02256484822370380 35	0.01218302906259306 8	0.07199573961273836	0.07199573961273836
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5358751	S45 mutants of beta-catenin aren't phosphorylated	3/157	15/8290	0.02256484822370380 35	0.01218302906259306 8	0.07199573961273836	0.07199573961273836
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5358752	T41 mutants of beta-catenin aren't phosphorylated	3/157	15/8290	0.02256484822370380 35	0.01218302906259306 8	0.07199573961273836	0.07199573961273836
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5637810	Constitutive Signaling by EGFRvIII	3/157	15/8290	0.02256484822370380 35	0.01218302906259306 8	0.07199573961273836	0.07199573961273836
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5637812	Signaling by EGFRvIII in Cancer	3/157	15/8290	0.02256484822370380 35	0.01218302906259306 8	0.07199573961273836	0.07199573961273836
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-9665348	Signaling by ERBB2 ECD mutants	3/157	15/8290	0.02256484822370380 35	0.01218302906259306 8	0.07199573961273836	0.07199573961273836
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-187687	Signaling to ERKs	6/157	81/8290	0.02261539396473258 26	0.01220517185341872	0.07212659525638779 35	0.07212659525638779 35
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-2173796	SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	4/157	31/8290	0.02261539396473258 26	0.01220517185341872	0.07212659525638779 35	0.07212659525638779 35
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-5693571	Nonhomologous End-Joining (NHEJ)	4/157	31/8290	0.02261539396473258 26	0.01220517185341872	0.07212659525638779 35	0.07212659525638779 35
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-194138	Signaling by VEGF	7/157	99/8290	0.02265070781913769 9	0.01227226893533809	0.07252320999592335	0.07252320999592335
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-1226099	Signaling by FGFR in disease	5/157	58/8290	0.02266053338322492 45	0.01227226893533809	0.07252320999592335	0.07252320999592335
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-69206	G1/S Transition	8/157	128/8290	0.02290226464458298 4	0.01331038612860474	0.07865786816534657	0.07865786816534657
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-389356	CD28 co-stimulation	4/157	32/8290	0.02945529810958839	0.01335529993832435	0.07899232868008 11	0.07899232868008 11
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-76009	Platelet Aggregation (Plug Formation)	4/157	32/8290	0.02945529810958839	0.01335529993832435	0.07899232868008 11	0.07899232868008 11
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-1295596	Spry regulation of FGF signaling	3/157	16/8290	0.03311319587775670 07	0.01387894028184272	0.08201774497118505	0.08201774497118505
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-180292	GAB1 signalosome	3/157	16/8290	0.03311319587775670 07	0.01387894028184272	0.08201774497118505	0.08201774497118505
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-881907	Gastrin-CREB signalling pathway via PKC and MAPK	3/157	16/8290	0.03311319587775670 07	0.01387894028184272	0.08201774497118505	0.08201774497118505
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-3108232	SUMO E3 ligases SUMOylate target proteins	9/157	160/8290	0.03329310424981260 53	0.01452777235567 34	0.08585202048830191 6	0.08585202048830191 6
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-4791275	Signaling by WNT in cancer	4/157	33/8290	0.03330306483026003	0.01452777235567 34	0.08585202048830191 6	0.08585202048830191 6
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-76005	Response to elevated platelet cytosolic Ca2+	7/157	103/8290	0.03313351585329021	0.01452777235567 34	0.08585202048830191 6	0.08585202048830191 6
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-112399	IRS-mediated signalling	4/157	34/8290	0.03368907304178685 45	0.01599524396924983	0.09452406404820513	0.09452406404820513
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-6802948	Signaling by high-kinase activity BRAF mutants	4/157	34/8290	0.03368907304178685 45	0.01599524396924983	0.09452406404820513	0.09452406404820513
aUC_CD66a+_vs_qUC_CD66a-	R-HSA-196299	Beta-catenin phosphorylation cascade	3/157	17/8290	0.03372821475974978 66	0.01599524396924983	0.09452406404820513	0.09452406404820513
aUC_CD66a+_vs_qUC

aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9664565	Signaling by ERBB2 KD Mutants	3/157	22/8290	0.00787885400374850 6	0.026528799556925352	0.015677222268173797
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-2426168	Activation of gene expression by SREBF (SREBP)	4/157	42/8290	0.00792222544332975	0.026562755898223028	0.015697288804120718
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-448424	Interleukin-17 signaling	5/157	66/8290	0.00807155184586097 1	0.026950202397477217	0.015926250727427093
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-2173793	Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	4/157	43/8290	0.00860581876497066 7	0.028623324893527 47	0.016914984239942366
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-69278	Cell Cycle, Mitotic	17/157	477/8290	0.00867051028180795 5	0.028708922426899366	0.016966100049413721
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-201681	TCF dependent signaling in response to WNT	8/157	154/8290	0.00877586949368294	0.028938610983991 07	0.017101302889893154
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-1227990	Signaling by ERBB2 in Cancer	3/157	23/8290	0.00893650248823324 1	0.029107465182245412	0.017201087457651 95
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-1839124	FGFR1 mutant receptor activation	3/157	23/8290	0.00893650248823324 1	0.029107465182245412	0.017201087457651 95
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9006335	Signaling by Erythropoietin	3/157	23/8290	0.00893650248823324 1	0.029107465182245412	0.017201087457651 95
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-1643713	Signaling by EGFR in Cancer	3/157	24/8290	0.01007330078756903	0.032544510236751 38	0.019232212882290 75
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-69273	Cyclin A/B1/B2 associated events during G2/M transition	3/157	24/8290	0.01007330078756903	0.032544510236751 38	0.019232212882290 75
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-1251985	Nuclear signaling by ERBB4	3/157	26/8290	0.01258855970685788	0.040506736476009 15	0.023937498933244 19
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-397795	G-protein beta:gamma signalling	3/157	27/8290	0.01396875611511 63	0.044767338874950 13	0.026455306445031083
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-73894	DNA Repair	11/157	272/8290	0.01410356198822374	0.045018569664101 8	0.026603771666207306
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-2032785	YAP1- and WWTR1 (TAZ)-stimulated gene expression	2/157	10/8290	0.01451509902261856	0.045602555197046646	0.026948878417460617
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-430116	GP1b-IX-V activation signalling	2/157	10/8290	0.01451509902261856	0.045602555197046646	0.026948878417460617
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-6803207	TP53 Regulates Transcription of Caspase Activators and Caspases	2/157	10/8290	0.01451509902261856	0.045602555197046646	0.026948878417460617
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9634285	Constitutive Signaling by Overexpressed ERBB2	2/157	10/8290	0.01451509902261856	0.045602555197046646	0.026948878417460617
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9612973	Autophagy	7/157	137/8290	0.01512891470892966 7	0.047344603677356837	0.027978343816702 9
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-449147	Signaling by Interleukins	85/508	876/8290	1.31372864148475e-27	1.4884545651153571e-24	0.071642074969019e-25
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling	39/508	87/8290	6.65719374379456e-25	3.7713002558623922e-22	2.2984837347012866e-22
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5663202	Diseases of signal transduction by growth factor receptors and second messengers	75/508	356/8290	2.44204677474959444e-22	9.2227966523673636e-20	5.6209918745113486e-20
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	84/508	439/8290	4.6363087765701 5e-22	1.3132342063463496e-19	8.0037314940605324e-20
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-2559583	Cellular Senescence	36/508	123/8290	6.69731217113754 2e-16	1.5859093797976 7e-13	9.6635653879289e-14
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-166520	Signaling by NTRKs	36/508	125/8290	1.23413138011447494e-15	2.3304514227833522e-13	1.4203336585180276e-13
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-2219528	PI3K/AKT Signaling in Cancer	29/508	83/8290	2.69939932613952555e-15	4.3691706235944040e-13	2.6628661021767347e-13
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-1257604	PIP3 activates AKT signaling	50/508	237/8290	3.88852070258647 3e-15	5.507117445038093e-13	3.3564073432851667e-13
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9006925	Intracellular signaling by second messengers	54/508	258/8290	5.23268075727432e-15	6.5873636644533396e-13	4.0147819611367884e-13
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-199418	Negative regulation of the PI3K/AKT network	28/508	91/8290	3.18744469134938413	3.6113745835295885e-11	2.2010142860552844e-11
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-187037	Signaling by NTRK1 (TRKA)	30/508	108/8290	8.93665198025231e-13	9.2047507339659871e-11	5.6099934793344991e-11
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-975138	TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation	25/508	82/8290	7.65507198363811e-12	7.2276637978497e-10	4.4050238783040 3e-10
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-168164	Toll Like Receptor 3 (TLR3) Cascade	26/508	89/8290	8.63779568432827e-12	7.5281711680303e-10	4.5881723541857097e-10
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-168181	Toll Like Receptor 7/8 (TLR7/8) Cascade	25/508	83/8290	1.03385657668956669e-11	7.8090633425951 96e-10	4.7593678197077 6e-10
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-975155	MyD88 dependent cascade initiated on endosome	25/508	83/8290	1.03385657668956669e-11	7.8090633425951 96e-10	4.7593678197077 6e-10
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-6811558	PIP5K, PP2A and IER3 Regulate PI3K/AKT Signaling	25/508	84/8290	1.38914782160756e-11	9.8369030128427846e-10	5.9952695485604 7e-10
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-166166	MyD88-independent TLR4 cascade	26/508	90/8290	1.99258323325166720e-11	1.2542204458007707e-9	7.6440619914089852e-10
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-937061	TRIF(TICAM1)-mediated TLR4 signaling	26/508	92/8290	1.99258323325166720e-11	1.2542204458007707e-9	7.6440619914089852e-10
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-168138	Toll Like Receptor 9 (TLR9) Cascade	25/508	86/8290	2.47119221623282233e-11	1.4736109373640987e-9	8.9811750351730 29e-10
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-166058	MyD88:MAL(TIRAP) cascade initiated on plasma membrane	25/508	89/8290	5.66199002659630e-11	3.0547784263650543e-9	1.8617871967153779e-9
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-168188	Toll Like Receptor TLR6:TLR2 Cascade	25/508	89/8290	5.66199002659630e-11	3.0547784263650543e-9	1.8617871967153779e-9
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-1433557	Signaling by SCF-KIT	17/508	41/8290	7.14164824363108 5e-11	3.4928343138895339e-9	2.1287678821122623e-9
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-168179	Toll Like Receptor TLR1:TLR2 Cascade	25/508	90/8290	7.39876641953652 1e-11	3.4928343138895339e-9	2.1287678821122623e-9
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-181438	Toll Like Receptor 2 (TLR2) Cascade	25/508	90/8290	7.39876641953652 1e-11	3.4928343138895339e-9	2.1287678821122623e-9
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9616222	Transcriptional regulation of granulopoiesis	14/508	27/8290	8.46397328930746 1e-11	3.8358726947141429e-9	2.3373385169623975e-9
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5683057	MAPK family signaling cascades	47/508	278/8290	1.15683780138572555e-10	5.0411431883462584e-9	3.0724113267572304e-9
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-166016	Toll Like Receptor 4 (TLR4) Cascade	28/508	116/8290	2.01182318369922444e-10	7.6014095356667029e-9	4.6328096392470989e-9
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-168142	Toll Like Receptor 10 (TLR10) Cascade	23/508	80/8290	2.01272797976169555e-10	7.6014095356667029e-9	4.6328096392470989e-9
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-168176	Toll Like Receptor 5 (TLR5) Cascade	23/508	80/8290	2.01272797976169555e-10	7.6014095356667029e-9	4.6328096392470989e-9
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-975871	MyD88 cascade initiated on plasma membrane	23/508	80/8290	2.01272797976169555e-10	7.6014095356667029e-9	4.6328096392470989e-9
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-186763	Downstream signal transduction	14/508	29/8290	2.91899267329175830e-10	1.0668447415610832e-8	6.5020685696369357e-9
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-109606	Intrinsic Pathway for Apoptosis	18/508	51/8290	4.63436161573711e-10	1.6408536555710207e-8	1.0000464539222186e-8
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-168898	Toll-like Receptor Cascades	30/508	137/8290	5.83090970691908 4e-10	2.0019456660422198e-8	1.2201201810969442e-8
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-8939211	ESR-mediated signaling	32/508	154/8290	6.37290325430310 8e-10	2.1236762903310 06e-8	1.2943110014913 39e-8
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-69231	Cyclin D associated events in G1	17/508	47/8290	9.14362868362828 3e-10	2.8777031384863598e-8	1.7538656188480668e-8
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-69236	G1 Phase	17/508	47/8290	9.14362868362828 3e-10	2.8777031384863598e-8	1.7538656188480668e-8
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9006931	Signaling by Nuclear Receptors	39/508	219/8290	1.02357473609379039e-9	3.1343518270115268e-8	1.9102845714865628e-8
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-450294	MAP kinase activation	19/508	61/8290	1.73468098688914494e-9	5.1720883109158218e-8	3.1522180814426348e-8
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9614085	FOXO-mediated transcription	18/508	55/8290	1.90058868496015 7e-9	5.5214537950257 6e-8	3.3651448780940978e-8
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-2559580	Oxidative Stress Induced Senescence	19/508	64/8290	2.36100198916838e-9	6.6875381343222586e-8	4.0763501088418874e-8
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-2559585	Oncogene Induced Senescence	14/508	33/8290	2.45179375463204e-9	6.7753227414587838e-8	4.1293368499065944e-8
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer	18/508	57/8290	3.64815770132506 2e-9	9.8413397038126076e-8	5.9979735640833 1e-8
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9669938	Signaling by KIT in disease	11/508	20/8290	4.17048026742917e-9	1.0738986886301 12e-7	6.5450599412285544e-8
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9670439	Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	11/508	20/8290	4.17048026742917e-9	1.0738986886301 12e-7	6.5450599412285544e-8
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5655302	Signaling by FGFR1 in disease	13/508	30/8290	6.74617996176812 3e-9	1.6985381992629518e-7	1.0352032877005589e-7
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-448424	Interleukin-17 signaling	19/508	66/8290	7.57507826891236 9e-9	1.8657747127560118e-7	1.1372184504975926e-7
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9659787	Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects	10/508	17/8290	9.01307140223837 1e-9	2.1274603955700156e-7	1.2966172884448184e-7
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9661069	Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	10/508	17/8290	9.01307140223837 1e-9	2.1274603955700156e-7	1.2966172884448184e-7
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-2428928	IRS-related events triggered by IGF1R	14/508	36/8290	9.57713578772345e-9	2.2144683622258669e-7	1.3496457737371831e-7
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-109582	Hemostasis	61/508	470/8290	1.12401173062777736e-8	2.5470105816025356e-7	1.5523193585090937e-7
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-2428924	IGF1R signaling cascade	14/508	37/8290	1.45515997880449669e-8	3.2327377568348686e-7	1.9702475676163276e-7
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-3700989	Transcriptional Regulation by TP53	49/508	343/8290	1.65151427115209e-8	3.5983955185129457e-7	2.1931039718906422e-7
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	14/508	38/8290	2.17615236975583478e-8	4.3789216880634836e-7	2.6688090559480143e-7
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5654736	Signaling by FGFR1	14/508	38/8290	2.17615236975583478e-8	4.3789216880634836e-7	2.6688090559480143e-7
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-186797	Signaling by PDGF	16/508	50/8290	2.20298796310342956e-8	4.3789216880634836e-7	2.6688090559480143e-7
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-8848021	Signaling by PTK6	16/508	50/8290	2.20298796310342956e-8	4.3789216880634836e-7	2.6688090559480143e-7
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9006927	Signaling by Non-Receptor Tyrosine Kinases	16/508	50/8290	2.20298796310342956e-8	4.3789216880634836e-7	2.6688090559480143e-7
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5684996	MAPK1/MAPK3 signaling	39/508	244/8290	2.41775744639132e-8	4.7229641151058 11e-7	2.8784916240158055e-7
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9006115	Signaling by NTRK2 (TRKB)	11/508	23/8290	2.83448473120918898e-8	5.4431715260304167 e-7	3.3174404441253994e-7
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-74751	Insulin receptor signalling cascade	14/508	39/8290	3.20645503976051 3e-8	6.0548559334114436e-7	3.6902359755840029e-7
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9617828	FOXO-mediated transcription of cell cycle genes	9/508	15/8290	4.08326688405208 4e-8	7.5841661961164127e-7	4.6223003898846727e-7
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9607240	FLT3 Signaling	39/508	252/8290	5.96646175036684e-8	1.0903227694713811e-6	6.6451594416988947e-7
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-198725	Nuclear Events (kinase and transcription factor activation)	17/508	60/8290	6.11738878117737188e-8	1.1001589666592415e-6	6.7051078376667666e-7
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9673767	Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants	8/508	12/8290	7.49481416135746e-8	1.3064037607412336e-6	7.9621021697983876e-7
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9673770	Signaling by PDGFRA extracellular domain mutants	8/508	12/8290	7.49481416135746e-8	1.3064037607412336e-6	7.9621021697983876e-7
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-450282	MAPK targets/ Nuclear events mediated by MAP kinases	12/508	30/8290	7.71779901014718 8e-8	1.3248888300752675e-6	8.0747626006728159e-7
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9009391	Extra-nuclear estrogen signaling	18/508	69/8290	7.94907990227129e-8	1.3422250074047656e-6	8.183610255561874e-7
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-6806003	Regulation of TP53 Expression and Degradation	13/508	36/8290	9.25250668153344 9e-8	1.5416308926731466e-6	9.3957343391432326e-7
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-3108232	SUMO E3 ligases SUMOylate target proteins	29/508	160/8290	1.01981932223304039e-7	1.6745728870870128e-6	1.0205972164529014e-6
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-109581	Apoptosis	29/508	161/8290	1.17388733547952 5e-7	1.8976938740644387e-6	1.1565821353521363e-6
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-2559582	Senescence-Associated Secretory Phenotype (SASP)	15/508	49/8290	1.18919916203505851e-7	1.8976938740644387e-6	1.1565821353521363e-6
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5673001	RAF/MAP kinase cascade	37/508	239/8290	1.30857918240465626e-7	2.0591947412006545e-6	1.2550116135342865e-6
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-76002	Platelet activation, signaling and aggregation	34/508	211/8290	1.61189171046452e-7	2.4693267714375276e-6	1.5049736257377624e-6
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9006936	Signaling by TGFB family members	21/508	94/8290	1.61279948002086033e-7	2.4693267714375276e-6	1.5049736257377624e-6
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5654741	Signaling by FGFR3	12/508	32/8290	1.79906708079970138e-7	2.7177906893415524e-6	1.6564042417689999e-6
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-1226099	Signaling by FGFR in disease	15/508	51/8290	2.14666298702967e-7	3.2002225847056999e-6	1.9504306364722803e-6
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-2990846	SUMOylation	29/508	166/8290	2.3252620823598652e-7	3.4214570640438012e-6	2.0852657908791134e-6
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-8853334	Signaling by FGFR3 fusions in cancer	7/508	10/8290	3.18145944319385 3e-7	4.6212737809469669e-6	2.8165147027465154e-6
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-8878159	Transcriptional regulation by RUNX3	20/508	90/8290	3.49206950334242056e-7	5.0082465155331176e-6	3.0523618843394e-6
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-1839124	FGFR1 mutant receptor activation	10/508	23/8290	3.78668790050351 1e-7	5.2994856682351586e-6	3.2298625896430195e-6
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9006335	Signaling by Erythropoietin	10/508	23/8290	3.78668790050351 1e-7	5.2994856682351586e-6	3.2298625896430195e-6
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-112399	IRS-mediated signalling	12/508	34/8290	3.90169919197785 13e-7	5.3910063225742756e-6	3.2856414248234546e-6
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5655332	Signaling by FGFR3 in disease	8/508	14/8290	4.07321824990525886e-7	5.4939955680269734e-6	3.3484099989897055e-6
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-8853338	Signaling by FGFR3 point mutants in cancer	8/508	14/8290	4.07321824990525886e-7	5.4939955680269734e-6	3.3484099989897055e-6
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-6804757	Regulation of TP53 Degradation	12/508	35/8290	5.61090756721356 8e-7	7.4790097337095e-6	4.5582109772039136e-6
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5357801	Programmed Cell Death	29/508	173/8290	5.74300989319653 8e-7	7.5660816383624156e-6	4.6118431542523 7e-6
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-8853659	RET signaling	12/508	36/8290	7.95373601674838 36e-7	1.0125374052776141e-5	6.1710831779822076e-6
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9675126	Diseases of mitotic cell cycle	12/508	36/8290	7.95373601674838 36e-7	1.0125374052776141e-5	6.1710831779822076e-6
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9687139	Aberrant regulation of mitotic cell cycle due to RB1 defects	12/508	36/8290	7.95373601674838 36e-7	1.0125374052776141e-5	6.1710831779822076e-6
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-6674400	Constitutive Signaling by AKT1 E17K in Cancer	10/508	25/8290	8.67946607213798 2e-7	1.2185372288591481e-5	7.4265844951140544e-6
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-170834	Signaling by TGF-beta Receptor Complex	17/508	72/8290	1.07579895415056346e-6	1.3394288077500972e-5	8.1633789027445886e-6
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-190236	Signaling by FGFR	17/508	73/8290	1.32422698121731 6e-6	1.6308143149121944e-5	9.9392780835880 2e-6
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-881907	Gastrin-CREB signalling pathway via PKC and MAPK	8/508	16/8290	1.56404828115150746e-6	1.9054480672532205e-5	1.1613080616133435e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-389356	CD28 co-stimulation	11/508	28/8290	1.62962539396766e-6	1.9642186127289105e-5	1.1971268037673894e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-74752	Signaling by Insulin receptor	15/508	60/8290	2.14181683763644 4e-6	2.5543983668841 13e-5	1.5568219894620586e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5654743	Signaling by FGFR4	11/508	33/8290	2.31085970471547286e-6	2.7272958806894075e-5	1.6621973314620075e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9664565	Signaling by ERBB2 KD Mutants	9/508	22/8290	2.51163215254363862e-6	3.1685094864694e-5	1.9311025438973265e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-452723	Transcriptional regulation of pluripotent stem cells	8/508	17/8290	2.79656618399765226e-6	3.1685094864694e-5	1.9311025438973265e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5654708	Downstream signaling of activated FGFR3	8/508	17/8290	2.79656618399765226e-6	3.1685094864694e-5	1.9311025438973265e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9034015	Signaling by NTRK3 (TRKC)	8/508	17/8290	2.79656618399765226e-6	3.1685094864694e-5	1.9311025438973265e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-1227986	Signaling by ERBB2	13/508	47/8290	3.01664911059042656e-6	3.3840232110989834e-5	2.0624510855104947e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-4420097	VEGFA-VEGFR2 Pathway	19/508	164/8290	3.14649219446216466e-6	3.4950741728864267e-5	2.1301303002649307 5e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-388841	Costimulation by the CD28 family	15/508	62/8290	3.34268748442169 7e-6	3.6769562328638676e-5	2.2409841489837848e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-6802957	Oncogenic MAPK signaling	17/508	78/8290	3.52824362132947 5e-6	3.8437500220829775e-5	2.3426394894657255e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5663008	TP53 Regulates Transcription of Cell Death Genes	12/508	41/8290	3.78425558911381636e-6	4.0834234547294 8e-5	2.4887131292816682e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-1236394	Signaling by ERBB4	13/508	48/8290	3.90916669459795 2e-6	4.1738288242035 6e-5	2.5465872415557 66e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-1227990	Signaling by ERBB2 in Cancer	9/508	23/8290	4.27698002843214 6e-6	4.5288022170221066 5e-5	2.7601563193817082e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-8878166	Transcriptional regulation by RUNX2	20/508	105/8290	4.55574084085638 5e-6	4.7793096043245 4e-5	2.9128323504890 72e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-1839117	Signaling by cytosolic FGFR1 fusion mutants	8/508	18/8290	4.76521296509271 3e-6	4.9081693540454944e-5	2.9913681388524593e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5654696	Downstream signaling of activated FGFR2	8/508	18/8290	4.76521296509271 3e-6	4.9081693540454944e-5	2.9913681388524593e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5633007	Regulation of TP53 Activity	25/508	152/8290	4.94937552745095e-6	5.0519301549723e-5	3.0789856292155746e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-451927	Interleukin-2 family signaling	11/508	36/8290	6.06156170640177e-6	6.1319191190653633e-5	3.7372034580822946e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-512988	Interleukin-3, Interleukin-5 and GM-CSF signaling	12/508	43/8290	6.56472092916253 6e-6	6.5821493918063315e-5	4.0116040330979256e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-109704	PI3K Cascade	10/508	29/8290	6.72991960424433 16e-6	6.6885955364592707e-5	4.0647944478120 2e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-8953897	Cellular responses to external stimuli	55/508	490/8290	6.88175123245719 45e-6	6.7800209968469588e-5	4.1322002823724676e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-194138	Signaling by VEGF	19/508	99/8290	7.02335789806869 1e-6	6.8598831883900415e-5	4.1808736671007266e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5617472	Activation of anterior HOX genes in hindbrain development during early embryogenesis	14/508	58/8290	7.30653550718959 1e-6	6.9127896715903005e-5	4.2131184322601756e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5619507	Activation of HOX genes during differentiation	14/508	58/8290	7.30653550718959 1e-6	6.9127896715903005e-5	4.2131184322601756e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-1963642	PI3K events in ERBB2 signaling	7/508	14/8290	7.32602036402088 5e-6	6.9127896715903005e-5	4.2131184322601756e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-73887	Death Receptor Signalling	23/508	136/8290	7.34690883737833 6e-6	6.9127896715903005e-5	4.2131184322601756e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-2262752	Cellular responses to stress	54/508	479/8290	7.38259091140712 1e-6	6.9127896715903005e-5	4.2131184322601756e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-453279	Mitotic G1 phase and G1/S transition	24/508	146/8290	7.72662553936754 4e-6	7.1562666501519229e-5	4.3733089536396577e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9671555	Signaling by PDGFR in disease	8/508	19/8290	7.79191652241723 6e-6	7.1774320486891 5e-5	4.3744092757430086e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5654710	PI-3K cascade:FGFR3	6/508	10/8290	8.73935478146042 8e-6	7.8548833074568 2e-5	4.7894876663642 79e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-8875555	MET activates PAK1 and RAC1	6/508	10/8290	8.73935478146042 8e-6	7.8548833074568 2e-5	4.7894876663642 79e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9617629	Regulation of FOXO transcriptional activity by acetylation	6/508	10/8290	8.73935478146042 8e-6	7.8548833074568 2e-5	4.7894876663642 79e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-1250196	SHC1 events in ERBB2 signaling	8/508	20/8290	1.22944933323093335e-5	1.0882547613676932e-4	6.6325555134826667e-5
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5654687	Downstream signaling of activated FGFR1	8/508	20/8290	1.22944933323093335e-5	1.0

aUC_CD66a+_vs_HC_CD66a+	R-HSA-5688426	Deubiquitination	29/508	224/8290	9.74045683835835e-5	6.49172799874132e-4	3.95649516158713e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1963640	GRB2 events in ERBB2 signaling	6/508	14/8290	1.01091160864202114e-4	6.65908635227564e-4	4.05849458496125e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8983432	Interleukin-15 signaling	6/508	14/8290	1.01091160864202114e-4	6.65908635227564e-4	4.05849458496125e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2173788	Downregulation of TGF-beta receptor signaling	8/508	26/8290	1.0986621874856192e-4	7.15393251966210e-4	4.36008704032463e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2559586	DNA Damage/Telomere Stress Induced Senescence	8/508	26/8290	1.0986621874856192e-4	7.15393251966210e-4	4.36008704032463e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-4791275	Signaling by WNT in cancer	9/508	33/8290	1.1621680944738945e-4	7.52420829165098e-4	4.5857580148864647e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1266695	Interleukin-7 signaling	7/508	20/8290	1.19725851578467576e-4	7.70735169536385e-4	4.69737790882025e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-422475	Axon guidance	50/508	483/8290	1.51558708940641112e-4	9.70146989998567e-4	5.91272750907286e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-140534	Caspase activation via Death Receptors in the presence of ligand	6/508	15/8290	1.59809445653989912e-4	0.00100035415428712 54	6.09683026164680 7e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2730905	Role of LAT2/NTAL/LAB on calcium mobilization	6/508	15/8290	1.59809445653989912e-4	0.00100035415428712 54	6.09683026164680 7e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5637810	Constitutive Signaling by EGFRvIII	6/508	15/8290	1.59809445653989912e-4	0.00100035415428712 54	6.09683026164680 7e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5637812	Signaling by EGFRvIII in Cancer	6/508	15/8290	1.59809445653989912e-4	0.00100035415428712 54	6.09683026164680 7e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1059683	Interleukin-6 signaling	5/508	10/8290	1.6500216750976962e-4	0.00101052678804631 88	6.15882912582694e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5654704	SHC-mediated cascade:FGFR3	5/508	10/8290	1.6500216750976962e-4	0.00101052678804631 88	6.15882912582694e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9027276	Erythropoietin activates Phosphoinositide-3-kinase (PI3K)	5/508	10/8290	1.6500216750976962e-4	0.00101052678804631 88	6.15882912582694e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8009731	Activated NTRK2 signals through FRS2 and FRS3	5/508	10/8290	1.6500216750976962e-4	0.00101052678804631 88	6.15882912582694e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-112409	RAF-independent MAPK1/3 activation	7/508	21/8290	1.7018741277643673e-4	0.00102565073763671 7	6.25100463501357 7e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8940973	RUNX2 regulates osteoblast differentiation	7/508	21/8290	1.7018741277643673e-4	0.00102565073763671 7	6.25100463501357 7e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9615017	FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	7/508	21/8290	1.7018741277643673e-4	0.00102565073763671 7	6.25100463501357 7e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8878171	Transcriptional regulation by RUNX1	22/508	155/8290	1.79350379191757178e-4	0.00107153331345263 2	6.55270669728706e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5673000	RAF activation	9/508	35/8290	1.90601175414178 8e-4	0.00113658490391182	6.92711970731374e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-912631	Regulation of signaling by CBL	7/508	22/8290	2.36553305912637e-4	0.01403021934868374 23	8.55261404157895e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8939243	RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known	9/508	36/8290	2.40546363496668434e-4	0.01419474113758992	8.65122886259948e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9645723	Regulation of KIT signaling	6/508	18/8290	2.42543686314928 7e-4	0.01423844541968358	8.67785518194 45e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-168643	Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways	11/508	52/8290	2.4904696876802956e-4	0.01444505709722374	8.80714876590212 8e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6802946	Signaling by moderate kinase activity BRAF mutants	10/508	44/8290	2.5529463168010594e-4	0.01444505709722374	8.80714876590212 8e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6802949	Signaling by RAS mutants	10/508	44/8290	2.5529463168010594e-4	0.01444505709722374	8.80714876590212 8e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6802955	Paradoxical activation of RAF signaling by kinase inactive BRAF	10/508	44/8290	2.5529463168010594e-4	0.01444505709722374	8.80714876590212 8e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9649948	Signaling downstream of RAS mutants	10/508	44/8290	2.5529463168010594e-4	0.01444505709722374	8.80714876590212 8e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-114452	Activation of BH3-only proteins	8/508	29/8290	2.56360526958690 8e-4	0.01444505709722374	8.80714876590212 8e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-4090294	SUMOylation of intracellular receptors	8/508	29/8290	2.56360526958690 8e-4	0.01444505709722374	8.80714876590212 8e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9645723	Diseases of programmed cell death	8/508	29/8290	2.56360526958690 8e-4	0.01444505709722374	8.80714876590212 8e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6804756	Regulation of TP53 Activity through Phosphorylation	15/508	88/8290	2.59879167314409 96e-4	0.01457639091916963	8.88383187901266e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5654688	SHC-mediated cascade:FGFR1	5/508	11/8290	2.87310530491660 13e-4	0.01587916249010004	9.67782839508552e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5654699	SHC-mediated cascade:FGFR2	5/508	11/8290	2.87310530491660 13e-4	0.01587916249010004	9.67782839508552e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6803211	TP53 Regulates Transcription of Death Receptors and Ligands	5/508	11/8290	2.87310530491660 13e-4	0.01587916249010004	9.67782839508552e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2151201	Transcriptional activation of mitochondrial biogenesis	11/508	53/8290	2.97242769970500025e-4	0.01634835234837513	9.96378421566929e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9020591	Interleukin-12 signaling	10/508	45/8290	3.10560232984049e-4	0.01699989353319288 6	0.01003599640802205 01
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5654733	Negative regulation of FGFR4 signaling	7/508	23/8290	3.22276921234070344e-4	0.01757479575760582	0.01096990718792058 17
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8864260	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	8/508	30/8290	3.3108770879981684e-4	0.01794843895072691 5	0.01093988448615864 3
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8934593	Regulation of RUNX1 Expression and Activity	6/508	17/8290	3.55583009009498803e-4	0.01918145543370295 93	0.01169235624572993 2
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1592230	Mitochondrial biogenesis	13/508	72/8290	3.70641330208579 4e-4	0.01999022098164132 9	0.01212197437074993
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9031628	NGF-stimulated transcription	9/508	38/8290	3.73201889703973 1e-4	0.01994517646839963	0.01215593049600726
aUC_CD66a+_vs_HC_CD66a+	R-HSA-114604	GPVI-mediated activation cascade	8/508	31/8290	4.22657810561128 2e-4	0.02223771635217644 06	0.01363814676478603 5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5655253	Signaling by FGFR2 in disease	8/508	31/8290	4.22657810561128 2e-4	0.02223771635217644 06	0.01363814676478603 5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5357769	Caspase activation via extrinsic apoptotic signalling pathway	7/508	24/8290	4.31227324473702e-4	0.02266080270580515 6	0.01381101553863351 5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-400253	Circadian Clock	12/508	64/8290	4.32015303129208685e-4	0.02266080270580515 6	0.01381101553863351 5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-383280	Nuclear Receptor transcription pathway	10/508	47/8290	4.51299478485828654e-4	0.02355632400518176 9	0.01436102148371065
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5654720	PI-3K cascade:FGFR4	5/508	12/8290	4.67832127924388 6e-4	0.02431439453845561	0.01481882549098808
aUC_CD66a+_vs_HC_CD66a+	R-HSA-3232118	SUMOylation of transcription factors	6/508	18/8290	5.06005110669727 6e-4	0.02611782552688954	0.01159547843568091
aUC_CD66a+_vs_HC_CD66a+	R-HSA-177929	Signaling by EGFR	10/508	48/8290	5.39418152641056 3e-4	0.02778003481014 9	0.01693101952787239
aUC_CD66a+_vs_HC_CD66a+	R-HSA-400685	Sema4D in semaphorin signaling	7/508	25/8290	5.67689923267313 0e-4	0.02911037413150194 6	0.01077377516853297
aUC_CD66a+_vs_HC_CD66a+	R-HSA-69473	G2/M DNA damage checkpoint	11/508	57/8290	5.75931378898155 9e-4	0.02939325460773021	0.01179142240188331
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2454202	Fc epsilon receptor (FCERI) signaling	18/508	126/8290	6.29452763749766 8e-4	0.03198071665151605	0.01949119721594746 7
aUC_CD66a+_vs_HC_CD66a+	R-HSA-195258	RHO GTPase Effectors	29/508	251/8290	6.86301228750470 46e-4	0.03247133612577304 6	0.01166544201729
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1236382	Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants	6/508	19/8290	7.01642141966997e-4	0.03351162334235376	0.02214021917831924 66
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5637815	Signaling by Ligand-Responsive EGFR Variants in Cancer	6/508	19/8290	7.01642141966997e-4	0.03351162334235376	0.02214021917831924 66
aUC_CD66a+_vs_HC_CD66a+	R-HSA-111461	Cytochrome c-mediated apoptotic response	5/508	13/8290	7.22160846220935e-4	0.03351162334235376	0.02214021917831924 66
aUC_CD66a+_vs_HC_CD66a+	R-HSA-354194	GRB2:SOS provides linkage to MAPK signaling for Integrins	5/508	13/8290	7.22160846220935e-4	0.03351162334235376	0.02214021917831924 66
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5210891	Uptake and function of anthrax toxins	5/508	13/8290	7.22160846220935e-4	0.03351162334235376	0.02214021917831924 66
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5357786	TNFR1-induced proapoptotic signaling	5/508	13/8290	7.22160846220935e-4	0.03351162334235376	0.02214021917831924 66
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6785631	ERBB2 Regulates Cell Motility	5/508	13/8290	7.22160846220935e-4	0.03351162334235376	0.02214021917831924 66
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6803205	TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain	5/508	13/8290	7.22160846220935e-4	0.03351162334235376	0.02214021917831924 66
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9027284	Erythropoietin activates RAS	5/508	13/8290	7.22160846220935e-4	0.03351162334235376	0.02214021917831924 66
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1538133	G0 and Early G1	7/508	26/8290	7.36361814405761e-4	0.03356357579362716 3	0.02217297953328922 94
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5675221	Negative regulation of MAPK pathway	9/508	42/8290	8.19932435295455e-4	0.03953121051867979	0.02240929754264488
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1566948	Elastic fibre formation	27/508	9.42341952133339e-4	0.04504945118889074	0.02745691990058404	0.02745691990058404
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2424491	DAP12 signaling	7/508	27/8290	9.42341952133339e-4	0.04504945118889074	0.02745691990058404
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5218921	VEGFR2 mediated cell proliferation	6/508	20/8290	9.51034837847792e-4	0.04452740534151911 3	0.02275930496960704 7
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2173793	Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	9/508	43/8290	9.81780543974281 7e-4	0.04465421488601197 15	0.02835659122152446 05
aUC_CD66a+_vs_HC_CD66a+	R-HSA-168928	DDX58/IFIH1-mediated induction of interferon-alpha/beta	11/508	60/8290	0.00104508747460167271	0.04845357556591258	0.02951989392559836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-4839735	AXIN mutants destabilize the destruction complex, activating WNT signaling	5/508	14/8290	0.00106719956030808855	0.04845357595551735	0.02951989392559836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-4839744	truncated APC mutants destabilize the destruction complex	5/508	14/8290	0.00106719956030808855	0.04845357595551735	0.02951989392559836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-4839748	AMER1 mutants destabilize the destruction complex	5/508	14/8290	0.00106719956030808855	0.04845357595551735	0.02951989392559836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5467337	APC truncation mutants have impaired AXIN binding	5/508	14/8290	0.00106719956030808855	0.04845357595551735	0.02951989392559836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5467340	AXIN missense mutants destabilize the destruction complex	5/508	14/8290	0.00106719956030808855	0.04845357595551735	0.02951989392559836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5467348	Truncations of AMER1 destabilize the destruction complex	5/508	14/8290	0.00106719956030808855	0.04845357595551735	0.02951989392559836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5654712	FRS-mediated FGFR3 signaling	5/508	14/8290	0.00106719956030808855	0.04845357595551735	0.02951989392559836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-877312	Regulation of IFNG signaling	5/508	14/8290	0.00106719956030808855	0.04845357595551735	0.02951989392559836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8849471	PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases	5/508	14/8290	0.00106719956030808855	0.04845357595551735	0.02951989392559836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9658195	Leishmania infection	22/508	176/8290	0.00108746159653973	0.04845357595551735	0.02951989392559836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-201681	TCF dependent signaling in response to WNT	20/508	154/8290	0.00110738454340238	0.04997561223998681	0.03004594455346374 4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-75153	Apoptotic execution phase	9/508	44/8290	0.00116859120735641 2	0.05254023165415403	0.03302215468219635 4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5689896	Ovarian tumor domain proteases	8/508	36/8290	0.01236527464130201 7	0.05515679361257947	0.03336162555022549 67
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5693565	Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks	8/508	36/8290	0.01236527464130201 7	0.05515679361257947	0.03336162555022549 67
aUC_CD66a+_vs_HC_CD66a+	R-HSA-525793	Myogenesis	6/508	21/8290	0.01263373807876337 2	0.05559141611064019 5	0.03340778461335064 44
aUC_CD66a+_vs_HC_CD66a+	R-HSA-982772	Growth hormone receptor signaling	6/508	21/8290	0.01263373807876337 2	0.05559141611064019 5	0.03340778461335064 44
aUC_CD66a+_vs_HC_CD66a+	R-HSA-193704	p75 NTR receptor-mediated signalling	14/508	93/8290	0.01147709574528742 2	0.06429752245450175	0.03391872297395836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2172127	DAP12 interactions	7/508	29/8290	0.01148853866905354 4	0.06429752245450175	0.03391872297395836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-445989	TAK1 activates NFkB by phosphorylation and activation of IKKs complex	7/508	29/8290	0.01148853866905354 4	0.06429752245450175	0.03391872297395836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5693606	DNA Double Strand Break Response	8/508	37/8290	0.01149463381950188 6	0.06429752245450175	0.03391872297395836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8853884	Transcriptional Regulation by VENTX	8/508	37/8290	0.01149463381950188 6	0.06429752245450175	0.03391872297395836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8950505	Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation	8/508	37/8290	0.01149463381950188 6	0.06429752245450175	0.03391872297395836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-4839743	phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex	5/508	15/8290	0.01152089461763513 23	0.06429752245450175	0.03391872297395836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5339716	Missplaced GSK3beta mutants stabilize beta-catenin	5/508	15/8290	0.01152089461763513 23	0.06429752245450175	0.03391872297395836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5358747	S33 mutants of beta-catenin aren't phosphorylated	5/508	15/8290	0.01152089461763513 23	0.06429752245450175	0.03391872297395836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5358749	S37 mutants of beta-catenin aren't phosphorylated	5/508	15/8290	0.01152089461763513 23	0.06429752245450175	0.03391872297395836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5358751	S45 mutants of beta-catenin aren't phosphorylated	5/508	15/8290	0.01152089461763513 23	0.06429752245450175	0.03391872297395836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5358752	T41 mutants of beta-catenin aren't phosphorylated	5/508	15/8290	0.01152089461763513 23	0.06429752245450175	0.03391872297395836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-373760	L1CAM interactions	14/508	94/8290	0.01164074196423612 4	0.06891781868322407	0.04420031486288614 2
aUC_CD66a+_vs_HC_CD66a+	R-HSA-201451	Signaling by BMP	6/508	22/8290	0.01164843149611286 18	0.06891781868322407	0.04420031486288614 2
aUC_CD66a+_vs_HC_CD66a+	R-HSA-933542	TRAF6 mediated NF-kB activation	6/508	22/8290	0.01164843149611286 18	0.06891781868322407	0.04420031486288614 2
aUC_CD66a+_vs_HC_CD66a+	R-HSA-3769402	Deactivation of the beta-catenin transactivating complex	8/508	38/8290	0.01179368233411466 09	0.07471478252029083	0.04455362078629728 2
aUC_CD66a+_vs_HC_CD66a+	R-HSA-69620	Cell Cycle Checkpoints	27/508	244/8290	0.01197410982787092 67	0.08019291734424088	0.04499331423591026 8
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2682334	EPH-Ephrin signaling	13/508	86/8290	0.02027520996610883	0.08566634285640954	0.05522108244658373 95
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1295596	Spry regulation of FGF signaling	13/508	86/8290	0.02019639222778277	0.08566634285640954	0.05522108244658373 95
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1362300	Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1	5/508	16/8290	0.02019639222778277	0.08566634285640954	0.05522108244658373 95
aUC_CD66a+_vs_HC_CD66a+	R-HSA-180292	GAB1 signalosome	5/508	16/8290	0.02019639222778277	0.08566634285640954	0.05522108244658373 95
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2173791	TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)	5/508	16/8290	0.02019639222778277	0.08566634285640954	0.05522108244658373 95
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2129379	Molecules associated with elastic fibres	8/508	23/8290	0.02211648605195243 96	0.08589490573352012 2	0.05238312960123751 5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-170968	Frs2-mediated activation	4/508	10/8290	0.02217435384506939 46	0.08644010198117 98	0.05268240525819106
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2559584	Formation of Senescence-Associated Heterochromatin Foci (SAHF)	4/508	10/8290	0.02217435384506939 46	0.08644010198117 98	0.05268240525819106
aUC_CD66a+_vs_HC_CD66a+	R-HSA-430116	GP1b-IX-V activation signalling	4/508	10/8290	0.02217435384506939 46	0.08644010198117 98	0.05268240525819106
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5625970	RHO GTPases activate KTN1	4/508	10/8290	0.02217435384506939 46	0.08644010198117 98	0.05268240525819106
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8851805	MET activates RAS signaling	4/508	10/8290	0.02217435384506939 46	0.08644010198117 98	0.05268240525819106
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9634285	Constitutive Signaling by Overexpressed ERBB2	4/508	10/8290	0.02217435384506939 46	0.08644010198117 98	0.05268240525819106
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2173796	SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	7/508	30/8290	0.02255443301070638 6	0.08893102308287531	0.05443195458421007 65
aUC_CD66a+_vs_HC_CD66a+	R-HSA-194315	Signaling by Rho GTPases	37/508	375/8290	0.02259012796585655 95	0.10022513932165614	0.06623186835143531
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1643713	Signaling by EGFR in Cancer	6/508	24/8290	0.02267823896110464 5	0.10499808799093966	0.06399288867195283
aUC_CD66a+_vs_HC_CD66a+	R-HSA-69273	Cyclin A/B1/B2 associated events during G2/M transition	6/508	24/8290	0.02267823896110464 5	0.10499808799093966	0.06399288867195283
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1181150	Signaling by NODAL	5/508	17/8290	0.02282962161139681 86	0.10097931947161847 8	0.06669153484918216
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1810476	RIP-mediated NFkB activation via ZBP1	5/508	17/8290	0.02282962161139681 86	0.10097931947161847 8	0.06669153484918216
aUC_CD66a+_vs_HC_CD66a+	R-HSA-196299	Beta-catenin phosphorylation cascade	5/508	17/8290	0.02282962161139681 86	0.10097931947161847 8	0.06669153484918216
aUC_CD66a+_vs_HC_CD66a+	R-HSA-69242	S Phase	19/508	156/8290	0.03308306732343264	0.11921895148360 37	0.07266003825265389
aUC_CD66a+_vs_HC_CD66a+	R-HSA-3371378	Regulation by c-FLIP	4/508	9/8290	0.03325264310542388 4	0.12243417487855568	0.07461961390655954
aUC_CD66a+_vs_HC_CD66a+	R-HSA-389359	CD28 dependent Vav1 pathway	4/508	11/8290	0.03325264310542388 4	0.12243417487855568	0.07461961390655954
aUC_CD66a+_vs_HC_CD66a+	R-HSA-428540	Activation of RAC1	4/508	11/8290	0.03325264310542388 4	0.12243417487855568	0.07461961390655954
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5218900	CASP8 activity is inhibited	4/508	11/8290	0.03325264310542388 4	0.12243417487855568	0.07461961390655954
aUC_CD66a+_vs_HC_CD66a+	R-HSA-69416	Dimerization of procaspase-8	4/508	11/8290	0.03325264310542388 4	0.12243417487855568	0.07461961390655954
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8847993	ERBB2 Activates PTK6 Signaling	4/508	11/8290	0.03325264310542388 4	0.12243417487855568	0.07461961390655954
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9614399	Regulation of localization of FOXO transcription factors	4/508	11/8290	0.03325264310542388 4	0.12243417487855568	0.07461961390655954
aUC_CD66a+_vs_HC_CD66a+	R-HSA-975110	TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling	4/508	11/8290	0.03325264310542388 4	0.12243417487855568	0.07461961390655954
aUC_CD66a+_vs_HC_CD66a+	R-HSA-416476	G alpha (q) signalling events	18/508	146/8290	0.03435411104318379	0.12888479037167076	0.07855104980246974
aUC_CD66a+_vs_HC_CD66a+	R-HSA-373752	Netrin-1 signaling	8/508	42/8290	0.03348977863425939	0.13049239116374881	0.07953082975186437
aUC_CD66a+_vs_HC_CD66a+	R-HSA-167044	Signaling to RAS	5/508	18/8290	0.03373232026552269 6	0.13374111355321536 3	0.08374757737640431
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1912420	Pre-NOTCH Processing in Golgi	5/508	18/8290	0.03373232026552269 6	0.13374111355321536 3	0.08374757737640431
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6803204	TP53 Regulates Transcription of Genes Involved in Cytochrome C Release	5/508	18/8290	0.03373232026552269 6	0.13374111355321536 3	0.08374757737640431
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6804760	Regulation of TP53 Activity through Methylation	5/508	18/8290	0.03373232026552269 6	0.13374111355321536 3	0.08374757737640431
aUC_CD66a+_vs_HC_CD66a+	R-HSA-69278	Cell Cycle, Mitotic	44/508	477/8290	0.03387814004164936 5	0.14266015153210427	0.08669466803596046
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6802948	Signaling by high-kinase activity BRAF mutants	7/508	34/8290	0.03393268555613127 85	0.14373269271279802	0.08760035900924001
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6802953	FGFR3A-mediated IL10 synthesis	7/508	34/8290	0.03393268555613127 85	0.14373269271279802	0.08760035900924001
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6802952	Signaling by BRAF and RAF fusions	10/508	62/8290	0.04105428892037054	0.14956433873562642	0.09911545558690378
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1251985	Nuclear signaling by ERBB4	6/508	26/8290	0.04172738025920637	0.14987694497974621	0.09913450791619225
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1250347	SHC1 events in ERBB4 signaling	4/508	12/8290	0.04645408404018533	0.16252576954731052	0.09990541225618392
aUC_CD66a+_vs_HC_CD66a+	R-HSA-162594	Early Phase of HIV Life Cycle	4/508	12/8290	0.04645408404018533	0.16252576954731052	0.09990541225618392
aUC_CD66a+_vs_HC_CD66a+	R-HSA-169893	Prolonged ERK activation events	4/508	12/8290	0.04645408404018533	0.16252576954731052	0.09990541225618392
aUC_CD66a+_vs_HC_CD66a+	R-HSA-170670	Adenylate cyclase inhibitory pathway	4/508	12/8290	0.04645408404018533	0.16252576954731052	0.09990541225618392
aUC_CD66a+_vs_HC_CD66a+	R-HSA-179812	GRB2 events in EGFR signaling	4/508	12/8290	0.04645408404018533	0.16252576954731052	0.09990541225618392
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2299718	Condensation of Prophase Chromosomes	4/508	12/8290	0.04645408404018533	0.16252576954731052	0.09990541225618392
aUC_CD66a+_vs_HC_CD66a+	R-HSA-264870	Caspase-mediated cleavage of cytoskeletal proteins	4/508	12/8290	0.04645408404018533	0.16252576954731052	0.09990541225618392
aUC_CD66a+_vs_HC_CD66a+	R-HSA-418885	DCC mediated attractive signaling	4/508	12/8290	0.04645408404018533	0.16252576954731052	0.09990541225618392
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5654719	SHC-mediated cascade:FGFR4	4/508	12/8290	0.04645408404018533	0.16252576954731052	0.09990541225618392
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8984722	Interleukin-35 Signalling	4/508	12/8290	0.04645408404018533	0.16252576954731052	0.09990541225618392
aUC_CD66a+_vs_HC

aUC_CD66a+_vs_HC_CD66a+	R-HSA-5693532	DNA Double-Strand Break Repair	15/508	125/8290	0.009234979843639423	0.029158426372720 39	0.017771103916206975
aUC_CD66a+_vs_HC_CD66a+	R-HSA-3000170	Syndecan interactions	5/508	22/8290	0.009342020099853620	0.029158426372720 39	0.017771103916206975
aUC_CD66a+_vs_HC_CD66a+	R-HSA-450302	activated TAK1 mediates p38 MAPK activation	5/508	22/8290	0.009342020099853620	0.029158426372720 39	0.017771103916206975
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8862803	Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models	5/508	22/8290	0.009342020099853620	0.029158426372720 39	0.017771103916206975
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8863678	Neurodegenerative Diseases	5/508	22/8290	0.009342020099853620	0.029158426372720 39	0.017771103916206975
aUC_CD66a+_vs_HC_CD66a+	R-HSA-912446	Meiotic recombination	5/508	22/8290	0.009342020099853620	0.029158426372720 39	0.017771103916206975
aUC_CD66a+_vs_HC_CD66a+	R-HSA-76005	Response to elevated platelet cytosolic Ca2+	13/508	103/8290	0.009902800944617386	0.030807826463525568	0.018776359139588 17
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9656223	Signaling by RAF1 mutants	7/508	40/8290	0.009924851420201521	0.030807826463525568	0.018776359139588 17
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5693571	Nonhomologous End-Joining (NHEJ)	6/508	31/8290	0.010180838111828945	0.031516091750552 44	0.019208023587459842
aUC_CD66a+_vs_HC_CD66a+	R-HSA-69656	Cyclin A:Cdk2-associated events at S phase entry	11/508	82/8290	0.010993295479892662	0.033780665582968 1	0.020587841336393433
aUC_CD66a+_vs_HC_CD66a+	R-HSA-193639	p75NTR signals via NF-kB	4/508	15/8290	0.011061257132640 04	0.033780665582968 1	0.020587841336393433
aUC_CD66a+_vs_HC_CD66a+	R-HSA-399954	Sema3A PAK dependent Axon repulsion	4/508	15/8290	0.011061257132640 04	0.033780665582968 1	0.020587841336393433
aUC_CD66a+_vs_HC_CD66a+	R-HSA-432142	Platelet sensitization by LDL	4/508	15/8290	0.011061257132640 04	0.033780665582968 1	0.020587841336393433
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5358508	Mismatch Repair	4/508	15/8290	0.011061257132640 04	0.033780665582968 1	0.020587841336393433
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1368108	BMAL1:CLOCK,NPAS2 activates circadian gene expression	5/508	23/8290	0.011349112890937305	0.034381136110780655	0.020954174096411 12
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5260271	Diseases of Immune System	5/508	23/8290	0.011349112890937305	0.034381136110780655	0.020954174096411 12
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5602358	Diseases associated with the TLR signaling cascade	5/508	23/8290	0.011349112890937305	0.034381136110780655	0.020954174096411 12
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1980143	Signaling by NOTCH1	10/508	72/8290	0.011864306955194117	0.035846026080364782	0.021849765482830 6
aUC_CD66a+_vs_HC_CD66a+	R-HSA-76009	Platelet Aggregation (Plug Formation)	6/508	32/8290	0.011898827560246301	0.035854711770635796	0.021852270099444494
aUC_CD66a+_vs_HC_CD66a+	R-HSA-112314	Neurotransmitter receptors and postsynaptic signal transmission	17/508	153/8290	0.012221142781393581	0.036728261992924 41	0.022384670290647776
aUC_CD66a+_vs_HC_CD66a+	R-HSA-69615	G1/S DNA Damage Checkpoints	9/508	62/8290	0.012591789922835705	0.037742058154958 67	0.023002545779396005
aUC_CD66a+_vs_HC_CD66a+	R-HSA-388396	GPCR downstream signalling	42/508	483/8290	0.012771723674558364	0.038180377106265505	0.023269867949181 7
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5627123	RHO GTPases activate PAKs	5/508	24/8290	0.013633921819839076	0.040641669531257033	0.024769763750178 49
aUC_CD66a+_vs_HC_CD66a+	R-HSA-983231	Factors involved in megakaryocyte development and platelet production	14/508	119/8290	0.013762961137805702	0.040927650329762168	0.024940599707156 8
aUC_CD66a+_vs_HC_CD66a+	R-HSA-4655427	SUMOylation of DNA methylation proteins	4/508	16/8290	0.014047688435927162	0.041665002612317995	0.025393451678060674
aUC_CD66a+_vs_HC_CD66a+	R-HSA-3899300	SUMOylation of transcription cofactors	7/508	43/8290	0.014650963362537992	0.043227972629571 73	0.026346030608072706
aUC_CD66a+_vs_HC_CD66a+	R-HSA-75893	TNF signaling	7/508	43/8290	0.014650963362537992	0.043227972629571 73	0.026346030608072706
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6807070	PTEN Regulation	15/508	152/8290	0.014842256568861689	0.043678640757979297	0.026620698042852407
aUC_CD66a+_vs_HC_CD66a+	R-HSA-186712	Regulation of beta-cell development	6/508	34/8290	0.015928012938164 77	0.046631624441707195	0.028420444682268706
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5357905	Regulation of TNFR1 signaling	6/508	34/8290	0.015928012938164 77	0.046631624441707195	0.028420444682268706
aUC_CD66a+_vs_HC_CD66a+	R-HSA-354192	Integrin signaling	5/508	25/8290	0.016202470242059945	0.047070253329295876	0.028687774571636 5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8874081	MET activates PTK2 signaling	5/508	25/8290	0.016202470242059945	0.047070253329295876	0.028687774571636 5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9013507	NOTCH3 Activation and Transmission of Signal to the Nucleus	5/508	25/8290	0.016202470242059945	0.047070253329295876	0.028687774571636 5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5663202	Diseases of signal transduction by growth factor receptors and second messengers	38/213	356/8290	3.161017458814736e-14	1.521231377049577e-11	1.022066260546816e-11
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling	20/213	87/8290	3.365556143914994e-14	1.521231377049577e-11	1.022066260546816e-11
aUC_CD66a+_vs_HC_CD66a+	R-HSA-449147	Signaling by Interleukins	37/213	376/8290	9.113352935658408e-13	2.640391522089408e-10	1.773993838199334e-10
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	40/213	439/8290	1.168314832782939e-12	2.640391522089408e-10	1.773993838199334e-10
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2559583	Cellular Senescence	19/213	123/8290	2.525455051877922 4e-10	4.422912408020539e-8	2.971612134878262e-8
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2559585	Oncogene Induced Senescence	11/213	33/8290	2.935561381075793e-10	4.422912408020539e-8	2.971612134878262e-8
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9006925	Intracellular signaling by second messengers	27/213	273/8290	1.346338661190326e-9	1.709557131635428 5e-7	1.148596256350354e-7
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1257604	PIP3 activates AKT signaling	25/213	237/8290	1.512882417376485 3e-9	1.709557131635428 5e-7	1.148596256350354e-7
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2219528	PI3K/AKT Signaling in Cancer	15/213	83/8290	2.230990301160992e-9	2.240905813610596 3e-7	1.505592285110985 4e-7
aUC_CD66a+_vs_HC_CD66a+	R-HSA-109606	Intrinsic Pathway for Apoptosis	12/213	51/8290	3.993006260402225e-9	3.609677610503646e-7	2.42522587461601e-7
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8939211	ESR-mediated signaling	19/213	154/8290	1.217863339106659 2e-8	1.000862235047654 4e-6	6.724470303009975e-7
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9006931	Signaling by Nuclear Receptors	22/213	219/8290	3.813264874706316e-8	2.872659538945247 6e-6	1.930047221671536e-6
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2262752	Cellular responses to stress	34/213	479/8290	4.899695343863044e-8	3.407177621939933e-6	2.289169403570021 5e-6
aUC_CD66a+_vs_HC_CD66a+	R-HSA-199418	Negative regulation of the PI3K/AKT network	14/213	91/8290	6.641504663194 8e-8	4.288514436658285 6e-6	2.881314429068143e-6
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8953897	Cellular responses to external stimuli	34/213	490/8290	8.535925342014287e-8	5.144317672787277e-6	3.456300998134908e-6
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9009391	Extra-nuclear estrogen signaling	12/213	68/8290	1.246666723239047e-7	7.043666986300608e-6	4.732412495453483e-6
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6811558	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	13/213	84/8290	1.847671591236105 9e-7	9.825265402808474e-6	6.601278688193395e-6
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2428928	IRS-related events triggered by IGF1R	9/213	2.124410528782247e-7	1.066926176677306 3e-5	7.168332602099698e-6	4.732412495453483e-6
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2428924	IGF1R signaling cascade	9/213	37/8290	2.745237283949355 4e-7	1.306155002468534e-5	8.775633866142815e-6
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	9/213	38/8290	3.517747503583523e-7	1.590021871619752 4e-5	1.068284373456806e-5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5683057	MAPK family signaling cascades	23/213	278/8290	6.453351700414097e-7	2.778014255797308 6e-5	1.866458110846583 7e-5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-4420097	VEGFA-VEGFR2 Pathway	13/213	94/8290	7.090290543256884e-7	2.913464841411002 6e-5	1.957462892301057 7e-5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-194138	Signaling by VEGF	13/213	99/8290	1.300217470452406e-6	5.110419970821609e-5	3.433522622632052 76e-5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer	10/213	57/8290	1.526350181694409 6e-6	5.749225315148942 5e-5	3.862737082621379e-5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9659787	Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects	6/213	17/8290	2.619515311210819 5e-6	9.107852335902233e-5	6.119272609589648 e-5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9661069	Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	6/213	17/8290	2.619515311210819 5e-6	9.107852335902233e-5	6.119272609589648 e-5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2559580	Oxidative Stress Induced Senescence	10/213	62/8290	3.397164912595562e-6	1.029458909842556 4e-4	6.916602130637578 e-5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-109581	Apoptosis	16/213	161/8290	3.443756697816296e-6	1.029458909842556 4e-4	6.916602130637578 e-5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-195721	Signaling by WNT	20/213	241/8290	3.455941940340827e-6	1.029458909842556 4e-4	6.916602130637578 e-5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-166520	Signaling by NTRKs	14/213	93/8290	3.521639821223141e-6	1.029458909842556 4e-4	6.916602130637578 e-5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-187037	Signaling by NTRK1 (TRKA)	13/213	108/8290	3.530224137734404e-6	1.029458909842556 4e-4	6.916602130637578 e-5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9616222	Transcriptional regulation of granulopoiesis	7/213	27/8290	3.840678741581918e-6	1.078874511520972e-4	7.248609608146261e-5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8848021	Signaling by PTK6	9/213	50/8290	4.136508069310199e-6	1.078874511520972e-4	7.248609608146261e-5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9006927	Signaling by Non-Receptor Tyrosine Kinases	9/213	50/8290	4.136508069310199e-6	1.078874511520972e-4	7.248609608146261e-5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5684996	MAPK1/MAPK3 signaling	20/213	244/8290	4.177058396375444 4e-06	1.078874511520972e-4	7.248609608146261e-5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-74751	Insulin receptor signalling cascade	8/213	39/8290	5.160000172133727e-6	1.295733376558024 8e-4	8.705614325500047e-5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9607240	FLT3 Signaling	20/213	252/8290	6.815063659064572e-6	1.665085237282009e-4	1.118717419994538e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5357801	Programmed Cell Death	16/213	173/8290	8.752072393434084e-6	2.082071958850558e-4	1.398879644878522e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-389357	CD28 dependent PI3K/Akt signaling	6/213	21/8290	1.053691400186096 8e-5	2.442402630174952 7e-4	1.640971492327605 7e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8986944	Transcriptional Regulation by MECP2	9/213	56/8290	1.094270061055921 2e-5	2.454595631780712 6e-4	1.649164181266784e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2173793	Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	8/213	43/8290	1.113257276581960 4e-5	2.454595631780712 6e-4	1.649164181266784e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5673001	RAF/MAP kinase cascade	19/213	239/8290	1.141800031152909 9e-5	2.457588636481510 3e-4	1.651174481140925e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-170834	Signaling by TGF-beta Receptor Complex	10/213	72/8290	1.354061881755539e-5	2.846678932806993e-4	1.912591690998644e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8878159	Transcriptional regulation by RUNX3	11/213	90/8290	1.745674865607357 4e-5	3.585658360247843 4e-4	2.409699515443649e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-74752	Signaling by Insulin receptor	9/213	60/8290	1.953330085276449e-5	3.923427428353387 6e-4	2.636024250306374e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-112399	IRS-mediated signalling	7/213	34/8290	1.996434310887858e-5	3.923427428353387 6e-4	2.636024250306374e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-69231	Cyclin D associated events in G1	8/213	47/8290	2.210002155743383e-5	4.162170726651921e-4	2.796428166369538 e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-69236	G1 Phase	8/213	47/8290	2.210002155743383e-5	4.162170726651921e-4	2.796428166369538 e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-157118	Signaling by NOTCH	15/213	168/8290	2.562893726027752e-5	4.728277404753240 6e-4	3.176776970822799e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9006936	Signaling by TGFB family members	11/213	94/8290	2.647749812555426e-5	4.787122926110020 6e-4	3.216313377230417e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2559582	Senescence-Associated Secretory Phenotype (SASP)	8/213	49/8290	3.032587755020966e-5	5.375410452037153e-4	3.611566777393383e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-201681	TCF dependent signaling in response to WNT	14/213	154/8290	3.922515668195785e-5	6.819142623171113e-4	4.581561822973615e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1226099	Signaling by FGFR in disease	8/213	51/8290	4.007054450184934e-5	6.988185439560124e-4	4.695134891274485e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1433557	Signaling by SCF-KIT	7/213	41/8290	7.161389633867375e-5	0.001988696720400189	8.054818360119831e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8878166	Transcriptional regulation by RUNX2	11/213	105/8290	7.462494635680776e-5	0.001207349771782408 5	8.111793411165556e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-114452	Activation of BHS-only proteins	6/213	29/8290	7.766234778919947e-5	0.001207349771782408 5	8.111793411165556e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-186763	Downstream signal transduction	6/213	29/8290	7.766234778919947e-5	0.001207349771782408 5	8.111793411165556e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2559584	Formation of Senescence-Associated Heterochromatin Foci (SAHF)	4/213	10/8290	7.879827050349796e-5	0.001207349771782408 5	8.111793411165556e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8853334	Signaling by FGFR3 fusions in cancer	4/213	10/8290	7.879827050349796e-5	0.001207349771782408 5	8.111793411165556e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-109704	PI3K Cascade	6/213	30/8290	9.501659698343856e-5	0.001408114814384703 6	9.460668932232718e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5655302	Signaling by FGFR1 in disease	6/213	30/8290	9.501659698343856e-5	0.001408114814384703 6	9.460668932232718e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2173796	SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	6/213	31/8290	1.153198079521724e-4	0.001681064257866392	0.001129452814146542 7
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5218921	VEGFR2 mediated cell proliferation	5/213	20/8290	1.208729831430658 6e-4	0.001681064257866392	0.001129452814146542 7
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9669938	Signaling by KIT in disease	5/213	20/8290	1.208729831430658 6e-4	0.001681064257866392	0.001129452814146542 7
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9670439	Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	5/213	20/8290	1.208729831430658 6e-4	0.001681064257866392	0.001129452814146542 7
aUC_CD66a+_vs_HC_CD66a+	R-HSA-389356	CD28 co-stimulation	6/213	32/8290	1.389207518879346e-4	0.001909073300750574	0.012772026019250 64
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6807070	PTEN Regulation	12/213	132/8290	1.408907029901267e-4	0.001909073300750574	0.012772026019250 64
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1912408	Pre-NOTCH Transcription and Translation	6/213	33/8290	1.661910980982594e-4	0.002160520790031294 3	0.014515841824034197
aUC_CD66a+_vs_HC_CD66a+	R-HSA-4791275	Signaling by WNT in cancer	6/213	33/8290	1.661910980982594e-4	0.002160520790031294 3	0.014515841824034197
aUC_CD66a+_vs_HC_CD66a+	R-HSA-109582	Hemostasis	26/213	470/8290	1.672969632985685e-4	0.002160520790031294 3	0.014515841824034197
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9673767	Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants	4/213	12/8290	1.783552524853476e-4	0.002239349281204916	0.015045465012287376
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9673770	Signaling by PDGFRA extracellular domain mutants	4/213	12/8290	1.783552524853476e-4	0.002239349281204916	0.015045465012287376
aUC_CD66a+_vs_HC_CD66a+	R-HSA-198753	ERK/MAPK targets	5/213	22/8290	1.968745809954252 6e-4	0.002372994945958192	0.015943387120611982
aUC_CD66a+_vs_HC_CD66a+	R-HSA-912526	Interleukin receptor SHC signaling	5/213	22/8290	1.968745809954252 6e-4	0.002372994945958192	0.015943387120611982
aUC_CD66a+_vs_HC_CD66a+	R-HSA-912631	Regulation of signaling by CBL	5/213	22/8290	1.968745809954252 6e-4	0.002372994945958192	0.015943387120611982
aUC_CD66a+_vs_HC_CD66a+	R-HSA-3371453	Regulation of HSF1-mediated heat shock response	6/213	35/8290	2.385967651261932 8e-4	0.002880460693957 13	0.019067915621168821
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9006335	Signaling by Erythropoietin	5/213	23/8290	2.463464800163716e-4	0.002892171661490908	0.019431567870054 19
aUC_CD66a+_vs_HC_CD66a+	R-HSA-3371556	Cellular response to heat stress	9/213	83/8290	2.605807185372 3e-4	0.002985141382909283	0.020005620141987257
aUC_CD66a+_vs_HC_CD66a+	R-HSA-451927	Interleukin-2 family signaling	6/213	36/8290	2.740782464396797e-4	0.002985141382909283	0.020005620141987257
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6806003	Regulation of TP53 Expression and Degradation	6/213	36/8290	2.740782464396797e-4	0.002985141382909283	0.020005620141987257
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8853659	RET signaling	6/213	36/8290	2.740782464396797e-4	0.002985141382909283	0.020005620141987257
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9675126	Diseases of mitotic cell cycle	6/213	36/8290	2.740782464396797e-4	0.002985141382909283	0.020005620141987257
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9687139	Aberrant regulation of mitotic cell cycle due to RB1 defects	6/213	36/8290	2.740782464396797e-4	0.002985141382909283	0.020005620141987257
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8853884	Transcriptional Regulation by VENTX	5/213	23/8290	3.201995130351314e-4	0.003445956664092823	0.023152270054409393
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5655332	Signaling by FGFR3 in disease	4/213	14/8290	3.463588345896947e-4	0.003598946970909012	0.024180163043950862
aUC_CD66a+_vs_HC_CD66a+	R-HSA-71336	Pentose phosphate pathway	4/213	14/8290	3.463588345896947e-4	0.003598946970909012	0.024180163043950862
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8853338	Signaling by FGFR3 point mutants in cancer	4/213	14/8290	3.463588345896947e-4	0.003598946970909012	0.024180163043950862
aUC_CD66a+_vs_HC_CD66a+	R-HSA-453279	Mitotic G1 phase and G1/S transition	12/213	146/8290	3.626375064645031 7e-4	0.003725278200771714	0.025028928387679645 3
aUC_CD66a+_vs_HC_CD66a+	R-HSA-210993	Tie2 Signaling	4/213	15/8290	4.628510441489052e-4	0.004701318470905734	0.003158664133340253
aUC_CD66a+_vs_HC_CD66a+	R-HSA-190236	Signaling by FGFR	8/213	73/8290	5.330445146068763e-4	0.005354136013384624	0.003597271168750499
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5689880	Ub-specific processing proteases	12/213	154/8290	5.890507352565991e-4	0.005851668842549073	0.039315474175021 13
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5218920	VEGFR2 mediated vascular permeability	5/213	28/8290	6.480739630454721e-4	0.006295576622914716	0.042332484548123 66
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8941326	RUNX2 regulates bone development	5/213	28/8290	6.480739630454721e-4	0.006295576622914716	0.042332469458712 366
aUC_CD66a+_vs_HC_CD66a+	R-HSA-512988	Interleukin-3, Interleukin-5 and GM-CSF signaling	6/213	43/8290	7.386450663463492e-4	0.007103565318905316	0.047726562517563 66
aUC_CD66a+_vs_HC_CD66a+	R-HSA-111471	Apoptotic factor-mediated response	4/213	17/8290	7.750681219027188e-4	0.007149607975061282	0.048035390826281277
aUC_CD66a+_vs_HC_CD66a+	R-HSA-452723	Transcriptional regulation of pluripotent stem cells	4/213	17/8290	7.750681219027188e-4	0.007149607975061282	0.048035390826281277
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5654708	Downstream signaling of activated FGFR3	4/213	17/8290	7.750681219027188e-4	0.007149607975061282	0.048035390826281277
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8934593	Regulation of RUNX1 Expression and Activity	4/213	17/8290	7.750681219027188e-4	0.007149607975061282	0.048035390826281277
aUC_CD66a+_vs_HC_CD66a+	R-HSA-450294	MAP kinase activation	7/213	61/8290	8.998693431689614e-4	0.008069768259817 9	0.054199413467530 18
aUC_CD66a+_vs_HC_CD66a+	R-HSA-450282	MAPK targets/ Nuclear events mediated by MAP kinases	5/213	30/8290	9.012883400709724e-4	0.008069768259817 9	0.054199413467530 18
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8864260	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	5/213	30/8290	9.012883400709724e-4	0.008069768259817 9	0.054199413467530 18
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5654696	Downstream signaling of activated FGFR2	4/213	18/8290	9.766126332299305e-4	0.008386660555419874	0.056347262593999 5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6803204	TP53 Regulates Transcription of Genes Involved in Cytochrome C Release	4/213	18/8290	9.766126332299305e-4	0.008386660555419874	0.056347262593999 5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-168142	Toll Like Receptor 10 (TLR10) Cascade	8/213	80/8290	9.859924433440034e-4	0.008386660555419874	0.056347262593999 5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-168176	Toll Like Receptor 5 (TLR5) Cascade	8/213	80/8290	9.859924433440034e-4	0.008386660555419874	0.056347262593999 5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-975871	MyD88 cascade initiated on plasma membrane	8/213	80/8290	9.859924433440034e-4	0.008386660555419874	0.056347262593999 5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-388841	Costimulation by the CD28 family	7/213	62/8290	0.009926688891469755	0.008386660555419874	0.056347262593999 5
aUC_CD66a+_vs_HC_CD66a+	R-HSA-76002	Platelet activation, signaling and aggregation	14/213	211/8290	0.010050528739700834	0.008728461153918 54	0.058643711556939 6
aUC_CD66a+_vs_HC_CD66a+	R-HSA-187687	Signalling to ERKs	5/213	31/8290	0.010052436134709204	0.008728461153918 54	0.058643711556939 6
aUC_CD66a+_vs_HC_CD66a+	R-HSA-202733	Cell surface interactions at the vascular wall	9/213	101/8290	0.011117907741989794	0.009138696726142815	0.061387873369635 75
aUC_CD66a+_vs_HC_CD66a+	R-HSA-975138	TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation	8/213	82/8290	0.011603878379941753	0.009450368157363 47	0.063439395756497289
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1227986	Signaling by ERBB2	6/213	47/8290	0.011946112675972468	0.009642185170242 9	0.064782960582341 6
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9671555	Signaling by PDGFR in disease	4/213	19/8290	0.012123535389599738	0.009687118488087 85	0.065084622352430 02
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5654741	Signaling by FGFR3	5/213	32/8290	0.012216056500464767	0.009687118488087 85	0.065084622352430 02
aUC_CD66a+_vs_HC_CD66a+	R-HSA-168181	Toll Like Receptor 7/8 (TLR7/8) Cascade	8/213	83/8290	0.01256367264069581	0.009791000057921563	0.065578256909866863
aUC_CD66a+_vs_HC_CD66a+	R-HSA-975155	MyD88 dependent cascade initiated on endosome	8/213	83/8290	0.01256367264069581	0.009791000057921563	0.065578256909866863
aUC_CD66a+_vs_HC_CD66a+	R-HSA-3700989	Transcriptional Regulation by TP53	19/213	343/8290	0.012883360178440075	0.009954322736131862	0.066887988144792833
aUC_CD66a+_vs_HC_CD66a+	R-HSA-448424	Interleukin-17 signaling	7/213	66/8290	0.014416375246975011	0.011044409511241873	0.074203822636080 13
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1250196	SHC1 events in ERBB2 signaling	4/213	20/8290	0.014852259912138874	0.011231542559211754	0.075461091833934
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1912422	Pre-NOTCH Expression and Processing	5/213	49/8290	0.014909127290989054	0.011231542559211754	0.075461091833934
aUC_CD66a+_vs_HC_CD66a+	R-HSA-168138	Toll Like Receptor 9 (TLR9) Cascade	8/213	86/8290	0.015827789313499862	0.011825059123474277	0.079948755457366
aUC_CD66a+_vs_HC_CD66a+	R-HSA-186797	Signaling by PDGF	6/213	50/8290	0.016565513348094025	0.012289593497276229	0.082569811922784044
aUC_CD66

qUC_CD66a+_vs_HC_CD66a+	R-HSA-1502540	Signaling by Activin	3/213	12/8290	0.003099410681008318 7	0.017511670347697003	0.011765526071985525
qUC_CD66a+_vs_HC_CD66a+	R-HSA-169893	Prolonged ERK activation events	3/213	12/8290	0.003099410681008318 7	0.017511670347697003	0.011765526071985525
qUC_CD66a+_vs_HC_CD66a+	R-HSA-2299718	Condensation of Prophase Chromosomes	3/213	12/8290	0.003099410681008318 7	0.017511670347697003	0.011765526071985525
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5654706	FRS-mediated FGFR3 signaling	3/213	12/8290	0.003099410681008318 7	0.017511670347697003	0.011765526071985525
qUC_CD66a+_vs_HC_CD66a+	R-HSA-6804759	Regulation of TP53 Activity through Association with Co-factors	3/213	12/8290	0.003099410681008318 7	0.017511670347697003	0.011765526071985525
qUC_CD66a+_vs_HC_CD66a+	R-HSA-400685	Sema4D in semaphorin signaling	4/213	25/8290	0.003507221850983721 5	0.019571163909193112	0.013149233320452 29
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5674400	Constitutive Signaling by AKT1 E17K in Cancer	4/213	25/8290	0.003507221850983721 5	0.019571163909193112	0.013149233320452 29
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5633008	TP53 Regulates Transcription of Cell Death Genes	5/213	41/8290	0.003770735489443823 5	0.020809122964665593	0.013989078051481196
qUC_CD66a+_vs_HC_CD66a+	R-HSA-6802957	Oncogenic MAPK signaling	7/213	78/8290	0.003775106378545528	0.020809122964665593	0.013989078051481196
qUC_CD66a+_vs_HC_CD66a+	R-HSA-373755	Semaphorin interactions	6/213	59/8290	0.003884916152895668 3	0.021147697351096 57	0.014208455253356685
qUC_CD66a+_vs_HC_CD66a+	R-HSA-203615	eNOS activation	3/213	13/8290	0.003953496518070044	0.021147697351096 57	0.014208455253356685
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5654700	FRS-mediated FGFR2 signaling	3/213	13/8290	0.003953496518070044	0.021147697351096 57	0.014208455253356685
qUC_CD66a+_vs_HC_CD66a+	R-HSA-6803205	TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain	3/213	13/8290	0.003953496518070044	0.021147697351096 57	0.014208455253356685
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9027284	Erythropoietin activates RAS	3/213	13/8290	0.003953496518070044	0.021147697351096 57	0.014208455253356685
qUC_CD66a+_vs_HC_CD66a+	R-HSA-2559586	DNA Damage/Telomere Stress Induced Senescence	4/213	26/8290	0.004062666573106123	0.021477488784139 97	0.014430031472343695
qUC_CD66a+_vs_HC_CD66a+	R-HSA-442742	CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling	4/213	26/8290	0.004062666573106123	0.021477488784139 97	0.014430031472343695
qUC_CD66a+_vs_HC_CD66a+	R-HSA-198725	Nuclear Events (kinase and transcription factor activation)	6/213	60/8290	0.004226123586840815	0.022211719316884 28	0.014923337268097617
qUC_CD66a+_vs_HC_CD66a+	R-HSA-69202	Cyclin E associated events during G1/S transition	7/213	80/8290	0.004348132971687 23	0.022720881506592634	0.015265426908830 87
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5654738	Signaling by FGFR2	6/213	61/8290	0.004588987686150484	0.023841637174023204	0.016018426466478098
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5628897	TP53 Regulates Metabolic Genes	7/213	81/8290	0.004568193358505014	0.024062897151815612	0.016167083990381 65
qUC_CD66a+_vs_HC_CD66a+	R-HSA-1963642	PI3K events in ERBB2 signaling	3/213	14/8290	0.004937261340837412	0.024523539846796817	0.016476574862135263
qUC_CD66a+_vs_HC_CD66a+	R-HSA-4839735	AXIN mutants destabilize the destruction complex, activating WNT signaling	3/213	14/8290	0.004937261340837412	0.024523539846796817	0.016476574862135263
qUC_CD66a+_vs_HC_CD66a+	R-HSA-4839744	truncated APC mutants destabilize the destruction complex	3/213	14/8290	0.004937261340837412	0.024523539846796817	0.016476574862135263
qUC_CD66a+_vs_HC_CD66a+	R-HSA-4839748	AMER1 mutants destabilize the destruction complex	3/213	14/8290	0.004937261340837412	0.024523539846796817	0.016476574862135263
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5467337	APC truncation mutants have impaired AXIN binding	3/213	14/8290	0.004937261340837412	0.024523539846796817	0.016476574862135263
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5467340	AXIN missense mutants destabilize the destruction complex	3/213	14/8290	0.004937261340837412	0.024523539846796817	0.016476574862135263
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5467348	Truncations of AMER1 destabilize the destruction complex	3/213	14/8290	0.004937261340837412	0.024523539846796817	0.016476574862135263
qUC_CD66a+_vs_HC_CD66a+	R-HSA-69656	Cyclin A:Cdk2-associated events at S phase entry	7/213	82/8290	0.004846554556600691	0.024823653179579 37	0.016543837779014088
qUC_CD66a+_vs_HC_CD66a+	R-HSA-2454202	Fc epsilon receptor (FCERI) signaling	9/213	126/8290	0.005056179252241636 5	0.024693861765358913	0.016591008661634 95
qUC_CD66a+_vs_HC_CD66a+	R-HSA-6802946	Signaling by moderate kinase activity BRAF mutants	5/213	44/8290	0.005135449128194 11	0.024693861765358913	0.016591008661634 95
qUC_CD66a+_vs_HC_CD66a+	R-HSA-6802949	Signaling by RAS mutants	5/213	44/8290	0.005135449128194 11	0.024693861765358913	0.016591008661634 95
qUC_CD66a+_vs_HC_CD66a+	R-HSA-6802955	Paradoxical activation of RAF signaling by kinase inactive BRAF	5/213	44/8290	0.005135449128194 11	0.024693861765358913	0.016591008661634 95
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9649948	Signaling downstream of RAS mutants	5/213	44/8290	0.005135449128194 11	0.024693861765358913	0.016591008661634 95
qUC_CD66a+_vs_HC_CD66a+	R-HSA-2730905	Role of LAT2/NTAL/LAB on calcium mobilization	3/213	15/8290	0.006055863915005 54	0.027612437590625 66	0.018551905554018405
qUC_CD66a+_vs_HC_CD66a+	R-HSA-4839743	phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex	3/213	15/8290	0.006055863915005 54	0.027612437590625 66	0.018551905554018405
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5339716	Missplaced GSK3beta mutants stabilize beta-catenin	3/213	15/8290	0.006055863915005 54	0.027612437590625 66	0.018551905554018405
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5358747	S33 mutants of beta-catenin aren't phosphorylated	3/213	15/8290	0.006055863915005 54	0.027612437590625 66	0.018551905554018405
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5358749	S37 mutants of beta-catenin aren't phosphorylated	3/213	15/8290	0.006055863915005 54	0.027612437590625 66	0.018551905554018405
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5358751	S45 mutants of beta-catenin aren't phosphorylated	3/213	15/8290	0.006055863915005 54	0.027612437590625 66	0.018551905554018405
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5358752	T41 mutants of beta-catenin aren't phosphorylated	3/213	15/8290	0.006055863915005 54	0.027612437590625 66	0.018551905554018405
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9617828	FOXO-mediated transcription of cell cycle genes	3/213	15/8290	0.006055863915005 54	0.027612437590625 66	0.018551905554018405
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9665348	Signaling by ERBB2 ECD mutants	3/213	15/8290	0.006055863915005 54	0.027612437590625 66	0.018551905554018405
qUC_CD66a+_vs_HC_CD66a+	R-HSA-4641262	Disassembly of the destruction complex and recruitment of AXIN to the membrane	4/213	29/8290	0.006078401637759409	0.027612437590625 66	0.018551905554018405
qUC_CD66a+_vs_HC_CD66a+	R-HSA-8979227	Triglyceride metabolism	4/213	29/8290	0.006078401637759409	0.027612437590625 66	0.018551905554018405
qUC_CD66a+_vs_HC_CD66a+	R-HSA-881907	Gastrin-CREB signalling pathway via PKC and MAPK	3/213	16/8290	0.007313804388265156	0.032893926203938814	0.022100367279544363
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9022699	MECP2 regulates neuronal receptors and channels	3/213	16/8290	0.007313804388265156	0.032893926203938814	0.022100367279544363
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5655253	Signaling by FGFR2 in disease	4/213	31/8290	0.007737464972845706	0.034287589879669 21	0.023036724919153626
qUC_CD66a+_vs_HC_CD66a+	R-HSA-8964043	Plasma lipoprotein clearance	4/213	31/8290	0.007737464972845706	0.034287589879669 21	0.023036724919153626
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9022692	Regulation of MECP2 expression and activity	4/213	31/8290	0.007737464972845706	0.034287589879669 21	0.023036724919153626
qUC_CD66a+_vs_HC_CD66a+	R-HSA-3858494	Beta-catenin independent WNT signaling	9/213	136/8290	0.008254639533575 42	0.036400947016352096	0.024456621365201627
qUC_CD66a+_vs_HC_CD66a+	R-HSA-2173789	TGF-beta receptor signaling activates SMADs	4/213	32/8290	0.008668302018959895	0.037515837106867 66	0.025205680031046 39
qUC_CD66a+_vs_HC_CD66a+	R-HSA-1181150	Signaling by NODAL	3/213	17/8290	0.008714962159781204	0.037515837106867 66	0.025205680031046 39
qUC_CD66a+_vs_HC_CD66a+	R-HSA-1810476	RIP-mediated NFkB activation via ZBP1	3/213	17/8290	0.008714962159781204	0.037515837106867 66	0.025205680031046 39
qUC_CD66a+_vs_HC_CD66a+	R-HSA-196299	Beta-catenin phosphorylation cascade	3/213	17/8290	0.008714962159781204	0.037515837106867 66	0.025205680031046 39
qUC_CD66a+_vs_HC_CD66a+	R-HSA-202131	Metabolism of nitric oxide: NOS3 activation and regulation	3/213	17/8290	0.008714962159781204	0.037515837106867 66	0.025205680031046 39
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5654743	Signaling by FGFR4	4/213	33/8290	0.009669437120109599	0.041427351452981 41	0.027833700259178 8
qUC_CD66a+_vs_HC_CD66a+	R-HSA-166016	Toll Like Receptor 4 (TLR4) Cascade	8/213	116/8290	0.009865124029955019	0.042066377939053 48	0.028263041535670 54
qUC_CD66a+_vs_HC_CD66a+	R-HSA-1980143	Signaling by NOTCH1	6/213	72/8290	0.010237686153991734	0.042556969664415 98	0.028592654280819776
qUC_CD66a+_vs_HC_CD66a+	R-HSA-163560	Triglyceride catabolism	3/213	18/8290	0.010262632065091464	0.042556969664415 98	0.028592654280819776
qUC_CD66a+_vs_HC_CD66a+	R-HSA-1839117	Signaling by cytosolic FGFR1 fusion mutants	3/213	18/8290	0.010262632065091464	0.042556969664415 98	0.028592654280819776
qUC_CD66a+_vs_HC_CD66a+	R-HSA-3232118	SUMOylation of transcription factors	3/213	18/8290	0.010262632065091464	0.042556969664415 98	0.028592654280819776
qUC_CD66a+_vs_HC_CD66a+	R-HSA-622312	Inflammasomes	3/213	18/8290	0.010262632065091464	0.042556969664415 98	0.028592654280819776
qUC_CD66a+_vs_HC_CD66a+	R-HSA-8964038	LDL clearance	3/213	18/8290	0.010262632065091464	0.042556969664415 98	0.028592654280819776
qUC_CD66a+_vs_HC_CD66a+	R-HSA-69278	Cell Cycle, Mitotic	21/213	477/8290	0.010827533076241886	0.044694474433436 83	0.030028774741608116
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5673000	RAF activation	4/213	35/8290	0.011890257984804638	0.048050850148171266	0.032283815248596 67
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9029569	NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux	4/213	35/8290	0.011890257984804638	0.048050850148171266	0.032283815248596 67
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5621575	CD209 (DC-SIGN) signaling	3/213	19/8290	0.011959558941746166	0.048050850148171266	0.032283815248596 67
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5654716	Downstream signaling of activated FGFR4	3/213	19/8290	0.011959558941746166	0.048050850148171266	0.032283815248596 67
qUC_CD66a+_vs_HC_CD66a+	R-HSA-6783589	Interleukin-6 family signaling	3/213	19/8290	0.011959558941746166	0.048050850148171266	0.032283815248596 67
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9665686	Signaling by ERBB2 TMD/JMD mutants	3/213	19/8290	0.011959558941746166	0.048050850148171266	0.032283815248596 67

For Review Only

Supplementary Table S6. The list of correlations between endoscopic Mayo score and normalized expression of miRNAs expressed in crypt-bottom (CD44+) colonic epithelial cell population

mir	cell_type	estimate	statistic	p.value	method	alternative	padj
hsa-let-7a-3p	CD44+	0,381959736	10021,52289	0,008807758	Spearman's rank correlation rho	two.sided	0,008807758
hsa-let-7a-5p	CD44+	-0,343472059	21784,39943	0,019437858	Spearman's rank correlation rho	two.sided	0,019437858
hsa-let-7b-3p	CD44+	0,309654918	11193,9455	0,036245582	Spearman's rank correlation rho	two.sided	0,036245582
hsa-let-7b-5p	CD44+	-0,514746255	24561,61052	0,000252206	Spearman's rank correlation rho	two.sided	0,000252206
hsa-let-7c-5p	CD44+	-0,290238221	20921,21276	0,050387026	Spearman's rank correlation rho	two.sided	0,050387026
hsa-let-7d-3p	CD44+	-0,154318315	18717,27147	0,305842948	Spearman's rank correlation rho	two.sided	0,305842948
hsa-let-7d-5p	CD44+	-0,322887487	21450,6206	0,028621868	Spearman's rank correlation rho	two.sided	0,028621868
hsa-let-7e-5p	CD44+	-0,420004442	23025,37203	0,003661731	Spearman's rank correlation rho	two.sided	0,003661731
hsa-let-7f-1-3p	CD44+	0,205256926	12886,75895	0,171177725	Spearman's rank correlation rho	two.sided	0,171177725
hsa-let-7f-2-3p	CD44+	0,441014098	9063,956399	0,00215697	Spearman's rank correlation rho	two.sided	0,00215697
hsa-let-7f-5p	CD44+	-0,241868722	20136,90133	0,105353872	Spearman's rank correlation rho	two.sided	0,105353872
hsa-let-7g-5p	CD44+	-0,235337079	20030,99074	0,115392622	Spearman's rank correlation rho	two.sided	0,115392622
hsa-let-7i-3p	CD44+	0,119376703	14279,30677	0,429409878	Spearman's rank correlation rho	two.sided	0,429409878
hsa-let-7i-5p	CD44+	0,098304527	14620,99209	0,515716749	Spearman's rank correlation rho	two.sided	0,515716749
hsa-miR-1-3p	CD44+	0,015174524	15968,94509	0,920271335	Spearman's rank correlation rho	two.sided	0,920271335
hsa-miR-100-5p	CD44+	-0,133086292	18372,99423	0,377925261	Spearman's rank correlation rho	two.sided	0,377925261
hsa-miR-101-3p	CD44+	0,159134577	13634,63284	0,290808367	Spearman's rank correlation rho	two.sided	0,290808367
hsa-miR-103a-3p	CD44+	0,281916271	11643,72767	0,057679166	Spearman's rank correlation rho	two.sided	0,057679166
hsa-miR-106b-3p	CD44+	0,059840407	15244,68781	0,692811658	Spearman's rank correlation rho	two.sided	0,692811658
hsa-miR-106b-5p	CD44+	-0,088935908	17657,09574	0,556693985	Spearman's rank correlation rho	two.sided	0,556693985
hsa-miR-10a-3p	CD44+	0,091508979	14731,1819	0,545288742	Spearman's rank correlation rho	two.sided	0,545288742
hsa-miR-10a-5p	CD44+	-0,284159462	20822,64567	0,055634958	Spearman's rank correlation rho	two.sided	0,055634958
hsa-miR-10b-3p	CD44+	0,161006736	13604,27578	0,28509604	Spearman's rank correlation rho	two.sided	0,28509604
hsa-miR-10b-5p	CD44+	-0,541994422	25003,43956	0,000100079	Spearman's rank correlation rho	two.sided	0,000100079
hsa-miR-1180-3p	CD44+	0,570929431	6957,37928	3,42351E-05	Spearman's rank correlation rho	two.sided	3,42351E-05
hsa-miR-122-5p	CD44+	0,048302021	15431,78273	0,749900445	Spearman's rank correlation rho	two.sided	0,749900445
hsa-miR-1224-5p	CD44+	0,184179313	13228,53244	0,220461425	Spearman's rank correlation rho	two.sided	0,220461425
hsa-miR-1246	CD44+	0,139341719	13955,57403	0,355710544	Spearman's rank correlation rho	two.sided	0,355710544
hsa-miR-1247-3p	CD44+	-0,370338339	22220,03617	0,01129546	Spearman's rank correlation rho	two.sided	0,01129546
hsa-miR-1247-5p	CD44+	0,128929408	14124,40965	0,393133324	Spearman's rank correlation rho	two.sided	0,393133324
hsa-miR-1248	CD44+	0,114911714	14351,70656	0,446988781	Spearman's rank correlation rho	two.sided	0,446988781
hsa-miR-1249-3p	CD44+	0,21836236	12674,25434	0,144866176	Spearman's rank correlation rho	two.sided	0,144866176
hsa-miR-125a-3p	CD44+	0,391410209	9868,283454	0,007148081	Spearman's rank correlation rho	two.sided	0,007148081
hsa-miR-125a-5p	CD44+	-0,134393504	18394,19067	0,373216125	Spearman's rank correlation rho	two.sided	0,373216125
hsa-miR-125b-5p	CD44+	-0,135185219	18407,02832	0,370381167	Spearman's rank correlation rho	two.sided	0,370381167
hsa-miR-126-3p	CD44+	0,285544962	11584,88845	0,054401745	Spearman's rank correlation rho	two.sided	0,054401745
hsa-miR-126-5p	CD44+	0,502305726	8070,112657	0,000375009	Spearman's rank correlation rho	two.sided	0,000375009
hsa-miR-1261	CD44+	0,271797846	11807,79793	0,06766082	Spearman's rank correlation rho	two.sided	0,06766082
hsa-miR-1262	CD44+	0,206708671	12863,2189	0,168103879	Spearman's rank correlation rho	two.sided	0,168103879
hsa-miR-1266-5p	CD44+	0,406369118	9625,72475	0,005073567	Spearman's rank correlation rho	two.sided	0,005073567
hsa-miR-1269a	CD44+	0,318205893	11055,29145	0,031150236	Spearman's rank correlation rho	two.sided	0,031150236
hsa-miR-127-3p	CD44+	0,260184245	11996,11246	0,080757563	Spearman's rank correlation rho	two.sided	0,080757563
hsa-miR-1271-5p	CD44+	0,231296486	12464,52748	0,121956551	Spearman's rank correlation rho	two.sided	0,121956551
hsa-miR-1275	CD44+	0,226477249	12542,67141	0,130149305	Spearman's rank correlation rho	two.sided	0,130149305
hsa-miR-128-3p	CD44+	0,069011097	15095,98505	0,648592153	Spearman's rank correlation rho	two.sided	0,648592153
hsa-miR-1287-5p	CD44+	0,252941349	12113,55602	0,089881601	Spearman's rank correlation rho	two.sided	0,089881601
hsa-miR-1290	CD44+	-0,235846446	20039,25012	0,114584573	Spearman's rank correlation rho	two.sided	0,114584573
hsa-miR-1291	CD44+	0,119838636	14271,81652	0,427613646	Spearman's rank correlation rho	two.sided	0,427613646
hsa-miR-1294	CD44+	0,45487209	8839,249058	0,001493243	Spearman's rank correlation rho	two.sided	0,001493243
hsa-miR-1296-5p	CD44+	0,286752603	11565,30654	0,053344885	Spearman's rank correlation rho	two.sided	0,053344885
hsa-miR-1299	CD44+	0,324804937	10948,28795	0,027636773	Spearman's rank correlation rho	two.sided	0,027636773
hsa-miR-1301-3p	CD44+	-0,009996318	16377,0903	0,947430314	Spearman's rank correlation rho	two.sided	0,947430314
hsa-miR-1303	CD44+	0,063051919	15192,61314	0,67720168	Spearman's rank correlation rho	two.sided	0,67720168
hsa-miR-1304-3p	CD44+	-0,265685912	20523,09706	0,074325295	Spearman's rank correlation rho	two.sided	0,074325295
hsa-miR-1304-5p	CD44+	-0,308439308	21216,34338	0,03702268	Spearman's rank correlation rho	two.sided	0,03702268
hsa-miR-1306-3p	CD44+	0,196585515	13027,36587	0,190387217	Spearman's rank correlation rho	two.sided	0,190387217
hsa-miR-1306-5p	CD44+	-0,070407454	17356,65686	0,641958274	Spearman's rank correlation rho	two.sided	0,641958274
hsa-miR-1307-3p	CD44+	0,039491623	15574,64334	0,794419825	Spearman's rank correlation rho	two.sided	0,794419825
hsa-miR-1307-5p	CD44+	-0,06753913	17310,14699	0,655614509	Spearman's rank correlation rho	two.sided	0,655614509
hsa-miR-130a-3p	CD44+	0,25712381	12045,73741	0,084520004	Spearman's rank correlation rho	two.sided	0,084520004
hsa-miR-130b-3p	CD44+	0,14820538	13811,84976	0,325628651	Spearman's rank correlation rho	two.sided	0,325628651
hsa-miR-130b-5p	CD44+	0,02305939	15841,09199	0,879098277	Spearman's rank correlation rho	two.sided	0,879098277
hsa-miR-132-3p	CD44+	-0,1729396	19019,21561	0,250416194	Spearman's rank correlation rho	two.sided	0,250416194
hsa-miR-132-5p	CD44+	0,270610091	11827,05737	0,068917355	Spearman's rank correlation rho	two.sided	0,068917355
hsa-miR-133a-3p	CD44+	0,132566611	14065,4324	0,379807147	Spearman's rank correlation rho	two.sided	0,379807147
hsa-miR-135a-3p	CD44+	0,325464841	10937,5876	0,027304344	Spearman's rank correlation rho	two.sided	0,027304344
hsa-miR-135a-5p	CD44+	0,30133604	11328,83611	0,041841922	Spearman's rank correlation rho	two.sided	0,041841922
hsa-miR-135b-5p	CD44+	0,298278367	11378,41628	0,044068517	Spearman's rank correlation rho	two.sided	0,044068517
hsa-miR-136-3p	CD44+	0,13257479	14065,29978	0,379777487	Spearman's rank correlation rho	two.sided	0,379777487
hsa-miR-139-3p	CD44+	0,172922609	13411,0599	0,250463456	Spearman's rank correlation rho	two.sided	0,250463456
hsa-miR-139-5p	CD44+	0,358525867	10401,50307	0,014418357	Spearman's rank correlation rho	two.sided	0,014418357
hsa-miR-140-3p	CD44+	0,314207697	11120,12219	0,033453462	Spearman's rank correlation rho	two.sided	0,033453462
hsa-miR-140-5p	CD44+	0,12985316	14109,43101	0,389723197	Spearman's rank correlation rho	two.sided	0,389723197
hsa-miR-141-3p	CD44+	0,258692651	12020,29866	0,082574556	Spearman's rank correlation rho	two.sided	0,082574556
hsa-miR-141-5p	CD44+	0,236179778	12385,3449	0,114058114	Spearman's rank correlation rho	two.sided	0,114058114
hsa-miR-142-3p	CD44+	0,338588156	10724,79306	0,021354053	Spearman's rank correlation rho	two.sided	0,021354053
hsa-miR-142-5p	CD44+	0,407468966	9607,890724	0,004944271	Spearman's rank correlation rho	two.sided	0,004944271
hsa-miR-143-3p	CD44+	-0,303490486	21136,09823	0,040328939	Spearman's rank correlation rho	two.sided	0,040328939
hsa-miR-143-5p	CD44+	0,350211255	10536,3245	0,017033396	Spearman's rank correlation rho	two.sided	0,017033396
hsa-miR-144-3p	CD44+	0,383050861	10003,83029	0,008600563	Spearman's rank correlation rho	two.sided	0,008600563
hsa-miR-144-5p	CD44+	0,267970569	11869,85722	0,07177599	Spearman's rank correlation rho	two.sided	0,07177599
hsa-miR-145-3p	CD44+	-0,385159778	22460,36581	0,008211992	Spearman's rank correlation rho	two.sided	0,008211992
hsa-miR-145-5p	CD44+	0,246238337	12222,24536	0,099021037	Spearman's rank correlation rho	two.sided	0,099021037
hsa-miR-1468-5p	CD44+	0,136290637	14005,04732	0,366444571	Spearman's rank correlation rho	two.sided	0,366444571
hsa-miR-146a-3p	CD44+	0,208793746	12829,4094	0,163759337	Spearman's rank correlation rho	two.sided	0,163759337
hsa-miR-146a-5p	CD44+	0,473115277	8543,435781	0,000898407	Spearman's rank correlation rho	two.sided	0,000898407
hsa-miR-146b-3p	CD44+	0,365938686	10281,3042	0,012383132	Spearman's rank correlation rho	two.sided	0,012383132
hsa-miR-146b-5p	CD44+	0,118889099	14287,21326	0,431310514	Spearman's rank correlation rho	two.sided	0,431310514
hsa-miR-147b-3p	CD44+	-0,232231856	19980,63954	0,120412548	Spearman's rank correlation rho	two.sided	0,120412548
hsa-miR-147b-5p	CD44+	0,108445249	14456,56028	0,473133683	Spearman's rank correlation rho	two.sided	0,473133683
hsa-miR-148a-3p	CD44+	0,121660099	14242,28149	0,420572174	Spearman's rank correlation rho	two.sided	0,420572174
hsa-miR-148a-5p	CD44+	0,214739385	12733,00088	0,151820215	Spearman's rank correlation rho	two.sided	0,151820215
hsa-miR-148b-3p	CD44+	0,478063492	8463,200483	0,000778931	Spearman's rank correlation rho	two.sided	0,000778931
hsa-miR-148b-5p	CD44+	0,441534156	9055,523658	0,00212799	Spearman's rank correlation rho	two.sided	0,00212799
hsa-miR-149-5p	CD44+	0,167209454	13503,6987	0,266696951	Spearman's rank correlation rho	two.sided	0,266696951
hsa-miR-150-3p	CD44+	0,386967929	9940,315026	0,007891006	Spearman's rank correlation rho	two.sided	0,007891006
hsa-miR-150-5p	CD44+	0,041367073	15544,23292	0,784883465	Spearman's rank correlation rho	two.sided	0,784883465

hsa-miR-151a-3p	CD44+	0,085109288	14834,95289	0,573860301	Spearman's rank correlation rho	two.sided	0,573860301
hsa-miR-151a-5p	CD44+	-0,03846412	16838,69571	0,799657209	Spearman's rank correlation rho	two.sided	0,799657209
hsa-miR-152-3p	CD44+	0,238518646	12347,42015	0,110415701	Spearman's rank correlation rho	two.sided	0,110415701
hsa-miR-153-3p	CD44+	-0,060777194	17200,50219	0,688244907	Spearman's rank correlation rho	two.sided	0,688244907
hsa-miR-155-5p	CD44+	0,182424173	13256,99204	0,224967637	Spearman's rank correlation rho	two.sided	0,224967637
hsa-miR-15a-5p	CD44+	0,022136378	15856,05863	0,883903875	Spearman's rank correlation rho	two.sided	0,883903875
hsa-miR-15b-3p	CD44+	0,180797069	13283,37552	0,2292015	Spearman's rank correlation rho	two.sided	0,2292015
hsa-miR-15b-5p	CD44+	0,527941493	7654,428687	0,000162791	Spearman's rank correlation rho	two.sided	0,000162791
hsa-miR-16-2-3p	CD44+	0,214950436	12729,57869	0,151408508	Spearman's rank correlation rho	two.sided	0,151408508
hsa-miR-16-5p	CD44+	0,300785462	11337,76373	0,042235921	Spearman's rank correlation rho	two.sided	0,042235921
hsa-miR-17-3p	CD44+	0,265306372	11913,05717	0,074755632	Spearman's rank correlation rho	two.sided	0,074755632
hsa-miR-17-5p	CD44+	-0,003595924	16273,30791	0,98107786	Spearman's rank correlation rho	two.sided	0,98107786
hsa-miR-181a-2-3p	CD44+	0,165412516	13532,83605	0,271944056	Spearman's rank correlation rho	two.sided	0,271944056
hsa-miR-181a-5p	CD44+	-0,026126572	16638,64237	0,863161008	Spearman's rank correlation rho	two.sided	0,863161008
hsa-miR-181b-5p	CD44+	-0,12805979	18291,48949	0,396359501	Spearman's rank correlation rho	two.sided	0,396359501
hsa-miR-181c-3p	CD44+	0,341764479	10673,28897	0,020090635	Spearman's rank correlation rho	two.sided	0,020090635
hsa-miR-181c-5p	CD44+	0,259772302	12002,79212	0,081256211	Spearman's rank correlation rho	two.sided	0,081256211
hsa-miR-181d-5p	CD44+	0,286842738	11563,84501	0,053266673	Spearman's rank correlation rho	two.sided	0,053266673
hsa-miR-182-5p	CD44+	0,536254494	7519,633388	0,000122397	Spearman's rank correlation rho	two.sided	0,000122397
hsa-miR-183-3p	CD44+	0,091360943	14733,5823	0,545941869	Spearman's rank correlation rho	two.sided	0,545941869
hsa-miR-183-5p	CD44+	0,358580607	10400,61546	0,014402344	Spearman's rank correlation rho	two.sided	0,014402344
hsa-miR-184	CD44+	0,050844064	15390,5635	0,73719654	Spearman's rank correlation rho	two.sided	0,73719654
hsa-miR-185-3p	CD44+	0,370272348	10211,03387	0,011311148	Spearman's rank correlation rho	two.sided	0,011311148
hsa-miR-185-5p	CD44+	0,15630242	13680,55626	0,299590123	Spearman's rank correlation rho	two.sided	0,299590123
hsa-miR-186-5p	CD44+	-0,247014865	20220,34604	0,097926987	Spearman's rank correlation rho	two.sided	0,097926987
hsa-miR-18a-3p	CD44+	0,312949999	11140,51577	0,034206406	Spearman's rank correlation rho	two.sided	0,034206406
hsa-miR-18a-5p	CD44+	0,156773937	13672,91061	0,298116352	Spearman's rank correlation rho	two.sided	0,298116352
hsa-miR-190a-5p	CD44+	0,279270071	11686,6358	0,060167658	Spearman's rank correlation rho	two.sided	0,060167658
hsa-miR-190b-5p	CD44+	0,022073121	15857,08435	0,884233372	Spearman's rank correlation rho	two.sided	0,884233372
hsa-miR-191-3p	CD44+	0,185251011	13211,15485	0,217740845	Spearman's rank correlation rho	two.sided	0,217740845
hsa-miR-191-5p	CD44+	0,258692651	12020,29866	0,082574556	Spearman's rank correlation rho	two.sided	0,082574556
hsa-miR-192-3p	CD44+	0,224459551	12575,38838	0,13369928	Spearman's rank correlation rho	two.sided	0,13369928
hsa-miR-192-5p	CD44+	0,133865695	14044,36776	0,375113282	Spearman's rank correlation rho	two.sided	0,375113282
hsa-miR-193a-5p	CD44+	0,118265972	14297,31726	0,433746248	Spearman's rank correlation rho	two.sided	0,433746248
hsa-miR-193b-3p	CD44+	0,272936452	11789,33543	0,066473427	Spearman's rank correlation rho	two.sided	0,066473427
hsa-miR-193b-5p	CD44+	0,292517565	11471,82768	0,048525584	Spearman's rank correlation rho	two.sided	0,048525584
hsa-miR-194-3p	CD44+	-0,076466407	17454,90279	0,613496852	Spearman's rank correlation rho	two.sided	0,613496852
hsa-miR-194-5p	CD44+	0,113413075	14376,00699	0,452976342	Spearman's rank correlation rho	two.sided	0,452976342
hsa-miR-195-5p	CD44+	0,026160367	15790,80965	0,862985696	Spearman's rank correlation rho	two.sided	0,862985696
hsa-miR-196a-1-3p	CD44+	-0,367664697	22176,68306	0,011946208	Spearman's rank correlation rho	two.sided	0,011946208
hsa-miR-196a-5p	CD44+	-0,039981573	16863,3012	0,791925582	Spearman's rank correlation rho	two.sided	0,791925582
hsa-miR-196b-5p	CD44+	-0,272085818	20626,87154	0,06735893	Spearman's rank correlation rho	two.sided	0,06735893
hsa-miR-197-3p	CD44+	0,04921824	15416,92624	0,745313873	Spearman's rank correlation rho	two.sided	0,745313873
hsa-miR-199a-5p	CD44+	-0,04275521	16908,27572	0,777844954	Spearman's rank correlation rho	two.sided	0,777844954
hsa-miR-199b-5p	CD44+	0,319067236	11041,32476	0,030671649	Spearman's rank correlation rho	two.sided	0,030671649
hsa-miR-19a-3p	CD44+	-0,018540454	16515,63345	0,902663603	Spearman's rank correlation rho	two.sided	0,902663603
hsa-miR-19b-3p	CD44+	0,243591615	12265,16197	0,102820855	Spearman's rank correlation rho	two.sided	0,102820855
hsa-miR-200a-3p	CD44+	0,267929318	11870,52611	0,071821399	Spearman's rank correlation rho	two.sided	0,071821399
hsa-miR-200a-5p	CD44+	0,315564129	11098,12764	0,032656803	Spearman's rank correlation rho	two.sided	0,032656803
hsa-miR-200b-3p	CD44+	0,1410571	13927,75913	0,349760657	Spearman's rank correlation rho	two.sided	0,349760657
hsa-miR-200b-5p	CD44+	0,162631315	13577,93323	0,280198906	Spearman's rank correlation rho	two.sided	0,280198906
hsa-miR-200c-3p	CD44+	0,223923198	12584,08535	0,134655004	Spearman's rank correlation rho	two.sided	0,134655004
hsa-miR-200c-5p	CD44+	-0,27243312	20632,50304	0,066996267	Spearman's rank correlation rho	two.sided	0,066996267
hsa-miR-203a-3p	CD44+	0,138352076	13971,62109	0,359171032	Spearman's rank correlation rho	two.sided	0,359171032
hsa-miR-203b-3p	CD44+	0,243581161	12265,33148	0,102836082	Spearman's rank correlation rho	two.sided	0,102836082
hsa-miR-204-5p	CD44+	0,120593806	14259,57144	0,424686277	Spearman's rank correlation rho	two.sided	0,424686277
hsa-miR-205-5p	CD44+	-0,088056091	17642,82951	0,560619392	Spearman's rank correlation rho	two.sided	0,560619392
hsa-miR-206	CD44+	0,004190264	16147,05488	0,977951097	Spearman's rank correlation rho	two.sided	0,977951097
hsa-miR-20a-3p	CD44+	-0,073610063	17408,58717	0,626847621	Spearman's rank correlation rho	two.sided	0,626847621
hsa-miR-20a-5p	CD44+	0,095863408	14660,57484	0,526246474	Spearman's rank correlation rho	two.sided	0,526246474
hsa-miR-21-3p	CD44+	-0,032263353	16738,15027	0,831440867	Spearman's rank correlation rho	two.sided	0,831440867
hsa-miR-21-5p	CD44+	0,357063154	10425,22095	0,014851904	Spearman's rank correlation rho	two.sided	0,014851904
hsa-miR-210-3p	CD44+	0,311894184	11157,6358	0,034849233	Spearman's rank correlation rho	two.sided	0,034849233
hsa-miR-210-5p	CD44+	-0,2153268	19706,52406	0,150676355	Spearman's rank correlation rho	two.sided	0,150676355
hsa-miR-2110	CD44+	0,149949394	13783,57058	0,319903659	Spearman's rank correlation rho	two.sided	0,319903659
hsa-miR-2116-3p	CD44+	-0,194857742	19374,61828	0,19439084	Spearman's rank correlation rho	two.sided	0,19439084
hsa-miR-215-3p	CD44+	0,27615187	11737,19743	0,063209512	Spearman's rank correlation rho	two.sided	0,063209512
hsa-miR-215-5p	CD44+	0,2931982	11460,79119	0,047980678	Spearman's rank correlation rho	two.sided	0,047980678
hsa-miR-218-5p	CD44+	0,179944823	13297,1947	0,231440825	Spearman's rank correlation rho	two.sided	0,231440825
hsa-miR-219a-1-3p	CD44+	-0,049654741	17020,15163	0,743131807	Spearman's rank correlation rho	two.sided	0,743131807
hsa-miR-22-3p	CD44+	0,213762864	12748,83516	0,153735878	Spearman's rank correlation rho	two.sided	0,153735878
hsa-miR-22-5p	CD44+	0,252291093	12124,09993	0,090738403	Spearman's rank correlation rho	two.sided	0,090738403
hsa-miR-221-3p	CD44+	0,392360417	9852,875831	0,006997285	Spearman's rank correlation rho	two.sided	0,006997285
hsa-miR-221-5p	CD44+	0,105350485	14506,74189	0,485927641	Spearman's rank correlation rho	two.sided	0,485927641
hsa-miR-222-3p	CD44+	0,344461702	10629,55351	0,01906779	Spearman's rank correlation rho	two.sided	0,01906779
hsa-miR-223-3p	CD44+	0,412285228	9529,795035	0,004411357	Spearman's rank correlation rho	two.sided	0,004411357
hsa-miR-223-5p	CD44+	0,414922276	9487,035294	0,004141422	Spearman's rank correlation rho	two.sided	0,004141422
hsa-miR-224-3p	CD44+	-0,059589366	17181,24156	0,694037301	Spearman's rank correlation rho	two.sided	0,694037301
hsa-miR-224-5p	CD44+	0,133469838	14050,78658	0,376539918	Spearman's rank correlation rho	two.sided	0,376539918
hsa-miR-23a-3p	CD44+	0,080490955	14909,83917	0,594894718	Spearman's rank correlation rho	two.sided	0,594894718
hsa-miR-23a-5p	CD44+	-0,239838252	20103,97725	0,108400145	Spearman's rank correlation rho	two.sided	0,108400145
hsa-miR-23b-3p	CD44+	-0,202019102	19490,73974	0,178179257	Spearman's rank correlation rho	two.sided	0,178179257
hsa-miR-23b-5p	CD44+	0,429993695	9242,652236	0,002858943	Spearman's rank correlation rho	two.sided	0,002858943
hsa-miR-24-2-5p	CD44+	-0,025206015	16623,71553	0,867938934	Spearman's rank correlation rho	two.sided	0,867938934
hsa-miR-24-3p	CD44+	0,064920574	15162,3129	0,668179551	Spearman's rank correlation rho	two.sided	0,668179551
hsa-miR-25-3p	CD44+	0,31642182	11084,22019	0,032161206	Spearman's rank correlation rho	two.sided	0,032161206
hsa-miR-25-5p	CD44+	0,373395376	10160,39398	0,010588847	Spearman's rank correlation rho	two.sided	0,010588847
hsa-miR-26a-2-3p	CD44+	0,250301732	12156,35742	0,093399069	Spearman's rank correlation rho	two.sided	0,093399069
hsa-miR-26a-5p	CD44+	-0,357195107	22006,91866	0,014812344	Spearman's rank correlation rho	two.sided	0,014812344
hsa-miR-26b-3p	CD44+	0,138476663	13969,60091	0,358734269	Spearman's rank correlation rho	two.sided	0,358734269
hsa-miR-26b-5p	CD44+	0,074025288	15014,67995	0,624899346	Spearman's rank correlation rho	two.sided	0,624899346
hsa-miR-27a-3p	CD44+	0,171472125	13434,5795	0,254520324	Spearman's rank correlation rho	two.sided	0,254520324
hsa-miR-27a-5p	CD44+	0,208458209	12834,85015	0,164452904	Spearman's rank correlation rho	two.sided	0,164452904
hsa-miR-27b-3p	CD44+	0,148248505	13811,15049	0,325486318	Spearman's rank correlation rho	two.sided	0,325486318
hsa-miR-27b-5p	CD44+	0,173978423	13393,93987	0,247538002	Spearman's rank correlation rho	two.sided	0,247538002
hsa-miR-28-3p	CD44+	-0,204724126	19534,6017	0,172315977	Spearman's rank correlation rho	two.sided	0,172315977
hsa-miR-28-5p	CD44+	-0,009434596	16367,98197	0,950380569	Spearman's rank correlation rho	two.sided	0,950380569
hsa-miR-296-5p	CD44+	0,161209667	13600,98524	0,284481288	Spearman's rank correlation rho	two.sided	0,284481288
hsa-miR-29a-3p	CD44+	0,470608182	8584,088331	0,000964986	Spearman's rank correlation rho	two.sided	0,000964986

hsa-miR-29a-5p	CD44+	-0,225185424	19866,38164	0,132413932	Spearman's rank correlation rho	two.sided	0,132413932
hsa-miR-29b-1-5p	CD44+	0,165219671	13535,96304	0,272511196	Spearman's rank correlation rho	two.sided	0,272511196
hsa-miR-29b-2-5p	CD44+	0,023194923	15838,89432	0,878392991	Spearman's rank correlation rho	two.sided	0,878392991
hsa-miR-29b-3p	CD44+	-0,005311411	16301,12453	0,972053773	Spearman's rank correlation rho	two.sided	0,972053773
hsa-miR-29c-3p	CD44+	0,103222936	14541,24009	0,494826712	Spearman's rank correlation rho	two.sided	0,494826712
hsa-miR-29c-5p	CD44+	-0,093904393	17737,65974	0,534772651	Spearman's rank correlation rho	two.sided	0,534772651
hsa-miR-30a-3p	CD44+	0,248281364	12189,11768	0,096162649	Spearman's rank correlation rho	two.sided	0,096162649
hsa-miR-30a-5p	CD44+	-0,102662121	17879,6663	0,4971864	Spearman's rank correlation rho	two.sided	0,4971864
hsa-miR-30b-3p	CD44+	0,232403985	12446,56939	0,120130034	Spearman's rank correlation rho	two.sided	0,120130034
hsa-miR-30b-5p	CD44+	0,182160268	13261,27126	0,225650649	Spearman's rank correlation rho	two.sided	0,225650649
hsa-miR-30c-1-3p	CD44+	-0,375287622	22300,28879	0,01017076	Spearman's rank correlation rho	two.sided	0,01017076
hsa-miR-30c-5p	CD44+	-0,126344409	18263,67459	0,402768408	Spearman's rank correlation rho	two.sided	0,402768408
hsa-miR-30d-3p	CD44+	0,0662544	15140,68491	0,661767749	Spearman's rank correlation rho	two.sided	0,661767749
hsa-miR-30d-5p	CD44+	0,068021455	15112,03211	0,653310193	Spearman's rank correlation rho	two.sided	0,653310193
hsa-miR-30e-3p	CD44+	0,077192145	14963,32936	0,610124095	Spearman's rank correlation rho	two.sided	0,610124095
hsa-miR-30e-5p	CD44+	0,035891049	15633,02664	0,812810419	Spearman's rank correlation rho	two.sided	0,812810419
hsa-miR-31-5p	CD44+	0,468610358	8616,483043	0,001021162	Spearman's rank correlation rho	two.sided	0,001021162
hsa-miR-3127-5p	CD44+	0,027450329	15769,89292	0,856298883	Spearman's rank correlation rho	two.sided	0,856298883
hsa-miR-3145-5p	CD44+	0,102813103	14547,88554	0,496550562	Spearman's rank correlation rho	two.sided	0,496550562
hsa-miR-3150b-5p	CD44+	-0,159960822	18808,76473	0,288278232	Spearman's rank correlation rho	two.sided	0,288278232
hsa-miR-3168	CD44+	0,230794438	12472,66819	0,122791412	Spearman's rank correlation rho	two.sided	0,122791412
hsa-miR-3173-5p	CD44+	0,307190057	11233,91323	0,037835498	Spearman's rank correlation rho	two.sided	0,037835498
hsa-miR-3177-3p	CD44+	-0,051934475	17057,11751	0,731768146	Spearman's rank correlation rho	two.sided	0,731768146
hsa-miR-3182	CD44+	0,073904731	15016,63479	0,625464751	Spearman's rank correlation rho	two.sided	0,625464751
hsa-miR-3187-3p	CD44+	-0,242118918	20140,95825	0,104983094	Spearman's rank correlation rho	two.sided	0,104983094
hsa-miR-3188	CD44+	0,024778645	15813,21427	0,870158684	Spearman's rank correlation rho	two.sided	0,870158684
hsa-miR-3195	CD44+	0,028900246	15746,38251	0,848794797	Spearman's rank correlation rho	two.sided	0,848794797
hsa-miR-32-3p	CD44+	0,343437854	10646,15519	0,019450756	Spearman's rank correlation rho	two.sided	0,019450756
hsa-miR-32-5p	CD44+	0,314863663	11109,48571	0,03306622	Spearman's rank correlation rho	two.sided	0,03306622
hsa-miR-320a-3p	CD44+	0,030481001	15720,75057	0,840628626	Spearman's rank correlation rho	two.sided	0,840628626
hsa-miR-324-3p	CD44+	0,467202061	8639,318577	0,001062499	Spearman's rank correlation rho	two.sided	0,001062499
hsa-miR-324-5p	CD44+	0,294275281	11443,32632	0,047128533	Spearman's rank correlation rho	two.sided	0,047128533
hsa-miR-326	CD44+	0,205256926	12886,75895	0,171177725	Spearman's rank correlation rho	two.sided	0,171177725
hsa-miR-328-3p	CD44+	-0,386395091	22480,3964	0,007991503	Spearman's rank correlation rho	two.sided	0,007991503
hsa-miR-328-5p	CD44+	-0,366642874	22160,11421	0,012203251	Spearman's rank correlation rho	two.sided	0,012203251
hsa-miR-329-3p	CD44+	0,254179486	12093,47964	0,088267584	Spearman's rank correlation rho	two.sided	0,088267584
hsa-miR-330-3p	CD44+	0,087431936	14797,29115	0,563411954	Spearman's rank correlation rho	two.sided	0,563411954
hsa-miR-331-3p	CD44+	0,063311966	15188,39647	0,675943416	Spearman's rank correlation rho	two.sided	0,675943416
hsa-miR-335-3p	CD44+	0,225704555	12555,20064	0,131500357	Spearman's rank correlation rho	two.sided	0,131500357
hsa-miR-335-5p	CD44+	-0,029491358	16693,20237	0,845739234	Spearman's rank correlation rho	two.sided	0,845739234
hsa-miR-338-3p	CD44+	0,116634501	14323,77156	0,440159712	Spearman's rank correlation rho	two.sided	0,440159712
hsa-miR-338-5p	CD44+	-0,180472714	19141,36506	0,230052	Spearman's rank correlation rho	two.sided	0,230052
hsa-miR-339-3p	CD44+	0,066708102	15133,32813	0,659592188	Spearman's rank correlation rho	two.sided	0,659592188
hsa-miR-339-5p	CD44+	0,192932236	13086,6038	0,198922511	Spearman's rank correlation rho	two.sided	0,198922511
hsa-miR-33b-3p	CD44+	-0,264951609	20511,19034	0,075159652	Spearman's rank correlation rho	two.sided	0,075159652
hsa-miR-340-3p	CD44+	-0,123819599	18222,73479	0,41230972	Spearman's rank correlation rho	two.sided	0,41230972
hsa-miR-340-5p	CD44+	0,420228288	9400,998318	0,003641773	Spearman's rank correlation rho	two.sided	0,003641773
hsa-miR-342-3p	CD44+	0,151613291	13756,59049	0,314501289	Spearman's rank correlation rho	two.sided	0,314501289
hsa-miR-342-5p	CD44+	0,427037424	9290,588165	0,00307857	Spearman's rank correlation rho	two.sided	0,00307857
hsa-miR-345-5p	CD44+	0,078714452	14938,64516	0,603075378	Spearman's rank correlation rho	two.sided	0,603075378
hsa-miR-34a-5p	CD44+	0,183991634	13231,57565	0,220940271	Spearman's rank correlation rho	two.sided	0,220940271
hsa-miR-3605-5p	CD44+	-0,04672123	16972,58475	0,757833872	Spearman's rank correlation rho	two.sided	0,757833872
hsa-miR-3609	CD44+	0,552222873	7260,706119	6,92726E-05	Spearman's rank correlation rho	two.sided	6,92726E-05
hsa-miR-361-3p	CD44+	0,341426797	10678,76449	0,020221888	Spearman's rank correlation rho	two.sided	0,020221888
hsa-miR-361-5p	CD44+	0,102790908	14548,24543	0,496644005	Spearman's rank correlation rho	two.sided	0,496644005
hsa-miR-3613-3p	CD44+	-0,113595531	18056,95153	0,452245042	Spearman's rank correlation rho	two.sided	0,452245042
hsa-miR-3613-5p	CD44+	0,160496987	13612,54136	0,286644074	Spearman's rank correlation rho	two.sided	0,286644074
hsa-miR-3615	CD44+	0,323376166	10971,45546	0,028368077	Spearman's rank correlation rho	two.sided	0,028368077
hsa-miR-362-3p	CD44+	0,335231426	10779,22243	0,022761151	Spearman's rank correlation rho	two.sided	0,022761151
hsa-miR-362-5p	CD44+	0,129548249	14114,37514	0,390846882	Spearman's rank correlation rho	two.sided	0,390846882
hsa-miR-363-3p	CD44+	0,369853587	10217,82408	0,011411138	Spearman's rank correlation rho	two.sided	0,011411138
hsa-miR-3651	CD44+	0,325464841	10937,5876	0,027304344	Spearman's rank correlation rho	two.sided	0,027304344
hsa-miR-3652	CD44+	-0,214099372	19686,62132	0,15307375	Spearman's rank correlation rho	two.sided	0,15307375
hsa-miR-3654	CD44+	0,245682401	12231,25986	0,099810062	Spearman's rank correlation rho	two.sided	0,099810062
hsa-miR-3659	CD44+	0,232609119	12443,24314	0,119794003	Spearman's rank correlation rho	two.sided	0,119794003
hsa-miR-3660	CD44+	-0,05127457	17046,41716	0,73505182	Spearman's rank correlation rho	two.sided	0,73505182
hsa-miR-369-3p	CD44+	-0,018113258	16508,70647	0,904895952	Spearman's rank correlation rho	two.sided	0,904895952
hsa-miR-369-5p	CD44+	-0,259474403	20422,37744	0,081618313	Spearman's rank correlation rho	two.sided	0,081618313
hsa-miR-370-3p	CD44+	0,250905422	12146,56859	0,092585358	Spearman's rank correlation rho	two.sided	0,092585358
hsa-miR-374a-3p	CD44+	0,347935382	10573,22779	0,017815542	Spearman's rank correlation rho	two.sided	0,017815542
hsa-miR-374a-5p	CD44+	0,382871652	10006,73616	0,008634302	Spearman's rank correlation rho	two.sided	0,008634302
hsa-miR-374b-3p	CD44+	-0,153220344	18699,46788	0,309338794	Spearman's rank correlation rho	two.sided	0,309338794
hsa-miR-374b-5p	CD44+	0,132942028	14059,34501	0,378447119	Spearman's rank correlation rho	two.sided	0,378447119
hsa-miR-375-3p	CD44+	0,013920977	15989,27136	0,926838959	Spearman's rank correlation rho	two.sided	0,926838959
hsa-miR-376a-3p	CD44+	0,388440731	9916,433541	0,007637624	Spearman's rank correlation rho	two.sided	0,007637624
hsa-miR-376c-3p	CD44+	0,360637744	10367,25897	0,013811431	Spearman's rank correlation rho	two.sided	0,013811431
hsa-miR-377-3p	CD44+	0,408612793	9589,343561	0,004812865	Spearman's rank correlation rho	two.sided	0,004812865
hsa-miR-378a-3p	CD44+	0,086956622	14804,99838	0,565542916	Spearman's rank correlation rho	two.sided	0,565542916
hsa-miR-378a-5p	CD44+	0,207105655	12856,78181	0,167270336	Spearman's rank correlation rho	two.sided	0,167270336
hsa-miR-378c	CD44+	0,069452794	15088,82295	0,646490777	Spearman's rank correlation rho	two.sided	0,646490777
hsa-miR-378d	CD44+	-0,032135361	16736,07487	0,832099923	Spearman's rank correlation rho	two.sided	0,832099923
hsa-miR-379-3p	CD44+	0,427288087	9286,523669	0,003059388	Spearman's rank correlation rho	two.sided	0,003059388
hsa-miR-379-5p	CD44+	0,246814393	12212,90462	0,098208535	Spearman's rank correlation rho	two.sided	0,098208535
hsa-miR-381-3p	CD44+	0,124883052	14190,02132	0,408275239	Spearman's rank correlation rho	two.sided	0,408275239
hsa-miR-382-3p	CD44+	-0,260002326	20430,93772	0,080977475	Spearman's rank correlation rho	two.sided	0,080977475
hsa-miR-382-5p	CD44+	0,414097446	9500,409906	0,004224255	Spearman's rank correlation rho	two.sided	0,004224255
hsa-miR-3909	CD44+	0,087767283	14791,85351	0,561910758	Spearman's rank correlation rho	two.sided	0,561910758
hsa-miR-3912-3p	CD44+	0,373230405	10163,06899	0,010625986	Spearman's rank correlation rho	two.sided	0,010625986
hsa-miR-3940-3p	CD44+	0,346911733	10589,82624	0,018177118	Spearman's rank correlation rho	two.sided	0,018177118
hsa-miR-3960	CD44+	0,220624388	12637,57555	0,140645538	Spearman's rank correlation rho	two.sided	0,140645538
hsa-miR-409-3p	CD44+	-0,191690396	19323,25978	0,201884422	Spearman's rank correlation rho	two.sided	0,201884422
hsa-miR-411-5p	CD44+	0,251565265	12135,86923	0,091702254	Spearman's rank correlation rho	two.sided	0,091702254
hsa-miR-421	CD44+	0,145594428	13854,18635	0,334318916	Spearman's rank correlation rho	two.sided	0,334318916
hsa-miR-423-3p	CD44+	0,290823057	11499,30413	0,049903995	Spearman's rank correlation rho	two.sided	0,049903995
hsa-miR-423-5p	CD44+	-0,358382678	22026,17513	0,014460317	Spearman's rank correlation rho	two.sided	0,014460317
hsa-miR-424-3p	CD44+	-0,199687066	19452,92577	0,183347987	Spearman's rank correlation rho	two.sided	0,183347987
hsa-miR-424-5p	CD44+	0,35852605	10401,50009	0,014418303	Spearman's rank correlation rho	two.sided	0,014418303
hsa-miR-425-3p	CD44+	0,456399546	8814,481356	0,001432572	Spearman's rank correlation rho	two.sided	0,001432572
hsa-miR-425-5p	CD44+	0,203866435	12909,30575	0,174159775	Spearman's rank correlation rho	two.sided	0,174159775

hsa-miR-4284	CD44+	0,418993362	9421,02264	0,003753077	Spearman's rank correlation rho	two.sided	0,003753077
hsa-miR-4286	CD44+	0,179955614	13297,01971	0,231412376	Spearman's rank correlation rho	two.sided	0,231412376
hsa-miR-429	CD44+	-0,052780954	17070,84317	0,727563019	Spearman's rank correlation rho	two.sided	0,727563019
hsa-miR-432-5p	CD44+	0,167082635	13505,75507	0,267065045	Spearman's rank correlation rho	two.sided	0,267065045
hsa-miR-4326	CD44+	-0,206708671	19566,7811	0,168103879	Spearman's rank correlation rho	two.sided	0,168103879
hsa-miR-4443	CD44+	0,203377885	12917,22759	0,17521636	Spearman's rank correlation rho	two.sided	0,17521636
hsa-miR-4444	CD44+	0,094726352	14679,01221	0,531187084	Spearman's rank correlation rho	two.sided	0,531187084
hsa-miR-4446-3p	CD44+	0,321505415	11001,7897	0,029349869	Spearman's rank correlation rho	two.sided	0,029349869
hsa-miR-4448	CD44+	0,103202678	14541,56858	0,49491185	Spearman's rank correlation rho	two.sided	0,49491185
hsa-miR-4455	CD44+	-0,205124949	19541,10105	0,171459167	Spearman's rank correlation rho	two.sided	0,171459167
hsa-miR-4468	CD44+	0,315962218	11091,67264	0,032425997	Spearman's rank correlation rho	two.sided	0,032425997
hsa-miR-4484	CD44+	-0,096670028	17782,5045	0,522755439	Spearman's rank correlation rho	two.sided	0,522755439
hsa-miR-4488	CD44+	0,12251779	14228,37404	0,41727939	Spearman's rank correlation rho	two.sided	0,41727939
hsa-miR-4492	CD44+	0,304630869	11275,41046	0,039546401	Spearman's rank correlation rho	two.sided	0,039546401
hsa-miR-4497	CD44+	0,421283972	9383,880399	0,003548932	Spearman's rank correlation rho	two.sided	0,003548932
hsa-miR-450a-5p	CD44+	0,045731374	15473,46578	0,762814237	Spearman's rank correlation rho	two.sided	0,762814237
hsa-miR-450b-5p	CD44+	0,417673594	9442,422679	0,003875316	Spearman's rank correlation rho	two.sided	0,003875316
hsa-miR-4516	CD44+	0,183749363	13235,50409	0,221559471	Spearman's rank correlation rho	two.sided	0,221559471
hsa-miR-451a	CD44+	0,26304708	11949,6916	0,077358112	Spearman's rank correlation rho	two.sided	0,077358112
hsa-miR-452-3p	CD44+	0,361517463	10352,99434	0,013565112	Spearman's rank correlation rho	two.sided	0,013565112
hsa-miR-452-5p	CD44+	0,093076642	14705,76225	0,538395362	Spearman's rank correlation rho	two.sided	0,538395362
hsa-miR-4525	CD44+	-0,2470682	20221,21087	0,097852187	Spearman's rank correlation rho	two.sided	0,097852187
hsa-miR-454-3p	CD44+	0,104674457	14517,70367	0,488746222	Spearman's rank correlation rho	two.sided	0,488746222
hsa-miR-454-5p	CD44+	0,16867156	13479,99066	0,262477508	Spearman's rank correlation rho	two.sided	0,262477508
hsa-miR-455-3p	CD44+	0,186498962	13190,91934	0,21460231	Spearman's rank correlation rho	two.sided	0,21460231
hsa-miR-4636	CD44+	-0,295741775	21010,45288	0,045988098	Spearman's rank correlation rho	two.sided	0,045988098
hsa-miR-4662a-5p	CD44+	0,303513657	11293,52605	0,040312914	Spearman's rank correlation rho	two.sided	0,040312914
hsa-miR-4681	CD44+	-0,042067607	16897,12624	0,781329265	Spearman's rank correlation rho	two.sided	0,781329265
hsa-miR-4685-3p	CD44+	0,112051764	14398,08065	0,458452906	Spearman's rank correlation rho	two.sided	0,458452906
hsa-miR-4708-3p	CD44+	-0,253403282	20323,93423	0,089276771	Spearman's rank correlation rho	two.sided	0,089276771
hsa-miR-4758-5p	CD44+	-0,401023893	22717,60242	0,005744831	Spearman's rank correlation rho	two.sided	0,005744831
hsa-miR-4791	CD44+	-0,079219077	17499,53734	0,600746653	Spearman's rank correlation rho	two.sided	0,600746653
hsa-miR-4804-5p	CD44+	-0,218282902	19754,45726	0,145016117	Spearman's rank correlation rho	two.sided	0,145016117
hsa-miR-484	CD44+	0,227262003	12529,94662	0,128787836	Spearman's rank correlation rho	two.sided	0,128787836
hsa-miR-485-3p	CD44+	0,116502525	14325,91156	0,440680811	Spearman's rank correlation rho	two.sided	0,440680811
hsa-miR-485-5p	CD44+	0,383404446	9998,096914	0,008534328	Spearman's rank correlation rho	two.sided	0,008534328
hsa-miR-486-3p	CD44+	0,080899286	14903,21808	0,593021324	Spearman's rank correlation rho	two.sided	0,593021324
hsa-miR-486-5p	CD44+	0,129577242	14113,90502	0,390739952	Spearman's rank correlation rho	two.sided	0,390739952
hsa-miR-487b-3p	CD44+	0,487177348	8315,419303	0,000595512	Spearman's rank correlation rho	two.sided	0,000595512
hsa-miR-493-5p	CD44+	0,002969387	16166,8514	0,984374319	Spearman's rank correlation rho	two.sided	0,984374319
hsa-miR-494-3p	CD44+	0,189050942	13149,53898	0,208282558	Spearman's rank correlation rho	two.sided	0,208282558
hsa-miR-495-3p	CD44+	0,440063082	9079,377128	0,002210871	Spearman's rank correlation rho	two.sided	0,002210871
hsa-miR-497-5p	CD44+	0,309301555	11199,67528	0,036470079	Spearman's rank correlation rho	two.sided	0,036470079
hsa-miR-499a-5p	CD44+	-0,253849554	20331,17052	0,088695457	Spearman's rank correlation rho	two.sided	0,088695457
hsa-miR-500a-3p	CD44+	0,226531198	12541,79662	0,130055365	Spearman's rank correlation rho	two.sided	0,130055365
hsa-miR-501-3p	CD44+	0,136154469	14007,25528	0,366928125	Spearman's rank correlation rho	two.sided	0,366928125
hsa-miR-501-5p	CD44+	-0,021147326	16557,90389	0,889057878	Spearman's rank correlation rho	two.sided	0,889057878
hsa-miR-502-3p	CD44+	0,225685486	12555,50985	0,131533832	Spearman's rank correlation rho	two.sided	0,131533832
hsa-miR-505-3p	CD44+	0,031901457	15697,71788	0,833304633	Spearman's rank correlation rho	two.sided	0,833304633
hsa-miR-505-5p	CD44+	-0,33430756	21635,79708	0,023161795	Spearman's rank correlation rho	two.sided	0,023161795
hsa-miR-5100	CD44+	0,165996101	13523,37323	0,270232548	Spearman's rank correlation rho	two.sided	0,270232548
hsa-miR-511-5p	CD44+	0,022106797	15856,53829	0,884057956	Spearman's rank correlation rho	two.sided	0,884057956
hsa-miR-5191	CD44+	-0,20932167	19609,15088	0,162672414	Spearman's rank correlation rho	two.sided	0,162672414
hsa-miR-532-3p	CD44+	0,058397935	15268,07749	0,69986465	Spearman's rank correlation rho	two.sided	0,69986465
hsa-miR-532-5p	CD44+	0,18004903	13295,50498	0,231166214	Spearman's rank correlation rho	two.sided	0,231166214
hsa-miR-539-5p	CD44+	-0,060447241	17195,15202	0,689852153	Spearman's rank correlation rho	two.sided	0,689852153
hsa-miR-543	CD44+	0,421104991	9386,782578	0,003564524	Spearman's rank correlation rho	two.sided	0,003564524
hsa-miR-548e-3p	CD44+	0,481286414	8410,940802	0,000708975	Spearman's rank correlation rho	two.sided	0,000708975
hsa-miR-548i	CD44+	0,43021139	9239,122309	0,00284333	Spearman's rank correlation rho	two.sided	0,00284333
hsa-miR-548k	CD44+	0,219352216	12658,20381	0,143007857	Spearman's rank correlation rho	two.sided	0,143007857
hsa-miR-548l	CD44+	-0,276260447	20694,56315	0,06310157	Spearman's rank correlation rho	two.sided	0,06310157
hsa-miR-550a-5p	CD44+	0,354500634	10466,77222	0,015638174	Spearman's rank correlation rho	two.sided	0,015638174
hsa-miR-552-3p	CD44+	0,149628703	13788,77059	0,320951579	Spearman's rank correlation rho	two.sided	0,320951579
hsa-miR-552-5p	CD44+	0,293747374	11451,88633	0,047544645	Spearman's rank correlation rho	two.sided	0,047544645
hsa-miR-556-5p	CD44+	0,002507637	16174,33867	0,986803933	Spearman's rank correlation rho	two.sided	0,986803933
hsa-miR-5571-3p	CD44+	0,376079507	10116,87079	0,010000052	Spearman's rank correlation rho	two.sided	0,010000052
hsa-miR-5697	CD44+	-0,171311177	18992,81074	0,254973182	Spearman's rank correlation rho	two.sided	0,254973182
hsa-miR-574-3p	CD44+	0,076930613	14967,57011	0,611338612	Spearman's rank correlation rho	two.sided	0,611338612
hsa-miR-574-5p	CD44+	0,114270766	14362,09954	0,449544247	Spearman's rank correlation rho	two.sided	0,449544247
hsa-miR-576-3p	CD44+	0,369414473	10224,94432	0,011516801	Spearman's rank correlation rho	two.sided	0,011516801
hsa-miR-576-5p	CD44+	0,381874885	10022,89873	0,00882405	Spearman's rank correlation rho	two.sided	0,00882405
hsa-miR-577	CD44+	0,010360499	16047,00451	0,945517947	Spearman's rank correlation rho	two.sided	0,945517947
hsa-miR-582-3p	CD44+	0,298738713	11370,95176	0,043727249	Spearman's rank correlation rho	two.sided	0,043727249
hsa-miR-582-5p	CD44+	0,254616251	12086,39749	0,087703636	Spearman's rank correlation rho	two.sided	0,087703636
hsa-miR-584-5p	CD44+	0,412546767	9525,554176	0,004383915	Spearman's rank correlation rho	two.sided	0,004383915
hsa-miR-589-5p	CD44+	0,427288087	9286,523669	0,003059388	Spearman's rank correlation rho	two.sided	0,003059388
hsa-miR-590-3p	CD44+	0,103304844	14539,91195	0,49448256	Spearman's rank correlation rho	two.sided	0,49448256
hsa-miR-592	CD44+	0,365366514	10290,58197	0,012530955	Spearman's rank correlation rho	two.sided	0,012530955
hsa-miR-598-3p	CD44+	-0,127320695	18279,50507	0,399113543	Spearman's rank correlation rho	two.sided	0,399113543
hsa-miR-6126	CD44+	-0,068957881	17333,15203	0,648845516	Spearman's rank correlation rho	two.sided	0,648845516
hsa-miR-622	CD44+	-0,211301383	19641,25192	0,158643238	Spearman's rank correlation rho	two.sided	0,158643238
hsa-miR-624-5p	CD44+	-0,071863587	17380,26807	0,635069669	Spearman's rank correlation rho	two.sided	0,635069669
hsa-miR-625-3p	CD44+	-0,014846017	16455,72816	0,921991971	Spearman's rank correlation rho	two.sided	0,921991971
hsa-miR-625-5p	CD44+	0,211393847	12787,24876	0,15845685	Spearman's rank correlation rho	two.sided	0,15845685
hsa-miR-628-3p	CD44+	-0,062756907	17232,60324	0,678630175	Spearman's rank correlation rho	two.sided	0,678630175
hsa-miR-628-5p	CD44+	0,31629217	11086,32246	0,032235719	Spearman's rank correlation rho	two.sided	0,032235719
hsa-miR-629-5p	CD44+	0,151688622	13755,369	0,31425808	Spearman's rank correlation rho	two.sided	0,31425808
hsa-miR-642a-3p	CD44+	0,214653652	12734,39103	0,151987692	Spearman's rank correlation rho	two.sided	0,151987692
hsa-miR-642a-5p	CD44+	-0,253337292	20322,86419	0,089362981	Spearman's rank correlation rho	two.sided	0,089362981
hsa-miR-651-5p	CD44+	0,033523143	15671,42224	0,824960154	Spearman's rank correlation rho	two.sided	0,824960154
hsa-miR-6511b-3p	CD44+	-0,046916307	16975,74792	0,7568535	Spearman's rank correlation rho	two.sided	0,7568535
hsa-miR-6513-3p	CD44+	-0,309452614	21232,77413	0,03637397	Spearman's rank correlation rho	two.sided	0,03637397
hsa-miR-652-3p	CD44+	0,197928578	13005,58811	0,187315804	Spearman's rank correlation rho	two.sided	0,187315804
hsa-miR-654-3p	CD44+	0,343546221	10644,39803	0,019409918	Spearman's rank correlation rho	two.sided	0,019409918
hsa-miR-660-5p	CD44+	0,341051973	10684,84225	0,020368422	Spearman's rank correlation rho	two.sided	0,020368422
hsa-miR-663a	CD44+	0,179746864	13300,4046	0,231963114	Spearman's rank correlation rho	two.sided	0,231963114
hsa-miR-664a-3p	CD44+	0,018047828	15922,35447	0,905237925	Spearman's rank correlation rho	two.sided	0,905237925
hsa-miR-664a-5p	CD44+	0,253339028	12107,10766	0,089360712	Spearman's rank correlation rho	two.sided	0,089360712
hsa-miR-671-3p	CD44+	0,2554741	12072,48746	0,086604159	Spearman's rank correlation rho	two.sided	0,086604159

hsa-miR-671-5p	CD44+	0,118650808	14291,07715	0,432241062	Spearman's rank correlation rho	two.sided	0,432241062
hsa-miR-6729-5p	CD44+	0,154153664	13715,39835	0,306365565	Spearman's rank correlation rho	two.sided	0,306365565
hsa-miR-6734-5p	CD44+	-0,431907418	23218,37878	0,002724241	Spearman's rank correlation rho	two.sided	0,002724241
hsa-miR-6787-5p	CD44+	0,277679198	11712,43181	0,0617046	Spearman's rank correlation rho	two.sided	0,0617046
hsa-miR-6803-3p	CD44+	0,071960353	15048,16288	0,634612965	Spearman's rank correlation rho	two.sided	0,634612965
hsa-miR-6803-5p	CD44+	-0,087767283	17638,14649	0,561910758	Spearman's rank correlation rho	two.sided	0,561910758
hsa-miR-6821-5p	CD44+	0,217636465	12686,02472	0,146240251	Spearman's rank correlation rho	two.sided	0,146240251
hsa-miR-6859-5p	CD44+	-0,315962218	21338,32736	0,032425997	Spearman's rank correlation rho	two.sided	0,032425997
hsa-miR-6866-5p	CD44+	0,362705254	10333,7343	0,013238485	Spearman's rank correlation rho	two.sided	0,013238485
hsa-miR-6869-5p	CD44+	-0,416901867	22975,06377	0,0039484	Spearman's rank correlation rho	two.sided	0,0039484
hsa-miR-6887-5p	CD44+	-0,366642874	22160,11421	0,012203251	Spearman's rank correlation rho	two.sided	0,012203251
hsa-miR-7-1-3p	CD44+	0,280417716	11668,02673	0,05907806	Spearman's rank correlation rho	two.sided	0,05907806
hsa-miR-7-5p	CD44+	0,379297131	10064,69702	0,009331518	Spearman's rank correlation rho	two.sided	0,009331518
hsa-miR-744-5p	CD44+	0,293579175	11454,61368	0,047677848	Spearman's rank correlation rho	two.sided	0,047677848
hsa-miR-769-5p	CD44+	0,152664169	13739,5505	0,311119297	Spearman's rank correlation rho	two.sided	0,311119297
hsa-miR-7704	CD44+	0,355545702	10449,82644	0,015313345	Spearman's rank correlation rho	two.sided	0,015313345
hsa-miR-7706	CD44+	0,136657766	13999,09432	0,365142752	Spearman's rank correlation rho	two.sided	0,365142752
hsa-miR-7854-3p	CD44+	-0,142143404	18519,85529	0,346024487	Spearman's rank correlation rho	two.sided	0,346024487
hsa-miR-7975	CD44+	-0,169623189	18965,44	0,259755276	Spearman's rank correlation rho	two.sided	0,259755276
hsa-miR-7976	CD44+	0,219286226	12659,27385	0,143131193	Spearman's rank correlation rho	two.sided	0,143131193
hsa-miR-7977	CD44+	-0,067627683	17311,58288	0,655191208	Spearman's rank correlation rho	two.sided	0,655191208
hsa-miR-8085	CD44+	-0,150722161	18658,95984	0,317387381	Spearman's rank correlation rho	two.sided	0,317387381
hsa-miR-874-3p	CD44+	0,234765012	12408,28534	0,116305287	Spearman's rank correlation rho	two.sided	0,116305287
hsa-miR-877-3p	CD44+	0,161676573	13593,41436	0,283070153	Spearman's rank correlation rho	two.sided	0,283070153
hsa-miR-877-5p	CD44+	-0,197371312	19415,37582	0,188585885	Spearman's rank correlation rho	two.sided	0,188585885
hsa-miR-9-3p	CD44+	0,225449377	12559,33835	0,131948831	Spearman's rank correlation rho	two.sided	0,131948831
hsa-miR-9-5p	CD44+	-0,247778808	20232,73338	0,096859789	Spearman's rank correlation rho	two.sided	0,096859789
hsa-miR-92a-1-5p	CD44+	0,122925019	14221,77082	0,415721136	Spearman's rank correlation rho	two.sided	0,415721136
hsa-miR-92a-3p	CD44+	-0,131952385	18354,60793	0,38203856	Spearman's rank correlation rho	two.sided	0,38203856
hsa-miR-92b-3p	CD44+	0,246172357	12223,31523	0,099114429	Spearman's rank correlation rho	two.sided	0,099114429
hsa-miR-92b-5p	CD44+	0,361385486	10355,13434	0,013601825	Spearman's rank correlation rho	two.sided	0,013601825
hsa-miR-93-3p	CD44+	0,340819586	10688,61042	0,02045972	Spearman's rank correlation rho	two.sided	0,02045972
hsa-miR-93-5p	CD44+	0,331398415	10841,37469	0,024462182	Spearman's rank correlation rho	two.sided	0,024462182
hsa-miR-940	CD44+	-0,272342538	20631,03426	0,067090705	Spearman's rank correlation rho	two.sided	0,067090705
hsa-miR-941	CD44+	0,089711233	14760,33235	0,553245537	Spearman's rank correlation rho	two.sided	0,553245537
hsa-miR-942-5p	CD44+	0,170888878	13444,03684	0,256163979	Spearman's rank correlation rho	two.sided	0,256163979
hsa-miR-95-3p	CD44+	0,252622841	12118,72063	0,09030049	Spearman's rank correlation rho	two.sided	0,09030049
hsa-miR-96-5p	CD44+	-0,021741837	16567,54389	0,885959291	Spearman's rank correlation rho	two.sided	0,885959291
hsa-miR-98-5p	CD44+	0,111103908	14413,45013	0,4622872	Spearman's rank correlation rho	two.sided	0,4622872
hsa-miR-99a-5p	CD44+	0,159583106	13627,35993	0,289433092	Spearman's rank correlation rho	two.sided	0,289433092
hsa-miR-99b-3p	CD44+	-0,171470864	18995,40006	0,254523869	Spearman's rank correlation rho	two.sided	0,254523869
hsa-miR-99b-5p	CD44+	0,220070377	12646,55884	0,141670706	Spearman's rank correlation rho	two.sided	0,141670706

For Review Only

Supplementary Table S7. The list of correlations between endoscopic Mayo score and normalized expression of miRNAs expressed in crypt-top (CD66a+) colonic epithelial cell population

mir	cell_type	estimate	statistic	p.value	method	alternative	padj
hsa-let-7a-3p	CD66a+	0,07775984	16991,3528	0,59935271	Spearman's rank correlation rho	two.sided	0,59935271
hsa-let-7a-5p	CD66a+	-0,07901	19879,6793	0,59347752	Spearman's rank correlation rho	two.sided	0,59347752
hsa-let-7b-3p	CD66a+	-0,1934417	21987,9691	0,18771848	Spearman's rank correlation rho	two.sided	0,18771848
hsa-let-7b-5p	CD66a+	0,07941903	16960,7839	0,59156053	Spearman's rank correlation rho	two.sided	0,59156053
hsa-let-7c-5p	CD66a+	0,02320041	17996,5557	0,87562227	Spearman's rank correlation rho	two.sided	0,87562227
hsa-let-7d-3p	CD66a+	0,18875898	14946,3046	0,19883605	Spearman's rank correlation rho	two.sided	0,19883605
hsa-let-7d-5p	CD66a+	-0,1087556	20427,7124	0,4618489	Spearman's rank correlation rho	two.sided	0,4618489
hsa-let-7e-5p	CD66a+	0,10203504	16544,1064	0,49013779	Spearman's rank correlation rho	two.sided	0,49013779
hsa-let-7f-1-3p	CD66a+	0,04787089	17542,0267	0,74661789	Spearman's rank correlation rho	two.sided	0,74661789
hsa-let-7f-2-3p	CD66a+	0,41418417	10793,0709	0,00342695	Spearman's rank correlation rho	two.sided	0,00342695
hsa-let-7f-5p	CD66a+	0,00619457	18309,8713	0,96666905	Spearman's rank correlation rho	two.sided	0,96666905
hsa-let-7g-5p	CD66a+	-0,2583018	23182,9516	0,07629298	Spearman's rank correlation rho	two.sided	0,07629298
hsa-let-7i-3p	CD66a+	-0,1207326	20648,3777	0,41369557	Spearman's rank correlation rho	two.sided	0,41369557
hsa-let-7i-5p	CD66a+	0,37103119	11588,1213	0,00942563	Spearman's rank correlation rho	two.sided	0,00942563
hsa-miR-1-3p	CD66a+	-0,3086556	24110,6708	0,03280345	Spearman's rank correlation rho	two.sided	0,03280345
hsa-miR-100-5p	CD66a+	-0,0754785	19814,6153	0,6101396	Spearman's rank correlation rho	two.sided	0,6101396
hsa-miR-101-3p	CD66a+	-0,0562771	19460,8485	0,70400286	Spearman's rank correlation rho	two.sided	0,70400286
hsa-miR-103a-3p	CD66a+	-0,1039635	20339,4242	0,48192913	Spearman's rank correlation rho	two.sided	0,48192913
hsa-miR-106b-3p	CD66a+	0,09055417	16755,6299	0,5404717	Spearman's rank correlation rho	two.sided	0,5404717
hsa-miR-106b-5p	CD66a+	-0,0258302	18899,8952	0,86165449	Spearman's rank correlation rho	two.sided	0,86165449
hsa-miR-10a-3p	CD66a+	0,1468912	15717,6766	0,31911241	Spearman's rank correlation rho	two.sided	0,31911241
hsa-miR-10a-5p	CD66a+	-0,1226641	20683,9637	0,40620891	Spearman's rank correlation rho	two.sided	0,40620891
hsa-miR-10b-3p	CD66a+	-0,0756912	19818,5353	0,60913006	Spearman's rank correlation rho	two.sided	0,60913006
hsa-miR-10b-5p	CD66a+	-0,4077895	25937,1141	0,00401488	Spearman's rank correlation rho	two.sided	0,00401488
hsa-miR-1180-3p	CD66a+	0,13500214	15936,7206	0,36026239	Spearman's rank correlation rho	two.sided	0,36026239
hsa-miR-122-5p	CD66a+	-0,1124324	20495,4551	0,44675331	Spearman's rank correlation rho	two.sided	0,44675331
hsa-miR-1224-5p	CD66a+	0,15622146	15545,7758	0,28899397	Spearman's rank correlation rho	two.sided	0,28899397
hsa-miR-1246	CD66a+	0,15369539	15592,3161	0,29695891	Spearman's rank correlation rho	two.sided	0,29695891
hsa-miR-1247-3p	CD66a+	-0,4458134	26637,6667	0,00149512	Spearman's rank correlation rho	two.sided	0,00149512
hsa-miR-1247-5p	CD66a+	-0,0159836	18718,4816	0,91413425	Spearman's rank correlation rho	two.sided	0,91413425
hsa-miR-1248	CD66a+	0,02878292	17893,7034	0,84602116	Spearman's rank correlation rho	two.sided	0,84602116
hsa-miR-1249-3p	CD66a+	0,08098525	16931,9277	0,58424652	Spearman's rank correlation rho	two.sided	0,58424652
hsa-miR-125a-3p	CD66a+	0,19542366	14823,5144	0,18314903	Spearman's rank correlation rho	two.sided	0,18314903
hsa-miR-125a-5p	CD66a+	-0,0152527	18705,015	0,91804716	Spearman's rank correlation rho	two.sided	0,91804716
hsa-miR-125b-5p	CD66a+	0,00759711	18284,0308	0,95912822	Spearman's rank correlation rho	two.sided	0,95912822
hsa-miR-126-3p	CD66a+	0,17981776	15111,0375	0,22133993	Spearman's rank correlation rho	two.sided	0,22133993
hsa-miR-126-5p	CD66a+	0,3695628	11615,1751	0,00973376	Spearman's rank correlation rho	two.sided	0,00973376
hsa-miR-1261	CD66a+	0,12575949	16107,0072	0,39437556	Spearman's rank correlation rho	two.sided	0,39437556
hsa-miR-1262	CD66a+	0,13336549	15966,8742	0,36616868	Spearman's rank correlation rho	two.sided	0,36616868
hsa-miR-1266-5p	CD66a+	0,50264629	9163,24466	0,00027184	Spearman's rank correlation rho	two.sided	0,00027184
hsa-miR-1269a	CD66a+	0,1399379	15845,7842	0,34280334	Spearman's rank correlation rho	two.sided	0,34280334
hsa-miR-127-3p	CD66a+	0,48328415	9519,97277	0,00050237	Spearman's rank correlation rho	two.sided	0,00050237
hsa-miR-1271-5p	CD66a+	0,32717621	12396,1055	0,02321592	Spearman's rank correlation rho	two.sided	0,02321592
hsa-miR-1275	CD66a+	0,17444135	15210,0926	0,23569107	Spearman's rank correlation rho	two.sided	0,23569107
hsa-miR-128-3p	CD66a+	0,08520452	16854,192	0,56474873	Spearman's rank correlation rho	two.sided	0,56474873
hsa-miR-1287-5p	CD66a+	0,28523204	13168,8849	0,04940396	Spearman's rank correlation rho	two.sided	0,04940396
hsa-miR-1290	CD66a+	0,01621735	18125,2116	0,91288324	Spearman's rank correlation rho	two.sided	0,91288324
hsa-miR-1291	CD66a+	0,01844261	18084,2134	0,90098547	Spearman's rank correlation rho	two.sided	0,90098547
hsa-miR-1294	CD66a+	0,27280291	13397,8792	0,06065949	Spearman's rank correlation rho	two.sided	0,06065949
hsa-miR-1296-5p	CD66a+	0,29766683	12939,7863	0,03990123	Spearman's rank correlation rho	two.sided	0,03990123
hsa-miR-1299	CD66a+	0,32975698	12348,5574	0,02208889	Spearman's rank correlation rho	two.sided	0,02208889
hsa-miR-1301-3p	CD66a+	-0,0734642	19777,5044	0,61973223	Spearman's rank correlation rho	two.sided	0,61973223
hsa-miR-1303	CD66a+	-0,1626719	21421,0676	0,26929216	Spearman's rank correlation rho	two.sided	0,26929216
hsa-miR-1304-3p	CD66a+	-0,1706553	21568,1525	0,24617122	Spearman's rank correlation rho	two.sided	0,24617122
hsa-miR-1304-5p	CD66a+	-0,0896361	20075,4564	0,54460161	Spearman's rank correlation rho	two.sided	0,54460161
hsa-miR-1306-3p	CD66a+	0,18892201	14943,301	0,19844134	Spearman's rank correlation rho	two.sided	0,19844134
hsa-miR-1306-5p	CD66a+	-0,171732	21587,9901	0,24315916	Spearman's rank correlation rho	two.sided	0,24315916
hsa-miR-1307-3p	CD66a+	0,15004701	15659,534	0,30871074	Spearman's rank correlation rho	two.sided	0,30871074
hsa-miR-1307-5p	CD66a+	0,01294782	18185,4493	0,93039797	Spearman's rank correlation rho	two.sided	0,93039797
hsa-miR-130a-3p	CD66a+	-0,1007713	20280,6096	0,49555628	Spearman's rank correlation rho	two.sided	0,49555628
hsa-miR-130b-3p	CD66a+	-0,0763864	19831,343	0,60583667	Spearman's rank correlation rho	two.sided	0,60583667
hsa-miR-130b-5p	CD66a+	-0,0352973	19074,3183	0,81174526	Spearman's rank correlation rho	two.sided	0,81174526
hsa-miR-132-3p	CD66a+	-0,1039248	20338,7113	0,48209312	Spearman's rank correlation rho	two.sided	0,48209312
hsa-miR-132-5p	CD66a+	0,17152741	15263,7791	0,24372952	Spearman's rank correlation rho	two.sided	0,24372952
hsa-miR-133a-3p	CD66a+	0,1672221	15343,1	0,2559436	Spearman's rank correlation rho	two.sided	0,2559436
hsa-miR-135a-3p	CD66a+	0,41535327	10771,5314	0,00332807	Spearman's rank correlation rho	two.sided	0,00332807
hsa-miR-135a-5p	CD66a+	0,22639076	14252,9767	0,12179027	Spearman's rank correlation rho	two.sided	0,12179027
hsa-miR-135b-5p	CD66a+	0,43633159	10385,0268	0,00193322	Spearman's rank correlation rho	two.sided	0,00193322
hsa-miR-136-3p	CD66a+	0,08176991	16917,4711	0,58059766	Spearman's rank correlation rho	two.sided	0,58059766
hsa-miR-139-3p	CD66a+	0,12248617	16167,3147	0,40689534	Spearman's rank correlation rho	two.sided	0,40689534
hsa-miR-139-5p	CD66a+	0,1951979	14827,6739	0,18366547	Spearman's rank correlation rho	two.sided	0,18366547
hsa-miR-140-3p	CD66a+	0,23729927	14051,9983	0,10437335	Spearman's rank correlation rho	two.sided	0,10437335
hsa-miR-140-5p	CD66a+	0,18196561	15071,4655	0,21577967	Spearman's rank correlation rho	two.sided	0,21577967
hsa-miR-141-3p	CD66a+	0,05201099	17465,7496	0,72552688	Spearman's rank correlation rho	two.sided	0,72552688
hsa-miR-141-5p	CD66a+	0,41229121	10827,9467	0,00359254	Spearman's rank correlation rho	two.sided	0,00359254
hsa-miR-142-3p	CD66a+	0,06966344	17140,5208	0,63800322	Spearman's rank correlation rho	two.sided	0,63800322
hsa-miR-142-5p	CD66a+	0,251815	13784,5605	0,08424269	Spearman's rank correlation rho	two.sided	0,08424269
hsa-miR-143-3p	CD66a+	0,17818146	15141,1847	0,225642	Spearman's rank correlation rho	two.sided	0,225642
hsa-miR-143-5p	CD66a+	0,38509226	11329,0602	0,00687628	Spearman's rank correlation rho	two.sided	0,00687628
hsa-miR-144-3p	CD66a+	-0,0518719	19379,6884	0,72623213	Spearman's rank correlation rho	two.sided	0,72623213
hsa-miR-144-5p	CD66a+	-0,0107534	18622,121	0,94217213	Spearman's rank correlation rho	two.sided	0,94217213
hsa-miR-145-3p	CD66a+	0,01551901	18138,0778	0,91662108	Spearman's rank correlation rho	two.sided	0,91662108
hsa-miR-145-5p	CD66a+	0,05750897	17364,4548	0,69782896	Spearman's rank correlation rho	two.sided	0,69782896
hsa-miR-1468-5p	CD66a+	0,14537013	15745,7007	0,32420417	Spearman's rank correlation rho	two.sided	0,32420417
hsa-miR-146a-3p	CD66a+	0,22703375	14241,1302	0,12070633	Spearman's rank correlation rho	two.sided	0,12070633
hsa-miR-146a-5p	CD66a+	0,54962173	8297,76922	5,2083E-05	Spearman's rank correlation rho	two.sided	5,2083E-05
hsa-miR-146b-3p	CD66a+	0,14755808	15705,39	0,31689607	Spearman's rank correlation rho	two.sided	0,31689607
hsa-miR-146b-5p	CD66a+	0,09122377	16743,2933	0,53746898	Spearman's rank correlation rho	two.sided	0,53746898
hsa-miR-147b-3p	CD66a+	-0,3023522	23994,5368	0,03673448	Spearman's rank correlation rho	two.sided	0,03673448
hsa-miR-147b-5p	CD66a+	0,0004968	18414,8469	0,99732613	Spearman's rank correlation rho	two.sided	0,99732613
hsa-miR-148a-3p	CD66a+	0,41006865	10868,8951	0,00379591	Spearman's rank correlation rho	two.sided	0,00379591
hsa-miR-148a-5p	CD66a+	0,3607266	11777,9732	0,01177734	Spearman's rank correlation rho	two.sided	0,01177734
hsa-miR-148b-3p	CD66a+	0,29348223	13016,8835	0,04291564	Spearman's rank correlation rho	two.sided	0,04291564
hsa-miR-148b-5p	CD66a+	0,17453768	15208,3177	0,23542845	Spearman's rank correlation rho	two.sided	0,23542845
hsa-miR-149-5p	CD66a+	0,06353905	17253,3565	0,66789294	Spearman's rank correlation rho	two.sided	0,66789294

hsa-miR-150-3p	CD66a+	0,42448998	10603,1966	0,00263797	Spearman's rank correlation rho	two.sided	0,00263797
hsa-miR-150-5p	CD66a+	-0,0975937	20222,0654	0,50931568	Spearman's rank correlation rho	two.sided	0,50931568
hsa-miR-151a-3p	CD66a+	-0,0622379	19570,6705	0,67431145	Spearman's rank correlation rho	two.sided	0,67431145
hsa-miR-151a-5p	CD66a+	0,18875898	14946,3046	0,19883605	Spearman's rank correlation rho	two.sided	0,19883605
hsa-miR-152-3p	CD66a+	0,24615974	13888,7529	0,09168959	Spearman's rank correlation rho	two.sided	0,09168959
hsa-miR-153-3p	CD66a+	-0,004267	18502,6151	0,97703729	Spearman's rank correlation rho	two.sided	0,97703729
hsa-miR-155-5p	CD66a+	0,15696799	15532,0217	0,286667	Spearman's rank correlation rho	two.sided	0,286667
hsa-miR-15a-5p	CD66a+	0,06136128	17293,4798	0,6786485	Spearman's rank correlation rho	two.sided	0,6786485
hsa-miR-15b-3p	CD66a+	-0,2175932	22432,9368	0,13736971	Spearman's rank correlation rho	two.sided	0,13736971
hsa-miR-15b-5p	CD66a+	0,02822619	17903,9607	0,84896451	Spearman's rank correlation rho	two.sided	0,84896451
hsa-miR-16-2-3p	CD66a+	0,04412168	17611,1022	0,76587775	Spearman's rank correlation rho	two.sided	0,76587775
hsa-miR-16-5p	CD66a+	0,04242694	17642,326	0,77463063	Spearman's rank correlation rho	two.sided	0,77463063
hsa-miR-17-3p	CD66a+	0,31621676	12598,0225	0,02855401	Spearman's rank correlation rho	two.sided	0,02855401
hsa-miR-17-5p	CD66a+	-0,226803	22602,6179	0,12109452	Spearman's rank correlation rho	two.sided	0,12109452
hsa-miR-181a-2-3p	CD66a+	0,1144366	16315,6201	0,43864085	Spearman's rank correlation rho	two.sided	0,43864085
hsa-miR-181a-5p	CD66a+	0,14481262	15755,9724	0,3260832	Spearman's rank correlation rho	two.sided	0,3260832
hsa-miR-181b-5p	CD66a+	0,10715139	16449,8428	0,46852016	Spearman's rank correlation rho	two.sided	0,46852016
hsa-miR-181c-3p	CD66a+	0,37794195	11460,7974	0,00808583	Spearman's rank correlation rho	two.sided	0,00808583
hsa-miR-181c-5p	CD66a+	0,15530276	15562,702	0,29187447	Spearman's rank correlation rho	two.sided	0,29187447
hsa-miR-181d-5p	CD66a+	0,05573096	17397,2128	0,7067458	Spearman's rank correlation rho	two.sided	0,7067458
hsa-miR-182-5p	CD66a+	0,38879674	11260,8088	0,00631386	Spearman's rank correlation rho	two.sided	0,00631386
hsa-miR-183-3p	CD66a+	0,05664153	17380,4365	0,70217427	Spearman's rank correlation rho	two.sided	0,70217427
hsa-miR-183-5p	CD66a+	0,24673078	13878,2322	0,09091521	Spearman's rank correlation rho	two.sided	0,09091521
hsa-miR-184	CD66a+	0,06368692	17250,6322	0,66716503	Spearman's rank correlation rho	two.sided	0,66716503
hsa-miR-185-3p	CD66a+	0,33573732	12238,3757	0,01965299	Spearman's rank correlation rho	two.sided	0,01965299
hsa-miR-185-5p	CD66a+	0,00295127	18369,6259	0,98411675	Spearman's rank correlation rho	two.sided	0,98411675
hsa-miR-186-5p	CD66a+	0,02641457	17937,338	0,85855606	Spearman's rank correlation rho	two.sided	0,85855606
hsa-miR-18a-3p	CD66a+	0,39198978	11201,9803	0,00586164	Spearman's rank correlation rho	two.sided	0,00586164
hsa-miR-18a-5p	CD66a+	-0,2835568	23648,2505	0,05081399	Spearman's rank correlation rho	two.sided	0,05081399
hsa-miR-190a-5p	CD66a+	0,19038156	14916,4101	0,19493226	Spearman's rank correlation rho	two.sided	0,19493226
hsa-miR-190b-5p	CD66a+	-0,0113985	18634,005	0,9387098	Spearman's rank correlation rho	two.sided	0,9387098
hsa-miR-191-3p	CD66a+	0,1587384	15499,4036	0,28119757	Spearman's rank correlation rho	two.sided	0,28119757
hsa-miR-191-5p	CD66a+	0,37255062	11560,1275	0,00911569	Spearman's rank correlation rho	two.sided	0,00911569
hsa-miR-192-3p	CD66a+	-0,0070435	18553,7688	0,96210453	Spearman's rank correlation rho	two.sided	0,96210453
hsa-miR-192-5p	CD66a+	-0,2492437	23016,0653	0,08756772	Spearman's rank correlation rho	two.sided	0,08756772
hsa-miR-193a-5p	CD66a+	-0,016363	18725,472	0,91210385	Spearman's rank correlation rho	two.sided	0,91210385
hsa-miR-193b-3p	CD66a+	0,38688331	11296,0619	0,00659915	Spearman's rank correlation rho	two.sided	0,00659915
hsa-miR-193b-5p	CD66a+	0,41772725	10727,7932	0,00313499	Spearman's rank correlation rho	two.sided	0,00313499
hsa-miR-194-3p	CD66a+	-0,6300342	30031,7506	1,6005E-06	Spearman's rank correlation rho	two.sided	1,6005E-06
hsa-miR-194-5p	CD66a+	0,12161221	16183,4167	0,41027645	Spearman's rank correlation rho	two.sided	0,41027645
hsa-miR-195-5p	CD66a+	-0,1818051	21773,5769	0,21619184	Spearman's rank correlation rho	two.sided	0,21619184
hsa-miR-196a-1-3p	CD66a+	-0,2731968	23457,378	0,06027372	Spearman's rank correlation rho	two.sided	0,06027372
hsa-miR-196a-5p	CD66a+	-0,1581368	21337,512	0,28304847	Spearman's rank correlation rho	two.sided	0,28304847
hsa-miR-196b-5p	CD66a+	-0,5273564	28140,0135	0,00011748	Spearman's rank correlation rho	two.sided	0,00011748
hsa-miR-197-3p	CD66a+	0,06165347	17288,0964	0,67720167	Spearman's rank correlation rho	two.sided	0,67720167
hsa-miR-199a-5p	CD66a+	-0,107128	20397,7259	0,46861787	Spearman's rank correlation rho	two.sided	0,46861787
hsa-miR-199b-5p	CD66a+	0,35228066	11933,5811	0,01406406	Spearman's rank correlation rho	two.sided	0,01406406
hsa-miR-19a-3p	CD66a+	0,05593553	17393,4438	0,70571785	Spearman's rank correlation rho	two.sided	0,70571785
hsa-miR-19b-3p	CD66a+	-0,0339834	19050,1098	0,81863287	Spearman's rank correlation rho	two.sided	0,81863287
hsa-miR-200a-3p	CD66a+	0,07895151	16969,3974	0,5937516	Spearman's rank correlation rho	two.sided	0,5937516
hsa-miR-200a-5p	CD66a+	0,11629423	16281,3951	0,43119521	Spearman's rank correlation rho	two.sided	0,43119521
hsa-miR-200b-3p	CD66a+	0,00210382	18385,2393	0,98867724	Spearman's rank correlation rho	two.sided	0,98867724
hsa-miR-200b-5p	CD66a+	-0,2636782	23282,0067	0,0701629	Spearman's rank correlation rho	two.sided	0,0701629
hsa-miR-200c-3p	CD66a+	-0,1122035	20491,2369	0,44768527	Spearman's rank correlation rho	two.sided	0,44768527
hsa-miR-200c-5p	CD66a+	-0,1835343	21805,4361	0,21178066	Spearman's rank correlation rho	two.sided	0,21178066
hsa-miR-203a-3p	CD66a+	-0,0246614	18878,3614	0,86785749	Spearman's rank correlation rho	two.sided	0,86785749
hsa-miR-203b-3p	CD66a+	-0,0684747	19685,5772	0,64376251	Spearman's rank correlation rho	two.sided	0,64376251
hsa-miR-204-5p	CD66a+	-0,1442635	21081,91	0,32794072	Spearman's rank correlation rho	two.sided	0,32794072
hsa-miR-205-5p	CD66a+	-0,1929688	21979,2574	0,18882052	Spearman's rank correlation rho	two.sided	0,18882052
hsa-miR-206	CD66a+	-0,0393068	19148,1892	0,79081703	Spearman's rank correlation rho	two.sided	0,79081703
hsa-miR-20a-3p	CD66a+	-0,2503343	23036,1592	0,08614512	Spearman's rank correlation rho	two.sided	0,08614512
hsa-miR-20a-5p	CD66a+	-0,1122619	20492,3136	0,44744729	Spearman's rank correlation rho	two.sided	0,44744729
hsa-miR-21-3p	CD66a+	0,2969251	12953,4519	0,04042249	Spearman's rank correlation rho	two.sided	0,04042249
hsa-miR-21-5p	CD66a+	0,53051208	8649,84551	0,00010505	Spearman's rank correlation rho	two.sided	0,00010505
hsa-miR-210-3p	CD66a+	0,09080272	16751,0506	0,53935615	Spearman's rank correlation rho	two.sided	0,53935615
hsa-miR-210-5p	CD66a+	-0,165318	21469,8194	0,26147434	Spearman's rank correlation rho	two.sided	0,26147434
hsa-miR-2110	CD66a+	0,0544991	17419,9087	0,71294667	Spearman's rank correlation rho	two.sided	0,71294667
hsa-miR-2116-3p	CD66a+	-0,1810794	21760,2067	0,21806198	Spearman's rank correlation rho	two.sided	0,21806198
hsa-miR-215-3p	CD66a+	0,19618077	14809,5655	0,18142476	Spearman's rank correlation rho	two.sided	0,18142476
hsa-miR-215-5p	CD66a+	-0,0174149	18744,8524	0,90647772	Spearman's rank correlation rho	two.sided	0,90647772
hsa-miR-218-5p	CD66a+	0,09131638	16741,587	0,53705429	Spearman's rank correlation rho	two.sided	0,53705429
hsa-miR-219a-1-3p	CD66a+	0,08773169	16807,6313	0,55321722	Spearman's rank correlation rho	two.sided	0,55321722
hsa-miR-22-3p	CD66a+	0,13154689	16000,3801	0,37279965	Spearman's rank correlation rho	two.sided	0,37279965
hsa-miR-22-5p	CD66a+	0,2537126	13749,5991	0,08185287	Spearman's rank correlation rho	two.sided	0,08185287
hsa-miR-221-3p	CD66a+	0,36489507	11701,1733	0,01077154	Spearman's rank correlation rho	two.sided	0,01077154
hsa-miR-221-5p	CD66a+	-0,2402928	22851,1545	0,09994571	Spearman's rank correlation rho	two.sided	0,09994571
hsa-miR-222-3p	CD66a+	0,4095427	10878,5853	0,00384549	Spearman's rank correlation rho	two.sided	0,00384549
hsa-miR-223-3p	CD66a+	0,56434844	8026,44438	2,9437E-05	Spearman's rank correlation rho	two.sided	2,9437E-05
hsa-miR-223-5p	CD66a+	0,34173964	12127,7888	0,0174402	Spearman's rank correlation rho	two.sided	0,0174402
hsa-miR-224-3p	CD66a+	-0,1947434	22011,9529	0,18470822	Spearman's rank correlation rho	two.sided	0,18470822
hsa-miR-224-5p	CD66a+	0,40352345	10989,4839	0,00445471	Spearman's rank correlation rho	two.sided	0,00445471
hsa-miR-23a-3p	CD66a+	0,45857328	9975,24584	0,00104561	Spearman's rank correlation rho	two.sided	0,00104561
hsa-miR-23a-5p	CD66a+	-0,145138	21098,022	0,32498581	Spearman's rank correlation rho	two.sided	0,32498581
hsa-miR-23b-3p	CD66a+	0,17923337	15121,8044	0,22286981	Spearman's rank correlation rho	two.sided	0,22286981
hsa-miR-23b-5p	CD66a+	0,28949927	13090,2654	0,04595523	Spearman's rank correlation rho	two.sided	0,04595523
hsa-miR-24-2-5p	CD66a+	0,13935989	15856,4335	0,34482043	Spearman's rank correlation rho	two.sided	0,34482043
hsa-miR-24-3p	CD66a+	0,53401843	8585,24436	9,2653E-05	Spearman's rank correlation rho	two.sided	9,2653E-05
hsa-miR-25-3p	CD66a+	0,12278099	16161,8829	0,40575841	Spearman's rank correlation rho	two.sided	0,40575841
hsa-miR-25-5p	CD66a+	0,21428519	14476,0098	0,14359685	Spearman's rank correlation rho	two.sided	0,14359685
hsa-miR-26a-2-3p	CD66a+	0,15423809	15582,3174	0,29523588	Spearman's rank correlation rho	two.sided	0,29523588
hsa-miR-26a-5p	CD66a+	-0,3181436	24285,478	0,02754766	Spearman's rank correlation rho	two.sided	0,02754766
hsa-miR-26b-3p	CD66a+	0,20786762	14594,2469	0,15627058	Spearman's rank correlation rho	two.sided	0,15627058
hsa-miR-26b-5p	CD66a+	0,12985215	16031,604	0,3790433	Spearman's rank correlation rho	two.sided	0,3790433
hsa-miR-27a-3p	CD66a+	0,55692665	8163,18349	3,9377E-05	Spearman's rank correlation rho	two.sided	3,9377E-05
hsa-miR-27a-5p	CD66a+	0,03114815	17850,1264	0,8335403	Spearman's rank correlation rho	two.sided	0,8335403
hsa-miR-27b-3p	CD66a+	0,27425569	13371,1131	0,05924643	Spearman's rank correlation rho	two.sided	0,05924643
hsa-miR-27b-5p	CD66a+	0,28224798	13223,8632	0,05193815	Spearman's rank correlation rho	two.sided	0,05193815

hsa-miR-28-3p	CD66a+	-0,2347507	22749,0472	0,10826023	Spearman's rank correlation rho	two.sided	0,10826023
hsa-miR-28-5p	CD66a+	-0,0250705	18885,8982	0,86568553	Spearman's rank correlation rho	two.sided	0,86568553
hsa-miR-296-5p	CD66a+	0,14499807	15752,5556	0,3254574	Spearman's rank correlation rho	two.sided	0,3254574
hsa-miR-29a-3p	CD66a+	0,07690613	17007,0814	0,60337945	Spearman's rank correlation rho	two.sided	0,60337945
hsa-miR-29a-5p	CD66a+	-0,2846475	23668,3454	0,04989232	Spearman's rank correlation rho	two.sided	0,04989232
hsa-miR-29b-1-5p	CD66a+	0,08801916	16802,335	0,55191262	Spearman's rank correlation rho	two.sided	0,55191262
hsa-miR-29b-2-5p	CD66a+	0,0021335	18384,6924	0,9885175	Spearman's rank correlation rho	two.sided	0,9885175
hsa-miR-29b-3p	CD66a+	0,1273135	16078,3761	0,38851158	Spearman's rank correlation rho	two.sided	0,38851158
hsa-miR-29c-3p	CD66a+	0,12961839	16035,9107	0,37990934	Spearman's rank correlation rho	two.sided	0,37990934
hsa-miR-29c-5p	CD66a+	-0,0207505	18806,3065	0,88866881	Spearman's rank correlation rho	two.sided	0,88866881
hsa-miR-30a-3p	CD66a+	0,22956401	14194,5126	0,11651161	Spearman's rank correlation rho	two.sided	0,11651161
hsa-miR-30a-5p	CD66a+	0,13855961	15871,1778	0,34762521	Spearman's rank correlation rho	two.sided	0,34762521
hsa-miR-30b-3p	CD66a+	0,25564824	13713,9368	0,07947025	Spearman's rank correlation rho	two.sided	0,07947025
hsa-miR-30b-5p	CD66a+	0,05616018	17389,3049	0,70458961	Spearman's rank correlation rho	two.sided	0,70458961
hsa-miR-30c-1-3p	CD66a+	-0,3436872	24756,0933	0,01676922	Spearman's rank correlation rho	two.sided	0,01676922
hsa-miR-30c-5p	CD66a+	-0,418893	26141,6844	0,00304384	Spearman's rank correlation rho	two.sided	0,00304384
hsa-miR-30d-3p	CD66a+	0,06327773	17258,1711	0,66918013	Spearman's rank correlation rho	two.sided	0,66918013
hsa-miR-30d-5p	CD66a+	-0,101626	20296,3568	0,49188833	Spearman's rank correlation rho	two.sided	0,49188833
hsa-miR-30e-3p	CD66a+	0,07883463	16971,5507	0,59429993	Spearman's rank correlation rho	two.sided	0,59429993
hsa-miR-30e-5p	CD66a+	-0,1060674	20378,1849	0,47305736	Spearman's rank correlation rho	two.sided	0,47305736
hsa-miR-31-5p	CD66a+	0,39754421	11099,6455	0,00514198	Spearman's rank correlation rho	two.sided	0,00514198
hsa-miR-3127-5p	CD66a+	-0,183252	21800,235	0,21249647	Spearman's rank correlation rho	two.sided	0,21249647
hsa-miR-3145-5p	CD66a+	0,13950328	15853,7915	0,34431934	Spearman's rank correlation rho	two.sided	0,34431934
hsa-miR-3150b-5p	CD66a+	-0,0683049	19682,449	0,64458679	Spearman's rank correlation rho	two.sided	0,64458679
hsa-miR-3168	CD66a+	0,17212246	15252,8158	0,24207305	Spearman's rank correlation rho	two.sided	0,24207305
hsa-miR-3173-5p	CD66a+	0,05339446	17440,2605	0,71852279	Spearman's rank correlation rho	two.sided	0,71852279
hsa-miR-3177-3p	CD66a+	-0,2430274	22901,5369	0,09602892	Spearman's rank correlation rho	two.sided	0,09602892
hsa-miR-3182	CD66a+	-0,1280718	20783,5952	0,38566883	Spearman's rank correlation rho	two.sided	0,38566883
hsa-miR-3187-3p	CD66a+	-0,256962	23158,2676	0,07788444	Spearman's rank correlation rho	two.sided	0,07788444
hsa-miR-3188	CD66a+	0,05921027	17333,1099	0,68933436	Spearman's rank correlation rho	two.sided	0,68933436
hsa-miR-3195	CD66a+	-0,0570091	19474,3356	0,70033183	Spearman's rank correlation rho	two.sided	0,70033183
hsa-miR-32-3p	CD66a+	0,01049071	18230,7191	0,94358256	Spearman's rank correlation rho	two.sided	0,94358256
hsa-miR-32-5p	CD66a+	0,18469329	15021,2108	0,20885959	Spearman's rank correlation rho	two.sided	0,20885959
hsa-miR-320a-3p	CD66a+	-0,2485424	23003,1451	0,08849207	Spearman's rank correlation rho	two.sided	0,08849207
hsa-miR-324-3p	CD66a+	0,20692123	14611,6832	0,15820686	Spearman's rank correlation rho	two.sided	0,15820686
hsa-miR-324-5p	CD66a+	0,25234597	13774,7778	0,08356855	Spearman's rank correlation rho	two.sided	0,08356855
hsa-miR-326	CD66a+	0,13492546	15938,1333	0,3605378	Spearman's rank correlation rho	two.sided	0,3605378
hsa-miR-328-3p	CD66a+	-0,3621591	25096,4185	0,01142298	Spearman's rank correlation rho	two.sided	0,01142298
hsa-miR-328-5p	CD66a+	-0,3076788	24092,6748	0,03338874	Spearman's rank correlation rho	two.sided	0,03338874
hsa-miR-329-3p	CD66a+	0,26929569	13462,4961	0,06418221	Spearman's rank correlation rho	two.sided	0,06418221
hsa-miR-330-3p	CD66a+	0,17288225	15238,8174	0,23996915	Spearman's rank correlation rho	two.sided	0,23996915
hsa-miR-331-3p	CD66a+	0,2286226	14211,8572	0,11805917	Spearman's rank correlation rho	two.sided	0,11805917
hsa-miR-335-3p	CD66a+	-0,1376905	20960,8096	0,3506871	Spearman's rank correlation rho	two.sided	0,3506871
hsa-miR-335-5p	CD66a+	-0,320189	24323,162	0,02651194	Spearman's rank correlation rho	two.sided	0,02651194
hsa-miR-338-3p	CD66a+	0,20705498	14609,219	0,15793216	Spearman's rank correlation rho	two.sided	0,15793216
hsa-miR-338-5p	CD66a+	-0,0894511	20072,0467	0,54543602	Spearman's rank correlation rho	two.sided	0,54543602
hsa-miR-339-3p	CD66a+	-0,0854698	19998,6958	0,56353295	Spearman's rank correlation rho	two.sided	0,56353295
hsa-miR-339-5p	CD66a+	0,09011831	16763,6602	0,54243062	Spearman's rank correlation rho	two.sided	0,54243062
hsa-miR-33b-3p	CD66a+	-0,2780345	23546,5077	0,05569438	Spearman's rank correlation rho	two.sided	0,05569438
hsa-miR-340-3p	CD66a+	-0,0282277	18944,0675	0,84895641	Spearman's rank correlation rho	two.sided	0,84895641
hsa-miR-340-5p	CD66a+	0,18578866	15001,0298	0,2061249	Spearman's rank correlation rho	two.sided	0,2061249
hsa-miR-342-3p	CD66a+	-0,0624132	19573,9005	0,67344529	Spearman's rank correlation rho	two.sided	0,67344529
hsa-miR-342-5p	CD66a+	0,16568221	15371,4711	0,26041039	Spearman's rank correlation rho	two.sided	0,26041039
hsa-miR-345-5p	CD66a+	0,08921487	16780,3052	0,54650186	Spearman's rank correlation rho	two.sided	0,54650186
hsa-miR-34a-5p	CD66a+	0,30054863	12886,692	0,03792804	Spearman's rank correlation rho	two.sided	0,03792804
hsa-miR-3605-5p	CD66a+	-0,0462952	19276,9436	0,75469419	Spearman's rank correlation rho	two.sided	0,75469419
hsa-miR-3609	CD66a+	0,31243822	12667,6382	0,03061642	Spearman's rank correlation rho	two.sided	0,03061642
hsa-miR-361-3p	CD66a+	0,15322788	15600,9296	0,29844844	Spearman's rank correlation rho	two.sided	0,29844844
hsa-miR-361-5p	CD66a+	-0,2920797	23805,2761	0,04396668	Spearman's rank correlation rho	two.sided	0,04396668
hsa-miR-3613-3p	CD66a+	-0,3345007	24586,8404	0,02013718	Spearman's rank correlation rho	two.sided	0,02013718
hsa-miR-3613-5p	CD66a+	-0,1721377	21595,4644	0,24203083	Spearman's rank correlation rho	two.sided	0,24203083
hsa-miR-3615	CD66a+	0,24880095	13840,0912	0,08815038	Spearman's rank correlation rho	two.sided	0,08815038
hsa-miR-362-3p	CD66a+	0,22626771	14255,2438	0,12199855	Spearman's rank correlation rho	two.sided	0,12199855
hsa-miR-362-5p	CD66a+	0,01285804	18187,1034	0,9308794	Spearman's rank correlation rho	two.sided	0,9308794
hsa-miR-363-3p	CD66a+	0,1568724	15533,7829	0,28696428	Spearman's rank correlation rho	two.sided	0,28696428
hsa-miR-3651	CD66a+	0,17067522	15279,4798	0,24611516	Spearman's rank correlation rho	two.sided	0,24611516
hsa-miR-3652	CD66a+	-0,0934991	20146,6266	0,52732664	Spearman's rank correlation rho	two.sided	0,52732664
hsa-miR-3654	CD66a+	0,22300045	14315,4397	0,12762766	Spearman's rank correlation rho	two.sided	0,12762766
hsa-miR-3659	CD66a+	0,19404196	14848,9709	0,18632599	Spearman's rank correlation rho	two.sided	0,18632599
hsa-miR-3660	CD66a+	-0,1036703	20334,0208	0,48317278	Spearman's rank correlation rho	two.sided	0,48317278
hsa-miR-369-3p	CD66a+	-0,0987281	20242,9668	0,50438122	Spearman's rank correlation rho	two.sided	0,50438122
hsa-miR-369-5p	CD66a+	-0,2714951	23426,0253	0,06195453	Spearman's rank correlation rho	two.sided	0,06195453
hsa-miR-370-3p	CD66a+	0,40058246	11043,6688	0,00478198	Spearman's rank correlation rho	two.sided	0,00478198
hsa-miR-374a-3p	CD66a+	0,09090975	16749,0787	0,53887613	Spearman's rank correlation rho	two.sided	0,53887613
hsa-miR-374a-5p	CD66a+	-0,1222617	20676,5491	0,40776232	Spearman's rank correlation rho	two.sided	0,40776232
hsa-miR-374b-3p	CD66a+	-0,2275182	22615,7962	0,11989439	Spearman's rank correlation rho	two.sided	0,11989439
hsa-miR-374b-5p	CD66a+	-0,0284315	18947,8219	0,84787884	Spearman's rank correlation rho	two.sided	0,84787884
hsa-miR-375-3p	CD66a+	-0,1065933	20387,8751	0,47085308	Spearman's rank correlation rho	two.sided	0,47085308
hsa-miR-376a-3p	CD66a+	0,36825762	11639,2215	0,01001487	Spearman's rank correlation rho	two.sided	0,01001487
hsa-miR-376c-3p	CD66a+	0,35210477	11936,8218	0,01411545	Spearman's rank correlation rho	two.sided	0,01411545
hsa-miR-377-3p	CD66a+	0,25185414	13783,8394	0,08419286	Spearman's rank correlation rho	two.sided	0,08419286
hsa-miR-378a-3p	CD66a+	-0,3721415	25280,3357	0,00919826	Spearman's rank correlation rho	two.sided	0,00919826
hsa-miR-378a-5p	CD66a+	-0,0522839	19387,2785	0,72414344	Spearman's rank correlation rho	two.sided	0,72414344
hsa-miR-378c	CD66a+	0,08522071	16853,8937	0,5646745	Spearman's rank correlation rho	two.sided	0,5646745
hsa-miR-378d	CD66a+	-0,0585429	19502,5937	0,69266229	Spearman's rank correlation rho	two.sided	0,69266229
hsa-miR-379-3p	CD66a+	0,23485378	14097,054	0,10810094	Spearman's rank correlation rho	two.sided	0,10810094
hsa-miR-379-5p	CD66a+	0,22717827	14238,4676	0,1204637	Spearman's rank correlation rho	two.sided	0,1204637
hsa-miR-381-3p	CD66a+	0,09232995	16722,9129	0,53252622	Spearman's rank correlation rho	two.sided	0,53252622
hsa-miR-382-3p	CD66a+	-0,3575996	25012,4142	0,01258375	Spearman's rank correlation rho	two.sided	0,01258375
hsa-miR-382-5p	CD66a+	0,39654916	11117,9782	0,00526492	Spearman's rank correlation rho	two.sided	0,00526492
hsa-miR-3909	CD66a+	0,09296286	16711,2522	0,52970825	Spearman's rank correlation rho	two.sided	0,52970825
hsa-miR-3912-3p	CD66a+	0,2785097	13292,7373	0,05526011	Spearman's rank correlation rho	two.sided	0,05526011
hsa-miR-3940-3p	CD66a+	0,09168695	16734,7597	0,53539665	Spearman's rank correlation rho	two.sided	0,53539665
hsa-miR-3960	CD66a+	0,14890337	15680,6044	0,31245488	Spearman's rank correlation rho	two.sided	0,31245488
hsa-miR-409-3p	CD66a+	-0,2041854	22185,9126	0,16390289	Spearman's rank correlation rho	two.sided	0,16390289
hsa-miR-411-5p	CD66a+	0,36556876	11688,7612	0,01061613	Spearman's rank correlation rho	two.sided	0,01061613
hsa-miR-421	CD66a+	0,12080062	16198,3695	0,41343066	Spearman's rank correlation rho	two.sided	0,41343066

hsa-miR-423-3p	CD66a+	-0,0416088	19190,6004	0,77886616	Spearman's rank correlation rho	two.sided	0,77886616
hsa-miR-423-5p	CD66a+	-0,0494397	19334,8763	0,73860351	Spearman's rank correlation rho	two.sided	0,73860351
hsa-miR-424-3p	CD66a+	-0,0570815	19475,6692	0,6999692	Spearman's rank correlation rho	two.sided	0,6999692
hsa-miR-424-5p	CD66a+	0,42057359	10675,3522	0,00291655	Spearman's rank correlation rho	two.sided	0,00291655
hsa-miR-425-3p	CD66a+	0,09685234	16639,5925	0,51255323	Spearman's rank correlation rho	two.sided	0,51255323
hsa-miR-425-5p	CD66a+	0,32264344	12479,6172	0,02531222	Spearman's rank correlation rho	two.sided	0,02531222
hsa-miR-4284	CD66a+	0,26321716	13574,487	0,07067272	Spearman's rank correlation rho	two.sided	0,07067272
hsa-miR-4286	CD66a+	-0,0341304	19052,8187	0,81786148	Spearman's rank correlation rho	two.sided	0,81786148
hsa-miR-429	CD66a+	-0,1113269	20475,0866	0,45126339	Spearman's rank correlation rho	two.sided	0,45126339
hsa-miR-432-5p	CD66a+	0,14499807	15752,5556	0,3254574	Spearman's rank correlation rho	two.sided	0,3254574
hsa-miR-4326	CD66a+	0,07823801	16982,543	0,59710243	Spearman's rank correlation rho	two.sided	0,59710243
hsa-miR-4443	CD66a+	0,04569954	17582,0316	0,7577544	Spearman's rank correlation rho	two.sided	0,7577544
hsa-miR-4444	CD66a+	-0,0677788	19672,7562	0,64714353	Spearman's rank correlation rho	two.sided	0,64714353
hsa-miR-4446-3p	CD66a+	0,35972333	11796,4574	0,01203109	Spearman's rank correlation rho	two.sided	0,01203109
hsa-miR-4448	CD66a+	0,13224048	15987,6014	0,37026226	Spearman's rank correlation rho	two.sided	0,37026226
hsa-miR-4455	CD66a+	-0,1786342	21715,156	0,22444602	Spearman's rank correlation rho	two.sided	0,22444602
hsa-miR-4468	CD66a+	0,2723719	13405,8201	0,06108386	Spearman's rank correlation rho	two.sided	0,06108386
hsa-miR-4484	CD66a+	0,17758713	15152,1347	0,22721878	Spearman's rank correlation rho	two.sided	0,22721878
hsa-miR-4488	CD66a+	0,14393603	15772,1227	0,32905143	Spearman's rank correlation rho	two.sided	0,32905143
hsa-miR-4492	CD66a+	-0,0762633	19829,0751	0,6064193	Spearman's rank correlation rho	two.sided	0,6064193
hsa-miR-4497	CD66a+	0,11428118	16318,4836	0,43926702	Spearman's rank correlation rho	two.sided	0,43926702
hsa-miR-450a-5p	CD66a+	0,09130451	16741,8057	0,53710744	Spearman's rank correlation rho	two.sided	0,53710744
hsa-miR-450b-5p	CD66a+	0,37314863	11549,1096	0,00899614	Spearman's rank correlation rho	two.sided	0,00899614
hsa-miR-4516	CD66a+	0,2904007	13073,6574	0,04525239	Spearman's rank correlation rho	two.sided	0,04525239
hsa-miR-451a	CD66a+	-0,0210966	18812,6836	0,88682373	Spearman's rank correlation rho	two.sided	0,88682373
hsa-miR-452-3p	CD66a+	0,27275147	13398,827	0,06071001	Spearman's rank correlation rho	two.sided	0,06071001
hsa-miR-452-5p	CD66a+	0,16123548	15453,3976	0,27360041	Spearman's rank correlation rho	two.sided	0,27360041
hsa-miR-4525	CD66a+	-0,2957299	23872,5274	0,04127419	Spearman's rank correlation rho	two.sided	0,04127419
hsa-miR-454-3p	CD66a+	0,38610854	11310,3363	0,00671782	Spearman's rank correlation rho	two.sided	0,00671782
hsa-miR-454-5p	CD66a+	-0,0952209	20178,3499	0,51971465	Spearman's rank correlation rho	two.sided	0,51971465
hsa-miR-455-3p	CD66a+	-0,1431295	21061,0184	0,33179722	Spearman's rank correlation rho	two.sided	0,33179722
hsa-miR-4636	CD66a+	-0,2814095	23608,6892	0,0526688	Spearman's rank correlation rho	two.sided	0,0526688
hsa-miR-4662a-5p	CD66a+	0,34425426	12081,4594	0,01657803	Spearman's rank correlation rho	two.sided	0,01657803
hsa-miR-4681	CD66a+	0,03451778	17788,0444	0,81582995	Spearman's rank correlation rho	two.sided	0,81582995
hsa-miR-4685-3p	CD66a+	0,25408396	13742,7571	0,08139146	Spearman's rank correlation rho	two.sided	0,08139146
hsa-miR-4708-3p	CD66a+	-0,2363279	22778,1046	0,10584203	Spearman's rank correlation rho	two.sided	0,10584203
hsa-miR-4758-5p	CD66a+	-0,2911945	23788,9669	0,04464078	Spearman's rank correlation rho	two.sided	0,04464078
hsa-miR-4791	CD66a+	-0,0730259	19769,4286	0,6218281	Spearman's rank correlation rho	two.sided	0,6218281
hsa-miR-4804-5p	CD66a+	-0,2327725	22712,5999	0,11135294	Spearman's rank correlation rho	two.sided	0,11135294
hsa-miR-484	CD66a+	-0,144462	21085,5675	0,32726847	Spearman's rank correlation rho	two.sided	0,32726847
hsa-miR-485-3p	CD66a+	-0,0724552	19758,9145	0,62456121	Spearman's rank correlation rho	two.sided	0,62456121
hsa-miR-485-5p	CD66a+	0,36948515	11616,6056	0,00975029	Spearman's rank correlation rho	two.sided	0,00975029
hsa-miR-486-3p	CD66a+	-0,0582198	19496,6412	0,69427537	Spearman's rank correlation rho	two.sided	0,69427537
hsa-miR-486-5p	CD66a+	0,0019285	18388,4694	0,98962075	Spearman's rank correlation rho	two.sided	0,98962075
hsa-miR-487b-3p	CD66a+	0,3637954	11721,4336	0,01102943	Spearman's rank correlation rho	two.sided	0,01102943
hsa-miR-493-5p	CD66a+	-0,0286407	18951,6763	0,84677285	Spearman's rank correlation rho	two.sided	0,84677285
hsa-miR-494-3p	CD66a+	0,07724852	17000,7733	0,60176308	Spearman's rank correlation rho	two.sided	0,60176308
hsa-miR-495-3p	CD66a+	0,25859869	13659,5778	0,07594377	Spearman's rank correlation rho	two.sided	0,07594377
hsa-miR-497-5p	CD66a+	0,21148509	14527,5987	0,14902947	Spearman's rank correlation rho	two.sided	0,14902947
hsa-miR-499a-5p	CD66a+	-0,4661674	27012,668	0,00083958	Spearman's rank correlation rho	two.sided	0,00083958
hsa-miR-500a-3p	CD66a+	-0,3474406	24825,2451	0,01553778	Spearman's rank correlation rho	two.sided	0,01553778
hsa-miR-501-3p	CD66a+	-0,3032206	24010,5363	0,03617091	Spearman's rank correlation rho	two.sided	0,03617091
hsa-miR-501-5p	CD66a+	-0,2010402	22127,9648	0,17063437	Spearman's rank correlation rho	two.sided	0,17063437
hsa-miR-502-3p	CD66a+	0,1718209	15258,3717	0,24291154	Spearman's rank correlation rho	two.sided	0,24291154
hsa-miR-505-3p	CD66a+	-0,1808795	21756,5237	0,2185791	Spearman's rank correlation rho	two.sided	0,2185791
hsa-miR-505-5p	CD66a+	-0,3624704	25102,155	0,01134718	Spearman's rank correlation rho	two.sided	0,01134718
hsa-miR-5100	CD66a+	-0,1852869	21837,7253	0,20737453	Spearman's rank correlation rho	two.sided	0,20737453
hsa-miR-511-5p	CD66a+	-0,1442927	21082,4485	0,32784169	Spearman's rank correlation rho	two.sided	0,32784169
hsa-miR-5191	CD66a+	-0,1524721	21233,1451	0,30086673	Spearman's rank correlation rho	two.sided	0,30086673
hsa-miR-532-3p	CD66a+	-0,0383424	19130,421	0,7958382	Spearman's rank correlation rho	two.sided	0,7958382
hsa-miR-532-5p	CD66a+	-0,0197525	18787,9198	0,89399183	Spearman's rank correlation rho	two.sided	0,89399183
hsa-miR-539-5p	CD66a+	-0,1188686	20614,0352	0,42099493	Spearman's rank correlation rho	two.sided	0,42099493
hsa-miR-543	CD66a+	0,26091469	13616,9078	0,07326304	Spearman's rank correlation rho	two.sided	0,07326304
hsa-miR-548e-3p	CD66a+	0,21887899	14391,3736	0,13500438	Spearman's rank correlation rho	two.sided	0,13500438
hsa-miR-548i	CD66a+	0,20400303	14665,4481	0,16428793	Spearman's rank correlation rho	two.sided	0,16428793
hsa-miR-548k	CD66a+	0,14279825	15793,0851	0,33292924	Spearman's rank correlation rho	two.sided	0,33292924
hsa-miR-548l	CD66a+	-0,4499587	26714,0397	0,00133313	Spearman's rank correlation rho	two.sided	0,00133313
hsa-miR-550a-5p	CD66a+	0,3825203	11376,446	0,0072919	Spearman's rank correlation rho	two.sided	0,0072919
hsa-miR-552-3p	CD66a+	0,07604193	17023,0035	0,60746767	Spearman's rank correlation rho	two.sided	0,60746767
hsa-miR-552-5p	CD66a+	0,17778204	15148,5437	0,22670085	Spearman's rank correlation rho	two.sided	0,22670085
hsa-miR-556-5p	CD66a+	0,12578188	16106,5946	0,39429068	Spearman's rank correlation rho	two.sided	0,39429068
hsa-miR-5571-3p	CD66a+	0,43021843	10497,6556	0,00227283	Spearman's rank correlation rho	two.sided	0,00227283
hsa-miR-5697	CD66a+	-0,1336578	20886,5107	0,36510966	Spearman's rank correlation rho	two.sided	0,36510966
hsa-miR-574-3p	CD66a+	-0,0584978	19501,7626	0,69288743	Spearman's rank correlation rho	two.sided	0,69288743
hsa-miR-574-5p	CD66a+	0,21166719	14524,2437	0,14867162	Spearman's rank correlation rho	two.sided	0,14867162
hsa-miR-576-3p	CD66a+	0,2038166	14668,8829	0,16468212	Spearman's rank correlation rho	two.sided	0,16468212
hsa-miR-576-5p	CD66a+	0,08949002	16775,2359	0,5452604	Spearman's rank correlation rho	two.sided	0,5452604
hsa-miR-577	CD66a+	0,00926389	18253,3221	0,95017137	Spearman's rank correlation rho	two.sided	0,95017137
hsa-miR-582-3p	CD66a+	0,41938174	10697,3108	0,00300632	Spearman's rank correlation rho	two.sided	0,00300632
hsa-miR-582-5p	CD66a+	0,52864045	8684,32844	0,00011227	Spearman's rank correlation rho	two.sided	0,00011227
hsa-miR-584-5p	CD66a+	0,30970354	12718,022	0,03218499	Spearman's rank correlation rho	two.sided	0,03218499
hsa-miR-589-5p	CD66a+	0,29352206	13016,1496	0,0428861	Spearman's rank correlation rho	two.sided	0,0428861
hsa-miR-590-3p	CD66a+	0,05339446	17440,2605	0,71852279	Spearman's rank correlation rho	two.sided	0,71852279
hsa-miR-592	CD66a+	-0,144694	21089,8424	0,32648384	Spearman's rank correlation rho	two.sided	0,32648384
hsa-miR-598-3p	CD66a+	-0,1856677	21844,7426	0,20642552	Spearman's rank correlation rho	two.sided	0,20642552
hsa-miR-6126	CD66a+	0,0050266	18331,3899	0,97295091	Spearman's rank correlation rho	two.sided	0,97295091
hsa-miR-622	CD66a+	-0,3000634	23952,3674	0,03825457	Spearman's rank correlation rho	two.sided	0,03825457
hsa-miR-624-5p	CD66a+	-0,0719544	19749,6882	0,62696369	Spearman's rank correlation rho	two.sided	0,62696369
hsa-miR-625-3p	CD66a+	0,05680609	17377,4045	0,70134917	Spearman's rank correlation rho	two.sided	0,70134917
hsa-miR-625-5p	CD66a+	0,42986771	10504,1173	0,00229382	Spearman's rank correlation rho	two.sided	0,00229382
hsa-miR-628-3p	CD66a+	-0,15552	21289,3005	0,29119165	Spearman's rank correlation rho	two.sided	0,29119165
hsa-miR-628-5p	CD66a+	0,05330823	17441,8492	0,71895868	Spearman's rank correlation rho	two.sided	0,71895868
hsa-miR-629-5p	CD66a+	0,274643	13363,9773	0,05887421	Spearman's rank correlation rho	two.sided	0,05887421
hsa-miR-642a-3p	CD66a+	0,04959653	17510,2336	0,73780362	Spearman's rank correlation rho	two.sided	0,73780362
hsa-miR-642a-5p	CD66a+	-0,2518765	23064,5731	0,08416436	Spearman's rank correlation rho	two.sided	0,08416436
hsa-miR-651-5p	CD66a+	-0,140694	21016,1458	0,34017589	Spearman's rank correlation rho	two.sided	0,34017589
hsa-miR-6511b-3p	CD66a+	-0,0671595	19661,3472	0,65015815	Spearman's rank correlation rho	two.sided	0,65015815

hsa-miR-6513-3p	CD66a+	-0,2042716	22187,5003	0,16372122	Spearman's rank correlation rho	two.sided	0,16372122
hsa-miR-652-3p	CD66a+	-0,0112788	18631,8004	0,93935203	Spearman's rank correlation rho	two.sided	0,93935203
hsa-miR-654-3p	CD66a+	0,30208816	12858,3278	0,03690725	Spearman's rank correlation rho	two.sided	0,03690725
hsa-miR-660-5p	CD66a+	0,20474769	14651,7286	0,16272025	Spearman's rank correlation rho	two.sided	0,16272025
hsa-miR-663a	CD66a+	0,12564258	16109,1611	0,39481878	Spearman's rank correlation rho	two.sided	0,39481878
hsa-miR-664a-3p	CD66a+	0,02750167	17917,3093	0,85279794	Spearman's rank correlation rho	two.sided	0,85279794
hsa-miR-664a-5p	CD66a+	0,17964736	15114,1771	0,22178528	Spearman's rank correlation rho	two.sided	0,22178528
hsa-miR-671-3p	CD66a+	-0,014643	18693,783	0,92131226	Spearman's rank correlation rho	two.sided	0,92131226
hsa-miR-671-5p	CD66a+	0,01937684	18067,0011	0,89599668	Spearman's rank correlation rho	two.sided	0,89599668
hsa-miR-6729-5p	CD66a+	0,20696056	14610,9587	0,15812606	Spearman's rank correlation rho	two.sided	0,15812606
hsa-miR-6734-5p	CD66a+	-0,3076788	24092,6748	0,03338874	Spearman's rank correlation rho	two.sided	0,03338874
hsa-miR-6787-5p	CD66a+	0,12711079	16082,1109	0,38927357	Spearman's rank correlation rho	two.sided	0,38927357
hsa-miR-6803-3p	CD66a+	0,00268872	18374,463	0,98552957	Spearman's rank correlation rho	two.sided	0,98552957
hsa-miR-6803-5p	CD66a+	-0,1350607	20912,3581	0,36005217	Spearman's rank correlation rho	two.sided	0,36005217
hsa-miR-6821-5p	CD66a+	0,16638815	15358,4648	0,25835623	Spearman's rank correlation rho	two.sided	0,25835623
hsa-miR-6859-5p	CD66a+	-0,2524971	23076,0073	0,0833774	Spearman's rank correlation rho	two.sided	0,0833774
hsa-miR-6866-5p	CD66a+	0,35280623	11923,8981	0,01391147	Spearman's rank correlation rho	two.sided	0,01391147
hsa-miR-6869-5p	CD66a+	-0,2267645	22601,9101	0,12115925	Spearman's rank correlation rho	two.sided	0,12115925
hsa-miR-6887-5p	CD66a+	-0,3546768	24958,5652	0,01337976	Spearman's rank correlation rho	two.sided	0,01337976
hsa-miR-7-1-3p	CD66a+	-0,1306075	20830,3118	0,37625301	Spearman's rank correlation rho	two.sided	0,37625301
hsa-miR-7-5p	CD66a+	0,05762116	17362,3877	0,69726762	Spearman's rank correlation rho	two.sided	0,69726762
hsa-miR-744-5p	CD66a+	0,33510921	12249,948	0,01989767	Spearman's rank correlation rho	two.sided	0,01989767
hsa-miR-769-5p	CD66a+	-0,174762	21643,8151	0,23481772	Spearman's rank correlation rho	two.sided	0,23481772
hsa-miR-7704	CD66a+	0,01326644	18179,579	0,92868956	Spearman's rank correlation rho	two.sided	0,92868956
hsa-miR-7706	CD66a+	-0,0756369	19817,5341	0,60938784	Spearman's rank correlation rho	two.sided	0,60938784
hsa-miR-7854-3p	CD66a+	-0,0985528	20239,7359	0,50514237	Spearman's rank correlation rho	two.sided	0,50514237
hsa-miR-7975	CD66a+	-0,327837	24464,0682	0,02292287	Spearman's rank correlation rho	two.sided	0,02292287
hsa-miR-7976	CD66a+	0,26646069	13514,7282	0,06714749	Spearman's rank correlation rho	two.sided	0,06714749
hsa-miR-7977	CD66a+	-0,1385926	20977,4299	0,34750934	Spearman's rank correlation rho	two.sided	0,34750934
hsa-miR-8085	CD66a+	-0,1874607	21877,7753	0,20199923	Spearman's rank correlation rho	two.sided	0,20199923
hsa-miR-874-3p	CD66a+	-0,1578952	21333,0617	0,28379384	Spearman's rank correlation rho	two.sided	0,28379384
hsa-miR-877-3p	CD66a+	-0,0419416	19196,7319	0,77714249	Spearman's rank correlation rho	two.sided	0,77714249
hsa-miR-877-5p	CD66a+	-0,2056161	22212,2708	0,16090587	Spearman's rank correlation rho	two.sided	0,16090587
hsa-miR-9-3p	CD66a+	0,39172406	11206,8759	0,00589816	Spearman's rank correlation rho	two.sided	0,00589816
hsa-miR-9-5p	CD66a+	-0,2718089	23431,8073	0,06164177	Spearman's rank correlation rho	two.sided	0,06164177
hsa-miR-92a-1-5p	CD66a+	0,00268865	18374,4644	0,98552997	Spearman's rank correlation rho	two.sided	0,98552997
hsa-miR-92a-3p	CD66a+	-0,0966002	20203,7618	0,51365685	Spearman's rank correlation rho	two.sided	0,51365685
hsa-miR-92b-3p	CD66a+	-0,0367019	19100,1954	0,80439843	Spearman's rank correlation rho	two.sided	0,80439843
hsa-miR-92b-5p	CD66a+	0,25623132	13703,1942	0,07876332	Spearman's rank correlation rho	two.sided	0,07876332
hsa-miR-93-3p	CD66a+	0,18426915	15029,0251	0,20992528	Spearman's rank correlation rho	two.sided	0,20992528
hsa-miR-93-5p	CD66a+	0,0831007	16892,9527	0,57443289	Spearman's rank correlation rho	two.sided	0,57443289
hsa-miR-940	CD66a+	-0,3165056	24255,2985	0,02840125	Spearman's rank correlation rho	two.sided	0,02840125
hsa-miR-941	CD66a+	0,13060391	16017,7535	0,37626608	Spearman's rank correlation rho	two.sided	0,37626608
hsa-miR-942-5p	CD66a+	0,21551251	14453,3975	0,1412625	Spearman's rank correlation rho	two.sided	0,1412625
hsa-miR-95-3p	CD66a+	0,21873835	14393,9647	0,1352616	Spearman's rank correlation rho	two.sided	0,1352616
hsa-miR-96-5p	CD66a+	-0,0035065	18488,6047	0,9811288	Spearman's rank correlation rho	two.sided	0,9811288
hsa-miR-98-5p	CD66a+	-0,0658611	19637,425	0,65649707	Spearman's rank correlation rho	two.sided	0,65649707
hsa-miR-99a-5p	CD66a+	0,06262282	17270,2371	0,67241013	Spearman's rank correlation rho	two.sided	0,67241013
hsa-miR-99b-3p	CD66a+	-0,1382173	20970,515	0,34882931	Spearman's rank correlation rho	two.sided	0,34882931
hsa-miR-99b-5p	CD66a+	0,03608725	17759,1284	0,80761139	Spearman's rank correlation rho	two.sided	0,80761139

For Review Only